PICOLINAMIDES AS FUNGICIDES

Abstract

This disclosure relates to picolinamides of Formula I and their use as fungicides.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 of U.S. provisional patent application Ser. No. 62/442,904 filed Jan. 5, 2017, which application is hereby incorporated by reference in its entirety.

BACKGROUND & SUMMARY

Fungicides are compounds, of natural or synthetic origin, which act to protect and/or cure plants against damage caused by agriculturally relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less.

The present disclosure relates to picolinamides and their use as fungicides. The compounds of the present disclosure may offer protection against ascomycetes, basidiomycetes, deuteromycetes and oomycetes.

One embodiment of the present disclosure may include compounds of Formula I:

wherein:

X is hydrogen or C(O)R₅;

Y is hydrogen, C(O)R₅, or Q;

Q is

wherein Z is N or N⁺→O⁻ and W is O or S;

R₁ is hydrogen or alkyl, substituted with 0, 1 or multiple R₈;

R₂ is methyl;

R₃ and R_3′ are independently chosen from C₂-C₆ alkyl, C₃-C₆ cycloalkyl, aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R₈; Alternatively, R₃ and R_3′ may be taken together to form a 3-6 membered saturated or partially saturated carbocycle or heterocycle, optionally substituted with 0, 1 or multiple R₈;

R₄ is chosen from aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R₈;

R₅ is chosen from alkoxy or benzyloxy, each optionally substituted with 0, 1, or multiple R₈;

R₆ is chosen from hydrogen, alkoxy, or halo, each optionally substituted with 0, 1, or multiple R₈;

R₇ is chosen from hydrogen, —C(O)R₉, or —CH₂OC(O)R₉;

R₈ is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkynyl, alkoxy, cyano, or heterocyclyl, each optionally substituted with 0, 1, or multiple R₁₀;

R₉ is chosen from alkyl, alkoxy, or aryl, each optionally substituted with 0, 1, or multiple R₈;

R₁₀ is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkoxy, or heterocyclyl; and

R₁₁ is chosen from hydrogen or alkyl, each substituted with 0, 1 or multiple R₈.

Another embodiment of the present disclosure may include a fungicidal composition for the control or prevention of fungal attack comprising the compounds described above and a phytologically acceptable carrier material.

Yet another embodiment of the present disclosure may include a method for the control or prevention of fungal attack on a plant, the method including the steps of applying a fungicidally effective amount of one or more of the compounds described above to at least one of the fungus, the plant, and an area adjacent to the plant.

It will be understood by those skilled in the art that the following terms may include generic “R”-groups within their definitions, e.g., “the term alkoxy refers to an —OR substituent”. It is also understood that within the definitions for the following terms, these “R” groups are included for illustration purposes and should not be construed as limiting or being limited by substitutions about Formula I.

The term “alkyl” refers to a branched, unbranched, or saturated cyclic carbon chain, including, but not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

The term “alkenyl” refers to a branched, unbranched or cyclic carbon chain containing one or more double bonds including, but not limited to, ethenyl, propenyl, butenyl, isopropenyl, isobutenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.

The terms “aryl” and “Ar” refer to any aromatic ring, mono- or bi-cyclic, containing 0 heteroatoms.

The term “heterocyclyl” refers to any aromatic or non-aromatic ring, mono- or bi-cyclic, containing one or more heteroatoms

The term “alkoxy” refers to an —OR substituent.

The term “acyloxy” refers to an —OC(O)R substituent.

The term “cyano” refers to a —C≡N substituent.

The term “hydroxyl” refers to a —OH substituent.

The term “amino” refers to an —N(R)₂ substituent.

The term “arylalkoxy” refers to —O(CH₂)_nAr where n is an integer selected from the list 1, 2, 3, 4, 5, or 6.

The term “haloalkoxy” refers to an —OR—X substituent, wherein X is Cl, F, Br, or I, or any combination thereof.

The term “haloalkyl” refers to an alkyl, which is substituted with Cl, F, I, or Br or any combination thereof.

The term “halogen” or “halo” refers to one or more halogen atoms, defined as F, Cl, Br, and I.

The term “nitro” refers to a —NO₂ substituent.

The term thioalkyl refers to a —SR substituent.

Throughout the disclosure, reference to the compounds of Formula I is read as also including all stereoisomers, for example diastereomers, enantiomers, and mixtures thereof. In another embodiment, Formula (I) is read as also including salts or hydrates thereof. Exemplary salts include, but are not limited to: hydrochloride, hydrobromide, hydroiodide, trifluoroacetate, and trifluoromethane sulfonate.

It is also understood by those skilled in the art that additional substitution is allowable, unless otherwise noted, as long as the rules of chemical bonding and strain energy are satisfied and the product still exhibits fungicidal activity.

Another embodiment of the present disclosure is a use of a compound of Formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots.

Additionally, another embodiment of the present disclosure is a composition useful for protecting a plant against attack by a phytopathogenic organism and/or treatment of a plant infested by a phytopathogenic organism comprising a compound of Formula I and a phytologically acceptable carrier material.

DETAILED DESCRIPTION

The compounds of the present disclosure may be applied by any of a variety of known techniques, either as the compounds or as formulations comprising the compounds. For example, the compounds may be applied to the roots or foliage of plants for the control of various fungi, without damaging the commercial value of the plants. The materials may be applied in the form of any of the generally used formulation types, for example, as solutions, dusts, wettable powders, flowable concentrate, or emulsifiable concentrates.

Preferably, the compounds of the present disclosure are applied in the form of a formulation, comprising one or more of the compounds of Formula I with a phytologically acceptable carrier. Concentrated formulations may be dispersed in water, or other liquids, for application, or formulations may be dust-like or granular, which may then be applied without further treatment. The formulations can be prepared according to procedures that are conventional in the agricultural chemical art.

The present disclosure contemplates all vehicles by which one or more of the compounds may be formulated for delivery and used as a fungicide. Typically, formulations are applied as aqueous suspensions or emulsions. Such suspensions or emulsions may be produced from water-soluble, water-suspendable, or emulsifiable formulations which are solids, usually known as wettable powders; or liquids, usually known as emulsifiable concentrates, aqueous suspensions, or suspension concentrates. As will be readily appreciated, any material to which these compounds may be added may be used, provided it yields the desired utility without significant interference with the activity of these compounds as antifungal agents.

Wettable powders, which may be compacted to form water-dispersible granules, comprise an intimate mixture of one or more of the compounds of Formula I, an inert carrier and surfactants. The concentration of the compound in the wettable powder may be from about 10 percent to about 90 percent by weight based on the total weight of the wettable powder, more preferably about 25 weight percent to about 75 weight percent. In the preparation of wettable powder formulations, the compounds may be compounded with any finely divided solid, such as prophyllite, talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite clays, diatomaceous earths, purified silicates or the like. In such operations, the finely divided carrier and surfactants are typically blended with the compound(s) and milled.

Emulsifiable concentrates of the compounds of Formula I may comprise a convenient concentration, such as from about 1 weight percent to about 50 weight percent of the compound, in a suitable liquid, based on the total weight of the concentrate. The compounds may be dissolved in an inert carrier, which is either a water-miscible solvent or a mixture of water-immiscible organic solvents, and emulsifiers. The concentrates may be diluted with water and oil to form spray mixtures in the form of oil-in-water emulsions. Useful organic solvents include aromatics, especially the high-boiling naphthalenic and olefinic portions of petroleum such as heavy aromatic naphtha. Other organic solvents may also be used, for example, terpenic solvents, including rosin derivatives, aliphatic ketones, such as cyclohexanone, and complex alcohols, such as 2-ethoxyethanol.

Emulsifiers which may be advantageously employed herein may be readily determined by those skilled in the art and include various nonionic, anionic, cationic and amphoteric emulsifiers, or a blend of two or more emulsifiers. Examples of nonionic emulsifiers useful in preparing the emulsifiable concentrates include the polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids with ethylene oxide, propylene oxides such as the ethoxylated alkyl phenols and carboxylic esters solubilized with the polyol or polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include the oil-soluble salts (e.g., calcium) of alkylaryl sulphonic acids, oil-soluble salts or sulfated polyglycol ethers and appropriate salts of phosphated polyglycol ether.

Representative organic liquids which may be employed in preparing the emulsifiable concentrates of the compounds of the present disclosure are the aromatic liquids such as xylene, propyl benzene fractions; or mixed naphthalene fractions, mineral oils, substituted aromatic organic liquids such as dioctyl phthalate; kerosene; dialkyl amides of various fatty acids, particularly the dimethyl amides of fatty glycols and glycol derivatives such as the n-butyl ether, ethyl ether or methyl ether of diethylene glycol, the methyl ether of triethylene glycol, petroleum fractions or hydrocarbons such as mineral oil, aromatic solvents, paraffinic oils, and the like; vegetable oils such as soy bean oil, rape seed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cotton seed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above vegetable oils; and the like. Mixtures of two or more organic liquids may also be employed in the preparation of the emulsifiable concentrate. Organic liquids include xylene, and propyl benzene fractions, with xylene being most preferred in some cases. Surface-active dispersing agents are typically employed in liquid formulations and in an amount of from 0.1 to 20 percent by weight based on the combined weight of the dispersing agent with one or more of the compounds. The formulations can also contain other compatible additives, for example, plant growth regulators and other biologically active compounds used in agriculture.

Aqueous suspensions comprise suspensions of one or more water-insoluble compounds of Formula I, dispersed in an aqueous vehicle at a concentration in the range from about 1 to about 50 weight percent, based on the total weight of the aqueous suspension. Suspensions are prepared by finely grinding one or more of the compounds, and vigorously mixing the ground material into a vehicle comprised of water and surfactants chosen from the same types discussed above. Other components, such as inorganic salts and synthetic or natural gums, may also be added to increase the density and viscosity of the aqueous vehicle.

The compounds of Formula I can also be applied as granular formulations, which are particularly useful for applications to the soil. Granular formulations generally contain from about 0.5 to about 10 weight percent, based on the total weight of the granular formulation of the compound(s), dispersed in an inert carrier which consists entirely or in large part of coarsely divided inert material such as attapulgite, bentonite, diatomite, clay or a similar inexpensive substance. Such formulations are usually prepared by dissolving the compounds in a suitable solvent and applying it to a granular carrier which has been preformed to the appropriate particle size, in the range of from about 0.5 to about 3 mm. A suitable solvent is a solvent in which the compound is substantially or completely soluble. Such formulations may also be prepared by making a dough or paste of the carrier and the compound and solvent, and crushing and drying to obtain the desired granular particle.

Dusts containing the compounds of Formula I may be prepared by intimately mixing one or more of the compounds in powdered form with a suitable dusty agricultural carrier, such as, for example, kaolin clay, ground volcanic rock, and the like. Dusts can suitably contain from about 1 to about 10 weight percent of the compounds, based on the total weight of the dust.

The formulations may additionally contain adjuvant surfactants to enhance deposition, wetting, and penetration of the compounds onto the target crop and organism. These adjuvant surfactants may optionally be employed as a component of the formulation or as a tank mix. The amount of adjuvant surfactant will typically vary from 0.01 to 1.0 percent by volume, based on a spray-volume of water, preferably 0.05 to 0.5 volume percent. Suitable adjuvant surfactants include, but are not limited to ethoxylated nonyl phenols, ethoxylated synthetic or natural alcohols, salts of the esters or sulphosuccinic acids, ethoxylated organosilicones, ethoxylated fatty amines, blends of surfactants with mineral or vegetable oils, crop oil concentrate (mineral oil (85%)+emulsifiers (15%)); nonylphenol ethoxylate; benzylcocoalkyldimethyl quaternary ammonium salt; blend of petroleum hydrocarbon, alkyl esters, organic acid, and anionic surfactant; C₉-C₁₁ alkylpolyglycoside; phosphated alcohol ethoxylate; natural primary alcohol (C₁₂-C₁₆) ethoxylate; di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap; nonylphenol ethoxylate+urea ammonium nitrate; emulsified methylated seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow amine ethoxylate (15 EO); PEG(400) dioleate-99. The formulations may also include oil-in-water emulsions such as those disclosed in U.S. patent application Ser. No. 11/495,228, the disclosure of which is expressly incorporated by reference herein.

The formulations may optionally include combinations that contain other pesticidal compounds. Such additional pesticidal compounds may be fungicides, insecticides, herbicides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds. Accordingly, in such embodiments, the other pesticidal compound is employed as a supplemental toxicant for the same or for a different pesticidal use. The compounds of Formula I and the pesticidal compound in the combination can generally be present in a weight ratio of from 1:100 to 100:1.

The compounds of the present disclosure may also be combined with other fungicides to form fungicidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure are often applied in conjunction with one or more other fungicides to control a wider variety of undesirable diseases. When used in conjunction with other fungicide(s), the presently claimed compounds may be formulated with the other fungicide(s), tank-mixed with the other fungicide(s) or applied sequentially with the other fungicide(s). Such other fungicides may include 2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, ametoctradin, amisulbrom, antimycin, Ampelomyces quisqualis, azaconazole, Bacillus subtilis, Bacillus subtilis strain QST713, benalaxyl, benomyl, benthiavalicarb-isopropyl, benzovindiflupyr, benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole, bupirimate, calcium polysulfide, captafol, captan, carbendazim, carboxin, carpropamid, carvone, chlazafenone, chloroneb, chlorothalonil, chlozolinate, Coniothyrium minitans, copper hydroxide, copper octanoate, copper oxychloride, copper sulfate, copper sulfate (tribasic), cuprous oxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dazomet, debacarb, diammonium ethylenebis-(dithiocarbamate), dichlofluanid, dichlorophen, diclocymet, diclomezine, dichloran, diethofencarb, difenoconazole, difenzoquat ion, diflumetorim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap, diphenylamine, dithianon, dodemorph, dodemorph acetate, dodine, dodine free base, edifenphos, enestrobin, enestroburin, epoxiconazole, ethaboxam, ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, fluindapyr, flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl, fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, guazatine, guazatine acetates, GY-81, hexachlorobenzene, hexaconazole, hymexazol, imazalil, imazalil sulfate, imibenconazole, iminoctadine, iminoctadine triacetate, iminoctadine tris(albesilate), iodocarb, ipconazole, ipfenpyrazolone, iprobenfos, iprodione, iprovalicarb, isofetamide, isoprothiolane, isopyrazam, isotianil, kasugamycin, kasugamycin hydrochloride hydrate, kresoxium-methyl, laminarin, mancopper, mancozeb, mandipropamid, maneb, mefenoxam, mepanipyrim, mepronil, meptyl-dinocap, mercuric chloride, mercuric oxide, mercurous chloride, metalaxyl, metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium, metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate, metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil, nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic acid (fatty acids), orysastrobin, oxadixyl, oxathiapiprolin, oxine-copper, oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, pentachlorophenyl laurate, penthiopyrad, phenylmercury acetate, phosphonic acid, phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim, potassium bicarbonate, potassium hydroxyquinoline sulfate, probenazole, prochloraz, procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pydiflumetofen, pyrametostrobin, pyraoxystrobin, pyraclostrobin, pyraziflumid, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyroquilon, quinoclamine, quinoxyfen, quintozene, Reynoutria sachalinensis extract, sedaxane, silthiofam, simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium pentachlorophenoxide, spiroxamine, sulfur, SYP-Z048, tar oils, tebuconazole, tebufloquin, tecnazene, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumizole, triforine, triticonazole, validamycin, valifenalate, valiphenal, vinclozolin, zineb, ziram, zoxamide, Candida oleophila, Fusarium oxysporum, Gliocladium spp., Phlebiopsis gigantea, Streptomyces griseoviridis, Trichoderma spp., (RS)—N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide, 1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone hydrate, 1-chloro-2,4-dinitronaphthalene, 1-chloro-2-nitropropane, 2-(2-heptadecyl-2-imidazolin-1-yl)ethanol, 2,3-dihydro-5-phenyl-1,4-dithi-ine 1,1,4,4-tetraoxide, 2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride, 2-methoxyethylmercury silicate, 3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-1-enyl)phenyl thiocyanateme, ampropylfos, anilazine, azithiram, barium polysulfide, Bayer 32394, benodanil, benquinox, bentaluron, benzamacril; benzamacril-isobutyl, benzamorf, binapacryl, bis(methylmercury) sulfate, bis(tributyltin) oxide, buthiobate, cadmium calcium copper zinc chromate sulfate, carbamorph, CECA, chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox, climbazole, copper bis(3-phenylsalicylate), copper zinc chromate, coumoxystrobin, cufraneb, cupric hydrazinium sulfate, cuprobam, cyclafuramid, cypendazole, cyprofuram, decafentin, dichlobentiazox, dichlone, dichlozoline, diclobutrazol, dimethirimol, dinocton, dinosulfon, dinoterbon, dipymetitrone, dipyrithione, ditalimfos, dodicin, drazoxolon, EBP, enoxastrobin, ESBP, etaconazole, etem, ethirim, fenaminstrobin, fenaminosulf, fenapanil, fenitropan, fenpicoxamid, flufenoxystrobin, fluotrimazole, furcarbanil, furconazole, furconazole-cis, furmecyclox, furophanate, glyodine, griseofulvin, halacrinate, Hercules 3944, hexylthiofos, ICIA0858, ipfentrifluconazole, isopamphos, isovaledione, mandestrobin, mebenil, mecarbinzid, mefentrifluconazole, metazoxolon, methfuroxam, methylmercury dicyandiamide, metsulfovax, milneb, mucochloric anhydride, myclozolin, N-3,5-dichlorophenyl-succinimide, N-3-nitrophenylitaconimide, natamycin, N-ethylmercurio-4-toluenesulfonanilide, nickel bis(dimethyldithiocarbamate), OCH, phenylmercury dimethyldithiocarbamate, phenylmercury nitrate, phosdiphen, prothiocarb; prothiocarb hydrochloride, pyracarbolid, pyridinitril, pyrisoxazole, pyroxychlor, pyroxyfur, quinacetol; quinacetol sulfate, quinazamid, quinconazole, quinofumelin, rabenzazole, salicylanilide, SSF-109, sultropen, tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate, thioquinox, tioxymid, triamiphos, triarimol, triazbutil, trichlamide, triclopyricarb, triflumezopyrim, urbacid, zarilamid, and any combinations thereof.

Additionally, the compounds described herein may be combined with other pesticides, including insecticides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more other pesticides to control a wider variety of undesirable pests. When used in conjunction with other pesticides, the presently claimed compounds may be formulated with the other pesticide(s), tank-mixed with the other pesticide(s) or applied sequentially with the other pesticide(s). Typical insecticides include, but are not limited to: 1,2-dichloropropane, abamectin, acephate, acetamiprid, acethion, acetoprole, acrinathrin, acrylonitrile, alanycarb, aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, allyxycarb, alpha-cypermethrin, alpha-ecdysone, alpha-endosulfan, amidithion, aminocarb, amiton, amiton oxalate, amitraz, anabasine, athidathion, azadirachtin, azamethiphos, azinphos-ethyl, azinphos-methyl, azothoate, barium hexafluorosilicate, barthrin, bendiocarb, benfuracarb, bensultap, beta-cyfluthrin, beta-cypermethrin, bifenthrin, bioallethrin, bioethanomethrin, biopermethrin, bistrifluron, borax, boric acid, bromfenvinfos, bromocyclen, bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin, butacarb, butathiofos, butocarboxim, butonate, butoxycarboxim, cadusafos, calcium arsenate, calcium polysulfide, camphechlor, carbanolate, carbaryl, carbofuran, carbon disulfide, carbon tetrachloride, carbophenothion, carbosulfan, cartap, cartap hydrochloride, chlorantraniliprole, chlorbicyclen, chlordane, chlordecone, chlordimeform, chlordimeform hydrochloride, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos, chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide, cinerin I, cinerin II, cinerins, cismethrin, cloethocarb, closantel, clothianidin, copper acetoarsenite, copper arsenate, copper naphthenate, copper oleate, coumaphos, coumithoate, crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin, cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cyromazine, cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O, demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl, demeton-S-methylsulphon, diafenthiuron, dialifos, diatomaceous earth, diazinon, dicapthon, dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil, dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan, dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex, dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan, dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos, d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC, empenthrin, endosulfan, endothion, endrin, EPN, epofenonane, eprinomectin, esdepalléthrine, esfenvalerate, etaphos, ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl formate, ethyl-DDD, ethylene dibromide, ethylene dichloride, ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos, fenazaflor, fenchlorphos, fenethacarb, fenfluthrin, fenitrothion, fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin, fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil, flonicamid, flubendiamide, flucofuron, flucycloxuron, flucythrinate, flufenerim, flufenoxuron, flufenprox, fluvalinate, fonofos, formetanate, formetanate hydrochloride, formothion, formparanate, formparanate hydrochloride, fosmethilan, fospirate, fosthietan, furathiocarb, furethrin, gamma-cyhalothrin, gamma-HCH, halfenprox, halofenozide, HCH, HEOD, heptachlor, heptenophos, heterophos, hexaflumuron, HHDN, hydramethylnon, hydrogen cyanide, hydroprene, hyquincarb, imidacloprid, imiprothrin, indoxacarb, iodomethane, IPSP, isazofos, isobenzan, isocarbophos, isodrin, isofenphos, isofenphos-methyl, isoprocarb, isoprothiolane, isothioate, isoxathion, ivermectin, jasmolin I, jasmolin II, jodfenphos, juvenile hormone I, juvenile hormone II, juvenile hormone III, kelevan, kinoprene, lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, lindane, lirimfos, lufenuron, lythidathion, malathion, malonoben, mazidox, mecarbam, mecarphon, menazon, mephosfolan, mercurous chloride, mesulfenfos, metaflumizone, methacrifos, methamidophos, methidathion, methiocarb, methocrotophos, methomyl, methoprene, methoxychlor, methoxyfenozide, methyl bromide, methyl isothiocyanate, methylchloroform, methylene chloride, metofluthrin, metolcarb, metoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin oxime, mipafox, mirex, molosultap, monocrotophos, monomehypo, monosultap, morphothion, moxidectin, naftalofos, naled, naphthalene, nicotine, nifluridide, nitenpyram, nithiazine, nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl, oxydemeton-methyl, oxydeprofos, oxydisulfoton, para-dichlorobenzene, parathion, parathion-methyl, penfluron, pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate, phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon, phosphine, phoxim, phoxim-methyl, pirimetaphos, pirimicarb, pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium thiocyanate, pp′-DDT, prallethrin, precocene I, precocene II, precocene III, primidophos, profenofos, profluralin, promacyl, promecarb, propaphos, propetamphos, propoxur, prothidathion, prothiofos, prothoate, protrifenbute, pyraclofos, pyrafluprole, pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins, pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon, pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia, quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin, rotenone, ryania, sabadilla, schradan, selamectin, silafluofen, silica gel, sodium arsenite, sodium fluoride, sodium hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram, spinosad, spiromesifen, spirotetramat, sulcofuron, sulcofuron-sodium, sulfluramid, sulfotep, sulfoxaflor, sulfuryl fluoride, sulprofos, tau-fluvalinate, tazimcarb, TDE, tebufenozide, tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos, TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos, tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid, thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam oxalate, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-disodium, thiosultap-monosodium, thuringiensin, tolfenpyrad, tralomethrin, transfluthrin, transpermethrin, triarathene, triazamate, triazophos, trichlorfon, trichlormetaphos-3, trichloronat, trifenofos, triflumuron, trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, zolaprofos, and any combinations thereof.

Additionally, the compounds described herein may be combined with herbicides that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more herbicides to control a wide variety of undesirable plants. When used in conjunction with herbicides, the presently claimed compounds may be formulated with the herbicide(s), tank-mixed with the herbicide(s) or applied sequentially with the herbicide(s). Typical herbicides include, but are not limited to: 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB; 3,4-DB; 2,4-DEB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB; acetochlor, acifluorfen, aclonifen, acrolein, alachlor, allidochlor, alloxydim, allyl alcohol, alorac, ametridione, ametryn, amibuzin, amicarbazone, amidosulfuron, aminocyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole, ammonium sulfamate, anilofos, anisuron, asulam, atraton, atrazine, azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid, benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron, bensulide, bentazone, benzadox, benzfendizone, benzipram, benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron, bicyclopyrone, bifenox, bilanafos, bispyribac, borax, bromacil, bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon, butachlor, butafenacil, butamifos, butenachlor, buthidazole, buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid, cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor, carbasulam, carbetamide, carboxazole chlorprocarb, carfentrazone, CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop, chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, chloridazon, chlorimuron, chlornitrofen, chloropon, chlorotoluron, chloroxuron, chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim, cliodinate, clodinafop, clofop, clomazone, clomeprop, cloprop, cloproxydim, clopyralid, cloransulam, CMA, copper sulfate, CPMF, CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate, cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyperquat, cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet, delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil, dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop, diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron, difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam, dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul, dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endothal, epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron, ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxysulfuron, etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop, fenoxaprop, fenoxaprop-P, fenoxasulfone, fenteracol, fenthiaprop, fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M, flazasulfuron, florasulam, fluazifop, fluazifop-P, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, flufenican, flufenpyr, flumetsulam, flumezin, flumiclorac, flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen, fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil, flupropanate, flupyrsulfuron, fluridone, flurochloridone, fluroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron, fosamine, furyloxyfen, glufosinate, glufosinate-P, glyphosate, halauxifen, halosafen, halosulfuron, haloxydine, haloxyfop, haloxyfop-P, hexachloroacetone, hexaflurate, hexazinone, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane, iodosulfuron, ioxynil, ipazine, ipfencarbazone, iprymidam, isocarbamid, isocil, isomethiozin, isonoruron, isopolinate, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen, lenacil, linuron, MAA, MAMA, MCPA, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, medinoterb, mefenacet, mefluidide, mesoprazine, mesosulfuron, mesotrione, metam, metamifop, metamitron, metazachlor, metazosulfuron, metflurazon, methabenzthiazuron, methalpropalin, methazole, methiobencarb, methiozolin, methiuron, methometon, methoprotryne, methyl bromide, methyl isothiocyanate, methyldymron, metobenzuron, metobromuron, metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, molinate, monalide, monisouron, monochloroacetic acid, monolinuron, monuron, morfamquat, MSMA, naproanilide, napropamide, naptalam, neburon, nicosulfuron, nipyraclofen, nitralin, nitrofen, nitrofluorfen, norflurazon, noruron, OCH, orbencarb, ortho-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxasulfuron, oxaziclomefone, oxyfluorfen, parafluron, paraquat, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham, phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram, picolinafen, pinoxaden, piperophos, potassium arsenite, potassium azide, potassium cyanate, pretilachlor, primisulfuron, procyazine, prodiamine, profluazol, profluralin, profoxydim, proglinazine, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfalin, prosulfocarb, prosulfuron, proxan, prynachlor, pydanon, pyraclonil, pyraflufen, pyrasulfotole, pyrazolynate, pyrazosulfuron, pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate, pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quinonamid, quizalofop, quizalofop-P, rhodethanil, rimsulfuron, saflufenacil, S-metolachlor, sebuthylazine, secbumeton, sethoxydim, siduron, simazine, simeton, simetryn, SMA, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone, sulfometuron, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine, terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr, thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron, thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tricamba, triclopyr, tridiphane, trietazine, trifloxysulfuron, trifluralin, triflusulfuron, trifop, trifopsime, trihydroxytriazine, trimeturon, tripropindan, tritac, tritosulfuron, vernolate, and xylachlor.

Another embodiment of the present disclosure is a method for the control or prevention of fungal attack. This method comprises applying to the soil, plant, roots, foliage, or locus of the fungus, or to a locus in which the infestation is to be prevented (for example applying to cereal or grape plants), a fungicidally effective amount of one or more of the compounds of Formula I. The compounds are suitable for treatment of various plants at fungicidal levels, while exhibiting low phytotoxicity. The compounds may be useful both in a protectant and/or an eradicant fashion.

The compounds have been found to have significant fungicidal effect particularly for agricultural use. Many of the compounds are particularly effective for use with agricultural crops and horticultural plants.

It will be understood by those skilled in the art that the efficacy of the compound for the foregoing fungi establishes the general utility of the compounds as fungicides.

The compounds have broad ranges of activity against fungal pathogens. Exemplary pathogens may include, but are not limited to, causing agent of wheat leaf blotch (Zymoseptoria tritici), wheat brown rust (Puccinia triticina), wheat stripe rust (Puccinia striiformis), scab of apple (Venturia inaequalis), powdery mildew of grapevine (Uncinula necator), barley scald (Rhynchosporium secalis), blast of rice (Magnaporthe grisea), rust of soybean (Phakopsora pachyrhizi), glume blotch of wheat (Leptosphaeria nodorum), powdery mildew of wheat (Blumeria graminis f. sp. tritici), powdery mildew of barley (Blumeria graminis f. sp. hordei), powdery mildew of cucurbits (Erysiphe cichoracearum), anthracnose of cucurbits (Glomerella lagenarium), leaf spot of beet (Cercospora beticola), early blight of tomato (Alternaria solani), and spot blotch of barley (Cochliobolus sativus). The exact amount of the active material to be applied is dependent not only on the specific active material being applied, but also on the particular action desired, the fungal species to be controlled, and the stage of growth thereof, as well as the part of the plant or other product to be contacted with the compound. Thus, all the compounds, and formulations containing the same, may not be equally effective at similar concentrations or against the same fungal species.

The compounds are effective in use with plants in a disease-inhibiting and phytologically acceptable amount. The term “disease-inhibiting and phytologically acceptable amount” refers to an amount of a compound that kills or inhibits the plant disease for which control is desired, but is not significantly toxic to the plant. This amount will generally be from about 0.1 to about 1000 ppm (parts per million), with 1 to 500 ppm being preferred. The exact concentration of compound required varies with the fungal disease to be controlled, the type of formulation employed, the method of application, the particular plant species, climate conditions, and the like. A suitable application rate is typically in the range from about 0.10 to about 4 pounds/acre (about 0.01 to 0.45 grams per square meter, g/m²).

Any range or desired value given herein may be extended or altered without losing the effects sought, as is apparent to the skilled person for an understanding of the teachings herein.

The compounds of Formula I may be made using well-known chemical procedures. Intermediates not specifically mentioned in this disclosure are either commercially available, may be made by routes disclosed in the chemical literature, or may be readily synthesized from commercial starting materials utilizing standard procedures.

General Schemes

The following schemes illustrate approaches to generating picolinamide compounds of Formula (I). The following descriptions and examples are provided for illustrative purposes and should not be construed as limiting in terms of substituents or substitution patterns.

Compounds of Formula 1.3 and 1.4 wherein R₄ is as originally defined, can be prepared by the methods shown in Scheme 1, steps a-c. Compounds of Formula 1.1, wherein R₄ is as originally defined, can be prepared by treatment of halogens (X) of Formula 1.0, wherein R₄ is as originally defined, first under standard Grignard conditions, using magnesium metal and an alkali base, such as lithium chloride, in a polar, aprotic solvent such as tetrahydrofuran (THF) or diethyl ether (Et₂O), at a temperature of about 0° C. to about 70° C., to afford the Grignard intermediate. The solution is then treated with a metal catalyst, such as iron (III) acetylacetonate, followed by allyl chloride, in a polar aprotic solvent, such as THF, at a temperature of about 0° C. to about 70° C., to give compounds of Formula 1.1, wherein R₄ is as previously defined, and shown in step a. Generally, the composition of compounds of Formula 1.1 derived from this process is a mixture of allyl and E, Z isomers of the styrene derived products. Compounds of Formula 1.1, wherein R₄ is as previously defined, can be isomerized to compounds of Formula 1.2 by treating with a metal catalyst system, such as bis(dibenzylideneactone)palladium (0), a phosphine coordinating reagent, such as tri-tert-butylphosphine, and an acid chloride, such as isobutyryl chloride, in an aromatic hydrocarbon solvent such as toluene, at a temperature of about 25° C. to 100° C., to afford compounds of Formula 1.2, wherein R₄ is as originally defined, and shown in step b. Alternatively, compounds of Formula 1.2, wherein R₄ is as originally defined, can be isomerized using the conditions of Mayer, M.; Welther, A.; Jacobi von Wangelin, A. ChemCatChem. 2011, 3, 1567-1571, and shown in step b. Epoxides of Formulas 1.3 and 1.4, wherein R₄ is as previously defined, can be obtained by a catalytic asymmetric epoxidation method using oxone as oxidant and a fructose derived ketone as described by Wang, Z-X; Tu, Y.; Frohn, M.; Zhang, J-R.; Shi, Y. J. Am. Chem. Soc. 1997, 119, 11224-11235, and depicted in step c. It will be understood by those skilled in the art that epoxides of Formulae 1.3 and 1.4, wherein R₄ is as previously defined, can be prepared by other catalytic asymmetric epoxidation methods, including, but not limited to, dioxiranes derived from other chiral ketones; catalytic metal salen complexes using an oxidant, such

as dioxygen or sodium hypochlorite; chiral iminium salts using oxone as the oxidizing species; chiral organic oxaziridine salts; and enzymatic epoxidation biocatalysts, such as monooxygenases and hydrolases. In certain other cases, compounds of Formula 1.2, wherein R₄ is as previously defined, can be prepared by the oxo-metathesis method of Franzen (Eur. J. Org. Chem. 2015, 1834) and shown in step d. Treatment of aldehydes of Formula 1.5, wherein R₄ is as previously defined, with an alkene, such as 2-methyl-2-butene, and a Lewis acidic catalyst, such as trityl tetrafluoroborate, in a polar, aprotic solvent, such as dichloromethane, at a temperature of about −78° C. to about room temperature, affords trans-alkenes of Formula 1.2, wherein R₄ is as previously defined.

Compounds of Formulas 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, can be prepared by the method shown in Scheme 2, step a. Subjection of epoxides of Formulas 1.3 and 1.4, wherein R₄ is as previously defined, to an

organometallic nucleophile, such as an alkyl magnesium halide, in the presence of a metal halide, such as copper iodide, in a polar, aprotic solvent, such as THF or Et₂O, at a temperature of about −78° C. to 55° C., affords compounds of Formulas 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, and shown in step a.

In certain cases, it is beneficial to employ an alkenyl organometallic reagent as the carbon nucleophile and shown in Scheme 3. Compounds of Formulas 3.1 and 3.3, wherein R₃ and R₄ are as previously defined, can be prepared by treating epoxides of Formulas 1.3 and 1.4, wherein R₄ is as previously defined, with an alkenyl magnesium halide, such as prop-1-en-2-ylmagnesium bromide, in the presence of a metal halide, such as copper iodide, in a polar, aprotic solvent, such as THF or Et₂O, at a temperature of about −78° C. to 25° C., and shown in step a. Compounds of

Formulas 3.2 and 3.4, wherein R₃ and R₄ are as previously defined, can be prepared by treatment of compounds of Formulas 3.1 and 3.3, wherein R₃ and R₄ are as previously defined, with a metal hydrogenation catalyst, such as tris(triphenylphosphine)rhodium(I) chloride (Wilkinson's catalyst) in a polar, aprotic solvent, such as THF, in the presence of a hydrogen atmosphere (1-4 atm); or, alternatively, with palladium absorbed on carbon, in a polar solvent, such as THF, in the presence of a hydrogen atmosphere (1-4 atm), and shown in step b.

In certain additional examples, compounds of Formula 4.2, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be prepared by the procedure shown in Scheme 4, steps a and b. Compounds of Formula 2.1, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be treated with an oxidizing reagent, such as the Dess-Martin periodinane, in a polar solvent such as dichloromethane (CH₂Cl₂), at a temperature of about 0° C. to 50° C., to give compounds of Formula 4.1, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, and shown in a. Compounds of Formula 4.1, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be treated with a chiral oxazaborolidine catalyst, such as (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole, in the presence of a boron hydride reducing agent, such as borane-dimethyl sulfide complex, in an aprotic solvent, such as toluene or

THF, at a temperature from about −78° C. to about room temperature, to afford compounds of Formula 4.2, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, and shown in b. Typical diastereomeric ratios obtained in b are generally in the 2:1 to 5:1 range with the anti isomer being favored over the syn. It will be understood by those skilled in the art that compounds of Formula 4.1, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be enantioselective reduced by other chiral catalyst/hydride reducing agent combinations, including, but not limited to, chirally modified lithium aluminum hydride or sodium borohydride reagents, phosphoramide catalysts, transfer hydrogenation catalyzed by chiral metal complexes, phase transfer catalysts, or enantioselective hydrogenation of pro-chiral ketones by enzymatic catalysis.

In yet other examples, it is beneficial to prepare compounds of Formula 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, by the method shown in Scheme 4A. Treatment of substituted acetic acids of Formula 4A.0, wherein R₄ is as previously defined, with two equivalents of a strong base, such as isopropylmagnesium chloride, and an alkylating reagent, such as 2-iodopropane, in a polar aprotic solvent, such as THF, at a temperature of about 25° C. to about 70° C. gives compounds of Formula 4A.1, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, and shown in step a. Compounds of Formula 4A.1, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be treated with an amine, such as N,O-dimethylhydroxylamine

hydrochloride, a coupling reagent, such as 3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine hydrochloride (EDC) or a polymer-supported carbodiimide (PS-CDI), and a catalyst, such as N,N-dimethylpyridin-4-amine (DMAP), in a halogenated or polar, aprotic solvent, such as CH₂Cl₂ or THF to afford compounds of Formula 4A.2, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in step b. Treatment of amides of Formula 4A.2, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, with a Grignard reagent, such as methylmagnesium bromide, in a polar, aprotic solvent, such as THF, at a temperature of about 0° C. to about 60° C. yields compounds of Formula 4A.3, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, and shown in step c. A racemic mixture of compounds of Formula 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, can be prepared by treating compounds of Formula 4A.3, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, with a hydride reducing agent, such as lithium aluminum hydride, in a polar, aprotic solvent, such as THF, at a temperature of about −78° C. to about 30° C., to afford and inseparable mixture of compounds of Formula 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, and shown in step d. A racemic mixture of compounds of Formula 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, can be separated by treatment of the mixture with an optically active carboxylic acid, such as (S)-2-methoxy-2-phenylacetic acid, a coupling reagent, such as 3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine hydrochloride (EDC) or a polymer-supported carbodiimide (PS-CDI), and a catalyst, such as N,N-dimethylpyridin-4-amine (DMAP), in a halogenated or polar, aprotic solvent, such as CH₂Cl₂ or THF to afford compounds of Formula 4A.4 and 4A.5, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in step e. The diastereomeric mixture can then separated into its individual components via silica gel chromatography using a mobile phase, such as 10% tert-butyl methyl ether in hexanes, as the eluant. The individual diastereomers, compounds of Formula 4A.4 and 4A.5, wherein R₃, R_3′ and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with a carbonate base, such as potassium carbonate, in a polar, alcoholic solvent, such as methanol, at a temperature of about 25° C. to about 60° C., to give compounds of Formula 2.1 and 2.2, wherein R₃, R_3′ and R₄ are as previously defined, and R₃ and R_3′ may or may not be equivalent, and shown in step f.

In certain additional examples, compounds of Formula 5.5 and 5.9, wherein R₃, R_3′ and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, can be prepared by the procedure shown in Scheme 5, steps a-i. The compound of Formula 5.0 can be treated with an aryl or heteroaryl organometallic reagent, such as phenylmagnesium bromide, in a polar aprotic solvent, such as THF or Et₂O, at a temperature of about 0° C. to room temperature, to afford compounds of Formula 5.1, wherein R₄ is as originally defined, and shown in step a. Subjection of compounds of Formula 5.1 to an oxidization procedure, such as the Swern process (oxalyl chloride, DMSO, Et₃N, CH₂Cl₂), affords compounds of Formula 5.2, wherein R₄ is as originally defined, depicted in b. Alternatively, compounds of Formula 5.2, wherein R₄ is as originally defined, can be prepared by treatment of pyrolidine amide 5.15 with an arylmagnesium halide, such as phenylmagnesium bromide, in a polar, aprotic solvent, such as THF, at a temperature of about −20° C. to about 40° C. to give compounds of Formula 5.2, wherein R₄ is as originally defined, and shown in step b2. Compounds of Formula 5.3, wherein R₃, R_3′ and R₄ are as previously defined, and

R₃ and R_3′ may or may not be equivalent, can be obtained by treating compounds of Formula 5.2, wherein R₄ is as originally defined, with an organometallic nucleophile, such as isopropylmagnesium bromide, in a polar aprotic solvent, such as THF or Et₂O, at a temperature of about 0° C. to room temperature, as depicted in step c. Compounds of Formula 5.4, wherein R₃, R_3′, and R₄ are as previously defined and R₃ and R_3′ may or may not be equivalent, and R₄ is not an electron-deficient aryl or heteroaryl group, can be obtained by treating the compounds of Formula 5.3, wherein R₃, R_3′ are as previously defined and may or may not be equivalent, and R₄ is not an electron-deficient aryl or heteroaryl group, with a mixture of a hydride reagent, such as triethylsilane (Et₃SiH), and an acid, such as 2,2,2-trifluoroacetic acid (TFA) in a halogenated solvent such as dichloromethane (DCM) at a temperature of about 0° C. to 23° C., as depicted in d. Compounds of Formula 5.5, wherein R₃, R_3′, and R₄ are as originally defined and R₃ may or may not be equivalent to R_3′, can be prepared from compounds of Formula 5.4, wherein R₃, R_3′, and R₄ are as originally defined and R₃ may or may not be equivalent to R_3′, by treating with a metal catalyst such as palladium on carbon (Pd/C) in a polar protic solvent, such as ethanol (EtOH), in a hydrogen atmosphere (1-4 atm) at a temperature of about 25° C. to 65° C., or with an alternate source of hydrogen, such as cyclohexene, in a polar solvent such as EtOH, and shown in step e. In certain other cases, it is beneficial to synthesize compounds of Formula 5.9, wherein R₃ and R₄ are as originally defined, by the method shown in steps f-i. Compounds of Formula 5.2, wherein R₄ is as previously defined, can be treated with an alkenyl organometallic reagent, such as isopropenylmagnesium bromide, in a polar aprotic solvent, such as THF or Et₂O, at a temperature of about 0° C. to room temperature, to afford compounds of Formula 5.6, wherein R₃ and R₄ are as originally defined, and shown in step f. Compounds of Formula 5.7, wherein R₃ and R₄ are as previously defined, can be prepared by treatment of compounds of Formula 5.6, wherein R₃ and R₄ are as previously defined, with a metal hydrogenation catalyst, such as tris(triphenylphosphine)rhodium(I) chloride (Wilkinson's catalyst) in a polar, aprotic solvent, such as THF, in the presence of a hydrogen atmosphere (1-4 atm), and shown in g. Compounds of Formula 5.8, wherein R₃ and R₄ are as previously defined, and R₄ is not an electron-deficient aryl or heteroaryl group, can be obtained by treating the compounds of Formula 5.7, wherein R₃ and R₄ are as previously defined, and R₄ is not an electron-deficient aryl or heteroaryl group, with a mixture of a hydride reagent, such as triethylsilane (Et₃SiH), and an acid, such as 2,2,2-trifluoroacetic acid (TFA) in a halogenated solvent such as dichloromethane (DCM) at a temperature of about 0° C. to 23° C., as depicted in h. Compounds of Formula 5.9, wherein R₃ and R₄ are as previously defined, can be prepared by treatment of compounds of Formula 5.8, wherein R₃ and R₄ are as previously defined, with a metal hydrogenation catalyst, such as tris(triphenylphosphine)rhodium(I) chloride (Wilkinson's catalyst) in a polar, aprotic solvent, such as THF, in the presence of a hydrogen atmosphere (1-4 atm); or, alternatively, with palladium absorbed on carbon, in a polar solvent, such as THF, in the presence of a hydrogen atmosphere (1-4 atm), and shown in step i.

In certain other examples, compounds of Formula 5.5, wherein R₃, R_3′, and R₄, are as originally defined, and R₃ and R_3′ may or may not be equivalent, may also be prepared according to the method outlined in Scheme 6, steps a and b. Treatment of compounds of Formula 2.1, wherein R₃, R_3′, and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, with an

electron deficient benzoic acid, such as p-nitrobenzoic acid, a phosphine nucleophile, such as triphenylphosphine; and a diazene coupling reagent, such as diethyl (E)-diazene-1,2-dicarboxylate, in a polar, aprotic solvent, such as THF, at a temperature of about 0° C. to about 25° C. affords compounds of Formula 6.1, wherein R₃, R_3′, and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, as depicted in step a. In step b, compounds of Formula 6.1, wherein R₃, R_3′, and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with an aqueous solution of an inorganic base, such as sodium hydroxide, in a polar aprotic solvent, such as THF, at a temperature of about 0° C. to about 40° C. to afford compounds of Formula 5.5, wherein R₃, R_3′, and R₄ are as originally defined, and R₃ and R_3′ may or may not be equivalent.

Compounds of Formula 7.2, wherein R₁, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, may be prepared according to the method outlined in Scheme 7, step a. Alcohols of Formula 5.5, wherein R₃, R_3′, and R₄, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with compounds of Formula 7.1, wherein R₁ and R₁₁ are as originally defined, a coupling reagent, such as 3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine hydrochloride (EDC) or a polymer-supported carbodiimide (PS-CDI), and a catalyst, such as N,N-dimethylpyridin-4-amine (DMAP), in a halogenated or polar, aprotic solvent, such as CH₂Cl₂ or THF to afford compounds of Formula 7.2, wherein R₁, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in step a.

Compounds of Formula 7.2, wherein R₁, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, may also be prepared according to the method outlined in Scheme 8, step a. Alcohols of Formula 2.1, wherein R₃, R_3′, and R₄, are as originally

defined, and R₃ and R_3′ may or may not be equivalent, can be treated with compounds of Formula 7.1, wherein R₁ and R₁₁ are as originally defined, a phosphine reagent, such as triphenylphosphine, and a diazine dicarboxylate electrophile, such as diisopropyl (E)-diazene-1,2-dicarboxylate (DIAD), in a polar aprotic solvent, such as THF, at a temperature of about 0° C. to 25° C. to afford compounds of Formula 7.2, wherein R₁, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in step a.

Compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared according to the methods outlined in Scheme 9, steps a-d. Compounds of Formula 9.1, wherein R₁, R₂, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, but not alkenyl, can be treated with an acid, such as a 4 N solution of HCl in dioxane, in a halogenated solvent such as CH₂Cl₂ to afford compounds of Formula 9.2, wherein R₁, R₂, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, but not alkenyl, as shown in step a. Compounds of Formula 9.3, wherein R₁, R₂, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared by treating compounds of Formula 9.1, wherein R₁, R₂, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, with an acid, such as 2,2,2-trifluoroacetic acid, in a halogenated solvent such as CH₂Cl₂, as shown in step c. Compounds of Formulas 9.2 and 9.3, wherein R₁, R₂, R₃, R_3′, R₄, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with compounds of Formula 9.4, wherein R₆ is as originally defined, in the presence of a base, such as diisopropylethylamine, and a peptide coupling reagent, such as benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) or O-(7-azabenzo-triazol-1-yl)-N,N,N′,N′tetramethyluronium hexafluorophosphate (HATU), in an halogenated solvent such as CH₂Cl₂, to afford compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆ and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in steps b and d.

Compounds of Formula 10.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, R₇, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared according to the method outlined in Scheme 10, steps a or b. Compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆ and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with an appropriate alkyl halide with or without a reagent such as sodium iodide (NaI) and an alkali carbonate base, such as sodium (Na₂CO₃) or potassium carbonate (K₂CO₃), in a solvent such as acetone, as shown in step a. Or, alternatively, by treatment with an acyl halide or anhydride in the presence of an amine base, such as pyridine, NEt₃, DMAP, or mixtures thereof, in an aprotic solvent, such as CH₂Cl₂, to afford compounds of Formula 10.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, R₇, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, as shown in step b.

Compounds of Formula 11.1 and 11.2, wherein R₁, R₂, R₃, R_3′, R₄, R₆, R₇, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared according to the method outlined in Scheme 11, steps a and b. Compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with a thionating reagent such as phosphorus pentasulfide, an additive, such as hexamethyldisiloxane, optionally in a polar aprotic solvent such as acetonitrile (CH₃CN), at a temperature of about 0° C. to 80° C. to afford compounds of Formula 11.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, and shown in step a. It will be understood by those skilled in the art that compounds such as Formula 11.1 may also be prepared using other thionating agents including, but not limited to: sulfur, sulfhydric acid, sodium sulfide, sodium hydrosulfide, boron trisulfide, bis(diethylaluminum)sulfide, ammonium sulfide, Lawesson's reagent, ammonium O,O′-diethyl dithiophosphate, rhodanine, or a polymer supported thionating reagent. Additives can include, but not limited to, aluminum oxide (Al₂O₃); inorganic bases, such as potassium carbonate and sodium bicarbonate; organic bases, such as triethylamine, diethylaniline, pyridine and morpholine. Optional solvents can include, but not limited to, aliphatic, alicyclic or aromatic hydrocarbons, such as hexane, cyclohexane or toluene; halogenated hydrocarbons, such as dichloromethane, 1,2-dichloroethane and chlorobenzene; ethers, such as diethyl ether, 1,4-dioxane, THF and 1,2-dimethoxyethane; and other polar aprotic solvents such as pyridine and hexamethylphosphoramide (HMPA). In step b, treatment of compounds of Formula 11.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, with an appropriate alkyl halide with or without a reagent such as sodium iodide (NaI) and an alkali carbonate base, such as sodium carbonate (Na₂CO₃) or potassium carbonate (K₂CO₃), in a solvent like acetone at a temperature of about 55° C., or by treatment with an acyl halide or anhydride in the presence of an amine base, such as pyridine, triethylamine (Et₃N), DMAP, or mixtures thereof, in an optional aprotic solvent such as DCM, at a temperature of about 23° C., can afford compounds of Formula 11.2 wherein R₁, R₂, R₃, R_3′, R₄, R₆, R₇, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent.

Compounds of Formula 12.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared according to the method outlined in Scheme 12, step a. Compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with a oxidizing reagent such as m-chloroperbenzoic acid (mCPBA) in a polar solvent such as dichloromethane (CH₂Cl₂), at a temperature of about 0° C. to 50° C., to give compounds of Formula 12.1, as shown in a. It will be understood by those skilled in the art that compounds of Formula 12.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, may also be prepared using other oxidizing agents, including, bit not limited to:

hydrogen peroxide, hydrogen peroxide-urea complex, magnesium monoperoxyphthalate hexahydrate (MMPP), peroxyacetic acid, oxone, sodium perchlorate or dimethyl dioxirane.

Compounds of Formula 13.1 wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be prepared according to the method outlined in Scheme 13, step a. Compounds of Formula 9.5, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, can be treated with a deactivated carbonyl reagent such as triphosgene, with a base, such as pyridine, in a polar solvent, such as dichloromethane (CH₂Cl₂), at a temperature of about 0° C. to 50° C. to afford compounds of Formula 13.1, wherein R₁, R₂, R₃, R_3′, R₄, R₆, and R₁₁, are as originally defined, and R₃ and R_3′ may or may not be equivalent, as depicted in a.

EXAMPLES

Example 1A: Preparation of (E)-1-methyl-4-(prop-1-en-1-yl)benzene

This compound was prepared by the method of Mayer, M.; Welther, A.; Jacobi von Wangelin, A. ChemCatChem. 2011, 3, 1567-1571.

Example 1B: Preparation of (E)-1-fluoro-4-(prop-1-en-1-yl)benzene

To a solution of 1-allyl-4-fluorobenzene (1.35 mL, 10 mmol) in toluene (20 mL) was added bis(dibenzylideneacetone)palladium (0.115 g, 0.200 mmol), tri-tert-butylphosphine (10% in hexane) (0.618 ml, 0.200 mmol) and isobutyryl chloride (0.021 ml, 0.200 mmol) in toluene (20.00 ml). The reaction was stirred at 80° C. overnight. The reaction mixture was purified by Isco chromatography (0 to 5% Et₂O in pet ether) to provide the desired product as solution in toluene (20 mL) (1.36 g, 95%). ¹H NMR (300 MHz, CDCl₃) δ 7.32-7.10 (m, 6H), 2.35 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −115.97.

Example 1C: Preparation of (E)-4-fluoro-2-methoxy-1-(prop-1-en-1-yl)benzene

Step 1: Preparation of (E,Z)-4-fluoro-2-methoxy-1-(prop-1-en-1-yl)benzene

To a mixture of magnesium (0.79 g, 32.5 mmol) and lithium chloride (1.52 g, 35.80 mmol) in THF (33 ml) at room temperature was added 1-bromo-4-fluoro-2-methoxybenzene (3.13 mL, 24.39 mmol) and the reaction was stirred at 70° C. for 1.5 hr. The reaction was then cooled to 0° C., and Fe(acac)₃ (0.574 g, 1.63 mmol) was added. After 1 minute, allyl chloride (1.33 mL, 16.26 mmol) was added and the reaction was stirred at 0° C. for 30 min. The mixture was warmed to room temperature over 1 hr and was heated at 70° C. overnight. The reaction was cooled and diluted with petroleum ether (100 mL). The reaction was then quenched by the addition of a saturated NH₄Cl solution (100 mL). The mixture was filtered through a Celite® pad and the layers were separated. The aqueous layer was extracted with petroleum ether (2×100 mL) and the combined organic phases were dried over Na₂SO₄ and carefully concentrated (25° C., 250 mbar). The residue was purified by Isco chromatography (100% pet ether as the eluent) to provide (E,Z)-4-fluoro-2-methoxy-1-(prop-1-en-1-yl)benzene (2.25 g, 83% yield) as a colorless oil. This mixture was approximately a 3:1 mixture of E and Z isomers with a trace of the allyl isomer present. This material was used directly in the next step. ¹H NMR (400 MHz, CDCl₃) δ 7.31 (dd, J=8.3, 6.8 Hz, 1H), 6.65-6.53 (m, 3H), 6.14 (dq, J=15.8, 6.6 Hz, 1H), 3.82 (s, 3H), 1.88 (dd, J=6.6, 1.7 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −113.30.

Step 2: Preparation of (E)-4-fluoro-2-methoxy-1-(prop-1-en-1-yl)benzene

To a solution of (E,Z)-4-fluoro-2-methoxy-1-(prop-1-en-1-yl)benzene (2.25 g, 13.54 mmol) in toluene (27 mL) was added bis(dibenzylideneacetone)palladium (0.156 g, 0.271 mmol), tri-tert-butylphosphine (10% in hexane) (0.84 mL, 0.271 mmol) and isobutyryl chloride (0.028 mL, 0.271 mmol). The reaction was stirred at 80° C. overnight. The reaction mixture was purified by Isco chromatography (100% petroleum ether) to provide the title compound as a 20:1 mixture of E vs Z isomers (2.25 g, 100%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (dd, J=8.3, 6.8 Hz, 1H), 6.65-6.53 (m, 3H), 6.14 (dq, J=15.8, 6.6 Hz, 1H), 3.82 (s, 3H), 1.88 (dd, J=6.6, 1.7 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −113.30.

Example 1D: Preparation of (E)-2,4-dimethyl-1-(prop-1-en-1-yl)benzene

Step 1: Preparation of 1-allyl-2,4-dimethylbenzene

To a solution of magnesium (1.17 g, 48.0 mmol) and lithium chloride (2.20 g, 60.0 mmol) in THF (40 ml) at room temperature was added 1-bromo-2,4-dimethylbenzene (5.4 mL, 40.0 mmol) and the reaction was heated gently to reflux with a heat gun. The reaction was cooled to room temperature over 1 hr. The reaction was then cooled to 0° C., and Fe(acac)₃ (0.71 g, 2.00 mmol) dissolved in 5 mL of THF was added. After 5 minutes, allyl chloride (4.23 mL, 52.0 mmol) was added and the reaction was stirred at 0° C. for 30 min. The mixture was warmed to room temperature over 1 hr and was heated at 70° C. overnight. The reaction was cooled to 0° C. and quenched by the addition of a saturated NaHCO₃ solution (50 mL). The mixture was extracted with hexane (3×40 mL), the combined organic phases were washed with brine (50 mL), dried over Na₂SO₄ and carefully concentrated (25° C., 250 mbar). The residue was purified by Isco chromatography (100% hexane as the eluent) to provide 1-allyl-2,4-dimethylbenzene (2.75 g, 15.04 mmol, 38% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.11-6.87 (m, 3H), 5.93 (ddt, J=16.6, 10.1, 6.4 Hz, 1H), 5.19-4.85 (m, 2H), 3.33 (dd, J=6.4, 1.5 Hz, 2H), 2.29 (s, 3H), 2.25 (s, 3H).

Step 2: Preparation of (E)-2,4-dimethyl-1-(prop-1-en-1-yl)benzene

To a 250 mL round bottom flask charged with 1-allyl-2,4-dimethylbenzene (2.75 g, 18.81 mmol) and tris(((Z)-4-oxopent-2-en-2-yl)oxy)iron (0.332 g, 0.940 mmol) in THF (38 mL) was added phenylmagnesium bromide (1.0 M in THF) (9.40 mL, 9.40 mmol) at room temperature. After stirring overnight, the reaction mixture was cooled to 0° C. and quenched by the addition of a saturated solution of NaHCO₃ (50 mL). The combined organic layers were extracted with hexane (3×40 mL), washed with brine (50 mL) and dried over Na₂SO₄. Upon concentration in vacuo, the crude residue was purified via automated silica gel chromatography (100% hexanes as the eluent) to afford (E)-2,4-dimethyl-1-(prop-1-en-1-yl)benzene (2.71 g, 16.68 mmol, 89% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, J=7.8 Hz, 1H), 7.05-6.86 (m, 2H), 6.56 (dd, J=15.6, 1.9 Hz, 1H), 6.06 (dq, J=15.6, 6.6 Hz, 1H), 2.30 (s, 3H), 2.29 (s, 3H), 1.89 (dd, J=6.6, 1.7 Hz, 3H).

Example 1E: Preparation of (E)-1-methyl-2-(prop-1-en-1-yl)benzene

This compound was prepared by the method of Franzen (Eur. J. Org. Chem. 2015, 1834). To a solution of 2-methylbenzaldehyde (48.4 mL, 416 mmol) dissolved in CH₂Cl₂ (300 mL) was added 2-methylbut-2-ene (8.82 mL, 83 mmol) and triphenylmethylium tetrafluoroborate (5.50 g, 16.65 mmol). The reaction was stirred at room temperature for 20 hr. The reaction was quenched by the addition of saturated NaHCO₃ and diluted with excess CH₂Cl₂. The organic layer was separated, dried over MgSO₄, filtered and concentrated at low temperature and mild pressure. The resulting residue was purified by flash chromatography (ISCO, 330 g SiO₂ column, 100% pet ether as the eluent) to give (E)-1-methyl-2-(prop-1-en-1-yl)benzene (10 g, 71.9 mmol, 86% yield) as a clear liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, J=7.0 Hz, 1H), 7.12 (qd, J=5.9, 2.1 Hz, 3H), 6.59 (dd, J=15.6, 1.9 Hz, 1H), 6.10 (dq, J=15.7, 6.6 Hz, 1H), 2.32 (s, 3H), 1.90 (dd, J=6.6, 1.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.08, 134.77, 130.11, 128.92, 126.93, 126.70, 125.99, 125.44. EIMS m/z 132.

Example 2A: 2A Denotes that this Epoxide is Commercially Available

Example 2B: Preparation of (2S,3S)-2-methyl-3-(p-tolyl)oxirane

To a 500 mL round-bottom flask containing 75 mL of a buffer solution containing 0.05 M Na₂B₄O₇-10H₂O in 4×10⁻⁴ M aqueous Na₂(EDTA), was added acetonitrile (117 ml), (E)-1-methyl-4-(prop-1-en-1-yl)benzene (1.24 g, 7.69 mmol), tetrabutylammonium hydrogen sulfate (0.104 g, 0.308 mmol), and (3aS,4′R,7aS)-2,2,2′,2′-tetramethyldihydrospiro[[1,3]dioxolo-[4,5-c]pyran-6,4′-[1,3]dioxolan]-7(7aH)-one (0.596 g, 2.307 mmol). The reaction mixture was cooled to 0° C. with an ice bath. A solution of oxone (6.53 g, 10.61 mmol) in aqueous Na₂(EDTA) (4×10⁻⁴ M, 50 mL) and a solution of potassium carbonate (6.17 g, 44.6 mmol) in water (50 mL) were added dropwise through two syringe pumps over a period of 1.5 h (under these conditions, the reaction pH is around 10.5; it is recommended that both oxone and K₂CO₃ be added uniformly over 1.5 h). At this point, the reaction was immediately quenched by the addition of 100 mL each of petroleum ether and water. The layers were separated and the aqueous layer was extracted with petroleum ether (3×150 mL). The combined organic layers were washed with brine (150 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography (0 to 10% acetone in hexanes as the eluent) to provide (2S,3S)-2-methyl-3-(p-tolyl)oxirane (1.09 g, 6.99 mmol, 91%) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.15 (s, 4H), 3.54 (d, J=2.1 Hz, 1H), 3.03 (qd, J=5.1, 2.1 Hz, 1H), 2.34 (s, 3H), 1.44 (d, J=5.1 Hz, 3H). EIMS m/z 148.

Example 3A: Preparation of (1S,2R)-1-cyclobutyl-1-(4-fluoro-2-methylphenyl)propan-2-ol

A suspension of magnesium (110 mg, 4.51 mmol) was prepared in THF (3 mL) and cooled to 0° C. After 5 min, bromocyclobutane (397 μL, 4.21 mmol) was added in one portion, and the resulting solution was vigorously stirred for 2 hr, slowly warming to room temperature. After 2 hr, the reaction was heated to 55° C. and stirred overnight. In a separate vial, a suspension of copper(I) iodide (401 mg, 2.106 mmol) in diethyl ether (7.5 mL) was cooled to −30° C. in a dry ice/acetonitrile bath. After −5 min, the grignard solution was added via syringe over 30 seconds, and the resulting solution was stirred at −30° C. for 30 min, yielding a turbid dark grey/brown mixture. After 30 min, the reaction was cooled to −78° C. in a dry ice/acetone bath, and (2R,3R)-2-(4-fluoro-2-methylphenyl)-3-methyloxirane (250 mg, 1.504 mmol) was added dropwise via syringe as a solution in diethyl ether (1.5 mL with 2×0.5 mL washes). The reaction was then stirred overnight, slowly warming to room temperature. TLC indicated consumption of starting material. The reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with diethyl ether (3×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to afford an oil. The oil was purified via silica gel Isco column chromatography (40 g silica gel column, 35 mL/min, 100% hexanes to 20% acetone:hexanes) to afford (1S,2R)-1-cyclobutyl-1-(4-fluoro-2-methylphenyl)propan-2-ol (133.4 mg, 0.600 mmol, 40% yield) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (dd, J=8.2, 6.1 Hz, 1H), 6.86 (t, J=8.5 Hz, 2H), 3.89 (p, J=6.4 Hz, 1H), 2.84 (dd, J=10.4, 6.0 Hz, 1H), 2.77-2.64 (m, 1H), 2.35 (s, 3H), 2.24-2.12 (m, 1H), 1.86-1.58 (m, 4H), 1.44-1.24 (m, 2H), 1.13 (d, J=6.3 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.58, −117.59. ₁₃C NMR (101 MHz, CDCl₃) δ 160.94 (d, J=244.2 Hz), 139.81 (d, J=7.3 Hz), 134.60 (d, J=3.3 Hz), 128.53 (d, J=8.0 Hz), 116.78 (d, J=20.7 Hz), 112.84 (d, J=20.6 Hz), 70.25, 53.68, 38.03, 29.54, 27.08, 21.55, 20.55 (d, J=1.7 Hz), 18.16. IR (thin film) 3413, 2967, 1495, 1252, 1021, 955, 860 cm⁻¹.

Example 3B: Preparation of (2R,3S)-4-ethyl-3-(4-fluoro-2-methylphenyl)hexan-2-ol

A suspension of copper(I) iodide (401 mg, 2.106 mmol) in anhydrous diethyl ether (7.5 mL) was cooled to −30° C. in a dry ice/acetonitrile bath. After −5 min, pentan-3-ylmagnesium bromide (2M in Et₂O) (2106 μL, 4.21 mmol) was added via syringe over 30 seconds, and the resulting solution was stirred at −30° C. for 30 min, yielding a turbid dark grey/brown mixture. After 30 min, the reaction was cooled to −78° C. in a dry ice/acetone bath, and (2R,3R)-2-(4-fluoro-2-methylphenyl)-3-methyloxirane (250 mg, 1.504 mmol) was added dropwise via syringe as a solution in diethyl ether (1.5 mL with 2×0.5 mL washes). The reaction was then stirred overnight, slowly warming to room temperature. TLC indicated consumption of starting material. The reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with diethyl ether (3×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to afford an oil. The oil was purified via silica gel Isco column chromatography (40 g silica gel column, 35 mL/min, 100% hexanes to 20% acetone:hexanes) to afford (2R,3S)-4-ethyl-3-(4-fluoro-2-methylphenyl)hexan-2-ol (116.7 mg, 0.490 mmol, 32.5% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, J=9.6, 6.1 Hz, 1H), 6.92-6.81 (m, 2H), 4.27 (dq, J=8.8, 4.7 Hz, 1H), 2.74 (dd, J=10.2, 3.6 Hz, 1H), 2.28 (s, 3H), 1.87 (qt, J=8.2, 3.6 Hz, 1H), 1.64 (dtd, J=14.9, 7.3, 4.4 Hz, 1H), 1.53 (tt, J=14.0, 6.7 Hz, 1H), 1.30-1.09 (m, 2H), 1.08-0.98 (m, 1H), 0.96 (d, J=6.4 Hz, 3H), 0.92 (t, J=7.5 Hz, 3H), 0.71 (t, J=7.4 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) d −118.01. ¹³C NMR (101 MHz, CDCl₃) δ 160.91 (d, J=243.7 Hz), 139.73 (d, J=7.1 Hz), 135.03 (d, J=3.3 Hz), 129.46 (d, J=7.9 Hz), 116.60 (d, J=20.5 Hz), 112.57 (d, J=20.4 Hz), 67.19, 47.45, 41.41, 22.08, 21.91, 21.53, 20.67 (d, J=1.6 Hz), 10.82, 9.78. IR (thin film) 3430, 2962, 1496, 1455, 1380, 1256, 956, 860, 801 cm⁻¹.

Example 4A: Preparation of (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpent-4-en-2-ol

A suspension of copper(I) iodide (0.160 g, 0.842 mmol) in anhydrous diethyl ether (4.0 mL) was cooled to −20° C. After ˜5 min, prop-1-en-2-ylmagnesium bromide (1M in 2-Me-THF) (1.685 mL, 1.685 mmol) was added via syringe over 30 seconds, and the resulting solution was stirred at −20° C. for 30 min. After 30 min, the reaction was cooled to −78° C. and (2R,3R)-2-(4-fluoro-2-methylphenyl)-3-methyloxirane (0.100 g, 0.602 mmol) was added dropwise via syringe as a solution in diethyl ether (1.0 mL with 2×0.5 mL washes). The reaction was then stirred overnight, slowly warming to room temperature. TLC indicated consumption of starting material. The reaction was quenched with sat. aq. NH₄Cl (20 mL) and extracted with diethyl ether (3×20 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to afford an oil. The oil was purified via silica gel Isco column chromatography (40 g silica gel column, 35 mL/min, 100% hexanes to 20% acetone:hexanes) to afford (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpent-4-en-2-ol (120.2 mg, 0.577 mmol, 96% yield) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.30 (m, 1H), 6.93-6.86 (m, 2H), 4.89 (s, 2H), 4.32 (dq, J=8.8, 6.1 Hz, 1H), 3.42 (d, J=8.7 Hz, 1H), 2.34 (s, 3H), 1.59 (s, 3H), 1.52 (s, 1H), 1.30 (d, J=6.1 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −116.95. ¹³C NMR (101 MHz, CDCl₃) δ 161.27 (d, J=244.8 Hz), 144.85, 140.40 (d, J=7.5 Hz), 133.79 (d, J=3.2 Hz), 128.19 (d, J=8.2 Hz), 117.47 (d, J=20.6 Hz), 113.12, 112.76 (d, J=20.8 Hz), 68.13, 56.04, 21.28, 21.22, 20.03 (d, J=1.5 Hz). IR (thin film) 3373, 2970, 1495, 1240, 958, 861 cm⁻¹.

Example 4B: Preparation of (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol

To a 20 mL vial containing (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpent-4-en-2-ol (120.2 mg, 0.577 mmol) and palladium on carbon (5%) (184 mg, 0.087 mmol) was added ethyl acetate (2886 μL). The black reaction mixture was flushed with H₂ gas via balloon. The resulting reaction was stirred at room temperature for 2 h, at which point TLC/UPLC indicated consumption of starting material. The reaction was filtered through a plug of celute, eluting with ethyl acetate (2×10 mL). The resulting solution was concentrated to afford an oil that was loaded directly onto a 25 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (40 column, 40 mL/min, 100% hexanes to 30% ethyl acetate:hexanes) to afford (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol (44.9 mg, 0.214 mmol, 37.0% yield) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.32 (dd, J=9.5, 6.1 Hz, 1H), 6.93-6.84 (m, 2H), 4.28 (qd, J=6.3, 4.4 Hz, 1H), 2.50 (dd, J=9.2, 4.4 Hz, 1H), 2.28 (s, 3H), 2.15 (dp, J=9.1, 6.6 Hz, 1H), 1.42-1.13 (m, 1H), 1.06 (d, J=6.6 Hz, 3H), 1.01 (d, J=6.3 Hz, 3H), 0.70 (d, J=6.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.93 (d, J=243.8 Hz), 139.78 (d, J=7.2 Hz), 134.96 (d, J=3.3 Hz), 129.17 (d, J=8.0 Hz), 116.64 (d, J=20.4 Hz), 112.57 (d, J=20.4 Hz), 67.70, 52.62, 30.26, 21.76, 21.32, 20.77. ¹⁹F NMR (376 MHz, CDCl₃) δ −117.97.

Example 4C: Preparation of (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol

To a 250 mL round bottom flask containing (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpent-4-en-2-ol (1.16 g, 5.57 mmol) and Wilkinson's catalyst (1.288 g, 1.392 mmol) was added THF (55.7 ml). The reddish-brown reaction mixture was flushed with H₂ gas via balloon. The resulting reaction was stirred at room temperature overnight. The reaction was concentrated to a dark orange-brown oil, and the resulting oil was loaded directly onto a 25 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (120 column, 85 mL/min, 100% hexanes to 30% ethyl acetate:hexanes) to afford (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol (880 mg, 4.18 mmol, 75% yield) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.32 (dd, J=9.5, 6.0 Hz, 1H), 6.92-6.84 (m, 2H), 4.28 (qd, J=6.3, 4.4 Hz, 1H), 2.50 (dd, J=9.2, 4.4 Hz, 1H), 2.28 (s, 3H), 2.15 (ddd, J=13.2, 6.8, 2.3 Hz, 1H), 1.31-1.17 (m, 1H), 1.06 (d, J=6.6 Hz, 3H), 1.01 (d, J=6.3 Hz, 3H), 0.70 (d, J=6.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.92 (d, J=243.8 Hz), 139.78 (d, J=7.2 Hz), 134.95 (d, J=3.2 Hz), 129.16 (d, J=7.8 Hz), 116.64 (d, J=20.4 Hz), 112.57 (d, J=20.3 Hz), 67.70, 52.62, 30.26, 21.76, 21.31, 20.76. ¹⁹F NMR (376 MHz, CDCl₃) δ −117.97.

Example 5: Preparation of (3S)-4-ethyl-3-phenylhexan-2-ol

Step 1: Preparation of (2R,3S)-4-ethyl-3-phenylhexan-2-ol

To a suspension of copper (I) iodide (667 mg, 3.50 mmol) in Et₂O (12.5 mL) cooled to −78° C. was added pentan-3-ylmagnesium bromide (2M in THF) (3.5 mL, 7.00 mmol). The reaction was warmed to −20° C. and stirred at that temperature for 30 min. The reaction was then cooled to −78° C. followed by the addition of (2R,3R)-2-methyl-3-phenyloxirane (335 mg, 2.5 mmol). The reaction was slowly warmed to room temperature and stirred overnight. The reaction was quenched by the addition of aqueous saturated NH₄Cl. The mixture was filtered through a pad of Celite, and the solution was extracted with Et₂O. The combined organic phases were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a 0-10% acetone/hexane mixture as the eluent to provide the title compound as colorless oil (200 mg, 27%). ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.18 (m, 5H), 4.38-4.19 (m, 1H), 2.47 (dd, J=8.5, 5.1 Hz, 1H), 1.81 (ttd, J=8.8, 5.9, 3.2 Hz, 1H), 1.55-1.25 (m, 3H), 1.20 (d, J=5.6 Hz, 1H), 1.05 (d, J=6.3 Hz, 3H), 1.03-0.94 (m, 1H), 0.93 (t, J=7.4 Hz, 3H), 0.76 (t, J=7.4 Hz, 3H). ESIMS (m/z) 413 [2M+H]⁺.

Step 2: Preparation of (S)-4-ethyl-3-phenylhexan-2-one

To a solution containing (2R,3S)-4-ethyl-3-phenylhexan-2-ol (190 mg, 0.921 mmol) dissolved in CH₂Cl₂ (4.6 mL) at 0° C. was added sodium bicarbonate (774 mg, 9.21 mmol) followed by Dess-Martin periodinane (781 mg, 1.842 mmol). The reaction was slowly warmed to room temperature over 3 hr. The reaction was quenched by the addition of aqueous saturated NaHCO₃ solution followed by extraction with CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a 0-5% acetone/hexane mixture as the eluent to provide the title compound as colorless oil (124 mg, 63%). ¹H NMR (400 MHz, CDCl₃) δ 7.54-7.10 (m, 5H), 3.61 (d, J=10.8 Hz, 1H), 2.21 (dtt, J=11.1, 7.5, 3.9 Hz, 1H), 2.09 (s, 3H), 1.49-1.32 (m, 2H), 1.31-1.15 (m, 1H), 1.05-0.94 (m, 1H), 0.89 (t, J=7.4 Hz, 3H), 0.69 (t, J=7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 208.87, 137.71, 128.98, 128.66, 127.12, 63.12, 41.13, 30.15, 22.76, 21.03, 10.46, 9.47.

Step 3: Preparation of (3S)-4-ethyl-3-phenylhexan-2-ol

To a stirred solution containing (S)-4-ethyl-3-phenylhexan-2-one (120 mg, 0.587 mmol) and (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole (1 M in toluene) (58.7 μL, 0.059 mmol) dissolved in toluene (5.9 mL) at −78° C. was added BH₃—SMe₂ complex (61.3 μL, 0.646 mmol) dropwise. The reaction was slowly warmed to room temperature and stirred overnight. The reaction was then quenched carefully with methanol (475 μL, 11.75 mmol). The mixture was diluted with H₂O and extracted with Et₂O. The combined organic phases were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a 0-10% acetone/hexane mixture as the eluent to provide the title compound as colorless oil (110 mg, 86%). ¹H NMR shows a 3.3:1 mixture of diastereomers with the desired product being the major diastereomer. ¹H NMR (major diastereomer) (300 MHz, CDCl₃) δ 7.37-7.04 (m, 5H), 4.22 (dt, J=13.8, 6.3 Hz, 1H), 2.75 (t, J=7.5 Hz, 1H), 1.85-1.73 (m, 1H), 1.55-1.21 (m, 3H), 1.18 (d, J=7.8 Hz, 1H), 1.05 (d, J=6.3 Hz, 3H), 1.03-0.97 (m, 1H), 0.94 (t, J=7.4 Hz, 3H), 0.81 (t, J=7.4 Hz, 3H). ESIMS (m/z) 413 [2M+H]+.

Example 6: Preparation of (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-ol

Step 1: Preparation of (2S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-ol

A round bottom flask was charged with (S)-2-(benzyloxy)propanal (1.0 g, 6.09 mmol) dissolved in anhydrous THF (6.77 mL). This solution was cooled in an ice bath under an atmosphere of N₂ and was treated dropwise with (4-fluorophenyl)magnesium bromide (6.70 mL, 6.70 mmol). The reaction was monitored by TLC (20% EtOAc in hexanes) until the reaction was complete. The reaction mixture was poured into saturated NH₄Cl and the phases separated. The aqueous phase was extracted with EtOAc. The organic fractions were dried with magnesium sulfate and concentrated under reduced pressure. The crude residue was purified by automated silica gel chromatography (0-25% EtOAc in hexanes) to provide (2S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-ol (1.404 g, 5.34 mmol, 88% yield) as a colorless oil. ¹H NMR analysis showed the mixture to be a 2:1 mixture of diastereomers. HRMS-ESI (m/z) [M+Na]+ calcd for C₁₆H₁₇FO₂Na, 283.1105; found, 283.1105.

Step 2: Preparation of (S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-one

A 100 mL round bottom flask was charged with CH₂Cl₂ (12.26 mL), and oxalyl chloride (0.519 mL, 5.93 mmol). This solution was cooled in a dry ice/acetone bath under an atmosphere of N₂ and treated dropwise with DMSO (0.842 mL, 11.87 mmol). The resultant mixture was stirred for ˜2 minutes and then treated dropwise with a solution of (2S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-ol (1.404 g, 5.39 mmol) in 3 mL of CH₂Cl₂ (extra rinse with 1 mL). After stirring for ˜15 minutes, the reaction mixture was treated dropwise with triethylamine (3.76 mL, 27.0 mmol). The reaction mixture was stirred for 5 minutes and then allowed to warm to room temperature. The reaction was monitored by TLC (20% EtOAc in hexanes). The reaction mixture was poured into H₂O and the phases were separated. The aqueous phase was extracted with CH₂Cl₂. The combined organics were dried with sodium sulfate and concentrated. The crude residue was purified by silica gel chromatography (0-15% EtOAc in hexanes) to provide (S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-one (1.1475 g, 4.44 mmol, 82% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.20-8.04 (m, 2H), 7.40-7.24 (m, 5H), 7.19-7.02 (m, 2H), 4.70 (q, J=6.9 Hz, 1H), 4.61 (d, J=11.6 Hz, 1H), 4.45 (d, J=11.6 Hz, 1H), 1.54 (d, J=6.9 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −104.39. ¹³C NMR (126 MHz, CDCl₃) δ 199.27, 165.83 (d, J=255.3 Hz), 137.41, 131.69 (d, J=9.2 Hz), 131.08 (d, J=2.9 Hz), 128.46, 127.98, 127.93, 115.71 (d, J=21.8 Hz), 78.72, 71.65, 18.81. HRMS-ESI (m/z) [M+Na]+ calcd for C₁₆H₁₅FO₂Na, 281.0948; found, 281.0950.

Step 2A: Preparation of (S)-1-(benzo[d][1,3]dioxol-5-yl)-2-(benzyloxy)propan-1-one.

To a vial charged with (S)-2-(benzyloxy)-1-(pyrrolidin-1-yl)propan-1-one (1 g, 4.29 mmol) dissolved in anhydrous THF (12 mL) was added dropwise benzo[d][1,3]dioxol-5-ylmagnesium bromide (1M in 1:1 toluene/THF, 4.29 mL, 4.29 mmol) at −5° C. The mixture was allowed to warm to ambient temperature and stirred overnight. The mixture was quenched by the addition of 1 N HCl. The layers were separated, followed by extraction with ethyl ether (3×10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified via automated silica gel chromatography (Isco, 0-25% EtOAc/hexanes as the eluent) to afford (S)-1-(benzo[d][1,3]dioxol-5-yl)-2-(benzyloxy)propan-1-one (0.39 g, 30%) as yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.73 (dd, J=8.2, 1.7 Hz, 1H), 7.55 (d, J=1.6 Hz, 1H), 7.39-7.27 (m, 5H), 6.84 (d, J=8.2 Hz, 1H), 6.04 (s, 2H), 4.70 (q, J=6.9 Hz, 1H), 4.53 (dd, J=103.5, 11.6 Hz, 2H), 1.52 (d, J=6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 198.8, 152.0, 148.1, 137.6, 129.4, 128.4, 127.9, 127.8, 125.2, 108.6, 107.9, 101.8, 78.4, 71.5, 19.1. HRMS-ESI (m/z) [M+H]+ calcd for C₁₇H₁₇O₄, 285.1121; found, 285.1121.

Step 3: Preparation of (2S)-2-(benzyloxy)-3-(4-fluorophenyl)-4-methylpentan-3-ol

A solution of isopropylmagnesium bromide (1.936 mL, 3.87 mmol) was added to anhydrous THF (6.45 ml) cooled to 0° C. in an ice bath. A solution of (S)-2-(benzyloxy)-1-(4-fluorophenyl)propan-1-one (0.5 g, 1.936 mmol) in THF (2 mL+1 mL to rinse the syringe) was added dropwise. The reaction was stirred until complete by consumption of starting material by TLC (20% EtOAc in hexanes). The reaction was quenched by the addition of saturated ammonium chloride and the mixture was extracted with EtOAc. The combined organic fractions were dried over MgSO₄, filtered and concentrated. The crude residue was purified by automated silica gel chromatography (0-10% EtOAc in hexanes) to provide (2S)-2-(benzyloxy)-3-(4-fluorophenyl)-4-methylpentan-3-ol (201.9 mg, 0.634 mmol, 33% yield) as a white foam. ¹H NMR data showed a 9.2:1 ratio of diastereomers. ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.20 (m, 7H), 7.00 (t, J=8.8 Hz, 2H), 4.72 (d, J=11.4 Hz, 1H), 4.49 (d, J=11.5 Hz, 1H), 4.09 (q, J=6.2 Hz, 1H), 2.46 (s, 1H), 2.35 (p, J=6.8 Hz, 1H), 1.00 (d, J=6.2 Hz, 3H), 0.77 (dd, J=8.8, 6.8 Hz, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.13. ¹³C NMR (126 MHz, CDCl₃) δ 161.55 (d, J=244.4 Hz), 138.28, 136.60 (d, J=3.2 Hz), 128.45, 128.14 (d, J=7.7 Hz), 127.80, 114.09 (d, J=20.9 Hz), 80.56, 70.91, 34.79, 17.93, 16.87, 13.63. HRMS-ESI (m/z) [M+Na]+ calcd for C₁₉H₂₃FO₂Na, 325.1574; found, 325.1574.

Step 4: Preparation of 1-((2S,3S)-2-(benzyloxy)-4-methylpentan-3-yl)-4-fluorobenzene

To a solution of (2S)-2-(benzyloxy)-3-(4-fluorophenyl)-4-methylpentan-3-ol (0.2 g, 0.661 mmol) dissolved in CH₂Cl₂ (2.205 ml) at 0° C. was added triethylsilane (1.056 mL, 6.61 mmol) followed by trifluoroacetic acid (0.510 mL, 6.61 mmol). The mixture was stirred at 0° C. for 1 hr. The mixture was then allowed to slowly warm to room temperature and stirred overnight. The reaction was carefully quenched by the addition of a saturated sodium bicarbonate solution and extracted with CH₂Cl₂. The combined organic layers were then dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by automated silica gel chromatography (0-5% EtOAc in hexanes) to provide 1-((2S,3S)-2-(benzyloxy)-4-methylpentan-3-yl)-4-fluorobenzene (152.2 mg, 0.505 mmol, 76% yield) as a colorless oil. ¹H NMR data revealed a 7.2:1 ratio of diastereomers. ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.26 (m, 5H), 7.07-6.91 (m, 4H), 4.66 (d, J=11.6 Hz, 1H), 4.50 (d, J=11.6 Hz, 1H), 3.88 (dq, J=8.5, 6.1 Hz, 1H), 2.61 (d, J=14.4 Hz, 1H), 2.37 (dq, J=13.4, 6.7 Hz, 1H), 1.01 (d, J=6.1 Hz, 3H), 0.80 (d, J=6.8 Hz, 3H), 0.74 (d, J=6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 161.48 (d, J=243.8 Hz), 138.84, 135.66 (d, J=3.3 Hz), 131.08 (d, J=7.6 Hz), 128.35, 127.71, 127.49, 114.48 (d, J=20.8 Hz), 75.31, 70.71, 57.21, 27.57, 21.59, 18.36, 17.35. HRMS-ESI (m/z) [M+Na]+ calcd for C₁₉H₂₃FONa, 309.1625; found, 309.1629.

Step 5: Preparation of (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-ol

A flask containing 1-((2S)-2-(benzyloxy)-4-methylpentan-3-yl)-4-fluorobenzene (0.15 g, 0.524 mmol) was charged with 5% palladium on carbon (0.056 g, 0.026 mmol) and then suspended in ethanol (2.62 mL). The reaction atmosphere was replaced with hydrogen gas via a balloon (1 atm) and monitored until complete by TLC (25% EtOAc in hexanes). The reaction was filtered through a pad of Celite© and the pad was washed with ethyl acetate. The filtrate was concentrated under reduced pressure. The crude residue was purified by automated column chromatography (0-20% EtOAc in hexanes as the eluent) to provide (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-ol (76.9 mg, 0.388 mmol, 74.1% yield) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.11-7.05 (m, 2H), 7.03-6.97 (m, 2H), 4.17 (dq, J=7.5, 6.2 Hz, 1H), 2.47 (t, J=7.5 Hz, 1H), 2.18 (dp, J=13.6, 6.8 Hz, 1H), 1.19 (d, J=7.2 Hz, 1H), 1.03 (d, J=6.3 Hz, 3H), 0.90 (d, J=6.7 Hz, 3H), 0.79 (d, J=6.7 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 161.65 (d, J=244.4 Hz), 135.15 (d, J=3.4 Hz), 131.11 (d, J=7.6 Hz), 114.76 (d, J=20.9 Hz), 68.13, 59.08, 28.28, 21.34, 20.53, 19.47. IR (thin film) 3348, 2960, 2929, 2872, 1604, 1508, 1465, 1368, 1223, 1160, 833 cm⁻¹.

Step 6: Preparation of (4S)-4-(benzyloxy)-3-(4-fluorophenyl)-2-methylpent-1-en-3-ol

To a solution containing prop-1-en-2-ylmagnesium bromide (1 M in 2-Me-THF) (4.29 mL, 4.29 mmol) dissolved in THF (21.44 mL) and cooled to 0° C. in an ice/water bath was added (S)-2-(benzyloxy)-1-(4-fluoro-3-methylphenyl)propan-1-one (0.584 g, 2.144 mmol) dropwise over 5 minutes as a solution in THF (3 mL). The resulting solution was stirred for 1 hr, at which point an additional 2.1 mL (1 equivalent) of the Grignard reagent was added, and the reaction was stirred for an additional hour. The reaction was quenched with saturated aqueous NH₄Cl (50 mL) solution and extracted with EtOAc (3×50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to an oil. The oil was loaded onto a prepacked 25 g silica gel column and purified using Isco silica gel column chromatography (40 column, 35 mL/min, 100% hexanes to 20% ethyl acetate:hexanes) to afford the title compound (671 mg, 100%) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.23 (m, 6H), 7.16 (ddd, J=7.9, 4.9, 2.4 Hz, 1H), 6.92 (t, J=9.0 Hz, 1H), 5.17 (t, J=1.0 Hz, 1H), 4.98 (p, J=1.4 Hz, 1H), 4.69 (d, J=11.4 Hz, 1H), 4.51 (d, J=11.4 Hz, 1H), 4.21 (q, J=6.1 Hz, 1H), 2.81 (s, 1H), 2.26 (d, J=1.9 Hz, 3H), 1.63 (t, J=1.0 Hz, 3H), 0.99 (d, J=6.1 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) d −120.68. IR (thin film) 3500, 2977, 2923, 1499, 1242, 1114, 1097, 894, 818, 733, 697 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₀H₂₃FNaO₂, 337.1574; found, 337.1584.

Step 7: Preparation of (2S)-2-(benzyloxy)-3-(4-fluorophenyl)-4-methylpentan-3-ol

A solution containing (3S,4S)-4-(benzyloxy)-3-(4-fluoro-3-methylphenyl)-2-methylpent-1-en-3-ol (0.6713 g, 2.135 mmol) and Wilkinson's catalyst (0.593 g, 0.641 mmol) dissolved in THF (14.23 mL) was flushed with hydrogen gas via balloon. The resulting reaction was stirred at room temperature overnight. The reaction mixture was concentrated to a dark orange-brown oil under reduced pressure. The resulting oil was loaded directly onto a 25 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (40 column, 35 mL/min, 100% hexanes to 20% ethyl acetate:hexanes) to afford the title compound (659 mg, 98%) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.28 (m, 5H), 7.16 (dd, J=7.6, 2.3 Hz, 1H), 7.05 (ddd, J=7.8, 5.0, 2.4 Hz, 1H), 6.92 (t, J=9.0 Hz, 1H), 4.72 (d, J=11.4 Hz, 1H), 4.49 (d, J=11.4 Hz, 1H), 4.08 (q, J=6.2 Hz, 1H), 2.44 (s, 1H), 2.34 (p, J=6.8 Hz, 1H), 2.27 (d, J=1.9 Hz, 3H), 1.01 (d, J=6.1 Hz, 3H), 0.77 (dd, J=10.6, 6.8 Hz, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ −121.44. ¹³C NMR (101 MHz, CDCl₃) δ 160.12 (d, J=243.5 Hz), 138.39, 136.31 (d, J=3.5 Hz), 129.74 (d, J=4.9 Hz), 128.45, 127.79, 127.75, 125.35 (d, J=7.8 Hz), 123.40 (d, J=17.0 Hz), 113.69 (d, J=22.1 Hz), 80.55, 77.07, 70.95, 34.84, 18.01, 16.94, 14.80 (d, J=3.5 Hz), 13.71. IR (thin film) 3564, 2962, 2935, 1501, 1374, 1243, 1105, 1089, 817, 757, 697 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₀H₂₅FNaO₂, 339.1731; found, 339.1728.

Example 6A: Preparation of (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol

Step 1: Preparation of 2-(2,5-dimethylphenyl)-3-methylbutanoic acid

A solution of isopropylmagnesium chloride (2 M in THF, 5.79 mL, 11.57 mmol) was added slowly to a solution of 2-(2,5-dimethylphenyl)acetic acid (0.95 g, 5.79 mmol) in THF (11.57 mL) at room temperature. The resulting thick suspension was stirred for 1 hr and treated with 2-iodopropane (1.736 mL, 17.36 mmol). The reaction was heated to 70° C. and stirred overnight. The reaction was quenched by the addition of 1N HCl and extracted with EtOAc. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by automated column chromatography (Isco, 0-30% EtOAc in hexanes as the eluent) to provide 2-(2,5-dimethylphenyl)-3-methylbutanoic acid (670 mg, 53.3%) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 11.32 (bs, 1H), 7.21 (s, 1H), 7.04 (d, J=7.7 Hz, 1H), 6.95 (d, J=8.5 Hz, 1H), 3.46 (d, J=10.9 Hz, 1H), 2.40-2.34 (m, 1H), 2.33 (s, 3H), 2.29 (s, 3H), 1.11 (d, J=6.4 Hz, 3H), 0.69 (d, J=6.7 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 179.72, 136.08, 135.79, 133.69, 130.22, 127.82, 127.67, 54.23, 31.46, 21.62, 21.12, 19.75, 19.69. HRMS-ESI (m/z) [2M+H]+ calcd for C₁₃H₁₈O₂, 413.2686; found, 413.2674.

Step 2: Preparation of 2-(2,5-dimethylphenyl)-N-methoxy-N,3-dimethylbutanamide

To a solution containing 2-(2,5-dimethylphenyl)-3-methylbutanoic acid (0.66 g, 3.20 mmol) dissolved in 32 mL of CH₂Cl₂ at 0° C. was added 4-methylmorpholine (0.70 mL, 6.40 mmol) and N,O-dimethylhydroxylamine hydrochloride (0.624 g, 5.71 mmol). 3-(((Ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (EDC, 1.23 g, 6.40 mmol) was added and the reaction was warmed to room temperature and stirred overnight. The reaction was concentrated under reduced pressure and the residue was purified by automated silica gel chromatography (Isco, 0-25% EtOAc in hexanes as the eluent) to provide 2-(2,5-dimethylphenyl)-N-methoxy-N,3-dimethylbutanamide (694 mg, 83%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 7.27 (s, 1H), 7.01 (d, J=7.7 Hz, 1H), 6.93-6.89 (m, 1H), 3.84 (d, J=10.3 Hz, 1H), 3.48 (s, 3H), 3.14 (s, 3H), 2.41-2.35 (m, 1H), 2.34 (s, 3H), 2.27 (s, 3H), 1.05 (d, J=6.4 Hz, 3H), 0.68 (d, J=6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 137.49, 135.69, 133.14, 129.89, 127.88, 127.23, 60.95, 49.90, 32.65, 32.21, 22.25, 21.11, 19.51. HRMS-ESI (m/z) [M+H]+ calcd for C₁₅H₂₃NO₂, 250.1802; found, 250.1799.

Step 3: Preparation of 3-(2,5-dimethylphenyl)-4-methylpentan-2-one

A solution containing 2-(2,5-dimethylphenyl)-N-methoxy-N,3-dimethylbutanamide (0.685 g, 2.75 mmol) dissolved in THF (18.31 mL) was cooled to 0° C. Methylmagnesium bromide (3.0 M in diethyl ether, 2.75 ml, 8.24 mmol) was added dropwise and the reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of saturated ammonium chloride solution and was extracted with EtOAc. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to provide 3-(2,5-dimethylphenyl)-4-methylpentan-2-one (573.3 mg, 97%) as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.27 (s, 1H), 7.06 (d, J=7.6 Hz, 1H), 6.94 (d, J=7.7 Hz, 1H), 3.58 (d, J=10.5 Hz, 1H), 2.44-2.38 (m, 1H), 2.37 (s, 3H), 2.27 (s, 3H), 2.02 (s, 3H), 1.01 (d, J=6.4 Hz, 3H), 0.65 (d, J=6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 208.55, 136.24, 135.95, 133.52, 130.48, 127.83, 127.61, 62.29, 30.53, 30.09, 21.86, 21.04, 19.91, 19.51. HRMS-ESI (m/z) [M+H]+ calcd for C₁₄H₂₀O, 205.1587; found, 205.1578.

Step 4: Preparation of (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol and (2S,3R)-3-(2,5-dimethylphenyl)-4-methylpentan-7-ol

Lithium aluminum hydride (2.80 mL, 2.80 mmol) as a solution (1.0 M in THF) was added to a flask containing THF (28.0 mL) cooled to −78° C. A solution of 3-(2,5-dimethylphenyl)-4-methylpentan-2-one (0.573 g, 2.80 mmol) in THF (3 mL) was added dropwise. The reaction was warmed to room temperature and stirred overnight. The reaction was cooled to 0° C. and quenched by the addition of 0.1 mL H₂O, 0.1 mL 1N NaOH, followed by an additional 0.3 mL of H₂O. The mixture was stirred vigorously for 15 min. The reaction was filtered and the solids were washed with EtOAc. The filtrate was concentrated under reduced pressure to provide a racemic mixture of (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol and (2S,3R)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol (491 mg, 72%) as a colorless oil. The syn product is the exclusive product as predicted by Cram's rule. ¹H NMR (500 MHz, CDCl₃) δ 7.12 (s, 1H), 7.05 (d, J=7.7 Hz, 1H), 6.94-6.91 (m, 1H), 4.32-4.20 (m, 1H), 2.55 (dd, J=8.9, 4.7 Hz, 1H), 2.31 (s, 3H), 2.25 (s, 3H), 2.17 (ddt, J=13.3, 8.8, 6.7 Hz, 1H), 1.26 (d, J=6.1 Hz, 1H), 1.05 (d, J=2.3 Hz, 3H), 1.04 (d, J=2.0 Hz, 3H), 0.72 (d, J=6.7 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 138.84, 135.13, 134.66, 130.18, 128.14, 126.71, 67.91, 62.20, 53.16, 30.01, 21.76, 21.36, 20.75, 20.29. ESIMS (m/z) 207 [M+H]+.

Step 5: Preparation of (2R,3S) and (2S,3R)-3-(2,5-dimethylphenyl)-4-methylpentan-2-yl (S)-2-methoxy-2-phenylacetate

To a racemic mixture containing (2R,3S) and (2S,3R)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol (0.491 g, 2.380 mmol) dissolved in 16 mL of CH₂Cl₂ was added N,N-dimethylpyridin-4-amine (0.029 g, 0.238 mmol) and (S)-2-methoxy-2-phenylacetic acid (0.514 g, 3.09 mmol). The reaction was cooled to 0° C. followed by addition of 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (0.912 g, 4.76 mmol) was added and the reaction was warmed to room temperature and stirred overnight. The mixture was concentrated under reduced pressure. The residue was purified by automated silica gel chromatography (Isco, 80 g SiO₂ column, 0-10% MTBE in hexanes as the eluent) to provide (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-yl (S)-2-methoxy-2-phenylacetate (284.7 mg 32%) and (2S,3R)-3-(2,5-dimethylphenyl)-4-methylpentan-2-yl (S)-2-methoxy-2-phenylacetate as colorless oils. Only the desired (2R,3S) diastereomer was characterized. ¹H NMR (500 MHz, CDCl₃) δ 7.44-7.37 (m, 2H), 7.36-7.27 (m, 3H), 7.18 (s, 1H), 7.00 (d, J=7.7 Hz, 1H), 6.93-6.80 (m, 1H), 5.42-5.34 (m, 1H), 4.74 (s, 1H), 3.40 (s, 3H), 2.62 (dd, J=9.7, 4.3 Hz, 1H), 2.30 (s, 3H), 2.21 (s, 3H), 2.05-1.92 (m, 1H), 0.93 (d, J=6.5 Hz, 3H), 0.87 (d, J=6.3 Hz, 3H), 0.68 (d, J=6.7 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 170.32, 139.03, 136.46, 134.96, 133.92, 129.67, 128.80, 128.51, 126.90, 126.67, 82.86, 72.23, 57.31, 51.06, 30.54, 21.31, 21.00, 20.93, 20.23, 17.82. HRMS-ESI (m/z) [M+Na]+ calcd for C₂₃H₃₀O₃, 377.2087; found, 377.2089.

Step 6: Preparation of (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol

To a solution containing (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-yl(S)-2-methoxy-2-phenylacetate (0.28 g, 0.790 mmol) dissolved in MeOH (7.90 mL) was added potassium carbonate (0.327 g, 2.370 mmol). The reaction was heated to 55° C. and stirred overnight. The reaction was cooled to room temperature, diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by automated silica gel chromatography (Isco, 0-20% EtOAc in hexanes as the eluent) to provide (2R,3S)-3-(2,5-dimethylphenyl)-4-methylpentan-2-ol (139 mg, 81%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 7.12 (s, 1H), 7.05 (d, J=7.7 Hz, 1H), 6.96-6.87 (m, 1H), 4.33-4.19 (m, 1H), 2.55 (dd, J=8.9, 4.7 Hz, 1H), 2.31 (s, 3H), 2.25 (s, 3H), 2.17 (ddt, J=13.4, 8.8, 6.7 Hz, 1H), 1.26 (d, J=6.1 Hz, 1H), 1.05 (d, J=2.1 Hz, 3H), 1.04 (d, J=1.8 Hz, 3H), 0.72 (d, J=6.7 Hz, 3H). IR (thin film) 3429 (b), 2956, 2925, 2868, 1500, 1457, 1382, 1151, 1027, 905, 806, 787 cm⁻¹. HRMS-ESI (m/z) [M+NH₄]+ calcd for C₁₄H₂₂O, 224.2009; found, 224.2001.

Example 7: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol

Step 1: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl 4-nitrobenzoate

In a 250 mL round bottom flask, a solution of (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol (0.880 g, 4.18 mmol), triphenylphosphine (4.17 g, 15.90 mmol) and 4-nitrobenzoic acid (2.87 g, 17.16 mmol) was prepared in anhydrous THF (41.8 ml) and cooled to 0° C. in an ice/water bath. After ˜5 min, diethyl (E)-diazene-1,2-dicarboxylate (2.97 ml, 18.83 mmol) was added dropwise, and the mixture was allowed to slowly warm to room temperature overnight. After 18 hr, TLC indicated ˜75% conversion to a single higher R_f spot. The reaction was then heated to 40° C. and stirred for an additional 12 hr. The mixture was cooled to room temperature and quenched with a saturated aqueous solution of NH₄Cl (40 mL) and extracted with CH₂Cl₂ (3×40 mL). The combined organic layers were passed through a phase separator and concentrated to an oil. The residue was purified via silica gel Isco column chromatography (80 g silica gel column, 60 mL/min, 100% hexanes to 20% acetone:hexanes) to afford (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl 4-nitrobenzoate (1.34 g, 3.73 mmol, 89% yield) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.33-8.26 (m, 2H), 8.17-8.11 (m, 2H), 7.14 (dd, J=9.5, 5.9 Hz, 1H), 6.98-6.86 (m, 2H), 5.65 (dq, J=8.2, 6.3 Hz, 1H), 3.18 (t, J=7.8 Hz, 1H), 2.30 (s, 3H), 2.19-2.09 (m, 1H), 1.19 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.7 Hz, 3H), 0.80 (d, J=6.8 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.11. IR (thin film) 3353, 2961, 1719, 1528, 1277, 1102, 720 cm⁻¹. ESIMS (m/z) 359.1 [M+H]⁺.

Step 2: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol

In a 250 mL round-bottom flask, a solution of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl 4-nitrobenzoate (1.34 g, 3.73 mmol) was prepared in THF (49.7 mL) and cooled to 0° C. in an ice/water bath. After ˜5 min, sodium hydroxide (10% aqueous solution) (44 mL, 3.73 mmol) (39.7 mL water+4.4 mL 50% w/w/NaOH) was added dropwise, and the mixture was allowed to slowly warm to room temperature over 1 hr and then heated to 40° C. and stirred for 2 days. The reaction was cooled to ambient temperature. The reaction was quenched by the addition of a saturated aqueous solution of NH₄Cl (100 mL) and extracted with CH₂Cl₂ (3×100 mL). Additional product remained in aqueous layer as evidenced by TLC, so 100 mL brine was added to aqueous layer, and the aqueous layer was extracted again with CH₂Cl₂ (2×100 mL), after which no additional product was observed in the aqueous layer. The combined organic layers were then passed through a phase separator and concentrated to afford an oil that was purified via silica gel Isco column chromatography (120 g silica gel column, 85 mL/min, 100% hexanes to 30% acetone:hexanes) to afford (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol (460 mg, 2.187 mmol, 58.7% yield) (52% over 2 steps) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.02 (dd, J=8.6, 6.0 Hz, 1H), 6.94-6.81 (m, 2H), 4.25-4.12 (m, 1H), 2.88 (t, J=7.6 Hz, 1H), 2.35 (s, 3H), 2.25-2.12 (m, 1H), 1.21 (d, J=6.0 Hz, 1H), 1.04 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.7 Hz, 3H), 0.80 (d, J=6.7 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.86. ¹³C NMR (101 MHz, CDCl₃) δ 160.86 (d, J=243.9 Hz), 140.35 (d, J=7.4 Hz), 134.42 (d, J=3.1 Hz), 129.29 (d, J=6.8 Hz), 116.88 (d, J=20.3 Hz), 112.20 (d, J=20.6 Hz), 69.48, 29.72, 21.12, 21.00, 20.99, 20.65, 19.98. IR (thin film) 3382, 2960, 2927, 1716, 1497, 1365, 1225, 736 cm⁻¹.

Example 8: (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-yl(tert-butoxycarbonyl)-L-alaninate

To a stirred solution of (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-ol (0.075 g, 0.382 mmol), (tert-butoxycarbonyl)-L-alanine (0.108 g, 0.573 mmol) and DMAP (4.67 mg, 0.038 mmol) dissolved in CH₂Cl₂ (3.82 mL) at 0° C. in an ice bath was added N¹-((ethylimino)methylene)-N³,N³-dimethylpropane-1,3-diamine hydrochloride (EDC; 0.147 g, 0.764 mmol) and the reaction was monitored until complete by TLC (25% EtOAc in hexanes). The reaction was purified by automated column chromatography (0-10% EtOAc in hexanes) to provide (2S,3S)-3-(4-fluorophenyl)-4-methylpentan-2-yl (tert-butoxycarbonyl)-L-alaninate (137.5 mg, 0.370 mmol, 97% yield) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.06 (dd, J=8.7, 5.6 Hz, 2H), 7.02-6.92 (m, 2H), 5.36 (dq, J=8.7, 6.3 Hz, 1H), 5.05 (s, 1H), 4.37-4.19 (m, 1H), 2.69 (dd, J=8.7, 6.4 Hz, 1H), 2.08 (h, J=6.7 Hz, 1H), 1.45 (s, 9H), 1.38 (d, J=7.2 Hz, 3H), 1.06 (d, J=6.2 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H), 0.74 (d, J=6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 172.79, 161.75 (d, J=244.8 Hz), 155.03, 134.29, 131.03 (d, J=7.6 Hz), 114.82 (d, J=21.0 Hz), 79.79, 72.32, 55.88, 49.50, 28.34, 28.18, 21.30, 18.81, 18.41, 17.74. IR (thin film) 3352, 2964, 2932, 1712, 1605, 1509, 1452, 1366, 1224, 1160, 835 cm⁻¹. HRMS-ESI (m/z) [M+Na]+ calcd for C₂₀H₃₀FNNaO₄, 390.2051; found, 390.2044.

Example 9: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl (tert-butoxycarbonyl)-L-alaninate

In a small vial, (2R,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-ol (115.5 mg, 0.549 mmol), (tert-butoxycarbonyl)-L-alanine (125 mg, 0.659 mmol) and triphenylphosphine (173 mg, 0.659 mmol) were dissolved in THF (2.75 mL) under a N₂ atmosphere and cooled to 0° C. in an ice/water bath. After ˜5 min, diisopropyl (E)-diazene-1,2-dicarboxylate (130 μL, 0.659 mmol) was added in dropwise via syringe over 3 min, and the resulting pale orange reaction was stirred overnight, slowly warming to room temperature as the ice melted. After 18 hr, the reaction was concentrated under reduced pressure to afford an oil. The oil was loaded directly onto a 12 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (120 column, 85 mL/min, 100% pet ether to 40% MTBE:pet ether) to afford (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl (tert-butoxycarbonyl)-L-alaninate (35.0 mg, 0.092 mmol, 17% yield) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.05 (dd, J=8.5, 6.0 Hz, 1H), 6.87 (ddt, J=11.6, 8.3, 4.1 Hz, 2H), 5.33 (dq, J=9.1, 6.2 Hz, 1H), 5.05 (d, J=8.1 Hz, 1H), 4.28 (d, J=7.6 Hz, 1H), 3.08 (dd, J=9.2, 6.2 Hz, 1H), 2.32 (s, 3H), 2.18-2.06 (m, 1H), 1.45 (s, 9H), 1.39 (d, J=7.2 Hz, 3H), 1.03 (d, J=6.2 Hz, 3H), 0.85 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.9 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.34. IR (thin film) 3355, 2965, 1714, 1499, 1366, 1167, 1052, 735 cm⁻¹. HRMS-ESI (m/z) [M+Na]+ calcd for C₂₁H₃₂FNNaO₄, 404.2208; found, 404.2201.

Example 10: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate

Step 1: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl-L-alaninate Hydrochloride

In a small vial, (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl-(tert-butoxycarbonyl)-L-alaninate (35.0 mg, 0.092 mmol) was dissolved in CH₂Cl₂ (2 mL). Hydrogen chloride (4M in dioxane) (0.344 mL, 1.376 mmol) was added in one portion via syringe. The resulting clear, colorless reaction was stirred at room temperature for 3 hr. After 3 hr, TLC indicated complete consumption of the starting material and conversion to a baseline product by TLC. The reaction was concentrated under a stream of N₂ and dried in a vacuum oven to provide (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl-L-alaninate (26.1 mg, 0.092 mmol, 100% yield) as a clear, colorless oil. ESIMS (m/z) 282.1 [M+H]+. This material was used directly in the next step without further purification.

Step 2: Preparation of (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate

To a vial containing (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl-L-alaninate (26.1 mg, 0.093 mmol) was added 3-hydroxy-4-methoxypicolinic acid (23.53 mg, 0.139 mmol) and ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium hexafluorophosphate(V) (72.4 mg, 0.139 mmol). Dichloromethane (1.86 mL) was added followed by N-ethyl-N-isopropylpropan-2-amine (121 μL, 0.696 mmol) dropwise over 45 seconds. After 10 min, most of the solids solubilized and the resultant pale pink colored reaction was stirred at room temperature overnight. TLC/UPLC indicated consumption of the starting material and formation of a major spot that glowed blue under UV. The reaction was then concentrated under reduced pressure to yield an orange oil. The oil was loaded directly onto a 12 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (24 column, 30 mL/min, 100% hexanes to 50% acetone:hexanes) to afford (2S,3S)-3-(4-fluoro-2-methylphenyl)-4-methylpentan-2-yl-(3-hydroxy-4-methoxypicolinoyl)-L-alaninate (24.4 mg, 0.056 mmol, 60.8% yield) as a clear, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 12.13 (s, 1H), 8.45 (d, J=8.0 Hz, 1H), 7.99 (d, J=5.2 Hz, 1H), 7.05 (dd, J=8.6, 5.9 Hz, 1H), 6.93-6.77 (m, 3H), 5.38 (dq, J=8.9, 6.3 Hz, 1H), 4.76-4.65 (m, 1H), 3.95 (s, 3H), 3.09 (dd, J=8.9, 6.5 Hz, 1H), 2.29 (s, 3H), 2.11 (h, J=6.8 Hz, 1H), 1.55 (d, J=7.2 Hz, 3H), 1.08 (d, J=6.2 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.7 Hz, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ −117.30. IR (thin film) 3366, 2961, 1734, 1650, 1529, 1264, 1183, 1049, 955, 801, 735 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₃H₃₀FN₂O₅, 433.2133; found, 433.2129.

Example 11A: Preparation of (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-acetoxy-4-methoxypicolinoyl)-L-alaninate

To a 20 mL vial charged with (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (30 mg, 0.070 mmol) dissolved in pyridine (1 mL, 12.36 mmol) was added acetic anhydride (25 μL, 2.65 mmol) at room temperature. After stirring for 45 min, the mixture was concentrated in vacuo and purified via automated silica gel chromatography (0-40% acetone/hexanes as the eluent) to afford (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-acetoxy-4-methoxypicolinoyl)-L-alaninate (32 mg, 0.061 mmol, 87% yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 8.35 (d, J=5.4 Hz, 1H), 7.19 (d, J=7.9 Hz, 1H), 7.00 (d, J=5.4 Hz, 1H), 6.94 (d, J=1.9 Hz, 1H), 6.90 (dd, J=7.9, 1.9 Hz, 1H), 5.41 (qd, J=6.3, 4.7 Hz, 1H), 4.77-4.61 (m, 1H), 3.91 (s, 3H), 2.68 (dd, J=9.3, 4.8 Hz, 1H), 2.39 (s, 3H), 2.27 (s, 3H), 2.25 (s, 3H), 2.03 (dp, J=9.2, 6.6 Hz, 1H), 1.38 (d, J=7.2 Hz, 3H), 1.05 (d, J=6.3 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.69 (d, J=6.8 Hz, 3H). IR (thin film) 3383, 2969, 1772, 1733, 1679, 1200, 1176 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₆H₃₅N₂O₆, 471.2490; found, 471.2485.

Example 11B: Preparation of (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-(acetoxymethoxy)-4-methoxypicolinoyl)-L-alaninate

To a 20 mL vial charged with in (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (30 mg, 0.070 mmol) and potassium carbonate (19.35 mg, 0.140 mmol) dissolved in acetone (1.5 mL) was added bromomethyl acetate (0.014 mL, 0.140 mmol) at room temperature. After stirring for 2 hr at 50° C., the mixture was concentrated in vacuo and purified via automated silica gel chromatography (0-40% acetone/hexanes as the eluent) to afford (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl(3-(acetoxymethoxy)-4-methoxypicolinoyl)-L-alaninate (21 mg, 0.038 mmol, 54% yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 8.38 (d, J=7.9 Hz, 1H), 8.29 (d, J=5.4 Hz, 1H), 7.20 (d, J=7.9 Hz, 1H), 7.00-6.87 (m, 3H), 5.80-5.69 (m, 2H), 5.42 (qd, J=6.2, 4.7 Hz, 1H), 4.71 (p, J=7.2 Hz, 1H), 3.91 (s, 3H), 2.69 (dd, J=9.2, 4.9 Hz, 1H), 2.27 (s, 3H), 2.25 (s, 3H), 2.10-1.97 (m, 1H), 2.06 (s, 3H), 1.39 (d, J=7.2 Hz, 3H), 1.07 (d, J=6.3 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.70 (d, J=6.7 Hz, 3H). IR (thin film) 3380, 2969, 1732, 1675, 1502, 1200, 1003, 967, 829 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₇H₃₇N₂O₇, 501.2595; found, 501.2589.

Example 11C: Preparation of (2S,3S)-3-(3-fluoro-4-methoxyphenyl)-4-methylpentan-2-yl (4-methoxy-3-((3-methoxypropanoyl)oxy)picolinoyl)-L-alaninate

To a stirred solution of (2S,3S)-3-(3-fluoro-4-methoxyphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (59.3 mg, 0.132 mmol) and 4-(dimethylamino)pyridine (3.23 mg, 0.026 mmol) dissolved in CH₂Cl₂ (2.0 mL) was added triethylamine (0.037 mL, 0.264 mmol) followed by 3-methoxypropanoyl chloride (0.022 mL, 0.198 mmol). The reaction was allowed to stir at room temperature overnight. The reaction was concentrated under a stream of nitrogen. The residue was loaded directly onto a 12 g prepacked silica column in a minimal amount of dichloromethane and purified using Isco silica gel column chromatography (24 g column, 35 mL/min, 100% hexanes to 50% acetone:hexanes as the eluent) to afford the title compound (58.5 mg, 83% yield) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, J=7.9 Hz, 1H), 8.34 (d, J=5.4 Hz, 1H), 7.01 (d, J=5.5 Hz, 1H), 6.92-6.75 (m, 3H), 5.34 (dq, J=8.3, 6.2 Hz, 1H), 4.66 (dt, J=8.1, 7.1 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.81 (t, J=6.6 Hz, 2H), 3.40 (s, 3H), 2.99 (t, J=6.6 Hz, 2H), 2.64 (dd, J=8.6, 6.5 Hz, 1H), 2.05 (h, J=6.8 Hz, 1H), 1.49 (d, J=7.2 Hz, 3H), 1.09 (d, J=6.3 Hz, 3H), 0.87 (d, J=6.7 Hz, 3H), 0.75 (d, J=6.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.19, 169.42, 162.36, 159.51, 151.94 (d, J=245.0 Hz), 146.73, 146.25 (d, J=10.8 Hz), 141.62, 137.42, 131.84 (d, J=5.6 Hz), 125.47 (d, J=3.6 Hz), 117.15 (d, J=18.2 Hz), 113.05-112.84 (m), 109.77, 72.51, 67.62, 58.76, 56.33, 56.24, 55.74, 48.21, 34.67, 28.35, 21.25, 18.77, 18.63, 17.47. ¹⁹F NMR (376 MHz, CDCl₃) δ −135.76. HRMS-ESI (m/z) [M+H]+ calcd for C₂₇H₃₆FN₂O₈, 535.2450; found, 535.2444.

Example 12: Preparation of (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl(3-acetoxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate

Step 1: Preparation of (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-hydroxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate

To a 30 mL vial charged with (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (99 mg, 0.232 mmol) dissolved in acetonitrile (2.32 mL) was added phosphorous pentasulfide (103 mg, 0.464 mmol) and 1,1,1,3,3,3-hexamethyldisiloxane (248 μL, 1.161 mmol). After stirring for 45 min at 45° C., sat. NaHCO₃ (15 mL) was added followed by aqueous extraction with dichloromethane (3×15 mL). The organics were dried over MgSO₄, filtered, and concentrated in vacuo. The crude residue was purified via flash chromatography (0-45% acetone/hexanes as the eluent) to furnish (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-hydroxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate (72 mg, 0.155 mmol, 66.6% yield) as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 12.94 (s, 1H), 10.71 (s, 1H), 8.01 (d, J=15.0 Hz, 1H), 7.22-7.17 (m, 3H), 7.15 (dd, J=6.7, 3.0 Hz, 2H), 6.89 (d, J=5.0 Hz, 1H), 5.39 (qd, J=6.4, 4.0 Hz, 1H), 5.12-5.03 (m, 1H), 3.97 (s, 3H), 2.41 (dd, J=10.4, 4.0 Hz, 1H), 2.25-2.14 (m, 1H), 1.95-1.84 (m, 1H), 1.69-1.59 (m, 1H), 1.56 (d, J=7.2 Hz, 3H), 1.54-1.45 (m, 2H), 1.44-1.28 (m, 2H), 1.19 (dq, J=12.3, 9.1 Hz, 1H), 1.09 (d, J=6.4 Hz, 3H), 0.92 (ddt, J=12.5, 10.0, 8.5 Hz, 1H). IR (thin film) 2951, 2868, 1733, 1581, 1514, 1480, 1454, 1377, 1342, 1274, 1249, 1211, 1131, 1095, 992, 913, 860, 801, 736, 703 cm⁻¹. HRMS-ESI (m/z) [M+Na]+ calcd for C₂₄H₃₀N₂O₄SNa, 465.1818; found, 465.1830.

Step 2: Preparation of (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-acetoxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate

To a solution of (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-hydroxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate (55 mg, 0.124 mmol) dissolved in pyridine (1 mL, 0.124 mmol) was added acetic anhydride (0.25 mL, 0.124 mmol). After stirring for 1 hr at room temperature, the mixture was concentrated in vacuo and purified via automated column chromatography (0-50% acetone/hexanes as the eluent) to furnish (1R,2S)-1-cyclopentyl-1-phenylpropan-2-yl (3-acetoxy-4-methoxypyridine-2-carbonothioyl)-L-alaninate (34 mg, 0.060 mmol, 48.0% yield) as a brown oil. ¹H NMR (500 MHz, CDCl₃) δ 9.98 (d, J=7.3 Hz, 1H), 8.35 (d, J=5.4 Hz, 1H), 7.25-7.13 (m, 5H), 7.01 (d, J=5.5 Hz, 1H), 5.39 (qd, J=6.3, 4.1 Hz, 1H), 5.16 (p, J=7.2 Hz, 1H), 3.91 (s, 3H), 2.42 (dd, J=10.3, 4.0 Hz, 1H), 2.35 (s, 3H), 2.28-2.19 (m, 1H), 1.93-1.83 (m, 1H), 1.68-1.59 (m, 1H), 1.52 (d, J=7.2 Hz, 3H), 1.50-1.31 (m, 4H), 1.20 (dq, J=12.5, 9.1 Hz, 1H), 1.08 (d, J=6.4 Hz, 3H), 0.97-0.90 (m, 1H). IR (thin film) 2950, 2868, 1770, 1731, 1585, 1496, 1438, 1365, 1311, 1278, 1193, 1175, 1131, 1102, 1040, 1010, 909, 847, 824, 759, 703 cm⁻¹. HRMS-ESI (m/z) [M+Na]+ calcd for C₂₆H₃₂N₂O₅SNa, 507.1924; found, 507.1920.

Example 13: Preparation of 2-(((S)-1-(((2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl)oxy)-1-oxopropan-2-yl)carbamoyl)-3-hydroxy-4-methoxypyridine 1-oxide

To a 25 mL vial charged with (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (38 mg, 0.089 mmol) dissolved in CH₂Cl₂ (1182 μL) was added 3-chlorobenzoperoxoic acid (mCPBA, 43.7 mg, 0.177 mmol) at room temperature. After stirring overnight, the reaction mixture was concentrated in vacuo and purified via automated silica gel chromatography (0-50% acetone/hexanes as the eluent) to afford 2-(((S)-1-(((2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl)oxy)-1-oxopropan-2-yl)carbamoyl)-3-hydroxy-4-methoxypyridine 1-oxide (27 mg, 0.055 mmol, 61.6% yield) as colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 14.37 (s, 1H), 12.78 (d, J=7.0 Hz, 1H), 7.88 (d, J=7.1 Hz, 1H), 7.15 (d, J=7.7 Hz, 1H), 6.90 (d, J=8.0 Hz, 2H), 6.77 (d, J=7.2 Hz, 1H), 5.42 (qd, J=6.3, 5.0 Hz, 1H), 4.69-4.61 (m, 1H), 3.96 (s, 3H), 2.69 (dd, J=9.1, 5.0 Hz, 1H), 2.25 (s, 3H), 2.23 (s, 3H), 2.00 (dp, J=8.8, 6.6 Hz, 1H), 1.44 (d, J=7.2 Hz, 3H), 1.08 (d, J=6.3 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.69 (d, J=6.8 Hz, 3H). IR (thin film) 2964, 1734, 1644, 1571, 1480, 1302, 1216 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₄H₃₃N₂O₆, 445.2333; found, 445.2370.

Example 14: Preparation of (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (S)-2-(8-methoxy-2,4-dioxo-2H-pyrido[2,3-e][1,3]oxazin-3(4H)-yl)propanoate

To a 20 mL vial charged with (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl (3-hydroxy-4-methoxypicolinoyl)-L-alaninate (30 mg, 0.070 mmol) and triphosgene (41.5 mg, 0.140 mmol) dissolved in CH₂Cl₂ (0.75 mL) was added pyridine (0.1 mL, 1.236 mmol) at room temperature. After stirring for 45 min at room temperature, the crude LCMS revealed a complete conversion to the desired mass. The reaction mixture was quenched by the addition of a saturated NaHCO₃ solution and was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (10 mL). The organic solution was dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified via automated silica gel chromatography (0-40% acetone/hexanes as the eluent) to afford (2S,3R)-3-(2,4-dimethylphenyl)-4-methylpentan-2-yl(S)-2-(8-methoxy-2,4-dioxo-2H-pyrido[2,3-e][1,3]oxazin-3(4H)-yl)propanoate (28 mg, 0.059 mmol, 84% yield) as orange oil. ¹H NMR (500 MHz, CDCl₃) δ 8.62 (d, J=5.3 Hz, 1H), 7.15 (d, J=5.4 Hz, 1H), 6.90 (d, J=7.9 Hz, 1H), 6.87-6.83 (m, 1H), 6.32-6.24 (m, 1H), 5.65 (q, J=7.1 Hz, 1H), 5.43 (qd, J=6.4, 3.2 Hz, 1H), 4.05 (s, 3H), 2.53 (dd, J=10.4, 3.2 Hz, 1H), 2.18 (s, 3H), 2.10 (s, 3H), 2.06-1.96 (m, 1H), 1.71 (d, J=7.0 Hz, 3H), 1.04 (d, J=6.5 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.60 (d, J=6.6 Hz, 3H). IR (thin film) 2958, 1770, 1715, 1371, 1244, 734 cm⁻¹. HRMS-ESI (m/z) [M+H]+ calcd for C₂₅H₃₁N₂O₆, 455.2177; found, 455.2171.

Example A: Evaluation of Fungicidal Activity: Leaf Blotch of Wheat (Zymoseptoria tritici; Bayer Code SEPTTR)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 110 ppm Triton X-100. The fungicide solutions were applied onto wheat seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling. All fungicides were evaluated using the aforementioned method for their activity vs. all target diseases, unless stated otherwise. Wheat leaf blotch and brown rust activity were also evaluated using track spray applications, in which case the fungicides were formulated as EC formulations, containing 0.1% Trycol 5941 in the spray solutions.

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Zymoseptoria tritici either prior to or after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. When disease symptoms were fully expressed on the 1^st leaves of untreated plants, infection levels were assessed on a scale of 0 to 100 percent disease severity. Percent disease control was calculated using the ratio of disease severity on treated plants relative to untreated plants.

Example B: Evaluation of Fungicidal Activity: Wheat Brown Rust (Puccinia triticina; Synonym: Puccinia recondita f. Sp. Tritici; Bayer Code PUCCRT)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Puccinia triticina either prior to or after fungicide treatments. After inoculation the plants were kept in a dark dew room at 22° C. with 100% relative humidity overnight to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 24° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.

Example C: Evaluation of Fungicidal Activity: Asian Soybean Rust (Phakopsora pachyrhizi; Bayer Code PHAKPA)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 0.011% Tween 20. The fungicide solutions were applied onto soybean seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling.

Soybean plants (variety Williams 82) were grown in soil-less Metro mix, with one plant per pot. Two week old seedlings were used for testing. Plants were inoculated either 3 days prior to or 1 day after fungicide treatments. Plants were incubated for 24 h in a dark dew room at 22° C. and 100% relative humidity then transferred to a growth room at 23° C. for disease to develop. Disease severity was assessed on the sprayed leaves.

Example D: Evaluation of Fungicidal Activity: Tomato Early Blight (Alternaria solani; Bayer Code ALTESO)

Tomato plants (variety Outdoor Girl) were propagated in soil-less Metro mix, with each pot having one plant, and used when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Alternaria solani 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example E: Evaluation of Fungicidal Activity: Leaf Spot of Sugar Beets (Cercospora beticola; Bayer Code CERCBE)

Sugar beet plants (variety HH88) were grown in soil-less Metro mix and trimmed regularly to maintain a uniform plant size prior to test. Plants were inoculated with a spore suspension 24 hr after fungicide treatments. Inoculated plants were kept in a dew chamber at 22° C. for 48 hr then incubated in a greenhouse set at 24° C. under a clear plastic hood with bottom ventilation until disease symptoms were fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example F: Evaluation of Fungicidal Activity: Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotrichum lagenarium; Bayer Code COLLLA)

Cucumber seedlings (variety Bush Pickle) were propagated in soil-less Metro mix, with each pot having one plant, and used in the test when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Colletotrichum lagenarium 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 22° C. with 100% relative humidity for 48 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room set at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example G: Evaluation of Fungicidal Activity: Wheat Glume Blotch (Parastagonospora nodorum; Bayer Code LEPTNO)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Parastagonospora nodorum 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.

Example H: Evaluation of Fungicidal Activity: Cucumber Downy Mildew (Pseudoperonospora cubensis; Bayer Code PSPECU)

Cucumber seedlings (variety Bush Pickle) were grown in soil-less Metro mix, with one plant per pot, and used in the test when 12 to 14 days old. Plants were inoculated with a spore suspension 24 hr following fungicide treatments. Test plants were inoculated with an aqueous spore suspension of Pseudoperonospora cubensis 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 22° C. with 100% relative humidity for 24 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. until disease was fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example I: Evaluation of Fungicidal Activity: Rice Blast (Magnaporthe grisea; Anamorph: Pyricularia oryzae; Bayer Code PYRIOR)

Rice seedlings (variety Japonica) were propagated in soil-less Metro mix, with each pot having 8 to 14 plants, and used in the test when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Pyricularia oryzae 24 hr after fungicide treatments. After inoculation, the plants were kept in a dew room at 22° C. with 100% relative humidity for 48 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 24° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example J: Evaluation of Fungicidal Activity: Barley Scald (Rhyncosporium secalis; Bayer Code RHYNSE)

Barley seedlings (variety Harrington) were propagated in soil-less Metro mix, with each pot having 8 to 12 plants, and used in the test when first leaf was fully emerged. Test plants were inoculated by an aqueous spore suspension of Rhyncosporium secalis 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 20° C. with 100% relative humidity for 48 hr. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.

Example K: Evaluation of Fungicidal Activity: Grape Powdery Mildew (Uncinula necator; Bayer Code UNCINE)

Grape seedlings (variety Carignane) were grown in soil-less Metro mix, with one plant per pot, and used in the test when approximately 1 month old. Plants were inoculated 24 hr after fungicide treatment by shaking spores from infected leaves over test plants. Plants were maintained in a greenhouse set at 20° C. until disease was fully developed. Fungicide formulation, application and disease assessment on sprayed leaves followed the procedures as described in the Example A.

TABLE 1
Compound Structure, Appearance, and Preparation Method
		As
		Prepared
Cmpd.		According
No.	Structure	To	Appearance
1		Example 2A Example 3B Example 8	Colorless Oil
2		Example 2A Example 3B Example 8	Colorless Oil
3		Example 2A Example 3B Example 9	Colorless Oil
4		Example 1A Example 2B Example 3B Example 8	Colorless Oil
5		Example 1A Example 2B Example 3B Example 8	Pale Yellow Oil
6		Example 1B Example 2B Example 3B Example 8	Colorless Oil
7		Example 2A Example 5 Example 8	Colorless Oil
8		Example 2A Example 5 Example 8	Colorless Oil
9		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
10		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
11		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
12		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
13		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
14		Example 1C; Step 1 Example 2B Example 3A Example 8	Clear, Colorless Oil
15		Example 1C; Step 1 Example 2B Example 3B Example 9	Clear, Colorless Oil
16		Example 1C; Step 1 Example 2B Example 3B Example 9	Clear, Colorless Oil
17		Example 1C; Step 1 Example 2B Example 4A Example 4C Example 9	Clear, Colorless Oil
18		Example 1C; Step 1 Example 2B Example 3B Example 9	Clear, Colorless Oil
19		Example 1C; Step 1 Example 2B Example 3B Example 9	Clear, Colorless Oil
20		Example 1C; Step 1 Example 2B Example 3A Example 9	Clear, Colorless Oil
21		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
22		Example 1C; Step 1 Example 2B Example 3B Example 8	Clear, Colorless Oil
23		Example 1C; Step 1 Example 2B Example 4A Example 4B Example 8	Clear, Colorless Oil
24		Example 1D Example 2B Example 3B Example 8	Yellow Oil
25		Example 1D Example 2B Example 3B Example 8	Colorless Oil
26		Example 1D Example 2B Example 3B Example 8	Colorless Oil
27		Example 1D Example 2B Example 3B Example 8	Colorless Oil
28		Example 1C Example 2B Example 3B Example 8	Clear, Colorless Oil
29		Example 1C Example 2B Example 3B Example 8	Clear, Colorless Oil
30		Example 1C Example 2B Example 3B Example 8	Clear, Colorless Oil
31		Example 1C Example 2B Example 3B Example 8	Clear, Colorless Oil
32		Example 1C Example 2B Example 3B Example 8	Clear, Colorless Oil
33		Example 6 Steps 1, 2, 3, 4, 5 Example 8	Colorless Oil
34		Example 1C Example 2B Example 3A Example 8	Clear, Colorless Oil
35		Example 1C Example 2B Example 3B Example 7 Example 8	Clear, Colorless Oil
36		Example 1C Example 2B Example 3B Example 7 Example 8	Clear, Colorless Oil
37		Example 1C Example 2B Example 3B Example 7 Example 8	Clear, Colorless Oil
38		Example 1C Example 2B Example 3B Example 7 Example 8	Clear, Colorless Oil
39		Example 1C Example 2B Example 3A Example 7 Example 8	Clear, Colorless Oil
40		Example 1C Example 2B Example 4A Example 4C Example 7 Example 8	Clear, Colorless Oil
41		Example 1D Example 2B Example 3A Example 8	Colorless Oil
42		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
43		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
44		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
45		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Pale Yellow Oil
46		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Clear, Colorless Oil
47		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Clear, Colorless Oil
48		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Pale Yellow Oil
49		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Clear, Colorless Oil
50		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
51		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
52		Example 10 Step 1	Colorless Oil
53		Example 10 Step 1	Colorless Oil
54		Example 10 Step 1	Colorless Oil
55		Example 10 Step 1	Colorless Oil
56		Example 10 Step 1	White Semisolid
57		Example 10 Step 1	Colorless Oil
58		Example 10 Step 1	Colorless Oil
59		Example 10 Step 1	Colorless Oil
60		Example 10 Step 1	Colorless Oil
61		Example 10 Step 1	Colorless Oil
62		Example 10 Step 1	Clear, Colorless Oil
63		Example 10 Step 1	Clear, Colorless Oil
64		Example 10 Step 1	Pale Yellow Oil
65		Example 10 Step 1	Clear, Colorless Oil
66		Example 10 Step 1	Clear, Colorless Oil
67		Example 10 Step 1	Clear, Colorless Oil
68		Example 10 Step 1	Pale Yellow Oil
69		Example 10 Step 1	Clear, Colorless Oil
70		Example 10 Step 1	Clear, Colorless Oil
71		Example 10 Step 1	Pale Yellow Oil
72		Example 10 Step 1	Pale Yellow Oil
73		Example 10 Step 1	Pale Yellow Oil
74		Example 10 Step 1	Clear, Colorless Oil
75		Example 10 Step 1	Clear, Colorless Oil
76		Example 10 Step 1	Clear, Colorless Oil
77		Example 10 Step 1	Yellow Oil
78		Example 10 Step 1	Yellow Oil
79		Example 10 Step 1	Yellow Oil
80		Example 10 Step 1	Yellow Oil
81		Example 10 Step 1	Thick Oil
82		Example 10 Step 1	Pale Yellow Oil
83		Example 10 Step 1	Clear, Colorless Oil
84		Example 10 Step 1	Clear, Colorless Oil
85		Example 10 Step 1	Clear, Colorless Oil
86		Example 10 Step 1	Clear, Colorless Oil
87		Example 10 Step 1	Clear, Colorless Oil
88		Example 10 Step 1	Clear, Colorless Oil
89		Example 10 Step 1	White Semisolid
90		Example 10 Step 1	Off-White Semisolid
91		Example 10 Step 1	Clear, Colorless Oil
92		Example 10 Step 1	Clear, Colorless Oil
93		Example 10 Step 1	Clear, Colorless Oil
94		Example 10 Step 1	Yellow Oil
95		Example 10 Step 1	Thick Oil
96		Example 10 Step 1	Thick Oil
97		Example 10 Step 1	Thick Oil
98		Example 10 Step 1	Pale Yellow Oil
99		Example 10 Step 1	White Semisolid
100		Example 10 Step 1	Clear, Colorless Oil
101		Example 10 Step 1	Pale Yellow Oil
102		Example 10 Step 1	Clear, Colorless Oil
103		Example 10 Step 1	Yellow Oil
104		Example 10 Step 1	Yellow Oil
105		Example 10 Step 2	Colorless Gel
106		Example 10 Step 2	Colorless Gel
107		Example 10 Step 2	Colorless Oil
108		Example 10 Step 2	Colorless Oil
109		Example 10 Step 2	Clear, Colorless Oil
110		Example 10 Step 2	Colorless Oil
111		Example 10 Step 2	Colorless Oil
112		Example 10 Step 2	Colorless Oil
113		Example 10 Step 2	Colorless Oil
114		Example 10 Step 2	Yellow Solid
115		Example 10 Step 2	Yellow Oil
116		Example 10 Step 2	Clear, Colorless Oil
117		Example 10 Step 2	Clear, Colorless Oil
118		Example 10 Step 2	Clear, Colorless Oil
119		Example 10 Step 2	Clear, Colorless Oil
120		Example 10 Step 2	Clear, Colorless Oil
121		Example 10 Step 2	Clear, Colorless Oil
122		Example 10 Step 2	Clear, Colorless Oil
123		Example 10 Step 2	Clear, Colorless Oil
124		Example 10 Step 2	Clear, Colorless Oil
125		Example 10 Step 2	Clear, Colorless Oil
126		Example 10 Step 2	Clear, Colorless Oil
127		Example 10 Step 2	Clear, Colorless Oil
128		Example 10 Step 2	Clear, Colorless Oil
129		Example 10 Step 2	Clear, Colorless Oil
130		Example 10 Step 2	Clear, Colorless Oil
131		Example 10 Step 2	Colorless Oil
132		Example 10 Step 2	Colorless Oil
133		Example 10 Step 2	White Wax
134		Example 10 Step 2	White Wax
135		Example 10 Step 2	Thick Oil
136		Example 10 Step 2	Bright Yellow Semisolid
137		Example 10 Step 2	Yellow Oil
138		Example 10 Step 2	Pale Yellow Oil
139		Example 10 Step 2	Yellow Oil
140		Example 10 Step 2	Pale Yellow Oil
141		Example 10 Step 2	Clear, Colorless Oil
142		Example 10 Step 2	Clear, Colorless Oil
143		Example 10 Step 2	Clear, Colorless Oil
144		Example 10 Step 2	Clear, Colorless Oil
145		Example 10 Step 2	Clear, Colorless Oil
146		Example 10 Step 2	Clear, Colorless Oil
147		Example 10 Step 2	Clear, Colorless Oil
148		Example 10 Step 2	Clear, Colorless Oil
149		Example 10 Step 2	Colorless Oil
150		Example 10 Step 2	Colorless Oil
151		Example 10 Step 2	Thick Oil
152		Example 10 Step 2	Thick Oil
153		Example 10 Step 2	Clear, Colorless Oil
154		Example 10 Step 2	Clear, Colorless Oil
155		Example 10 Step 2	Clear, Colorless Oil
156		Example 10 Step 2	Clear, Colorless Oil
157		Example 10 Step 2	Clear, Colorless Oil
158		Example 10 Step 2	Colorless Oil
159		Example 10 Step 2	Colorless Oil
160		Example 11A	Colorless Oil
161		Example 11A	Colorless Oil
162		Example 11B	Colorless Oil
163		Example 11B	Colorless Oil
164		Example 11B	Colorless Oil
165		Example 11A	Colorless Oil
166		Example 11A	Colorless Oil
167		Example 11B	Colorless Oil
168		Example 11A	Clear, Colorless Oil
169		Example 11A	Colorless Oil
170		Example 11A	Colorless Oil
171		Example 11B	Colorless Oil
172		Example 11A	Colorless Oil
173		Example 11A	Colorless Oil
174		Example 11B	Colorless Oil
175		Example 11B	Colorless Oil
176		Example 12	Orange Wax
177		Example 12	Brown Oil
178		Example 11A	Clear, Colorless Oil
179		Example 11A	Clear, Colorless Oil
180		Example 11A	Clear, Colorless Oil
181		Example 11A	Pale Yellow Oil
182		Example 11A	Clear, Colorless Oil
183		Example 11A	Clear, Colorless Oil
184		Example 11A	Clear, Colorless Oil
185		Example 11A	Clear, Colorless Oil
186		Example 11A	Clear, Colorless Oil
187		Example 11A	Clear, Colorless Oil
188		Example 11A	Clear, Colorless Oil
189		Example 11A	Clear, Colorless Oil
190		Example 11A	Clear, Colorless Oil
191		Example 11A	Clear, Colorless Oil
192		Example 11A	Clear, Colorless Oil
193		Example 11B	Clear, Colorless Oil
194		Example 11B	Clear, Colorless Oil
195		Example 11B	Clear, Colorless Oil
196		Example 11B	Clear, Colorless Oil
197		Example 11B	Clear, Colorless Oil
198		Example 11B	White Semisolid
199		Example 11B	Clear, Colorless Oil
200		Example 11A	Colorless Oil
201		Example 11A	Colorless Oil
202		Example 11A	Colorless Oil
203		Example 11A	Colorless Oil
204		Example 11B	Colorless Oil
205		Example 11B	Colorless Oil
206		Example 11B	Colorless Oil
207		Example 11B	Colorless Oil
208		Example 14	Orange Oil
209		Example 14	Orange Oil
210		Example 14	Orange Foam
211		Example 13	Colorless Oil
212		Example 13	Colorless Oil
213		Example 13	Colorless Oil
214		Example 11A	White Foam
215		Example 11B	Pale Yellow Oil
216		Example 11C	Clear, Colorless Oil
217		Example 14	Pale Yellow Oil
218		Example 13	Clear, Colorless Oil
219		Example 12	Yellow Oil
220		Example 11C	Pale Yellow Oil
221		Example 11A	Pale Yellow Oil
222		Example 11A	Yellow Oil
223		Example 11A	Clear, Colorless Oil
224		Example 11A	Clear, Colorless Oil
225		Example 11A	Clear, Colorless Oil
226		Example 11A	Clear, Colorless Oil
227		Example 11A	Clear, Colorless Oil
228		Example 11A	Clear, Colorless Oil
229		Example 11A	Clear, Colorless Oil
230		Example 11A	Clear, Colorless Oil
231		Example 11A	Clear, Colorless Oil
232		Example 11A	Clear, Colorless Oil
233		Example 11B	Clear, Colorless Oil
234		Example 11B	Clear, Colorless Oil
235		Example 11B	Clear, Colorless Oil
236		Example 11B	Clear, Colorless Oil
237		Example 11B	Clear, Colorless Oil
238		Example 11C	Clear, Colorless Oil
239		Example 11C	Clear, Colorless Oil
240		Example 11B	Yellow Oil
241		Example 11A	Colorless Oil
242		Example 11A	Thick Oil
243		Example 11A	White Foam
244		Example 11A	Thick Oil
245		Example 11C	Pale Yellow Oil
246		Example 11C	Clear, Colorless Oil
247		Example 11C	Pale Yellow Oil
248		Example 11C	Pale Yellow Oil
249		Example 11C	Clear, Colorless Oil
250		Example 11A	Clear, Colorless Oil
251		Example 11A	Clear, Colorless Oil
252		Example 11A	Clear, Colorless Oil
253		Example 11A	Clear, Colorless Oil
254		Example 11A	Clear, Colorless Oil
255		Example 11B	Clear, Colorless Oil
256		Example 11B	Clear, Colorless Oil
257		Example 11B	Clear, Colorless Oil
258		Example 11B	Clear, Colorless Oil
259		Example 11B	Clear, Colorless Oil
260		Example 11B	Clear, Colorless Oil
261		Example 11A	Colorless Oil
262		Example 11A	Colorless Oil
263		Example 11B	Yellow Oil
264		Example 11B	Yellow Oil
265		Example 10 Step 1	Clear, Colorless Oil
266		Example 10 Step 1	Clear, Colorless Oil
267		Example 10 Step 1	Clear, Colorless Oil
268		Example 10 Step 1	White Semisolid
269		Example 10 Step 1	White Solid
270		Example 10 Step 1	White Solid
271		Example 10 Step 1	White Solid
272		Example 10 Step 1	White Solid
273		Example 10 Step 1	White Solid
274		Example 10 Step 1	White Solid
275		Example 10 Step 1	White Solid
276		Example 10 Step 1	Thick Oil
277		Example 10 Step 1	Thick Oil
278		Example 10 Step 1	Thick Oil
279		Example 10 Step 1	Thick Oil
280		Example 10 Step 1	Thick Oil
281		Example 10 Step 1	Thick Oil
282		Example 10 Step 1	Yellow Oil
283		Example 10 Step 1	Colorless Semi-Solid
284		Example 10 Step 1	Yellow Oil
285		Example 10 Step 1	Yellow Oil
286		Example 10 Step 1	Colorless Oil
287		Example 10 Step 1	Residue
288		Example 1D Example 2B Example 4A Example 4B Example 7 Example 8	Clear, Colorless Oil
289		Example 1D Example 2B Example 4A Example 4B Example 7 Example 8	Clear, Colorless Oil
290		Example 1D Example 2B Example 4A Example 4B Example 7 Example 8	White Semisolid
291		Example 1D Example 2B Example 4A Example 4B Example 7 Example 8	Clear, Colorless Oil
292		Example 6A Example 7 Example 8	Colorless Oil
293		Example 6A Example 7 Example 8	Colorless Oil
294		Example 6A Example 7 Example 8	Colorless Oil
295		Example 6A Example 7 Example 8	Colorless Oil
296		Example 6A Example 7 Example 8	Colorless Oil
297		Example 6A Example 7 Example 8	Colorless Oil
298		Example 6A Example 7 Example 8	Colorless Oil
299		Example 6A Example 7 Example 8	Oil
300		Example 6A Example 7 Example 8	Oil
301		Example 6A Example 7 Example 8	Oil
302		Example 6A Example 7 Example 8	Colorless Oil
303		Example 6A Example 7 Example 8	Oil
304		Example 6A Example 7 Example 8	Oil
305		Example 6 Steps 2A, 6, 7, 4, 5 Example 7 Example 8	Colorless Oil
306		Example 6 Steps 2A, 6, 7, 4, 5 Example 7 Example 8	Colorless Oil
307		Example 6 Steps 2A, 6, 7, 4, 5 Example 7 Example 8	White Wax
308		Example 6 Steps 2A, 6, 7, 4, 5 Example 7 Example 8	Colorless Oil
309		Example 6 Steps 1, 2, 6, 7, 4, 5 Example 8	Colorless Oil
310		Example 1E Example 2B Example 3B Example 7 Example 8	Residue
311		Example 1E Example 2B Example 3B Example 7 Example 8	Residue
312		Example 6A Example 7 Example 8	Residue
313		Example 6A Example 7 Example 8	Residue
314		Example 6A Example 7 Example 8	Residue
315		Example 6A Example 7 Example 8	Residue
316		Example 6A Example 7 Example 8	Residue
317		Example 10 Step 2	Clear, Colorless Oil
318		Example 10 Step 2	Clear, Colorless Oil
319		Example 10 Step 2	Clear, Colorless Oil
320		Example 10 Step 2	Clear, Colorless Oil
321		Example 10 Step 2	Colorless Oil
322		Example 10 Step 2	Colorless Oil
323		Example 10 Step 2	Colorless Oil
324		Example 10 Step 2	Colorless Oil
325		Example 10 Step 2	Colorless Oil
326		Example 10 Step 2	Colorless Oil
327		Example 10 Step 2	Off-White Wax
328		Example 10 Step 2	White Foam
329		Example 10 Step 2	White Foam
330		Example 10 Step 2	Thick Oil
331		Example 10 Step 2	Thick Oil
332		Example 10 Step 2	Thick Oil
333		Example 10 Step 2	Thick Oil
334		Example 10 Step 2	Yellow Oil
335		Example 10 Step 2	Yellow Oil
336		Example 10 Step 2	Yellow Oil
337		Example 10 Step 2	Colorless Oil
338		Example 10 Step 2	Colorless Oil
339		Example 10 Step 2	Residue
340		Example 10 Step 2	Residue
341		Example 10 Step 2	Residue
342		Example 10 Step 2	Residue
343		Example 10 Step 2	Residue
344		Example 10 Step 2	Residue
345		Example 10 Step 2	Residue
346		Example 11A	Clear, Colorless Oil
347		Example 11A	Clear, Colorless Oil
348		Example 11A	Clear, Colorless Oil
349		Example 11A	Clear, Colorless Oil
350		Example 11C	Clear, Colorless Oil
351		Example 11C	Clear, Colorless Oil
352		Example 11C	Clear, Colorless Oil
353		Example 11C	Clear, Colorless Oil
354		Example 11C	Clear, Colorless Oil
355		Example 11C	Pale Yellow Oil
356		Example 11C	Clear, Colorless Oil
357		Example 11C	Clear, Colorless Oil
358		Example 11A	White Foam
359		Example 11A	White Foam
360		Example 11A	Colorless Oil
361		Example 11A	Colorless Oil
362		Example 11A	Colorless Oil
363		Example 11A	Colorless Oil
364		Example 11A	Colorless Oil
365		Example 11A	White Foam
366		Example 11A	White Foam
367		Example 11A	White Foam
368		Example 11A	White Foam
369		Example 11A	Thick Oil
370		Example 11A	Thick Oil
371		Example 11C	White Foam
372		Example 11C	Thick Oil
373		Example 11C	Colorless Oil
374		Example 11C	Thick Oil
375		Example 11C	Colorless Oil
376		Example 11A	Colorless Oil
377		Example 11A	Colorless Oil
378		Example 11B	Yellow Oil
379		Example 11B	Yellow Oil
380		Example 11A	Glassy White Solid
381		Example 11A	Colorless Oil
382		Example 11B	Yellow Oil
383		Example 11A	Colorless Oil
384		Example 11A	Residue
385		Example 11A	Residue
386		Example 11C	Residue
387		Example 11C	Residue
388		Example 11A	Residue
389		Example 11A	Residue
390		Example 11A	Residue
391		Example 11A	Residue
392		Example 11A	Residue
*Cmpd. No.—Compound Number

TABLE 2
Analytical Data
	Melting
Cmpd.	Point
No.	(° C.)	IR (cm−1)	MASS SPEC	NMR
1			ESIMS m/z 350.5	1H NMR (400 MHz, CDCl3) δ
			([M + H]+)	7.31-7.12 (m, 5H), 5.50-5.38 (m, 1H),
				5.02 (d, J = 7.8 Hz, 1H), 4.29-4.17 (m, 1H),
				2.36 (dd, J = 8.4, 5.6 Hz, 1H),
				2.13-1.96 (m, 1H), 1.44 (s, 9H), 1.14 (d, J = 7.2 Hz,
				3H), 1.11 (d, J = 6.3 Hz, 3H),
				0.94 (d, J = 6.6 Hz, 3H), 0.72 (d, J = 6.7 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.83,
				157.91, 139.85, 129.62, 127.92, 126.50,
				79.70, 71.92, 58.00, 49.41, 29.18,
				28.33, 21.29, 20.19, 18.97, 18.54.
2			ESIMS m/z 376.6	1H NMR (400 MHz, CDCl3) δ
			([M + H]+)	7.38-7.14 (m, 5H), 5.33 (qd, J = 6.4, 3.9 Hz,
				1H), 5.07 (d, J = 8.0 Hz, 1H),
				4.40-4.23 (m, 1H), 2.41 (dd, J = 10.3, 4.0 Hz,
				1H), 2.29-2.13 (m, 1H),
				1.92-1.79 (m, 1H), 1.70-1.61 (m, 1H),
				1.59-1.48 (m, 2H), 1.45 (s, 9H),
				1.45-1.32 (m, 2H), 1.31 (d, J = 7.2 Hz, 3H),
				1.27-1.13 (m, 1H), 1.06 (d, J = 6.3 Hz, 3H),
				1.04-0.88 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.79,
				155.00, 140.76, 129.49, 127.96, 126.49,
				79.75, 73.15, 56.65, 49.52, 42.13,
				31.61, 31.47, 28.34, 25.12, 24.53,
				18.81.
3			ESIMS m/z 350.5	1H NMR (300 MHz, CDCl3) δ
			([M + H]+)	7.36-7.20 (m, 3H), 7.16-7.03 (m, 2H),
				5.40 (dq, J = 8.8, 6.2 Hz, 1H), 5.09 (d, J = 8.0 Hz,
				1H), 4.39-4.15 (m, 1H),
				2.70 (dd, J = 8.9, 6.3 Hz, 1H),
				2.20-2.01 (m, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
				3H), 1.08 (d, J = 6.2 Hz, 3H),
				0.86 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
				3H).
4			ESIMS m/z 365 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				7.18-7.02 (m, 4H), 5.36-5.22 (m, 1H),
				5.07 (s, 1H), 4.36-4.19 (m, 1H), 2.33 (s,
				3H), 1.97 (dd, J = 10.0, 7.1 Hz, 1H),
				1.45 (s, 9H), 1.36 (d, J = 7.2 Hz, 3H),
				1.15 (d, J = 6.3 Hz, 3H), 1.12-1.00 (m,
				1H), 0.73-0.57 (m, 1H),
				0.47-0.27 (m, 2H), −0.01-−0.15 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.79,
				155.03, 138.55, 136.15, 128.94, 128.28,
				75.73, 68.48, 55.27, 49.50, 28.35,
				21.01, 18.87, 18.19, 13.04, 6.90, 2.83.
5		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3358,	calcd for C21H33NNaO4,	7.13-7.05 (m, 2H), 7.00-6.94 (m, 2H),
		2976,	386.2302; found, 386.2306	5.38 (dq, J = 8.9, 6.3 Hz, 1H), 5.13 (d, J = 7.9 Hz,
		1715,		1H), 4.28 (p, J = 7.5 Hz, 1H),
		1514,		2.66 (dd, J = 8.9, 6.2 Hz, 1H), 2.33 (s,
		1366,		3H), 2.09 (h, J = 6.8 Hz, 1H), 1.45 (s,
		1167, 1052 cm−1		9H), 1.39 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 6.3 Hz,
				3H), 0.85 (d, J = 6.8 Hz, 3H),
				0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.82,
				155.03, 136.11, 135.47, 129.67, 128.65,
				79.66, 72.59, 56.29, 49.56, 28.36,
				28.16, 21.39, 21.00, 18.81, 18.42,
				17.98.
6			ESIMS m/z 366 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				7.22-7.12 (m, 2H), 7.03-6.94 (m, 2H),
				5.32-5.20 (m, 1H), 5.04 (d, J = 8.0 Hz, 1H),
				4.40-4.22 (m, 1H), 2.01 (dd, J = 10.1,
				6.7 Hz, 1H), 1.45 (s, 9H), 1.34 (d, J = 7.2 Hz,
				3H), 1.16 (d, J = 6.4 Hz, 3H),
				1.13-1.07 (m, 1H), 0.76-0.63 (m,
				1H), 0.46-0.31 (m, 2H),
				−0.03-−0.10 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −116.47.
7			ESIMS m/z 378 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				7.32-7.02 (m, 5H), 5.48-5.34 (m, 1H),
				5.10 (bs, 1H), 4.35-4.21 (m, 1H), 2.94 (dd,
				J = 8.6, 6.3 Hz, 1H), 1.64-1.55 (m,
				1H), 1.45 (s, 9H), 1.66-1.54 (m, 2H),
				1.30-1.12 (m, 2H), 1.39 (d, J = 7.2 Hz,
				3H), 1.08 (d, J = 6.3 Hz, 3H),
				0.96 (t, J = 7.4 Hz, 3H), 0.78 (t, J = 7.3 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.72,
				154.99, 138.99, 129.76, 127.94, 126.61,
				72.12, 51.91, 49.49, 41.54, 28.35,
				22.30, 19.03, 17.95, 11.68, 11.13.
8			ESIMS m/z 376 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				7.36-7.04 (m, 5H), 5.34-5.26 (m, 1H),
				5.14-4.97 (m, 1H), 4.28 (m, 1H), 2.76 (dd,
				J = 9.9, 6.1 Hz, 1H), 2.35-2.10 (m,
				2H), 1.96-1.83 (m, 2H), 1.45 (s, 9H),
				1.36 (d, J = 7.2 Hz, 3H), 1.33-0.98 m,
				5H), 1.10 (d, J = 6.5 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.62,
				140.75, 140.10, 129.62, 127.90, 126.55,
				74.02, 55.12, 41.77, 31.46, 31.26,
				28.35, 25.30, 24.45, 18.88, 16.30.
9		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.27 (q,
		film) 3358,	calcd for C21H32FNNaO4,	J = 3.3 Hz, 1H), 6.91-6.82 (m, 2H),
		2975,	404.2208; found, 404.2202	5.45-5.33 (m, 1H), 5.03 (d, J = 7.9 Hz,
		1712,		1H), 4.35-4.18 (m, 1H), 2.69 (dd,
		1498,		J = 9.2, 5.0 Hz, 1H), 2.28 (s, 3H),
		1165, 862 cm−1		2.02 (dp, J = 9.1, 6.7 Hz, 1H), 1.44 (s, 9H),
				1.34-1.17 (m, 4H), 1.06 (d, J = 6.3 Hz,
				3H), 0.98 (d, J = 6.5 Hz, 3H),
				0.70 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.75,
				160.98 (d, J = 243.9 Hz), 155.01,
				139.40 (d, J = 7.3 Hz), 134.70 (d, J = 2.9 Hz),
				129.37 (d, J = 8.1 Hz),
				116.46 (d, J = 20.4 Hz), 112.69 (d, J = 20.5 Hz),
				79.81, 72.22, 50.66, 49.49, 30.41,
				28.34, 20.99, 20.73 (d, J = 1.5 Hz),
				20.44, 18.65, 18.40.
				19F NMR (376 MHz, CDCl3) δ −117.64.
10		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.31 (dd,
		film) 3358,	calcd for C23H36FNNaO4,	J = 8.4, 6.1 Hz, 1H), 6.86 (dd, J = 9.2,
		2966,	432.2521; found, 432.2515	7.4 Hz, 2H), 5.36 (qd, J = 6.3, 4.5 Hz,
		1715,		1H), 5.05 (d, J = 8.0 Hz, 1H),
		1498, 1167 cm−1		4.39-4.21 (m, 1H), 2.91 (dd, J = 10.0, 4.3 Hz,
				1H), 2.30 (s, 3H), 1.74 (ddq, J = 14.1,
				10.2, 4.6 Hz, 1H), 1.52 (ddt, J = 14.5,
				7.4, 4.0 Hz, 1H), 1.44 (d, J = 2.1 Hz,
				9H), 1.42-1.34 (m, 2H),
				1.34-1.28 (m, 2H), 1.26-1.03 (m, 2H),
				1.01 (d, J = 6.2 Hz, 3H), 0.88 (t, J = 7.4 Hz,
				3H), 0.76 (q, J = 7.7 Hz, 1H), 0.70 (t, J = 7.4 Hz,
				2H).
				13C NMR (101 MHz, CDCl3) δ 172.82,
				160.98 (d, J = 244.1 Hz), 154.98,
				139.43 (d, J = 7.3 Hz), 134.74 (d, J = 3.3 Hz),
				129.78 (d, J = 8.0 Hz),
				116.45 (d, J = 20.6 Hz), 112.75 (d, J = 20.7 Hz),
				79.82, 71.95, 49.49, 45.70, 41.63,
				28.36, 21.76, 21.12, 20.61, 18.83,
				18.39, 10.77, 9.56.
				19F NMR (376 MHz, CDCl3) δ −117.60.
11		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.30 (dd,
		film) 3357,	calcd for C23H34FNNaO4,	J = 8.5, 6.1 Hz, 1H), 6.86 (t, J = 8.2 Hz,
		2954,	430.2364; found, 430.2361	2H), 5.31 (td, J = 6.5, 4.4 Hz, 1H),
		1711,		5.06 (d, J = 7.8 Hz, 1H), 4.39-4.20 (m,
		1497,		1H), 2.80 (dd, J = 10.3, 4.3 Hz, 1H),
		1164, 860,		2.30 (s, 3H), 2.26-2.10 (m, 1H),
		732 cm−1		1.88 (dtd, J = 11.0, 6.9, 3.3 Hz, 1H),
				1.74-1.48 (m, 2H), 1.48-1.33 (m, 11H),
				1.33-1.13 (m, 4H), 1.11-1.00 (m,
				4H), 0.96-0.81 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.69,
				160.94 (d, J = 243.9 Hz), 155.01,
				138.84 (d, J = 7.2 Hz), 135.28 (d, J = 3.1 Hz),
				129.66 (d, J = 8.1 Hz),
				116.43 (d, J = 20.2 Hz), 112.70 (d, J = 20.4 Hz),
				79.82, 73.45, 49.55, 49.41, 42.93,
				31.61, 31.35, 28.35, 25.13, 24.42,
				20.61, 18.72, 18.22.
				19F NMR (376 MHz, CDCl3) δ −117.66.
12		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3357,	calcd for C24H36FNNaO4,	7.32-7.26 (m, 1H), 6.90-6.81 (m, 2H),
		2928,	444.2521; found, 444.2514	5.47-5.35 (m, 1H), 5.07 (d, J = 7.9 Hz,
		1709,		1H), 4.31 (q, J = 7.4 Hz, 1H), 2.76 (dd,
		1497,		J = 9.2, 4.9 Hz, 1H), 2.27 (s, 3H),
		1206, 860,		1.84 (dt, J = 12.6, 3.2 Hz, 1H),
		731 cm−1		1.79-1.53 (m, 3H), 1.45 (s, 9H), 1.41-1.30 (m,
				1H), 1.30-1.25 (m, 3H),
				1.25-0.87 (m, 8H), 0.80 (qt, J = 12.1, 6.1 Hz, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.81,
				160.94 (d, J = 243.9 Hz), 154.99,
				139.46 (d, J = 7.2 Hz), 134.70 (d, J = 3.2 Hz),
				129.43 (d, J = 7.9 Hz),
				116.39 (d, J = 20.5 Hz), 112.73 (d, J = 20.5 Hz),
				79.78, 71.54, 49.67, 49.44, 40.28,
				31.31, 30.73, 28.38, 26.45, 26.40,
				26.34, 20.73, 18.79, 18.29.
				19F NMR (376 MHz, CDCl3) δ −117.65.
13		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.27 (d,
		film) 3357,	calcd for C22H34FNNaO4,	J = 6.3 Hz, 1H), 6.91-6.80 (m, 2H),
		2971,	418.2364; found, 418.2360	5.50-5.32 (m, 1H), 5.03 (s, 1H),
		1712,		4.27 (dt, J = 13.6, 7.2 Hz, 1H), 2.79 (ddd, J = 43.4,
		1498,		9.2, 5.1 Hz, 1H), 2.28 (d, J = 1.8 Hz,
		1164, 860 cm−1		3H), 1.81 (dtdd, J = 19.1, 9.5, 6.3,
				3.1 Hz, 1H), 1.68-1.50 (m, 1H),
				1.44 (d, J = 3.1 Hz, 9H), 1.36-1.13 (m,
				3H), 1.13-0.57 (m, 10H).
				19F NMR (376 MHz, CDCl3) δ −117.61,
				−117.68.
14		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.09 (dd,
		film) 3355,	calcd for C22H32FNNaO4,	J = 8.3, 6.0 Hz, 1H), 6.82 (t, J = 8.4 Hz,
		2976,	416.2208; found, 416.2203	2H), 5.11 (t, J = 6.4 Hz, 1H), 4.95 (d, J = 8.0 Hz,
		1713		1H), 4.17 (t, J = 7.5 Hz, 1H),
		1498, 1166 cm−1		3.02 (dd, J = 10.4, 6.7 Hz, 1H), 2.65 (q,
				J = 8.6, 7.8 Hz, 1H), 2.35 (s, 3H),
				2.15 (dp, J = 7.4, 5.1, 4.1 Hz, 1H),
				1.92-1.75 (m, 2H), 1.75-1.55 (m, 2H),
				1.49-1.32 (m, 10H), 1.17 (d, J = 6.3 Hz,
				3H), 1.06 (d, J = 7.2 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.57.
15		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.09 (dd,
		film) 3356,	calcd for C23H34FNNaO4,	J = 9.5, 5.9 Hz, 1H), 6.91-6.82 (m,
		2954,	430.2364; found, 430.2360	2H), 5.26 (p, J = 6.5 Hz, 1H), 5.03 (s,
		1711,		1H), 4.35-4.19 (m, 1H), 3.10 (t, J = 8.3 Hz,
		1497,		1H), 2.30 (s, 3H),
		1163,		2.21-2.06 (m, 1H), 1.85 (dtd, J = 11.2, 7.3, 3.5 Hz,
		1056, 860,		1H), 1.72-1.46 (m, 2H), 1.44 (s,
		732 cm−1		9H), 1.42-1.14 (m, 6H), 1.08 (d, J = 6.4 Hz,
				3H), 1.03 (dd, J = 9.1, 6.4 Hz,
				1H), 0.91 (dtt, J = 15.2, 7.8, 4.4 Hz,
				1H).
				19F NMR (376 MHz, CDCl3) δ −117.51.
16		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.05 (dd,
		film) 2928,	calcd for C24H36FNNaO4,	J = 8.3, 5.9 Hz, 1H), 6.91-6.81 (m,
		1714,	444.2521; found, 444.2516	2H), 5.36 (dq, J = 9.2, 6.3 Hz, 1H),
		1497,		5.08 (d, J = 7.8 Hz, 1H), 4.31 (d, J = 9.1 Hz,
		1450,		1H), 3.11 (dd, J = 9.2, 6.0 Hz, 1H),
		1366,		2.31 (s, 3H), 1.82-1.50 (m, 6H), 1.45 (s,
		1166,		9H), 1.40 (d, J = 7.1 Hz, 3H),
		1029, 861,		1.35-1.06 (m, 2H), 1.02 (d, J = 6.3 Hz, 3H),
		733 cm−1		1.00-0.77 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.40.
17		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.05 (dd,
		film) 3355,	calcd for C21H32FNNaO4,	J = 8.5, 6.0 Hz, 1H), 6.87 (ddt, J = 11.6,
		2965,	404.2208; found, 404.2201	8.3, 4.1 Hz, 2H), 5.33 (dq, J = 9.1, 6.2 Hz,
		1714,		1H), 5.05 (d, J = 8.1 Hz, 1H),
		1499,		4.28 (d, J = 7.6 Hz, 1H), 3.08 (dd, J = 9.2,
		1366,		6.2 Hz, 1H), 2.32 (s, 3H),
		1167,		2.18-2.06 (m, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
		1052, 735 cm−1		3H), 1.03 (d, J = 6.2 Hz, 3H),
				0.85 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.9 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.34.
18		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 2963,	calcd for C23H36FNNaO4,	7.34 (dd, J = 9.7, 6.0 Hz, 1H), 6.86 (ddd, J = 8.3,
		1714,	432.2521; found, 432.2516	5.8, 2.9 Hz, 2H), 5.38 (dq, J = 8.1,
		1497,		6.3 Hz, 1H), 5.05 (d, J = 8.2 Hz, 1H),
		1453,		4.27 (qd, J = 6.4, 3.6 Hz, 1H), 2.74 (dd,
		1367,		J = 10.2, 3.6 Hz, 1H), 2.28 (s, 3H),
		1166,		1.88 (ddq, J = 10.1, 6.2, 4.0, 3.2 Hz, 1H),
		1055, 860 cm−1		1.69-1.48 (m, 1H), 1.44 (s, 9H),
				1.36 (d, J = 7.2 Hz, 1H), 1.35-1.11 (m,
				2H), 1.10-0.83 (m, 6H), 0.74 (dt, J = 25.4,
				7.3 Hz, 6H).
				19F NMR (376 MHz, CDCl3) δ −117.41,
				−118.02.
19		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.33 (dd,
		film) 3442,	calcd for C22H34FNNaO4,	J = 9.5, 6.0 Hz, 1H), 6.86 (ddt, J = 12.5,
		2965,	418.2364; found, 418.2360	8.4, 3.6 Hz, 2H), 5.36 (ddq, J = 15.7,
		1713,		9.5, 6.2 Hz, 1H), 5.08 (s, 1H), 4.28 (p, J = 6.3 Hz,
		1497,		1H), 2.28 (d, J = 3.9 Hz, 3H),
		1453,		2.04-1.57 (m, 1H), 1.45 (d, J = 1.9 Hz,
		1367,		9H), 1.42-1.11 (m, 2H),
		1165,		1.09-0.99 (m, 3H), 0.99-0.83 (m, 6H),
		1055, 954,		0.83-0.74 (m, 3H), 0.68 (d, J = 6.8 Hz,
		860 cm−1		1H).
				19F NMR (376 MHz, CDCl3) δ −117.94,
				−118.00.
20		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.01 (dd,
		film) 3356,	calcd for C22H32FNNaO4,	J = 8.4, 5.9 Hz, 1H), 6.85 (ddt, J = 11.3,
		2977,	416.2208; found, 416.2202	8.3, 4.1 Hz, 2H), 5.08 (dd, J = 14.2, 7.6 Hz,
		1708,		2H), 4.36-4.05 (m, 1H),
		1498,		3.23-3.03 (m, 1H), 2.70 (tt, J = 19.6, 9.3 Hz,
		1163, 909		1H), 2.35 (s, 3H), 2.19-2.04 (m, 2H),
		731 cm−1		1.94-1.72 (m, 2H), 1.72-1.54 (m,
				1H), 1.44 (s, 9H), 1.37 (d, J = 7.1 Hz,
				4H), 1.05 (d, J = 6.3 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.31.
21		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.33 (dd,
		film) 3355,	calcd for C23H34FNNaO4,	J = 8.4, 6.1 Hz, 1H), 6.86 (tt, J = 9.8,
		2954,	430.2364; found, 430.2360	2.8 Hz, 2H), 5.30 (qd, J = 6.1, 3.3 Hz,
		1711,		1H), 5.05 (d, J = 7.7 Hz, 1H),
		1497,		4.42-4.22 (m, 1H), 2.77 (dd, J = 10.8, 3.4 Hz,
		1163,		1H), 2.30 (s, 3H), 2.28-2.10 (m,
		1066,		2H), 1.93 (dtd, J = 11.5, 7.3, 3.4 Hz,
		1019, 860,		1H), 1.75-1.46 (m, 2H),
		733 cm−1		1.46-1.42 (m, 10H), 1.42-1.16 (m, 5H), 1.02 (d,
				J = 6.4 Hz, 3H), 0.86 (tdd, J = 12.0, 8.6,
				6.0 Hz, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.72,
				160.92 (d, J = 243.9 Hz), 155.10,
				138.76 (d, J = 7.3 Hz), 135.17 (d, J = 3.3 Hz),
				129.94 (d, J = 7.8 Hz),
				116.33 (d, J = 20.5 Hz), 112.67 (d, J = 20.6 Hz),
				79.77, 73.09, 49.53, 42.66, 31.71,
				28.31, 25.19, 24.50, 20.59, 18.55,
				17.80.
				19F NMR (376 MHz, CDCl3) δ −117.74.
22		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.33 (dd,
		film) 3357,	calcd for C24H36FNNaO4,	J = 8.6, 6.1 Hz, 1H), 6.86 (ddt, J = 9.8,
		2928,	444.2521; found, 444.2515	7.1, 4.0 Hz, 2H), 5.47-5.36 (m, 1H),
		1711,		5.10-4.94 (m, 1H), 4.37-4.21 (m,
		1497,		1H), 2.72 (dd, J = 9.9, 4.0 Hz, 1H),
		1165, 860,		2.27 (s, 3H), 1.93 (d, J = 12.7 Hz, 1H),
		733 cm−1		1.80-1.48 (m, 4H), 1.44 (s, 10H), 1.29 (dd,
				J = 18.3, 7.7 Hz, 4H), 1.16-0.87 (m,
				6H), 0.87-0.68 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.73,
				160.93 (d, J = 244.0 Hz), 155.06,
				139.41 (d, J = 7.3 Hz), 134.65 (d, J = 3.3 Hz),
				129.67 (d, J = 7.8 Hz),
				116.33 (d, J = 20.6 Hz), 112.74 (d, J = 20.5 Hz),
				79.80, 71.03, 49.68, 39.93, 31.35,
				28.35, 26.51, 26.37, 26.28, 20.74,
				18.54, 17.99.
				19F NMR (376 MHz, CDCl3) δ −117.76.
23		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.32 (dd,
		film) 3356,	calcd for C21H32FNNaO4,	J = 8.4, 6.1 Hz, 1H), 6.92-6.82 (m,
		2975,	404.2208; found, 404.2202	2H), 5.40 (qd, J = 6.3, 3.9 Hz, 1H),
		1712,		5.00 (d, J = 7.8 Hz, 1H), 4.41-4.18 (m,
		1498,		1H), 2.63 (dd, J = 9.5, 4.3 Hz, 1H),
		1366,		2.28 (s, 3H), 2.03 (dp, J = 9.7, 6.4 Hz, 1H),
		1165,		1.44 (d, J = 3.7 Hz, 9H),
		1063, 862,		1.41-1.12 (m, 3H), 1.10-0.95 (m, 5H),
		735 cm−1		0.92-0.74 (m, 1H), 0.67 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.72.
24		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3355,	calcd for C22H35NO4Na,	7.21-6.94 (m, 3H), 5.44-5.34 (m, 1H),
		2973,	400.2458; found, 400.2452	5.06 (d, J = 7.8 Hz, 1H), 4.33-4.23 (m,
		2871,		1H), 2.68 (dd, J = 9.2, 4.9 Hz, 1H),
		1713,		2.28 (s, 3H), 2.25 (s, 3H), 2.03 (dp, J = 9.0,
		1366,		6.6 Hz, 1H), 1.44 (s, 9H), 1.25 (d, J = 7.3 Hz,
		1163, 733 cm−1		3H), 1.05 (d, J = 6.3 Hz, 3H),
				0.98 (d, J = 6.6 Hz, 3H), 0.70 (d, J = 6.7 Hz,
				3H).
25		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3366,	calcd for C24H37NO4Na,	7.24-6.91 (m, 3H), 5.30 (dq, J = 6.5, 3.4, 2.2 Hz,
		2953,	426.2615; found, 426.2608	1H), 5.08 (d, J = 8.2 Hz, 1H),
		1712,		4.34-4.25 (m, 1H), 2.79 (dd, J = 10.3, 4.1 Hz,
		1161, 731 cm−1		1H), 2.29 (s, 3H), 2.27 (s, 3H),
				2.25-2.14 (m, 1H), 1.97-1.80 (m, 1H),
				1.70-1.61 (m, 1H), 1.58-1.35 (m,
				12H), 1.34-1.17 (m, 5H), 1.07 (d, J = 6.3 Hz,
				3H), 0.93-0.87 (m, 1H).
26		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.21 (d,
		film) 3360,	calcd for C25H39NO4Na,	J = 7.9 Hz, 1H), 6.98-6.94 (m, 2H),
		2924,	440.2771; found, 440.2765	5.48-5.30 (m, 1H), 5.08 (d, J = 7.9 Hz,
		1712,		1H), 4.38-4.23 (m, 1H), 2.75 (dd, J = 9.3,
		1162, 732 cm−1		4.8 Hz, 1H), 2.28 (s, 3H), 2.24 (s,
				3H), 1.90-1.83 (m, 1H)
				1.79-1.53 (m, 3H), 1.45 (s, 9H), 1.42-1.05 (m,
				8H), 1.03 (d, J = 6.2 Hz, 3H),
				1.01-0.73 (m, 2H).
27		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3358,	calcd for C23H37NO4Na,	7.23-6.90 (m, 3H), 5.40 (dd, J = 7.7, 4.7 Hz,
		2970,	414.2615; found, 414.2610	1H), 5.06 (t, J = 9.1 Hz, 1H),
		2931,		4.35-4.21 (m, 1H), 2.87-2.70 (m, 1H),
		1713,		2.30-2.24 (m, 6H), 1.92-1.75 (m, 1H),
		1163, 733 cm−1		1.64-1.53 (m, 1H), 1.44 (d, J = 4.3 Hz,
				9H), 1.35-1.14 (m, 3H),
				1.15-0.62 (m, 10H).
28		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.21 (dd,
		film) 3358,	calcd for C21H32FNNaO5,	J = 8.5, 6.9 Hz, 1H), 6.69-6.53 (m,
		2973,	420.2157; found, 420.2149	2H), 5.39 (p, J = 5.9 Hz, 1H), 5.05 (d, J = 7.8 Hz,
		1711,		1H), 4.33-4.17 (m, 1H),
		1501, 1163 cm−1		3.78 (s, 3H), 3.06 (dd, J = 9.4, 5.0 Hz,
				1H), 1.97 (dp, J = 9.2, 6.6 Hz, 1H),
				1.44 (s, 9H), 1.27-1.20 (m, 3H), 1.05 (d, J = 6.2 Hz,
				3H), 0.95 (d, J = 6.6 Hz, 3H),
				0.68 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.15.
29		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.24 (dd,
		film) 3358,	calcd for C23H36FNNaO5,	J = 8.6, 6.9 Hz, 1H), 6.68-6.50 (m,
		2965,	448.2470; found, 448.2464	2H), 5.44-5.30 (m, 1H), 5.05 (d, J = 8.1 Hz,
		1714,		1H), 4.37-4.18 (m, 1H),
		1501, 1165 cm−1		3.78 (s, 3H), 3.31 (dd, J = 9.7, 4.7 Hz, 1H),
				1.76-1.56 (m, 2H), 1.44 (s, 9H),
				1.41-1.17 (m, 5H), 1.02 (d, J = 6.2 Hz,
				3H), 0.96 (ddd, J = 11.8, 9.1, 6.1 Hz,
				1H), 0.88 (t, J = 7.4 Hz, 3H), 0.69 (t, J = 7.4 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.81,
				162.06 (d, J = 244.1 Hz), 159.15 (d, J = 9.2 Hz),
				154.95, 130.14 (d, J = 9.1 Hz),
				124.35 (d, J = 3.5 Hz), 106.70 (d, J = 20.5 Hz),
				98.44 (d, J = 25.3 Hz), 79.73,
				77.21, 72.04, 55.59, 49.46, 40.99,
				28.34, 21.70, 21.48, 18.84, 18.42,
				10.26, 10.03.
				19F NMR (376 MHz, CDCl3) δ −114.14.
30		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.23 (t, J = 7.8 Hz,
		film) 3356,	calcd for C24H36FNNaO5,	1H), 6.69-6.48 (m, 2H),
		2929,	460.2470; found, 460.2466	5.47-5.33 (m, 1H), 5.07 (d, J = 8.2 Hz,
		1714,		1H), 4.35-4.21 (m, 1H), 3.77 (s,
		1502, 1165 cm−1		3H), 3.13 (s, 1H), 1.87-1.53 (m, 6H),
				1.44 (s, 9H), 1.39-1.16 (m, 4H),
				1.16-0.85 (m, 6H), 0.78 (qd, J = 12.2, 3.2 Hz,
				1H).
				19F NMR (376 MHz, CDCl3) δ −114.17.
31		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ
		film) 3358,	calcd for C23H34FNNaO5,	7.29-7.22 (m, 1H), 6.68-6.55 (m, 2H),
		2954,	446.2313; found, 446.2309	5.38-5.24 (m, 1H), 5.08 (d, J = 7.9 Hz,
		1713,		1H), 4.38-4.21 (m, 1H), 3.78 (s, 3H),
		1502, 1165 cm−1		3.12 (d, J = 10.7 Hz, 1H), 2.16 (qd, J = 10.0,
				7.8, 2.9 Hz, 1H), 1.85 (ddt, J = 14.5,
				11.1, 5.0 Hz, 1H), 1.74-1.59 (m,
				1H), 1.52 (dtd, J = 15.4, 8.4, 3.7 Hz,
				1H), 1.44 (d, J = 2.3 Hz, 9H),
				1.43-1.14 (m, 6H), 1.03 (d, J = 6.3 Hz, 3H),
				1.00-0.81 (m, 2H).
				19F NMR (376 MHz, CDCl3) δ −114.20.
32		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3358,	calcd for C22H34FNNaO5,	7.21 (ddd, J = 14.6, 8.6, 6.9 Hz, 1H),
		2968,	434.2313; found, 434.2306	6.61 (dddd, J = 15.1, 10.8, 4.4, 2.5 Hz, 2H),
		1711,		5.47-5.33 (m, 1H), 5.05 (dd, J = 16.0,
		1501, 1163 cm−1		7.7 Hz, 1H), 4.25 (dt, J = 23.5, 7.3 Hz,
				1H), 3.78 (d, J = 1.3 Hz, 3H),
				3.31-3.08 (m, 1H), 1.78 (ttd, J = 7.9, 6.3, 5.9,
				3.5 Hz, 1H), 1.55-1.35 (m, 10H),
				1.34-1.18 (m, 2H), 1.10 (td, J = 15.7, 14.1,
				6.9 Hz, 3H), 1.04-0.81 (m, 5H),
				0.77-0.61 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.11,
				−114.21.
33		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.06 (dd,
		film) 3352,	calcd for C20H30FNO4Na,	J = 8.7, 5.6 Hz, 2H), 7.02-6.92 (m,
		2964,	390.2051; found, 390.2044	2H), 5.36 (dq, J = 8.7, 6.3 Hz, 1H),
		2932,		5.05 (s, 1H), 4.37-4.19 (m, 1H), 2.69 (dd, J = 8.7,
		1712,		6.4 Hz, 1H), 2.08 (h, J = 6.7 Hz,
		1605,		1H), 1.45 (s, 8H), 1.38 (d, J = 7.2 Hz,
		1509,		3H), 1.06 (d, J = 6.2 Hz, 3H), 0.86 (d, J = 6.8 Hz,
		1452,		3H), 0.74 (d, J = 6.8 Hz, 3H).
		1366,		13C NMR (126 MHz, CDCl3) δ 172.79,
		1224,		161.75 (d, J = 244.8 Hz), 155.03,
		1160,		134.29, 131.03 (d, J = 7.6 Hz),
		1052, 835 cm−1		114.82 (d, J = 21.0 Hz), 79.79, 72.32, 55.88,
				49.50, 28.34, 28.18, 21.30, 18.81,
				18.41, 17.74.
34		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.07 (dd,
		film) 3358,	calcd for C22H32FNNaO5,	J = 8.3, 6.8 Hz, 1H), 6.63-6.53 (m,
		2976,	432.2157; found, 432.2159	2H), 5.19 (q, J = 6.2 Hz, 1H), 5.00 (d, J = 7.8 Hz,
		1710,		1H), 4.18 (d, J = 7.4 Hz, 1H),
		1501,		3.79 (s, 3H), 3.24 (s, 1H), 2.64 (h, J = 8.6 Hz,
		1276,		1H), 2.11 (ddt, J = 11.6, 6.9, 4.3 Hz,
		1164,		1H), 1.88-1.55 (m, 4H),
		1035, 954,		1.51-1.35 (m, 10H), 1.16 (d, J = 7.4 Hz, 3H),
		833 cm−1		1.11 (d, J = 6.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.07.
35		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.00 (dd,
		film) 3358,	calcd for C24H36FNNaO5,	J = 8.3, 6.8 Hz, 1H), 6.60 (ddt, J = 10.7,
		2928,	460.2470; found, 460.2470	7.4, 4.1 Hz, 2H), 5.41 (s, 1H), 5.10 (d, J = 8.0 Hz,
		1712,		1H), 4.37-4.17 (m, 1H),
		1502,		3.76 (s, 3H), 3.36 (s, 1H),
		1450,		1.76-1.48 (m, 5H), 1.45 (s, 9H), 1.38 (d, J = 7.1 Hz,
		1163,		3H), 1.32-1.16 (m, 2H),
		1033, 955,		1.16-0.92 (m, 5H), 0.92-0.72 (m, 2H).
		834 cm−1		19F NMR (376 MHz, CDCl3) δ −113.94.
36		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.05 (t, J = 7.7 Hz,
		film) 3358,	calcd for C32H34FNNaO5,	1H), 6.67-6.53 (m, 2H),
		2954,	446.2313; found, 446.2313	5.29 (s, 1H), 5.07 (s, 1H), 4.23 (d, J = 7.9 Hz,
		1710,		1H), 3.76 (s, 3H), 3.49 (d, J = 67.4 Hz,
		1502,		1H), 2.11 (d, J = 53.5 Hz, 1H),
		1450,		1.84 (dtd, J = 10.9, 7.1, 3.4 Hz, 1H),
		1366,		1.70-1.58 (m, 1H), 1.58-1.37 (m,
		1164,		12H), 1.34 (d, J = 7.1 Hz, 3H),
		1033, 953,		1.30-1.18 (m, 2H), 1.09 (d, J = 6.4 Hz, 3H),
		834, 732 cm−1		0.99-0.83 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.07.
37		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.04 (dd,
		film) 3359,	calcd for C23H36FNNaO5,	J = 8.3, 6.8 Hz, 1H), 6.60 (ddt, J = 11.0,
		2965,	448.2470; found, 448.2469	7.6, 2.5 Hz, 2H), 5.40 (dt, J = 12.5, 6.3 Hz,
		1713,		1H), 5.20-5.02 (m, 1H), 4.27 (s,
		1501,		1H), 3.77 (s, 2H), 3.57 (d, J = 10.1 Hz,
		1165,		1H), 1.55 (dt, J = 9.8, 6.7 Hz, 1H),
		1054,		1.50-1.42 (m, 10H), 1.42-1.30 (m, 4H),
		1035, 955,		1.29-1.09 (m, 2H), 1.06 (d, J = 6.3 Hz,
		834 cm−1		3H), 0.94 (t, J = 7.4 Hz, 3H),
				0.91-0.78 (m, 1H), 0.75 (t, J = 7.2 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.91.
38		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.02 (t, J = 7.6 Hz,
		film) 3358,	calcd for C22H34FNNaO5,	1H), 6.66-6.56 (m, 2H),
		2966,	434.2313; found, 434.2312	5.40 (tt, J = 10.1, 5.5 Hz, 1H), 5.11 (s,
		1711,		1H), 4.29 (dd, J = 15.4, 7.9 Hz, 1H),
		1600,		3.77 (d, J = 2.3 Hz, 3H), 3.42 (d, J = 27.2 Hz,
		1502,		1H), 1.80 (ddt, J = 8.9, 6.8, 4.4 Hz,
		1452,		1H), 1.45 (d, J = 2.2 Hz, 9H),
		1366,		1.36 (ddd, J = 14.4, 12.6, 6.9 Hz, 4H),
		1164,		1.05 (dd, J = 8.1, 6.2 Hz, 3H),
		1053,		0.97-0.82 (m, 4H), 0.76 (dd, J = 11.5, 7.0 Hz,
		1035, 954,		3H).
		834 cm−1		19F NMR (376 MHz, CDCl3) δ −113.85,
				−113.92.
39		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ
		film) 3359,	calcd for C22H32FNNaO5,	7.00-6.93 (m, 1H), 6.58 (ddd, J = 10.0, 6.6,
		2976,	432.2157; found, 432.2147	2.0 Hz, 2H), 5.21-4.97 (m, 2H),
		1709,		4.24 (d, J = 7.9 Hz, 1H), 3.79 (s, 3H),
		1501,		3.31 (s, 1H), 2.76 (h, J = 8.5 Hz, 1H),
		1164,		2.12 (dddd, J = 22.7, 20.7, 11.3, 6.7 Hz, 1H),
		1035, 954,		1.97-1.74 (m, 2H), 1.74-1.57 (m,
		834, 732 cm−1		2H), 1.50-1.37 (m, 10H), 1.34 (d, J = 7.1 Hz,
				3H), 1.06 (d, J = 6.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.90.
40		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.01 (dd,
		film) 3359,	calcd for C21H32FNNaO5,	J = 8.2, 6.7 Hz, 1H), 6.66-6.57 (m,
		2964,	420.2157; found, 420.2154	2H), 5.38 (t, J = 7.4 Hz, 1H), 5.09 (d, J = 7.7 Hz,
		1710,		1H), 4.38-4.20 (m, 1H),
		1502,		3.77 (s, 3H), 3.32 (s, 1H),
		1164,		2.14-2.01 (m, 1H), 1.45 (s, 9H), 1.37 (d, J = 7.2 Hz,
		1050,		3H), 1.05 (d, J = 6.2 Hz, 3H),
		1034, 954,		0.84 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.7 Hz,
		834, 732 cm−1		3H).
				19F NMR (376 MHz, CDCl3) δ −113.87.
41		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3358,	calcd for C23H35NO4Na,	7.09-6.87 (m, 3H), 5.21-5.07 (m, 1H),
		2975,	412.2458; found, 412.2463	4.98 (d, J = 7.9 Hz, 1H), 4.29-4.07 (m, 1H),
		2935,		3.02 (dd, J = 10.5, 6.3 Hz, 1H),
		1713,		2.68 (hept, J = 8.0, 7.1 Hz, 1H), 2.32 (s, 3H),
		1164, 1021 cm−1		2.26 (s, 3H), 2.19-2.08 (m, 1H),
				1.88-1.62 (m, 4H), 1.43 (s, 9H),
				1.32-1.22 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H),
				1.07 (d, J = 7.1 Hz, 3H).
42		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.27 (d,
		film) 3365,	calcd for C20H30ClNO4,	J = 9.9 Hz, 2H), 7.03 (d, J = 8.5 Hz,
		2969,	409.1763; found, 409.1764	2H), 5.42-5.31 (m, 1H),
		2932,		5.13-4.95 (m, 1H), 4.27 (t, 1H), 2.68 (dd, J = 8.6,
		2875,		6.5 Hz, 1H), 2.16-1.98 (m, 1H),
		1714,		1.45 (s, 9H), 1.38 (d, J = 7.2 Hz, 3H),
		1492,		1.07 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.8 Hz,
		1366,		3H), 0.74 (d, J = 6.8 Hz, 3H).
		1166, 1053 cm−1		13C NMR (126 MHz, CDCl3) δ 172.76,
				137.14, 132.52, 131.02, 128.15, 77.21,
				72.15, 56.07, 49.49, 28.35, 28.15,
				25.29, 21.27, 18.81, 18.47, 17.70,
				14.13.
43		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.09 (t, J = 8.0 Hz,
		film) 3353,	calcd for C21H32FNO4,	1H), 6.80-6.71 (m, 2H),
		2969,	406.2268; found, 406.2269	5.40-5.25 (m, 1H), 5.06 (s, 1H),
		2931,		4.33-4.22 (m, 1H), 2.65 (dd, J = 8.7, 6.5 Hz,
		1714,		1H), 2.25 (d, J = 1.8 Hz, 3H),
		1506,		2.13-1.98 (m, 1H), 1.45 (s, 9H), 1.38 (d, J = 7.2 Hz,
		1366,		3H), 1.08 (d, J = 6.3 Hz, 3H),
		1163, 1052 cm−1		0.86 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
				3H).
				13C NMR (126 MHz, CDCl3) δ 172.79,
				161.92, 159.98, 138.35, 138.30, 130.82,
				130.78, 125.20, 125.17, 123.01, 122.88,
				116.22, 116.04, 79.77, 77.21, 72.28,
				56.12, 49.50, 34.67, 31.59, 28.34,
				28.19, 25.28, 21.29, 18.81, 18.51,
				17.74, 14.21, 14.18, 14.13.
44		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.09 (dt,
		film) 3351,	calcd for C20H29F2NO4,	J = 10.1, 8.3 Hz, 1H), 6.92 (ddd, J = 11.7,
		2976,	408.1957; found, 408.1956	7.6, 2.2 Hz, 1H), 6.86-6.76 (m,
		1709,		1H), 5.31 (dt, J = 8.5, 6.3 Hz, 1H),
		1515,		5.03 (s, 1H), 4.27 (s, 1H), 2.72-2.62 (m,
		1280,		1H), 2.13-1.96 (m, 1H), 1.45 (s, 9H),
		1163,		1.37 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.3 Hz,
		1053, 771 cm−1		3H), 0.88 (d, J = 6.8 Hz, 3H),
				0.75 (d, J = 6.8 Hz, 3H).
				13C NMR (126 MHz, CDCl3) δ 172.72,
				125.58, 118.35, 118.21, 116.77, 116.63,
				79.84, 77.21, 71.98, 55.92, 49.48,
				28.33, 28.24, 21.20, 18.75, 18.57,
				17.51.
45		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 2965,	calcd for C21H32FNNaO4,	6.96-6.84 (m, 3H), 5.35 (dq, J = 8.8, 6.2 Hz,
		1714,	404.2208; found, 404.2208	1H), 5.11 (d, J = 7.8 Hz, 1H), 4.28 (p, J = 7.5 Hz,
		1503,		1H), 2.65 (dd, J = 8.9, 6.3 Hz,
		1366,		1H), 2.26 (d, J = 1.9 Hz, 3H),
		1211,		2.13-2.03 (m, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
		1164, 1052 cm−1		3H), 1.07 (d, J = 6.3 Hz, 3H),
				0.85 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.82,
				160.30 (d, J = 243.6 Hz), 155.04,
				134.03 (d, J = 3.9 Hz), 132.62 (d, J = 4.9 Hz),
				128.31 (d, J = 7.7 Hz),
				124.13 (d, J = 17.1 Hz), 114.42 (d, J = 22.0 Hz),
				79.75, 72.46, 55.89, 49.56, 28.36,
				28.19, 21.34, 18.76, 18.46, 17.87,
				14.64 (d, J = 3.5 Hz).
				19F NMR (376 MHz, CDCl3) δ −120.77.
46		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.03 (t, J = 8.5 Hz,
		film) 3369,	calcd for C21H32FNNaO5,	1H), 6.67 (ddd, J = 8.6, 2.6,
		2965,	420.2157; found, 420.2158	0.8 Hz, 1H), 6.60 (dd, J = 12.0, 2.6 Hz,
		1714,		1H), 5.44-5.34 (m, 1H), 5.13 (d, J = 8.0 Hz,
		1508,		1H), 4.28 (dd, J = 11.1, 4.2 Hz,
		1366,		1H), 3.79 (s, 3H), 3.08 (dd, J = 8.5, 6.8 Hz,
		1293,		1H), 2.15-2.05 (m, 1H), 1.45 (s,
		1165,		9H), 1.38 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
		1053, 1032 cm−1		3H), 0.90 (dd, J = 6.7, 1.0 Hz,
				3H), 0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.80,
				162.10 (d, J = 244.2 Hz), 159.37 (d, J = 11.4 Hz),
				155.06, 130.68 (d, J = 6.6 Hz),
				117.55 (d, J = 15.5 Hz), 109.59 (d,
				J = 3.0 Hz), 101.42 (d, J = 27.9 Hz),
				79.66, 72.25, 55.44, 49.55, 47.97,
				28.35, 21.11, 18.84, 18.60, 17.55.
				19F NMR (376 MHz, CDCl3) δ −113.07.
47		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3369,	calcd for C21H32FNNaO5,	6.93-6.77 (m, 3H), 5.32 (dq, J = 8.6, 6.2 Hz,
		2965,	420.2157; found, 420.2160	1H), 5.17-5.04 (m, 1H), 4.28 (dd, J = 11.1,
		1712,		4.1 Hz, 1H), 3.88 (s, 3H),
		1515,		2.63 (dd, J = 8.7, 6.4 Hz, 1H),
		1273,		2.13-2.00 (m, 1H), 1.45 (s, 9H), 1.38 (d, J = 7.2 Hz,
		1221,		3H), 1.08 (d, J = 6.3 Hz, 3H),
		1164,		0.86 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
		1052, 1028 cm−1		3H).
				13C NMR (101 MHz, CDCl3) δ 172.78,
				155.04, 151.97 (d, J = 245.2 Hz),
				146.32 (d, J = 10.6 Hz), 131.77 (d, J = 5.7 Hz),
				125.40 (d, J = 3.6 Hz),
				117.21 (d, J = 18.3 Hz), 112.98 (d, J = 2.1 Hz),
				79.75, 72.30, 56.25, 55.81, 49.53,
				28.35, 28.25, 21.30, 18.75, 18.51,
				17.72.
				19F NMR (376 MHz, CDCl3) δ −135.65.
48		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 6.94 (d,
		film) 3355,	calcd for C22H35NNaO5,	J = 7.7 Hz, 1H), 6.72 (dd, J = 7.6, 1.5 Hz,
		2963,	416.2407; found, 416.2410	1H), 6.68 (d, J = 1.6 Hz, 1H),
		1714,		5.40 (t, J = 7.7 Hz, 1H), 5.14 (d, J = 7.4 Hz,
		1506,		1H), 4.35-4.20 (m, 1H), 3.76 (s, 3H),
		1454,		3.32 (s, 1H), 2.33 (s, 3H), 2.08 (dq, J = 12.5,
		1366,		6.3, 5.8 Hz, 1H), 1.45 (s, 9H),
		1256,		1.38 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 6.2 Hz,
		1163,		3H), 0.84 (d, J = 6.8 Hz, 3H),
		1050 cm−1		0.74 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.75,
				158.09, 155.01, 137.18, 129.51, 124.60,
				120.74, 111.75, 79.60, 73.28, 55.34,
				53.89, 49.67, 29.30, 28.76, 28.37,
				21.44, 21.12, 18.79, 18.12.
49		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3364,	calcd for C22H35NNaO5,	7.03-6.95 (m, 1H), 6.71 (d, J = 7.9 Hz, 2H),
		2961,	416.2407; found, 416.2404	5.33 (dq, J = 9.4, 6.2 Hz, 1H), 5.12 (d, J = 7.9 Hz,
		1712,		1H), 4.38-4.20 (m, 1H),
		1502,		3.78 (s, 3H), 3.05 (dd, J = 9.4, 5.9 Hz,
		1453,		1H), 2.31 (s, 3H), 2.12 (dq, J = 13.4,
		1366,		6.7 Hz, 1H), 1.45 (s, 9H), 1.40 (d, J = 7.2 Hz,
		1250,		3H), 1.03 (d, J = 6.2 Hz, 3H),
		1162,		0.84 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.9 Hz,
		1048, 732 cm−1		3H).
				13C NMR (101 MHz, CDCl3) δ 172.89,
				157.60, 155.00, 138.86, 129.96, 128.86,
				115.89, 110.91, 79.71, 73.89, 55.04,
				49.60, 49.24, 29.58, 28.35, 21.08,
				20.98, 18.72, 18.64, 18.33.
50		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3363,	calcd for C22H35NO6Na,	7.04-6.82 (m, 1H), 6.50-6.30 (m, 2H),
		2962,	432.2357; found, 432.2347	5.50-5.28 (m, 1H), 5.11 (d, J = 7.4 Hz, 1H),
		1712,		4.36-4.17 (m, 1H), 3.80 (s, 3H),
		1505,		3.76 (s, 3H), 3.44-3.00 (m, 1H), 2.06 (h, J = 6.7 Hz,
		1207,		1H), 1.45 (s, 9H), 1.38 (d, J = 7.1 Hz,
		1157,		3H), 1.05 (d, J = 6.2 Hz, 3H),
		1045, 732 cm−1		0.83 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.8 Hz,
				3H).
51		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3359,	calcd for C21H33NO5Na,	7.25-7.13 (m, 1H), 7.07 (dd, J = 7.6, 1.8 Hz,
		2968,	402.23; found, 402.2194	1H), 6.95-6.81 (m, 2H),
		1713,		5.58-5.36 (m, 1H), 5.20-5.02 (m, 1H),
		1493,		4.38-4.17 (m, 1H), 3.78 (s, 3H),
		1242,		3.55-3.08 (m, 1H), 2.10 (h, J = 6.7 Hz, 1H),
		1163,		1.45 (s, 9H), 1.38 (d, J = 7.1 Hz, 3H),
		1051, 755 cm−1		1.06 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.8 Hz,
				3H), 0.74 (d, J = 6.8 Hz, 3H).
52			ESIMS m/z 250.4
			([M + H]+)
53			ESIMS m/z 375.5
			([M + Boc]+)
54			ESIMS m/z 250.4
			([M + H]+)
55			ESIMS m/z 262 ([M + H]+)
56			ESIMS m/z 264.3
			([M + H]+)
57			ESIMS m/z 264.4
			([M + H]+)
58			ESIMS m/z 268 ([M + H]+)
59			ESIMS m/z 266 ([M + H]+)
60			HRMS-ESI (m/z) [M + H]+
			calcd for C17H28NO2,
			278.2120; found, 278.2115
61			HRMS-ESI (m/z) [M + H]+
			calcd for C17H26NO2,
			276.1963; found, 276.1960
62			ESIMS m/z 282.2
			([M + H]+)
63			ESIMS m/z 310.2
			([M + H]+)
64			ESIMS m/z 308.2
			([M + H]+)
65			ESIMS m/z 322.2
			([M + H]+)
66			ESIMS m/z 296.2
			([M + H]+)
67			ESIMS m/z 294.2
			([M + H]+)
68			ESIMS m/z 308.2
			([M + H]+)
69			ESIMS m/z 322.2
			([M + H]+)
70			ESIMS m/z 282.1
			([M + H]+)
71			ESIMS m/z 310.2
			([M + H]+)
72			ESIMS m/z 296.2
			([M + H]+)
73			ESIMS m/z 294.2
			([M + H]+)
74			ESIMS m/z 308.1
			([M + H]+)
75			ESIMS m/z 322.2
			([M + H]+)
76			ESIMS m/z 282.2
			([M + H]+)
77			HRMS-ESI (m/z) [M + H]+
			calcd for C18H30NO2,
			292.2271; found, 292.2268
78			HRMS-ESI (m/z) [M + H]+
			calcd for C20H32NO2,
			318.2428; found, 318.2525
79			HRMS-ESI (m/z) [M + H]+
			calcd for C19H30NO2,
			304.2271; found, 304.2267
80			HRMS-ESI (m/z) [M + H]+
			calcd for C17H28NO2,
			278.2115; found, 278.2112
81		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 3383,	calcd for C15H23FNO2,
		2960,	268.1707; found, 268.1717
		1737,
		1603,
		1509,
		1460,
		1386,
		1223,
		1117, 834 cm−1
82			ESIMS m/z 298.3
			([M + H]+)
83			EIMS m/z 324.9
84			ESIMS m/z 338.3
			([M + H]+)
85			EIMS m/z 324.2
86			EIMS m/z 311.1
87			EIMS m/z 310.2
88			EIMS m/z 337.3
89			EIMS m/z 323.0
90			EIMS m/z 326.2
91			EIMS m/z 311.9
92			ESIMS m/z 310.0
			([M + H]+)
93			EIMS m/z 298.2
94			HRMS-ESI (m/z) [M + H]+
			calcd for C18H28NO2,
			290.2115; found, 290.2116
95		IR (thin	ESIMS m/z 284.1
		film) 3451,	([M + H]+)
		3381,
		2957,
		2751,
		2626,
		2506,
		1757,
		1515,
		1492,
		1240,
		1214,
		1092, 832 cm−1
96		IR (thin	ESIMS m/z 282.2
		film) 2959,	([M + H]+)
		2928,
		1738,
		1507,
		1235,
		1117, 731 cm−1
97		IR (thin	ESIMS m/z 286.2
		film) 3386,	([M + H]+)
		2961,
		1739,
		1515,
		1238,
		1210, 1115 cm−1
98			ESIMS m/z 282.3
			([M + H]+)
99			ESIMS m/z 298.3
			([M + H]+)
100			ESIMS m/z 298.3
			([M + H]+)
101			ESIMS m/z 294.3
			([M + H]+)
102			ESIMS m/z 294.3
			([M + H]+)
103			HRMS-ESI (m/z) [M + H]+
			calcd for C16H26NO3,
			280.1907; found, 280.1908
104			HRMS-ESI (m/z) [M + Na]+
			calcd for C17H27NO4Na,
			382.1832; found, 332.1811
105			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
			calcd for C22H29N2O5,	1H), 8.46 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 5.2 Hz,
			401.2076; found, 401.2078	1H), 7.27-7.08 (m, 5H),
				6.88 (d, J = 5.2 Hz, 1H), 5.56-5.43 (m, 1H),
				4.74-4.54 (m, 1H), 3.94 (s, 3H),
				2.37 (dd, J = 8.4, 5.7 Hz, 1H), 2.03 (dh, J = 8.4,
				6.6 Hz, 1H), 1.32 (d, J = 7.2 Hz,
				3H), 1.13 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.6 Hz,
				3H), 0.71 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.67,
				168.64, 155.38, 148.77, 140.46, 139.69,
				130.49, 129.58, 127.91, 126.49, 109.45,
				72.39, 57.96, 56.07, 48.05, 29.19,
				21.30, 20.17, 18.93, 18.06.
106			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.17 (s,
			calcd for C24H31N2O5,	1H), 8.52 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 5.2 Hz,
			427.2233; found, 427.2235	1H), 7.31-7.12 (m, 5H), 6.88 (d,
				J = 5.2 Hz, 1H), 5.37 (qd, J = 6.3, 3.9 Hz,
				1H), 4.81-4.58 (m, 1H), 3.94 (s, 3H),
				2.42 (dd, J = 10.3, 4.1 Hz, 1H),
				2.25-2.16 (m, 1H), 1.88 (dtd, J = 11.2, 7.2, 3.3 Hz,
				1H), 1.69-1.50 (m, 3H), 1.49 (d, J = 7.2 Hz,
				3H), 1.47-1.30 (m, 2H),
				1.24-1.13 (m, 1H), 1.08 (d, J = 6.4 Hz, 3H),
				0.99-0.85 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 171.60,
				168.73, 155.39, 148.80, 140.63, 140.49,
				130.45, 129.44, 127.93, 126.45, 109.49,
				73.59, 56.60, 56.07, 48.21, 42.11, 31.63,
				31.45, 25.07, 24.52, 18.73, 18.22.
107			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 12.16 (s,
			calcd for C22H29N2O5,	1H), 8.50 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
			401.2076; found, 401.2073	1H), 7.38-7.17 (m, 3H),
				7.13-7.04 (m, 2H), 6.88 (d, J = 5.2 Hz, 1H),
				5.44 (dq, J = 8.6, 6.3 Hz, 1H),
				4.81-4.59 (m, 1H), 3.95 (s, 3H), 2.72 (dd, J = 8.6,
				6.5 Hz, 1H), 2.24-2.00 (m, 1H),
				1.55 (d, J = 7.2 Hz, 3H), 1.11 (d, J = 6.3 Hz
				3H), 0.86 (d, J = 6.8 Hz, 3H),
				0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (75 MHz, CDCl3) δ 171.73,
				168.72, 155.37, 148.75, 140.50, 138.53,
				130.49, 129.78, 127.93, 126.66, 109.45,
				73.04, 56.60, 56.11, 48.21, 28.31,
				21.31, 18.65, 18.35, 17.76.
108			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (s,
			calcd for C23H29N2O5	1H), 8.50 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 5.2 Hz,
			413.2071; found, 413.2070	1H), 7.12-7.05 (m, 4H),
				6.88 (d, J = 5.2 Hz, 1H), 5.42-5.24 (m, 1H),
				4.82-4.63 (m, 1H), 3.95 (s, 3H),
				2.32 (s, 3H), 1.99 (dd, J = 10.1, 7.0 Hz, 1H),
				1.52 (d, J = 7.2 Hz, 3H), 1.18 (d, J = 6.4 Hz,
				3H), 1.15-1.06 (m, 1H),
				0.70-0.61 (m, 1H), 0.44-0.29 (m, 2H),
				−0.01-−0.10 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 171.66,
				168.63, 155.40, 148.79, 140.43, 138.48,
				136.16, 130.58, 128.94, 128.25, 109.44,
				76.20, 56.06, 55.24, 48.15, 21.01,
				18.39, 18.13, 12.99, 6.94, 2.89.
109		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.17 (d,
		film) 3370,	calcd for C23H31N2O5,	J = 0.6 Hz, 1H), 8.51 (d, J = 7.9 Hz,
		2960,	415.2227; found, 415.2222	1H), 8.00 (d, J = 5.2 Hz, 1H),
		1732,		7.11-7.05 (m, 2H), 7.00-6.95 (m, 2H),
		1649,		6.88 (d, J = 5.2 Hz, 1H), 5.42 (dq, J = 8.6,
		1527,		6.3 Hz, 1H), 4.75-4.65 (m, 1H),
		1481,		3.94 (s, 3H), 2.68 (dd, J = 8.6, 6.5 Hz, 1H),
		1451,		2.31 (s, 3H), 2.09 (h, J = 6.7 Hz, 1H),
		1263,		1.56 (d, J = 7.2 Hz, 3H), 1.11 (d, J = 6.2 Hz,
		1150,		3H), 0.85 (d, J = 6.8 Hz, 3H),
		1048, 799,		0.76 (d, J = 6.8 Hz, 3H).
		730 cm−1		13C NMR (101 MHz, CDCl3) δ 171.72,
				168.74, 155.39, 148.79, 140.47, 136.11,
				135.40, 130.54, 129.64, 128.64, 109.47,
				73.12, 56.22, 56.07, 48.23, 28.28,
				21.32, 20.99, 18.65, 18.33, 17.75.
110			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
			calcd for C22H28FN2O5,	1H), 8.61-8.38 (m, 1H),
			419.1977; found, 419.1978	8.06-7.94 (m, 1H), 7.12-6.82 (m, 5H),
				5.51-5.33 (m, 1H), 4.75-4.60 (m, 1H),
				3.95 (s, 3H), 2.77-2.63 (m, 1H),
				2.16-1.99 (m, 1H), 1.59-1.47 (m, 3H),
				1.16-1.04 (m, 3H), 0.94-0.83 (m, 3H),
				0.79-0.71 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −116.41,
				−116.47.
111			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
			calcd for C22H26FN2O5,	1H), 8.46 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 5.2 Hz,
			417.1821; found, 417.1813	1H), 7.21-7.07 (m, 2H),
				7.02-6.92 (m, 2H), 6.88 (d, J = 5.2 Hz, 1H),
				5.37-5.25 (m, 1H), 4.85-4.60 (m,
				1H), 3.95 (s, 3H), 2.03 (dd, J = 10.2,
				6.6 Hz, 1H), 1.51 (d, J = 7.2 Hz, 3H),
				1.19 (d, J = 6.4 Hz, 3H), 1.16-1.03 (m,
				1H), 0.74-0.62 (m, 1H),
				0.49-0.29 (m, 2H), −0.02-−0.12 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −116.42.
112		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 12.16 (s,
		film) 3372,	calcd for C24H33N2O5,	1H), 8.51 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2962,	429.2389; found, 429.2385	1H), 7.38-7.00 (m, 5H),
		2934,		6.88 (d, J = 5.2 Hz, 1H),
		2879,		5.59-5.37 (m, 1H), 4.70 (p, J = 7.2 Hz, 1H),
		1734,		3.95 (s, 3H), 2.97 (dd, J = 8.5, 6.4 Hz, 1H),
		1650,		1.55 (d, J = 7.2 Hz, 3H),
		1576,		1.51-1.31 (m, 5H), 1.12 (d, J = 6.3 Hz, 3H),
		1528,		0.93 (t, J = 7.4 Hz, 3H), 0.77 (t, J = 7.2 Hz,
		1481,		3H).
		1452,
		1324,
		1280,
		1264,
		1213,
		1149,
		1059, 954,
		802, 737,
		705 cm−1.
113		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 12.17 (s,
		film) 3370,	calcd for C24H31N2O5,	1H), 8.48 (t, J = 8.9 Hz, 1H), 8.00 (d, J = 5.9 Hz,
		2943,	427.2233; found, 427.2237	1H), 7.33-7.03 (m, 5H),
		2868,		6.93-6.83 (m, 1H), 5.41-5.26 (m,
		1731,		1H), 4.80-4.58 (m, 1H), 3.95 (s, 3H),
		1648,		2.78 (dd, J = 10.1, 5.9 Hz, 1H),
		1527,		2.33-2.11 (m, 2H), 1.99-1.80 (m, 2H),
		1450,		1.69-1.56 (m, 2H), 1.52 (dd, J = 7.2 Hz,
		1263,		3H), 1.44-1.16 (m, 4H), 1.13 (d, J = 6.5 Hz,
		1144,		2H).
		1038, 799,
		734, 702 cm−1.
114		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.94 (s,
		film) 3254,	calcd for C24H31N2O4S,	1H), 10.69 (s, 1H), 7.98 (s, 1H),
		2947,	443.1999; found, 443.2026	7.26-7.18 (m, 4H), 7.14-7.08 (m, 1H),
		2867,		6.88 (s, 1H), 5.43-5.25 (m, 1H), 5.07 (dp, J = 17.6,
		1729,		7.2 Hz, 1H), 3.97 (d, J = 3.1 Hz,
		1512,		3H), 2.79 (dd, J = 9.9, 6.0 Hz, 1H),
		1485,		2.45-2.27 (m, 1H), 2.27-2.12 (m, 1H),
		1273,		2.00-1.77 (m, 1H), 1.61 (d, J = 7.1 Hz,
		1207, 730 cm−1		3H), 1.57-1.39 (m, 4H),
				1.35-1.23 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H).
115		IR	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 12.94 (s,
		(CDCl3)	calcd for C24H30N2O4S,	1H), 10.71 (s, 1H), 8.01 (d, J = 15.0 Hz,
		2951,	465.1818; found, 465.1830	1H), 7.22-7.17 (m, 3H), 7.15 (dd, J = 6.7,
		2868,		3.0 Hz, 2H), 6.89 (d, J = 5.0 Hz,
		1733,		1H), 5.39 (qd, J = 6.4, 4.0 Hz, 1H),
		1581,		5.12-5.03 (m, 1H), 3.97 (s, 3H), 2.41 (dd, J = 10.4,
		1514,		4.0 Hz, 1H), 2.25-2.14 (m,
		1486,		1H), 1.95-1.84 (m, 1H),
		1454,		1.69-1.59 (m, 1H), 1.56 (d, J = 7.2 Hz, 3H),
		1377,		1.54-1.45 (m, 2H), 1.44-1.28 (m, 2H),
		1342,		1.19 (dq, J = 12.3, 9.1 Hz, 1H), 1.09 (d,
		1274,		J = 6.4 Hz, 3H), 0.92 (ddt, J = 12.5,
		1249,		10.0, 8.5 Hz, 1H).
		1211,
		1131,
		1095, 992,
		913, 860,
		801, 736,
		703 cm−1
116		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 12.13 (s,
		film) 3369,	calcd for C23H29FN2NaO5,	1H), 8.46 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2967,	455.1953; found, 455.1947	1H), 7.22 (dd, J = 8.7, 6.0 Hz,
		1733,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.83 (dd,
		1650,		J = 9.9, 2.7 Hz, 1H), 6.73 (td, J = 8.5,
		1529,		2.9 Hz, 1H), 5.49-5.41 (m, 1H),
		1481,		4.69 (p, J = 7.3 Hz, 1H), 3.95 (s, 3H),
		1264, 954,		2.69 (dd, J = 9.2, 5.0 Hz, 1H), 2.27 (s, 3H),
		801, 733 cm−1		2.07-1.86 (m, 1H), 1.43 (d, J = 7.2 Hz,
				3H), 1.07 (d, J = 6.3 Hz, 3H),
				0.99 (d, J = 6.6 Hz, 3H), 0.68 (d, J = 6.7 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 171.56,
				168.72, 160.94 (d, J = 244.1 Hz),
				155.46, 148.86, 140.50, 139.36 (d, J = 7.2 Hz),
				134.57 (d, J = 3.3 Hz), 130.48,
				129.32 (d, J = 8.2 Hz), 116.44 (d, J = 20.5 Hz),
				112.67 (d, J = 20.5 Hz),
				109.54, 72.65, 56.10, 50.65, 48.12,
				30.45, 21.00, 20.72, 20.47, 18.37,
				18.16.
				19F NMR (376 MHz, CDCl3) δ −117.61.
117		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3372,	calcd for C25H33FN2NaO5,	1H), 8.47 (d, J = 8.1 Hz, 1H), 8.03 (d, J = 5.2 Hz,
		2963,	483.2266; found, 483.2262	1H), 7.28-7.21 (m, 1H),
		1732,		6.89 (d, J = 5.2 Hz, 1H), 6.82 (dd, J = 9.9,
		1649,		2.8 Hz, 1H), 6.73 (td, J = 8.5, 2.9 Hz,
		1528,		1H), 5.40 (qt, J = 6.2, 3.0 Hz, 1H),
		1450,		4.71 (p, J = 7.3 Hz, 1H), 3.95 (s, 3H),
		1263,		2.90 (dd, J = 10.0, 4.3 Hz, 1H), 2.27 (s,
		1060, 954,		3H), 1.63-1.46 (m, 4H),
		800, 731 cm−1		1.46-1.32 (m, 1H), 1.15-0.83 (m, 9H), 0.65 (t, J = 7.4 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 171.62,
				168.78, 160.93 (d, J = 244.2 Hz),
				155.49, 148.90, 140.52, 139.40 (d, J = 7.2 Hz),
				134.65 (d, J = 3.2 Hz), 130.47,
				129.74 (d, J = 7.9 Hz), 116.41 (d, J = 20.6 Hz),
				112.73 (d, J = 20.5 Hz),
				109.57, 72.33, 56.11, 48.24, 41.62,
				29.30, 21.72, 21.09, 20.60, 18.28,
				18.20, 10.79, 9.43.
				19F NMR (376 MHz, CDCl3) δ −117.60.
118		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3372,	calcd for C25H31FN2NaO5,	1H), 8.47 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2951,	481.2109; found, 481.2106	1H), 7.22 (dd, J = 8.7, 6.0 Hz,
		1732,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.82 (dd,
		1649,		J = 9.8, 2.9 Hz, 1H), 6.71 (td, J = 8.5,
		1528,		2.9 Hz, 1H), 5.34 (qd, J = 6.4, 4.1 Hz,
		1263,		1H), 4.71 (p, J = 7.3 Hz, 1H), 3.95 (s,
		1060, 952,		3H), 2.79 (dd, J = 10.3, 4.3 Hz, 1H),
		911, 800,		2.28 (s, 3H), 2.20-2.08 (m, 1H),
		730 cm−1		1.90 (dtd, J = 11.3, 7.2, 3.6 Hz, 1H),
				1.77-1.14 (m, 9H), 1.08 (d, J = 6.3 Hz, 3H),
				0.85 (ddt, J = 12.4, 10.2, 8.4 Hz, 1H).
				13C NMR (101 MHz, CDCl3) δ 171.50,
				168.76, 160.89 (d, J = 244.1 Hz),
				155.47, 148.87, 140.51, 138.79 (d, J = 7.3 Hz),
				135.16 (d, J = 3.3 Hz), 130.47,
				129.60 (d, J = 8.0 Hz), 116.40 (d, J = 20.4 Hz),
				112.67 (d, J = 20.6 Hz),
				109.56, 73.88, 56.11, 49.39, 48.22,
				42.94, 31.60, 31.38, 25.08, 24.42,
				20.60, 18.19, 18.13.
				19F NMR (376 MHz, CDCl3) δ −117.66.
119		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3372,	calcd for C26H34FN2O5,	1H), 8.47 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2928,	473.2446; found, 473.2440	1H), 7.23 (dd, J = 8.7, 6.0 Hz,
		1732,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.82 (dd,
		1649,		J = 9.9, 2.9 Hz, 1H), 6.74 (td, J = 8.5,
		1528,		2.9 Hz, 1H), 5.50-5.39 (m, 1H),
		1448,		4.70 (p, J = 7.3 Hz, 1H), 3.95 (s, 3H),
		1263,		2.75 (dd, J = 9.3, 4.8 Hz, 1H), 2.26 (s, 3H),
		1060, 954,		1.87 (dt, J = 12.7, 3.2 Hz, 1H),
		910, 730 cm−1		1.80-1.70 (m, 1H), 1.70-1.52 (m, 3H),
				1.45 (d, J = 7.2 Hz, 3H), 1.35-1.15 (m,
				2H), 1.15-0.85 (m, 6H), 0.76 (qd, J = 12.2,
				3.6 Hz, 1H).
				13C NMR (101 MHz, CDCl3) δ 171.59,
				168.75, 160.90 (d, J = 243.9 Hz),
				155.48, 148.86, 140.51, 139.44 (d, J = 7.2 Hz),
				134.60 (d, J = 3.3 Hz), 130.48,
				129.40 (d, J = 8.0 Hz), 116.37 (d, J = 20.5 Hz),
				112.71 (d, J = 20.5 Hz),
				109.56, 71.90, 56.11, 49.65, 48.16,
				40.26, 31.30, 30.80, 26.44, 26.40,
				26.30, 20.72, 18.19, 18.19.
				19F NMR (376 MHz, CDCl3) δ −117.64.
120		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.13 (d,
		film) 3372,	calcd for C24H32FN2O5,	J = 3.1 Hz, 1H), 8.45 (t, J = 6.7 Hz,
		2965,	447.2290; found, 447.2296	1H), 8.02 (dd, J = 5.2, 3.5 Hz, 1H),
		1734,		7.22 (ddd, J = 8.8, 6.1, 4.0 Hz, 1H), 6.89 (dd,
		1650,		J = 5.3, 1.7 Hz, 1H), 6.82 (dd, J = 10.0,
		1529,		2.9 Hz, 1H), 6.73 (qd, J = 8.7, 2.9 Hz,
		1265, 954,		1H), 5.44 (tdd, J = 9.1, 6.4, 3.5 Hz, 1H),
		801, 734 cm−1		4.68 (dp, J = 10.9, 7.3 Hz, 1H), 3.95 (s,
				3H), 2.78 (ddd, J = 48.5, 9.2, 4.9 Hz,
				1H), 2.27 (d, J = 3.9 Hz, 3H),
				1.87-1.33 (m, 4H), 1.26 (s, 1H),
				1.23-0.76 (m, 7H), 0.76-0.60 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.60,
				−117.64.
121		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.12 (s,
		film) 3368,	calcd for C24H30FN2O5,	1H), 8.38 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 5.1 Hz,
		2938,	445.2133; found, 445.2130	1H), 7.06 (dd, J = 8.6, 5.9 Hz,
		1733,		1H), 6.87 (d, J = 5.2 Hz, 1H), 6.80 (dd,
		1648,		J = 9.9, 2.8 Hz, 1H), 6.74 (td, J = 8.5,
		1528,		2.9 Hz, 1H), 5.16 (p, J = 6.3 Hz, 1H),
		1481,		4.58 (p, J = 7.3 Hz, 1H), 3.94 (s, 3H),
		1439,		3.03 (dd, J = 10.4, 6.6 Hz, 1H),
		1263, 953,		2.70-2.57 (m, 1H), 2.34 (s, 3H),
		800, 730 cm−1		2.23-2.10 (m, 1H), 1.86-1.55 (m, 4H),
				1.45-1.34 (m, 1H), 1.28-1.22 (m, 3H),
				1.19 (d, J = 6.3 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.39,
				168.64, 160.91 (d, J = 243.9 Hz),
				155.43, 148.81, 140.45, 139.10 (d, J = 6.7 Hz),
				134.12 (d, J = 3.2 Hz), 130.49,
				128.52 (d, J = 5.2 Hz), 116.50 (d, J = 20.4 Hz),
				112.72 (d, J = 20.7 Hz),
				109.49, 74.20, 56.09, 50.86, 47.99,
				37.76, 29.39, 26.99, 20.45, 18.51,
				18.19, 17.92.
				19F NMR (376 MHz, CDCl3) δ −117.49.
122		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.13 (s,
		film) 3369,	calcd for C25H32FN2O5,	1H), 8.41 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.2 Hz,
		2946,	459.2290; found, 459.2318	1H), 7.09 (dd, J = 8.6, 5.9 Hz,
		1732,		1H), 6.92-6.80 (m, 2H), 6.77 (dd, J = 9.9,
		1648,		2.8 Hz, 1H), 5.31 (p, J = 6.4 Hz,
		1528,		1H), 4.75-4.64 (m, 1H), 3.95 (s, 3H),
		1262,		3.10 (dt, J = 7.1, 5.4 Hz, 1H), 2.26 (s,
		1153, 953,		3H), 2.20-2.06 (m, 1H), 1.87 (qdd, J = 11.1,
		800, 730 cm−1		8.9, 7.1, 3.8 Hz, 1H),
				1.69-1.06 (m, 12H), 0.98-0.82 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 171.59,
				168.65, 160.84 (d, J = 244.2 Hz),
				155.41, 148.81, 140.44, 139.16 (d, J = 7.4 Hz),
				134.99 (d, J = 3.0 Hz), 130.48,
				129.07 (d, J = 8.3 Hz), 116.78 (d, J = 20.4 Hz),
				112.48 (d, J = 20.6 Hz),
				109.49, 75.73, 56.09, 48.21, 48.21,
				43.47, 31.50, 31.09, 25.12, 24.13,
				20.72, 18.23, 17.26.
				19F NMR (376 MHz, CDCl3) δ −117.47.
123		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3371,	calcd for C26H34FN2O5,	1H), 8.47 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2928,	473.2446; found, 473.2467	1H), 7.05 (dd, J = 8.6, 5.9 Hz,
		1733,		1H), 6.92-6.75 (m, 4H), 5.40 (dq, J = 9.0,
		1650,		6.3 Hz, 1H), 4.77-4.68 (m, 1H),
		1528,		3.95 (s, 3H), 3.12 (dd, J = 9.0, 6.1 Hz,
		1450,		1H), 2.29 (s, 3H), 1.82-1.59 (m, 3H),
		1264,		1.53 (dd, J = 21.9, 7.2 Hz, 5H),
		1155, 954,		1.28-0.78 (m, 8H).
		800, 732 cm−1		13C NMR (101 MHz, CDCl3) δ 171.67,
				168.67, 160.89 (d, J = 244.6 Hz),
				155.42, 148.82, 140.47, 139.76 (d, J = 7.6 Hz),
				133.87 (d, J = 3.3 Hz),
				130.50, 129.20 (d, J = 7.2 Hz), 116.93 (d, J = 20.6 Hz),
				112.37 (d, J = 20.7 Hz),
				109.50, 73.49, 56.10, 49.06, 48.20,
				40.18, 31.47, 29.14, 26.60, 26.55,
				26.32, 20.95, 18.38, 17.98.
				19F NMR (376 MHz, CDCl3) δ −117.35.
124		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.13 (s,
		film) 3366,	calcd for C23H30FN2O5,	1H), 8.45 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2961,	433.2133; found, 433.2129	1H), 7.05 (dd, J = 8.6, 5.9 Hz,
		1734,		1H), 6.93-6.77 (m, 3H), 5.38 (dq, J = 8.9,
		1650,		6.3 Hz, 1H), 4.76-4.65 (m, 1H),
		1529,		3.95 (s, 3H), 3.09 (dd, J = 8.9, 6.5 Hz,
		1264,		1H), 2.29 (s, 3H), 2.11 (h, J = 6.8 Hz,
		1153,		1H), 1.55 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.2 Hz,
		1049, 955,		3H), 0.86 (d, J = 6.8 Hz, 3H),
		801, 735 cm−1		0.78 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.30.
125		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.13 (s,
		film) 3368,	calcd for C25H34FN2O5,	1H), 8.42 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 5.3 Hz,
		2962,	461.2446; found, 461.2442	1H), 7.10 (dd, J = 8.7, 5.9 Hz,
		1733,		1H), 6.88 (d, J = 5.1 Hz, 1H), 6.83 (td,
		1650,		J = 8.3, 2.8 Hz, 1H), 6.77 (dd, J = 9.9,
		1528,		2.9 Hz, 1H), 5.46-5.40 (m, 1H),
		1263,		4.75-4.66 (m, 1H), 3.95 (d, J = 2.2 Hz, 3H),
		1154,		3.27 (t, J = 7.7 Hz, 1H), 2.27 (s, 2H),
		1057, 954,		1.67-1.24 (m, 8H), 1.14-0.82 (m,
		800, 733 cm−1		7H), 0.76 (t, J = 7.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.38.
126		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.13 (d,
		film) 3369,	calcd for C24H32FN2O5,	J = 4.6 Hz, 1H), 8.50-8.39 (m, 1H),
		2964,	447.2290; found, 447.2302	7.99 (dd, J = 5.3, 2.8 Hz, 1H),
		1733,		7.07 (ddd, J = 8.9, 5.9, 3.1 Hz, 1H),
		1649,		6.93-6.75 (m, 3H), 5.40 (ddq, J = 21.8, 9.3,
		1528,		6.3 Hz, 1H), 4.77-4.64 (m, 1H),
		1262,		3.95 (s, 3H), 3.16 (ddd, J = 24.5, 8.9, 6.4 Hz,
		1056, 953,		1H), 2.35-2.26 (m, 3H),
		800, 730 cm−1		1.94-1.73 (m, 1H), 1.55 (t, J = 6.9 Hz, 3H),
				1.52-1.33 (m, 1H), 1.08 (dd, J = 9.4, 6.2 Hz,
				3H), 1.01-0.72 (m, 7H).
				19F NMR (376 MHz, CDCl3) δ −117.29,
				−117.34.
127		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3369,	calcd for C24H29FN2O5,	1H), 8.46 (d, J = 8.1 Hz, 1H), 8.00 (dd,
		2939,	467.1953; found, 467.1940	J = 8.2, 5.2 Hz, 1H), 7.01 (ddd, J = 9.3,
		1733,		4.6, 2.2 Hz, 1H), 6.88 (d, J = 5.2 Hz,
		1649,		1H), 6.82 (dd, J = 8.0, 3.4 Hz, 2H),
		1438,		5.12 (p, J = 6.3 Hz, 1H), 4.78-4.64 (m,
		1261,		1H), 3.95 (s, 3H), 3.14 (dd, J = 10.0,
		1039, 953,		7.4 Hz, 1H), 2.74 (h, J = 8.3 Hz, 1H),
		800, 729 cm−1		2.33 (s, 3H), 2.23-2.06 (m, 1H),
				2.05-1.57 (m, 4H), 1.54 (d, J = 7.1 Hz,
				3H), 1.45-1.33 (m, 1H), 1.09 (d, J = 6.3 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.25.
128		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3369,	calcd for C25H31FN2NaO5,	1H), 8.45 (d, J = 7.7 Hz, 1H), 8.02 (d, J = 5.1 Hz,
		2951,	481.2109; found, 481.2105	1H), 7.30 (dd, J = 8.7, 6.1 Hz,
		1735,		1H), 6.90 (d, J = 5.2 Hz, 1H), 6.82 (dd,
		1650,		J = 9.9, 2.9 Hz, 1H), 6.71 (td, J = 8.5,
		1529,		2.9 Hz, 1H), 5.33 (qd, J = 6.3, 3.4 Hz,
		1264, 953,		1H), 4.71 (p, J = 7.3 Hz, 1H), 3.96 (s,
		733 cm−1		3H), 2.78 (dd, J = 10.5, 3.7 Hz, 1H),
				2.29 (s, 3H), 2.28-2.16 (m, 1H),
				1.92 (ddq, J = 10.8, 7.1, 3.4 Hz, 1H),
				1.73-1.60 (m, 1H), 1.60-1.47 (m, 5H),
				1.47-1.31 (m, 2H), 1.31-1.15 (m, 1H),
				1.04 (d, J = 6.4 Hz, 3H),
				0.92-0.77 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −117.71.
129		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
		film) 3372,	calcd for C26H34FN2O5,	1H), 8.42 (d, J = 7.7 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2928,	473.2446; found, 473.2455	1H), 7.30 (dd, J = 8.7, 6.1 Hz,
		1733,		1H), 6.90 (d, J = 5.2 Hz, 1H), 6.81 (dd,
		1527,		J = 9.9, 2.8 Hz, 1H), 6.68 (td, J = 8.5,
		1263, 955,		2.9 Hz, 1H), 5.45 (qd, J = 6.2, 4.0 Hz,
		800, 730 cm−1		1H), 4.70 (p, J = 7.2 Hz, 1H), 3.96 (s,
				3H), 2.73 (dd, J = 9.9, 4.1 Hz, 1H),
				2.26 (s, 3H), 1.92 (dt, J = 12.9, 3.2 Hz, 1H),
				1.80-1.53 (m, 4H), 1.51 (d, J = 7.2 Hz,
				3H), 1.35-1.03 (m, 4H), 1.00 (d, J = 6.3 Hz,
				3H), 0.95 (td, J = 12.1, 3.7 Hz,
				1H), 0.74 (qd, J = 12.2, 3.6 Hz,
				1H).
				19F NMR (376 MHz, CDCl3) δ −117.72.
130		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.12 (s,
		film) 3372,	calcd for C23H30FN2O5,	1H), 8.43 (d, J = 8.3 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2964,	433.2133; found, 433.2130	1H), 7.33-7.23 (m, 1H),
		1734,		6.90 (d, J = 5.2 Hz, 1H), 6.82 (dd, J = 10.0,
		1528,		3.0 Hz, 1H), 6.66 (td, J = 8.5, 2.9 Hz,
		1264, 954,		1H), 5.44 (qd, J = 6.3, 4.0 Hz, 1H),
		801, 732 cm−1		4.70 (p, J = 7.3 Hz, 1H), 3.96 (s, 3H),
				2.68-2.62 (m, 1H), 2.27 (s, 3H),
				2.15-1.82 (m, 1H), 1.50 (d, J = 7.2 Hz,
				3H), 1.02 (dd, J = 6.4, 2.1 Hz, 6H),
				0.67 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.67.
131		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.16 (s,
		film) 3369,	calcd for C24H33N2O5,	1H), 8.49 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 5.2 Hz,
		2968,	451.2203; found, 451.2190	1H), 7.15 (d, J = 7.9 Hz, 1H),
		1732,		6.93 (d, J = 1.8 Hz, 1H),
		1649,		6.92-6.85 (m, 2H), 5.44 (qd, J = 6.2, 4.1 Hz, 1H),
		1527,		4.76-4.60 (m, 1H), 3.94 (s, 3H),
		1263, 800,		2.70 (dd, J = 9.2, 5.0 Hz, 1H), 2.27 (s, 3H),
		730 cm−1		2.24 (s, 3H), 2.02 (dp, J = 9.1, 6.7 Hz,
				1H), 1.42 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
				3H), 0.99 (d, J = 6.6 Hz, 3H),
				0.70 (d, J = 6.7 Hz, 3H).
132		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.17 (s,
		film) 3369,	calcd for C26H35N2O5,	1H), 8.50 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2947,	455.2540; found, 455.2536	1H), 7.16 (d, J = 7.9 Hz, 1H),
		2868,		6.93 (d, J = 1.8 Hz, 1H),
		2256,		6.91-6.85 (m, 2H), 5.33 (qd, J = 6.3, 4.2 Hz, 1H),
		1713,		4.70 (p, J = 7.4 Hz, 1H), 3.94 (s, 3H),
		1527,		2.80 (dd, J = 10.2, 4.2 Hz, 1H), 2.26 (s,
		1263, 730 cm−1		3H), 2.26 (s, 3H), 2.17 (dddd, J = 17.0,
				10.2, 6.8, 3.1 Hz, 1H), 1.89 (dtd, J = 11.0,
				7.1, 3.3 Hz, 1H), 1.69-1.31 (m,
				8H), 1.21 (dq, J = 12.3, 9.2 Hz, 1H),
				1.09 (d, J = 6.4 Hz, 3H),
				0.92-0.81 (m, 1H).
133		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.17 (d,
		film) 3369,	calcd for C27H37N2O5,	J = 0.6 Hz, 1H), 8.50 (d, J = 8.0 Hz,
		2925,	491.2516; found, 491.2520	1H), 8.02 (d, J = 5.2 Hz, 1H), 7.16 (d, J = 7.9 Hz,
		2850,		1H), 6.92 (d, J = 1.9 Hz, 1H),
		1731,		6.91-6.86 (m, 2H), 5.44 (qd, J = 6.3,
		1527,		4.7 Hz, 1H), 4.75-4.64 (m, 1H),
		1262, 729 cm−1		3.94 (s, 3H), 2.76 (dd, J = 9.3, 4.8 Hz, 1H),
				2.27 (s, 3H), 2.23 (s, 3H), 1.87 (dt, J = 12.5,
				3.3 Hz, 1H), 1.78-1.47 (m, 4H),
				1.44 (d, J = 7.2 Hz, 3H),
				1.39-1.14 (m, 2H), 1.05 (d, J = 6.3 Hz, 3H),
				1.03-0.69 (m, 4H).
134		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ
		film) 3369,	calcd for C25H35N2O5,	12.15 (dd, J = 3.6, 0.6 Hz, 1H),
		2964,	443.2540; found, 443.2562	8.52-8.44 (m, 1H), 8.01 (t, J = 5.1 Hz, 1H),
		2933,		7.15 (dd, J = 7.9, 2.0 Hz, 1H),
		2875,		6.95-6.91 (m, 1H), 6.91-6.85 (m, 2H),
		1732,		5.49-5.40 (m, 1H), 4.73-4.61 (m, 1H),
		1527,		3.94 (s, 3H), 2.88-2.70 (m, 1H),
		1263, 800,		2.28-2.22 (m, 6H), 1.91-1.68 (m, 1H),
		730 cm−1		1.49-1.33 (m, 3H), 1.14-0.64 (m, 11H).
135		IR (thin	ESIMS m/z 419.1	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3370,	([M + H]+)	1H), 8.45 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2961,		1H), 7.09-6.99 (m, 2H),
		1733,		6.99-6.90 (m, 2H), 6.89 (d, J = 5.2 Hz,
		1648,		1H), 5.40 (dq, J = 8.4, 6.3 Hz, 1H),
		1575,		4.69 (p, J = 7.3 Hz, 1H), 3.96 (s, 3H),
		1528,		3.71 (t, J = 6.9 Hz, 1H), 2.70 (dd, J = 8.3,
		1509,		6.8 Hz, 1H), 1.54 (d, J = 7.1 Hz,
		1480,		3H), 1.10 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 6.8 Hz,
		1453,		3H), 0.74 (d, J = 6.7 Hz, 3H).
		1437,		13C NMR (126 MHz, CDCl3) δ 171.63,
		1307,		168.72, 168.30, 161.72 (d, J = 244.8 Hz),
		1280,		155.40, 155.06, 150.14, 148.78,
		1261,		140.49, 139.14, 134.23 (d, J = 3.3 Hz),
		1241,		131.01 (d, J = 7.7 Hz), 130.46,
		1150, 801 cm−1		114.80 (d, J = 21.1 Hz), 109.47, 108.37, 72.80,
				56.10, 55.83, 50.65, 48.19, 47.95,
				28.35, 27.05, 23.40, 21.21, 18.75,
				18.32, 17.41.
136		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.92 (s,
		film) 3131,	calcd for C23H30FN2O4S,	1H), 10.79-10.61 (m, 1H), 7.98 (d, J = 5.1 Hz,
		2959,	449.1905; found, 449.1906	1H), 7.05 (dd, J = 8.6, 5.9 Hz,
		1748,		1H), 6.85 (ddt, J = 17.1, 9.5, 4.7 Hz,
		1511,		3H), 5.40 (dq, J = 13.0, 6.4 Hz, 1H),
		1479,		5.09 (p, J = 7.2 Hz, 1H), 3.97 (s, 3H),
		1280,		3.11 (dd, J = 9.0, 6.3 Hz, 1H), 2.30 (s,
		1207,		3H), 2.13 (dt, J = 13.5, 6.8 Hz, 1H),
		1142, 797 cm−1		1.64 (d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.3 Hz,
				3H), 0.86 (d, J = 6.7 Hz, 3H),
				0.79 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.20.
137		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (d,
		film) 3372,	calcd for C25H34FN2O6,	J = 0.6 Hz, 1H), 8.47 (d, J = 8.1 Hz,
		2963,	477.2395; found, 477.2392	1H), 8.02 (d, J = 5.3 Hz, 1H), 7.18 (dd,
		1731,		J = 8.5, 6.9 Hz, 1H), 6.89 (d, J = 5.1 Hz,
		1649,		1H), 6.57 (dd, J = 11.0, 2.5 Hz,
		1528,		1H), 6.51 (td, J = 8.4, 2.6 Hz, 1H),
		1450,		5.40 (qd, J = 6.2, 4.5 Hz, 1H),
		1263,		4.75-4.62 (m, 1H), 3.95 (s, 3H), 3.77 (s, 4H),
		1149,		3.31 (dd, J = 9.9, 4.5 Hz, 1H), 1.63 (d, J = 12.1 Hz,
		1036, 953 cm−1		1H), 1.45 (d, J = 7.2 Hz, 3H),
				1.42-1.27 (m, 1H), 1.24-1.08 (m,
				1H), 1.03 (d, J = 6.2 Hz, 3H),
				1.01-0.91 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H),
				0.65 (t, J = 7.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.13.
138		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
		film) 3370,	calcd for C23H30FN2O6,	1H), 8.46 (d, J = 8.0 Hz, 1H), 8.01 (d, J = 5.2 Hz,
		2964,	449.2082; found, 449.2079	1H), 7.16 (dd, J = 8.5, 6.9 Hz,
		1731,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.57 (dd,
		1649,		J = 11.1, 2.5 Hz, 1H), 6.51 (td, J = 8.3,
		1528,		2.5 Hz, 1H), 5.49-5.40 (m, 1H),
		1263,		4.74-4.61 (m, 1H), 3.95 (s, 3H), 3.77 (s, 3H),
		1149, 953,		3.06 (dd, J = 9.4, 5.0 Hz, 1H),
		731 cm−1		1.96 (ddq, J = 13.1, 9.1, 6.6 Hz, 1H), 1.42 (d,
				J = 7.2 Hz, 3H), 1.07 (d, J = 6.3 Hz,
				3H), 0.97 (d, J = 6.6 Hz, 3H), 0.66 (d, J = 6.6 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −114.12.
139		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.16 (s,
		film) 3371,	calcd for C26H34FN2O6,	1H), 8.47 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2928,	489.2395; found, 489.2401	1H), 7.17 (t, J = 7.7 Hz, 1H),
		1731,		6.89 (d, J = 5.2 Hz, 1H),
		1649,		6.61-6.46 (m, 2H), 5.44 (p, J = 6.1 Hz, 1H),
		1528,		4.69 (p, J = 7.3 Hz, 1H), 3.95 (s, 3H),
		1449,		3.76 (s, 3H), 3.12 (d, J = 6.7 Hz, 1H),
		1262,		1.84 (d, J = 13.0 Hz, 1H), 1.78-1.48 (m,
		1150,		4H), 1.45 (d, J = 7.2 Hz, 3H),
		1128,		1.37-1.05 (m, 4H), 1.04 (d, J = 6.3 Hz, 3H),
		1035, 953,		1.01-0.86 (m, 1H), 0.75 (qd, J = 12.1,
		729 cm−1		3.6 Hz, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.15.
140		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.17 (s,
		film) 3370,	calcd for C25H32FN2O6,	1H), 8.48 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 5.2 Hz,
		2944,	475.2239; found, 475.2233	1H), 7.21-7.13 (m, 1H),
		1732,		6.89 (d, J = 5.2 Hz, 1H), 6.57 (dd, J = 11.1,
		1649,		2.5 Hz, 1H), 6.48 (td, J = 8.3, 2.5 Hz,
		1528,		1H), 5.34 (qd, J = 6.2, 3.3 Hz, 1H),
		1450,		4.71 (p, J = 7.4 Hz, 1H), 3.95 (s, 3H),
		1263,		3.77 (s, 3H), 3.18-3.06 (m, 1H),
		1149,		2.21-2.05 (m, 1H), 1.87 (dtd, J = 11.2, 7.1,
		1036, 952,		3.5 Hz, 1H), 1.74-1.59 (m, 1H),
		731 cm−1		1.58-1.45 (m, 4H), 1.37 (dddd, J = 26.9,
				11.8, 7.7, 3.1 Hz, 1H), 1.28-1.16 (m,
				2H), 1.04 (d, J = 6.3 Hz, 3H),
				1.02-0.97 (m, 1H), 0.95-0.82 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.21.
141		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (d,
		film) 3371,	calcd for C24H32FN2O6,	J = 5.4 Hz, 1H), 8.45 (dd, J = 13.9, 8.0 Hz,
		2964,	463.2239; found, 463.2234	1H), 8.01 (dd, J = 6.2, 5.2 Hz, 1H),
		1731,		7.16 (ddd, J = 8.5, 6.9, 4.0 Hz, 1H),
		1649,		6.88 (dd, J = 5.2, 3.9 Hz, 1H),
		1451,		6.63-6.47 (m, 2H), 5.50-5.39 (m, 1H),
		1263,		4.75-4.59 (m, 1H), 3.95 (d, J = 0.9 Hz,
		1149,		3H), 3.77 (s, 3H), 3.29-3.06 (m, 1H),
		1036, 952,		1.82-1.66 (m, 1H), 1.49 (dd, J = 12.2,
		730 cm−1		7.1 Hz, 2H), 1.33 (d, J = 7.2 Hz, 1H),
				1.20-1.00 (m, 4H), 1.00-0.78 (m,
				4H), 0.74-0.63 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.11,
				−114.15.
142		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.16 (s,
		film) 3371,	calcd for C24H30FN2O6,	1H), 8.41 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2938,	461.2082; found, 461.2073	1H), 7.03 (dd, J = 8.5, 6.8 Hz,
		1732,		1H), 6.88 (d, J = 5.2 Hz, 1H), 6.55 (dd,
		1649,		J = 11.0, 2.5 Hz, 1H), 6.47 (td, J = 8.3,
		1529,		2.5 Hz, 1H), 5.24 (q, J = 6.5 Hz, 1H),
		1451,		4.61 (p, J = 7.3 Hz, 1H), 3.95 (s, 3H),
		1264,		3.79 (s, 3H), 3.25 (s, 1H),
		1148, 953,		2.69-2.58 (m, 1H), 2.16-2.04 (m, 1H),
		732 cm−1		1.89-1.57 (m, 4H), 1.51-1.37 (m, 1H),
				1.34 (d, J = 7.2 Hz, 3H), 1.13 (d, J = 6.4 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −114.03.
143		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (s,
		film) 3369,	calcd for C26H34FN2O6,	1H), 8.50 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 5.2 Hz,
		2927,	489.2395; found, 489.2399	1H), 7.01 (dd, J = 8.5, 6.8 Hz,
		1732,		1H), 6.88 (d, J = 5.2 Hz, 1H), 6.60 (td,
		1649,		J = 8.2, 2.6 Hz, 1H), 6.54 (dd, J = 11.0,
		1528,		2.5 Hz, 1H), 5.46 (s, 1H),
		1450,		4.76-4.62 (m, 1H), 3.95 (s, 3H), 3.75 (s, 3H),
		1278,		3.39 (s, 1H), 1.80-1.59 (m, 5H),
		1263,		1.59-1.46 (m, 4H), 1.17 (qt, J = 13.4, 3.6 Hz,
		1035, 954,		1H), 1.08 (d, J = 6.3 Hz, 3H),
		731 cm−1		1.07-0.91 (m, 2H), 0.82 (qt, J = 15.4, 7.4 Hz,
				2H).
				19F NMR (376 MHz, CDCl3) δ −113.87.
144		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (s,
		film) 3370,	calcd for C25H32FN2O6,	1H), 8.46 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 5.2 Hz,
		2943,	475.2239; found, 475.2223	1H), 7.05 (t, J = 7.6 Hz, 1H),
		1731,		6.87 (d, J = 5.2 Hz, 1H), 6.59 (td, J = 8.3,
		1528,		2.5 Hz, 1H), 6.50 (dd, J = 11.1, 2.5 Hz,
		1450,		1H), 5.34 (s, 1H), 4.77-4.59 (m,
		1279,		1H), 3.95 (s, 3H), 3.73 (s, 3H),
		1263,		3.65-3.13 (m, 1H), 2.30-2.02 (m, 1H),
		1148,		1.84 (td, J = 11.6, 10.9, 6.8 Hz, 1H),
		1034, 953,		1.69-1.54 (m, 2H), 1.54-1.33 (m, 6H),
		731 cm−1		1.33-1.21 (m, 1H), 1.13 (d, J = 6.4 Hz,
				3H), 0.98-0.81 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.03.
145		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (s,
		film) 3370,	calcd for C25H34FN2O6,	1H), 8.48 (d, J = 7.9 Hz, 1H), 7.97 (d, J = 5.3 Hz,
		2962,	477.2395; found, 477.2389	1H), 7.04 (dd, J = 8.6, 6.8 Hz,
		1762,		1H), 6.87 (d, J = 5.2 Hz, 1H), 6.59 (td,
		1649,		J = 8.2, 2.5 Hz, 1H), 6.52 (dd, J = 11.0,
		1528,		2.6 Hz, 1H), 5.50-5.41 (m, 1H),
		1451,		4.74-4.64 (m, 1H), 3.95 (s, 3H), 3.74 (s, 3H),
		1262,		3.57 (d, J = 10.4 Hz, 1H),
		1150,		1.65-1.55 (m, 1H), 1.53 (d, J = 7.2 Hz, 3H),
		1034, 954,		1.51-1.23 (m, 2H), 1.17 (dq, J = 14.2, 7.2 Hz,
		731 cm−1		1H), 1.10 (d, J = 6.2 Hz, 3H),
				1.01-0.83 (m, 4H), 0.82-0.68 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.85.
146		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.17 (s,
		film) 3370,	calcd for C24H32FN2O6,	1H), 8.50 (q, J = 10.0, 8.1 Hz, 1H),
		2963,	463.2239; found, 463.2227	7.98 (t, J = 5.5 Hz, 1H), 7.02 (dd, J = 8.4,
		1732,		6.8 Hz, 1H), 6.88 (d, J = 5.2 Hz, 1H),
		1649,		6.66-6.48 (m, 2H), 5.45 (dd, J = 13.7,
		1527,		7.1 Hz, 1H), 4.79-4.63 (m, 1H),
		1451,		3.95 (s, 3H), 3.82-3.70 (m, 3H), 3.46 (s,
		1278,		1H), 1.87-1.72 (m, 1H), 1.54 (dd, J = 14.3,
		1263,		7.1 Hz, 3H), 1.43-1.23 (m, 1H),
		1149,		1.09 (dd, J = 11.6, 6.2 Hz, 3H),
		1035, 730 cm−1		0.99-0.80 (m, 4H), 0.80-0.69 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.79,
				−113.87.
147		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (s,
		film) 3371,	calcd for C24H30FN2O6,	1H), 8.47 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 5.2 Hz,
		2939,	461.2082; found, 461.2060	1H), 6.97 (dd, J = 8.5, 6.7 Hz,
		1733,		1H), 6.87 (d, J = 5.2 Hz, 1H),
		1529,		6.61-6.50 (m, 2H), 5.19 (s, 1H),
		1280,		4.74-4.60 (m, 1H), 3.95 (s, 3H), 3.78 (s, 3H),
		1264,		3.34 (s, 1H), 2.79 (hept, J = 8.8, 7.9 Hz, 1H),
		11748, 954 cm−1		2.20-2.06 (m, 1H), 2.00-1.83 (m,
				1H), 1.83-1.71 (m, 1H),
				1.71-1.59 (m, 2H), 1.51 (dd, J = 7.2, 2.7 Hz, 3H),
				1.42 (qd, J = 9.6, 1.7 Hz, 1H), 1.10 (d, J = 6.4 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −113.83.
148		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ
		film) 3371,	calcd for C23H30FN2O6,	12.18-12.16 (m, 1H), 8.50 (d, J = 7.9 Hz, 1H),
		2961,	449.2082; found, 449.2063	7.98 (d, J = 5.2 Hz, 1H), 7.01 (dd, J = 8.5,
		1732,		6.7 Hz, 1H), 6.88 (d, J = 5.2 Hz,
		1528,		1H), 6.61 (td, J = 8.3, 2.6 Hz, 1H),
		1280,		6.55 (dd, J = 11.0, 2.5 Hz, 1H), 5.44 (d, J = 7.5 Hz,
		1262,		1H), 4.76-4.64 (m, 1H),
		1149,		4.12 (q, J = 7.2 Hz, 0H), 3.95 (s, 3H),
		1034, 953,		3.75 (s, 3H), 3.34 (s, 1H), 2.14-2.02 (m,
		730 cm−1		1H), 1.54 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
				3H), 0.85 (d, J = 6.7 Hz, 3H),
				0.73 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.80.
149		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.15 (d,
		film) 2937,	calcd for C25H33F4N2O5,	J = 0.6 Hz, 1H), 8.40 (d, J = 8.0 Hz,
		1732,	441.2384; found, 441.2378	1H), 7.99 (d, J = 5.2 Hz, 1H), 7.00 (d, J = 7.8 Hz,
		1689,		1H), 6.93-6.83 (m, 3H),
		1527,		5.24-5.12 (m, 1H), 4.65-4.51 (m,
		1439, 910,		1H), 3.94 (s, 3H), 3.04 (dd, J = 10.5,
		800, 729 cm−1		6.5 Hz, 1H), 2.75-2.60 (m, 1H),
				2.31 (s, 3H), 2.24 (s, 3H), 2.21-2.09 (m,
				1H), 1.88-1.61 (m, 4H), 1.41 (pd, J = 10.1,
				3.5 Hz, 1H), 1.24 (d, J = 7.2 Hz,
				3H), 1.19 (d, J = 6.3 Hz, 3H).
150		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3370,	calcd for C22H28ClN2O5,	1H), 8.44 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2962,	435.1681; found, 435.168	1H), 7.22 (d, J = 8.4 Hz, 2H),
		1735,		7.02 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 5.2 Hz,
		1649,		1H), 5.45-5.34 (m, 1H),
		1529,		4.76-4.61 (m, 1H), 3.96 (s, 3H), 2.69 (t, J = 7.6 Hz,
		1481,		1H), 2.13-2.00 (m, 1H),
		1264,		1.54 (d, J = 6.6 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1152,		3H), 0.88 (d, J = 6.7 Hz, 3H), 0.74 (d, J = 6.7 Hz,
		1052, 826,		3H).
		801 cm−1		13C NMR (126 MHz, CDCl3) δ 171.59,
				168.72, 155.41, 148.78, 140.51, 137.11,
				132.47, 130.99, 130.44, 128.13, 109.49,
				77.21, 72.62, 56.11, 56.01, 48.18,
				28.32, 21.17, 18.86, 18.31, 17.31.
151		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
		film) 3370,	calcd for C23H30FN2O5,	1H), 8.48 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2961,	434.2165; found, 434.2169	1H), 7.06 (t, J = 7.9 Hz, 1H),
		1734,		6.88 (d, J = 5.2 Hz, 1H),
		1649,		6.81-6.71 (m, 2H), 5.43-5.32 (m, 1H),
		1576,		4.73-4.63 (m, 1H), 3.95 (s, 3H), 2.67 (t, 1H),
		1528,		2.24 (s, 3H), 2.12-1.99 (m, 1H),
		1481,		1.55 (d, 3H), 1.11 (d, J = 6.3 Hz, 3H),
		1280,		0.87 (d, J = 6.7 Hz, 3H), 0.76 (d, J = 6.8 Hz,
		1262, 800 cm−1		3H).
				13C NMR (126 MHz, CDCl3) δ 171.66,
				168.71, 161.91, 159.97, 155.38, 148.76,
				140.49, 138.29, 138.23, 130.83, 130.79,
				130.48, 125.23, 125.20, 123.02, 122.88,
				116.15, 115.98, 109.44, 77.22, 72.79,
				56.09, 56.07, 48.17, 34.67, 31.59,
				28.33, 25.28, 22.66, 21.22, 20.71,
				18.75, 18.34, 17.51, 14.20, 14.17,
				14.13.
152		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.12 (s,
		film) 2963,	calcd for	1H), 8.43 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		1736,	C22H27F2N2O5, 438.1915;	1H), 7.09-6.98 (m, 1H),
		1649,	found, 438.1921	6.95-6.86 (m, 2H), 6.84-6.75 (m,
		1517,		1H), 5.43-5.33 (m, 1H),
		1481,		4.74-4.60 (m, 1H), 3.96 (s, 3H), 2.68 (t, J = 7.6 Hz,
		1281,		1H), 2.11-2.00 (m, 1H), 1.53 (d,
		1264,		3H), 1.12 (d, J = 6.3 Hz, 3H), 0.89 (d, J = 6.7 Hz,
		1212,		3H), 0.75 (d, J = 6.7 Hz, 3H).
		1053, 801 cm−1		13C NMR (126 MHz, CDCl3) δ 171.54,
				168.73, 155.41, 148.78, 140.52, 130.40,
				118.11, 109.49, 77.21, 72.45, 56.11,
				55.86, 48.16, 28.43, 21.11, 18.94,
				18.28, 17.15.
153		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (d,
		film) 2962,	calcd for C23H31FN2O5,	J = 0.6 Hz, 1H), 8.49 (d, J = 7.9 Hz,
		1734,	433.2133; found, 433.2129	1H), 8.00 (d, J = 5.2 Hz, 1H),
		1715,		6.93-6.82 (m, 4H), 5.38 (dq, J = 8.6, 6.3 Hz,
		1530,		1H), 4.73-4.63 (m, 1H), 3.95 (s, 3H),
		1481,		2.66 (dd, J = 8.6, 6.6 Hz, 1H), 2.24 (d, J = 1.9 Hz,
		1282,		3H), 2.06 (hept, J = 6.8 Hz,
		1264,		1H), 1.55 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1244,		3H), 0.85 (d, J = 6.7 Hz, 3H),
		1220, 801 cm−1		0.75 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.65,
				168.73, 160.27 (d, J = 243.5 Hz),
				155.40, 148.79, 140.47, 133.95 (d, J = 3.8 Hz),
				132.52 (d, J = 4.9 Hz), 130.50,
				128.31 (d, J = 7.7 Hz), 124.11 (d, J = 17.0 Hz),
				114.39 (d, J = 22.0 Hz),
				109.48, 72.95, 56.07, 55.82, 48.20,
				28.32, 21.25, 18.68, 18.29, 17.62,
				14.61 (d, J = 3.5 Hz).
				19F NMR (376 MHz, CDCl3) δ −120.75.
154		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.16 (d,
		film) 3367,	calcd for C23H30FN2O6,	J = 0.6 Hz, 1H), 8.50 (d, J = 7.9 Hz,
		2963,	449.2082; found, 449.2076	1H), 7.99 (d, J = 5.2 Hz, 1H), 7.03 (t, J = 8.5 Hz,
		1734,		1H), 6.91-6.84 (m, 1H),
		1649,		6.66 (ddd, J = 8.6, 2.6, 0.8 Hz, 1H),
		1530,		6.57 (dd, J = 12.0, 2.6 Hz, 1H),
		1508,		5.44 (dqd, J = 7.6, 6.3, 1.2 Hz, 1H),
		1282,		4.75-4.63 (m, 1H), 3.94 (s, 3H), 3.78 (s, 3H),
		1264,		3.10 (t, J = 7.7 Hz, 1H), 2.09 (tt, J = 13.5,
		1149, 801,		6.6 Hz, 1H), 1.55 (d, J = 7.2 Hz,
		731 cm−1		3H), 1.12 (d, J = 6.3 Hz, 3H),
				0.94-0.87 (m, 3H), 0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.68,
				168.74, 162.09 (d, J = 244.2 Hz),
				159.37 (d, J = 11.4 Hz), 155.38, 148.78,
				140.47, 130.67 (d, J = 6.6 Hz), 130.56,
				117.46 (d, J = 15.4 Hz), 109.59 (d, J = 3.0 Hz),
				109.46, 101.41 (d, J = 27.9 Hz),
				72.76, 56.07, 55.44, 48.21, 47.95,
				28.41, 21.06, 19.09, 18.15, 17.30.
				19F NMR (376 MHz, CDCl3) δ −113.05.
155		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (d,
		film) 3367,	calcd for C23H30FN2O6,	J = 0.6 Hz, 1H), 8.48 (d, J = 7.9 Hz,
		2962,	449.2082; found, 449.2082	1H), 8.00 (d, J = 5.2 Hz, 1H),
		1715,		6.90-6.77 (m, 4H), 5.36 (dq, J = 8.4, 6.3 Hz,
		1518,		1H), 4.73-4.64 (m, 1H), 3.95 (s, 3H),
		1273,		3.87 (s, 3H), 2.68-2.60 (m, 1H),
		1222, 801 cm−1		2.05 (h, J = 6.7 Hz, 1H), 1.55 (d, J = 7.2 Hz,
				3H), 1.11 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 6.7 Hz,
				3H), 0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.63,
				168.76, 155.40, 151.94 (d, J = 245.1 Hz),
				148.79, 146.29 (d, J = 10.7 Hz),
				140.51, 131.69 (d, J = 5.6 Hz), 130.50,
				125.45 (d, J = 3.5 Hz), 117.10 (d, J = 18.2 Hz),
				112.94 (d, J = 2.2 Hz),
				109.50, 72.80, 56.21, 56.08, 55.73,
				48.21, 28.40, 21.21, 18.79, 18.30,
				17.45.
				19F NMR (376 MHz, CDCl3) δ −135.65.
156		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.19 (d,
		film) 3367,	calcd for C24H33N2O6,	J = 0.6 Hz, 1H), 8.53 (d, J = 7.9 Hz,
		2960,	445.2333; found, 445.2332	1H), 7.98 (d, J = 5.2 Hz, 1H), 6.94 (d, J = 7.7 Hz,
		1732,		1H), 6.87 (d, J = 5.1 Hz, 1H),
		1649,		6.71 (dt, J = 7.7, 1.1 Hz, 1H), 6.66 (d, J = 1.5 Hz,
		1528,		1H), 5.51-5.35 (m, 1H),
		1262,		4.75-4.64 (m, 1H), 3.94 (s, 3H),
		1041, 800,		3.76 (s, 3H), 3.34 (s, 1H), 2.32 (s, 3H),
		730 cm−1		2.09 (h, J = 6.7 Hz, 1H), 1.55 (d, J = 7.2 Hz,
				3H), 1.09 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.7 Hz,
				3H), 0.74 (d, J = 6.8 Hz, 3H).
157		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (d,
		film) 2960,	calcd for C24H33N2O6,	J = 0.6 Hz, 1H), 8.51 (d, J = 7.9 Hz,
		1715,	445.2333; found, 445.2328	1H), 7.99 (d, J = 5.2 Hz, 1H), 7.00 (dd,
		1529,		J = 8.1, 0.8 Hz, 1H), 6.90-6.85 (m,
		1281,		1H), 6.70 (d, J = 8.2 Hz, 2H), 5.37 (dq,
		1222,		J = 9.2, 6.2 Hz, 1H), 4.76-4.66 (m,
		1048, 801,		1H), 3.95 (s, 3H), 3.78 (s, 3H),
		732 cm−1		3.07 (dd, J = 9.2, 6.1 Hz, 1H), 2.29 (s, 3H),
				2.11 (dq, J = 13.4, 6.8 Hz, 1H), 1.56 (d,
				J = 7.1 Hz, 3H), 1.07 (d, J = 6.2 Hz,
				3H), 0.84 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 171.80,
				168.71, 157.59, 155.39, 148.79, 140.47,
				138.86, 130.54, 129.90, 128.80, 115.92,
				110.88, 109.47, 74.41, 56.08, 55.04,
				48.26, 29.71, 29.29, 21.08, 20.96,
				18.76, 18.27, 18.23.
158		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.18 (d,
		film) 3370,	calcd for C23H31N2O6,	J = 0.6 Hz, 1H), 8.52 (d, J = 7.9 Hz,
		2961,	431.2177; found, 431.2155	1H), 7.99 (d, J = 5.2 Hz, 1H),
		1732,		7.22-6.77 (m, 5H), 5.55-5.36 (m, 1H),
		1649,		4.76-4.59 (m, 1H), 3.94 (s, 3H), 3.77 (s,
		1528,		3H), 3.55-3.22 (m, 1H),
		1241,		2.18-2.05 (m, 1H), 1.55 (d, J = 7.2 Hz, 3H),
		1050, 755,		1.09 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.8 Hz,
		731 cm−1		3H), 0.74 (d, J = 6.8 Hz, 3H).
159		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.19 (s,
		film) 3369,	calcd for C24H33N2O7,	1H), 8.53 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2960,	461.2282; found, 461.2266	1H), 6.96 (d, J = 8.2 Hz, 1H),
		1732,		6.87 (d, J = 5.3 Hz, 1H),
		1649,		6.52-6.38 (m, 2H), 5.43 (s, 1H), 4.77-4.60 (m,
		1528,		1H), 3.95 (s, 3H), 3.79 (s, 3H), 3.75 (s,
		1262,		3H), 3.41-3.14 (m, 1H), 2.07 (dq, J = 13.4,
		1207,		6.7 Hz, 1H), 1.55 (d, J = 7.1 Hz,
		1156,		3H), 1.09 (d, J = 6.2 Hz, 3H), 0.83 (d, J = 6.7 Hz,
		1042, 730 cm−1		3H), 0.73 (d, J = 6.8 Hz, 3H).
160			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.54 (d,
			calcd for C24H31N2O6,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.4 Hz,
			443.2182; found, 443.2187	1H), 7.33-7.10 (m, 5H), 7.00 (d, J = 5.4 Hz,
				1H), 5.56-5.34 (m, 1H),
				4.79-4.54 (m, 1H), 3.89 (s, 3H), 2.39 (s, 3H),
				2.34 (dd, J = 8.7, 5.4 Hz, 1H),
				2.14-1.95 (m, 1H), 1.29 (d, J = 7.2 Hz, 3H),
				1.09 (d, J = 6.2 Hz, 3H), 0.95 (d, J = 6.6 Hz,
				3H), 0.71 (d, J = 6.7 Hz, 3H).
				13C NMR (75 MHz, CDCl3) δ 172.24,
				168.91, 162.34, 159.46, 146.68, 141.49,
				139.86, 137.49, 129.63, 127.90, 126.47,
				109.79, 72.07, 58.01, 56.30, 56.26,
				48.08, 29.24, 21.24, 20.74, 20.42,
				18.92, 18.49.
161			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.58 (d,
			calcd for C26H33N2O6,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.4 Hz,
			469.2338; found, 469.2345	1H), 7.33-7.09 (m, 5H), 7.01 (d, J = 5.5 Hz,
				1H), 5.35 (qd, J = 6.3, 3.8 Hz,
				1H), 4.83-4.65 (m, 1H), 3.89 (s, 3H),
				2.43-2.38 (m, 1H), 2.40 (s, 3H),
				2.29-2.14 (m, 1H), 1.93-1.78 (m, 1H),
				1.70-1.50 (m, 3H), 1.45 (d, J = 7.2 Hz, 3H),
				1.41-1.26 (m, 2H), 1.24-1.14 (m,
				1H), 1.06 (d, J = 6.3 Hz, 3H),
				0.95-0.77 (m, 1H).
				13C NMR (75 MHz, CDCl3) δ 172.20,
				168.90, 162.36, 159.49, 146.67, 141.47,
				140.72, 137.53, 129.49, 127.92, 126.44,
				109.82, 73.34, 56.66, 56.31, 56.27,
				48.20, 42.11, 31.70, 31.45, 25.11,
				24.51, 20.74, 18.72.
162			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.36 (d,
			calcd for C25H33N2O7,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.3 Hz,
			473.2288; found, 473.2294	1H), 7.28-7.11 (m, 5H), 6.96 (d, J = 5.4 Hz,
				1H), 5.83-5.67 (m, 2H),
				5.60-5.35 (m, 1H), 4.83-4.55 (m, 1H),
				3.90 (s, 3H), 2.37 (dd, J = 8.5, 5.6 Hz, 1H),
				2.12-2.00 (m, 1H), 2.06 (s, 3zH),
				1.29 (d, J = 7.2 Hz, 3H), 1.12 (d, J = 6.2 Hz,
				3H), 0.95 (d, J = 6.6 Hz, 3H), 0.72 (d, J = 6.7 Hz,
				3H).
				13C NMR (75 MHz, CDCl3) δ 172.35,
				170.26, 162.90, 160.29, 145.71, 143.99,
				142.47, 139.82, 129.61, 127.90, 126.46,
				109.58, 89.54, 72.07, 57.98, 56.20,
				56.17, 48.26, 29.22, 21.27, 20.88,
				20.85, 20.28, 18.93, 18.32.
163			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.41 (d,
			calcd for C27H35N2O7,	J = 7.8 Hz, 1H), 8.30 (d, J = 5.3 Hz,
			499.2444; found, 499.2449	1H), 7.30-7.15 (m, 5H), 6.97 (d, J = 5.4 Hz,
				1H), 5.87-5.65 (m, 2H),
				5.36 (qd, J = 6.4, 3.9 Hz, 1H),
				4.94-4.63 (m, 1H), 3.91 (s, 3H), 2.42 (dd, J = 10.3,
				3.9 Hz, 1H), 2.34-2.14 (m, 1H),
				2.07 (s, 3H), 1.96-1.79 (m, 1H),
				1.75-1.49 (m, 3H), 1.46 (d, J = 7.1 Hz, 3H),
				1.45-1.28 (m, 2H), 1.27-1.16 (m,
				1H), 1.08 (d, J = 6.3 Hz, 3H),
				0.95-0.73 (m, 1H).
				13C NMR (75 MHz, CDCl3) δ 172.32,
				170.28, 162.93, 160.32, 145.71, 144.05,
				142.45, 140.73, 129.48, 127.94, 126.44,
				109.60, 89.58, 73.34, 56.64, 56.22,
				56.18, 48.39, 42.14, 31.64, 31.45,
				25.10, 24.50, 20.89, 20.86, 18.76,
				18.57.
164			HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.38 (d,
			calcd for C25H33N2O7,	J = 7.7 Hz, 1H), 8.29 (d, J = 5.4 Hz,
			473.2288; found, 473.2279	1H), 7.30-7.19 (m, 3H),
				7.17-7.06 (m, 2H), 6.96 (d, J = 5.4 Hz, 1H),
				5.75 (s, 2H), 5.43 (dq, J = 8.7, 6.2 Hz, 1H),
				4.90-4.52 (m, 1H), 3.92 (s, 3H),
				2.72 (dd, J = 8.8, 6.4 Hz, 1H),
				2.19-2.09 (m, 1H), 2.08 (s, 3H), 1.53 (d, J = 7.2 Hz,
				3H), 1.10 (d, J = 6.3 Hz, 3H),
				0.86 (d, J = 6.7 Hz, 3H), 0.77 (d, J = 6.8 Hz,
				3H).
				13C NMR (75 MHz, CDCl3) δ 172.39,
				170.32, 162.98, 160.29, 145.73, 144.03,
				142.52, 138.62, 129.81, 127.90, 126.61,
				109.56, 89.60, 72.72, 56.61, 56.22,
				56.18, 48.41, 28.24, 21.34, 20.89,
				18.54, 17.86.
165			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
			calcd for C24H31N2O6,	J = 8.1 Hz, 1H), 8.33 (d, J = 5.4 Hz,
			443.2182; found, 443.2177	1H), 7.30-7.17 (m, 3H),
				7.14-7.05 (m, 2H), 7.00 (d, J = 5.4 Hz, 1H),
				5.42 (dq, J = 8.7, 6.3 Hz, 1H), 4.69 (p, J = 7.3 Hz,
				1H), 3.90 (s, 3H), 2.71 (dd, J = 8.6,
				6.5 Hz, 1H), 2.39 (s, 3H),
				2.17-2.03 (m, 1H), 1.50 (d, J = 7.2 Hz, 3H),
				1.09 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.8 Hz,
				3H), 0.76 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.22,
				168.83, 162.38, 159.48, 146.63, 141.63,
				138.69, 137.54, 129.79, 127.88, 126.58,
				109.74, 72.74, 56.64, 56.26, 48.21,
				28.26, 21.32, 20.72, 18.64, 18.62,
				17.80.
166			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.60 (d,
			calcd for C25H31N2O6,	J = 8.0 Hz, 1H), 8.37 (d, J = 5.4 Hz,
			455.2177; found, 455.2169	1H), 7.18-7.10 (m, 4H), 7.05 (d, J = 5.5 Hz,
				1H), 5.50-5.31 (m, 1H),
				4.91-4.66 (m, 1H), 3.94 (s, 3H), 2.44 (s, 3H),
				2.36 (s, 3H), 2.03 (dd, J = 10.0, 7.0 Hz,
				1H), 1.52 (d, J = 7.1 Hz, 3H), 1.20 (d, J = 6.4 Hz,
				3H), 1.19-1.08 (m, 1H),
				0.76-0.62 (m, 1H), 0.51-0.34 (m, 2H),
				0.05-−0.08 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.21,
				168.85, 162.33, 159.48, 146.64, 141.64,
				138.58, 137.52, 136.08, 128.92, 128.29,
				109.76, 75.92, 56.27, 55.25, 48.18,
				21.01, 20.73, 18.68, 18.12, 13.03, 6.93,
				2.87.
167			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.43 (d,
			calcd for C26H33N2O7,	J = 7.9 Hz, 1H), 8.33 (d, J = 5.3 Hz,
			485.2283; found, 485.2281	1H), 7.18-7.10 (m, 4H), 7.01 (d, J = 5.4 Hz,
				1H), 5.80 (s, 2H),
				5.46-5.25 (m, 1H), 4.90-4.72 (m, 1H), 3.96 (s,
				3H), 2.37 (s, 3H), 2.12 (s, 3H),
				2.05 (dd, J = 10.0, 7.0 Hz, 1H), 1.55 (d, J = 7.1 Hz,
				3H), 1.22 (d, J = 6.3 Hz, 3H),
				1.20-1.09 (m, 1H), 0.75-0.65 (m,
				1H), 0.51-0.37 (m, 2H),
				0.08-−0.06 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.32,
				170.20, 162.91, 160.30, 145.68, 143.99,
				142.61, 138.58, 136.07, 128.91, 128.28,
				109.57, 89.55, 75.89, 56.17, 55.24,
				48.37, 21.00, 20.83, 18.53, 18.14,
				13.01, 6.94, 2.87.
168		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (d,
		film) 3380,	calcd for C25H33N2O6,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.4 Hz,
		2961,	457.2333; found, 457.2328	1H), 7.06 (t, J = 6.4 Hz, 2H),
		1771,		7.03-6.94 (m, 3H), 5.40 (dq, J = 8.7, 6.3 Hz,
		1732,		1H), 4.74-4.62 (m, 1H), 3.91 (s, 3H),
		1676,		2.67 (dd, J = 8.8, 6.3 Hz, 1H), 2.40 (s,
		1508,		3H), 2.32 (s, 3H), 2.14-2.05 (m, 1H),
		1199,		1.50 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.3 Hz,
		1175, 908,		3H), 0.85 (d, J = 6.7 Hz, 3H),
		823, 802,		0.75 (d, J = 6.7 Hz, 3H).
		731 cm−1		13C NMR (101 MHz, CDCl3) δ 172.28,
				168.90, 162.39, 159.49, 146.65, 141.67,
				137.55, 136.06, 135.51, 129.68, 128.62,
				109.73, 72.85, 56.29, 56.23, 48.23,
				28.21, 21.36, 21.01, 20.75, 18.69,
				18.56, 17.85.
169			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
			calcd for C24H30FN2O6,	J = 7.9 Hz, 1H), 8.39-8.28 (m, 1H),
			461.2083; found, 461.2082	7.12-6.89 (m, 5H), 5.50-5.32 (m,
				1H), 4.78-4.60 (m, 1H), 3.91 (s, 3H),
				2.77-2.64 (m, 1H), 2.41 (s, 3H),
				2.14-2.02 (m, 1H), 1.54-1.35 (m, 3H),
				1.12-0.97 (m, 3H), 0.94-0.83 (m, 3H),
				0.79-0.68 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −116.57,
				−116.61.
170			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
			calcd for C24H28FN2O6,	J = 8.3 Hz, 1H), 8.32 (d, J = 5.4 Hz,
			459.1926; found, 459.1923	1H), 7.22-7.10 (m, 2H),
				7.09-6.86 (m, 3H), 5.39-5.19 (m, 1H), 4.71 (dq,
				J = 8.2, 7.2 Hz, 1H), 3.90 (s, 3H),
				2.40 (s, 3H), 2.02 (dd, J = 10.1, 6.5 Hz, 1H),
				1.46 (d, J = 7.2 Hz, 3H), 1.17 (d, J = 6.4 Hz,
				3H), 1.12-1.03 (m, 1H),
				0.73-0.62 (m, 1H), 0.47-0.31 (m, 2H),
				−0.01-−0.14 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −116.54.
171			HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.35 (d,
			calcd for C25H30FN2O7,	J = 8.0 Hz, 1H), 8.31-8.19 (m, 1H),
			489.2032; found, 489.2027	7.23-7.14 (m, 2H), 7.03-6.82 (m,
				3H), 5.75 (s, 2H), 5.36-5.19 (m, 1H),
				4.82-4.65 (m, 1H), 3.92 (s, 3H),
				2.07 (s, 3H), 2.03 (dd, J = 10.2, 6.5 Hz, 1H),
				1.48 (d, J = 7.2 Hz, 3H), 1.18 (d, J = 6.4 Hz,
				3H), 1.15-1.06 (m, 1H),
				0.75-0.63 (m, 1H), 0.48-0.33 (m, 2H),
				−0.03-−0.12 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −116.54.
172		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.57 (d,
		film) 3382,	calcd for C26H35N2O6,	J = 7.3 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2962,	471.2495; found, 471.2494	1H), 7.33-7.06 (m, 5H), 7.01 (d, J = 5.5 Hz,
		2933,		1H), 5.52-5.36 (m, 1H),
		2875,		4.70 (p, J = 7.1 Hz, 1H), 3.90 (s, 3H),
		1771,		2.96 (dd, J = 8.6, 6.3 Hz, 1H), 2.40 (s, 3H),
		1732,		1.50 (d, J = 7.2 Hz, 3H),
		1676,		1.46-1.22 (m, 3H), 1.10 (d, J = 6.2 Hz, 3H),
		1505,		0.99-0.82 (m, 5H), 0.78 (t, J = 7.2 Hz,
		1309,		3H).
		1193,
		1174,
		1040, 826,
		734, 703 cm−1.
173		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.53 (d,
		film) 3381,	calcd for C26H33N2O6,	J = 7.8 Hz, 1H), 8.32 (d, J = 4.6 Hz,
		2950,	469.2338; found, 469.2342	1H), 7.33-7.06 (m, 5H), 7.01 (d, J = 5.5 Hz,
		1771,		1H), 5.48-5.16 (m, 1H),
		1732,		4.85-4.55 (m, 1H), 3.89 (s, 3H), 2.78 (dd, J = 10.0,
		1676,		5.9 Hz, 1H), 2.39 (s, 3H),
		1505,		1.98-1.80 (m, 1H), 1.73-1.19 (m, 11H),
		1309,		1.11 (d, J = 6.5 Hz, 3H).
		1195,
		1174,
		1038, 826,
		802, 734,
		702 cm−1.
174		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.40 (d,
		film) 3380,	calcd for C27H37N2O7,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2962,	501.2601; found, 501.2606	1H), 7.34-7.06 (m, 5H), 6.96 (d, J = 5.4 Hz,
		2933,		1H), 5.75 (s, 2H),
		1734,		5.57-5.35 (m, 1H), 4.81-4.54 (m, 1H), 3.91 (s,
		1676,		3H), 2.97 (dd, J = 8.6, 6.3 Hz, 1H),
		1502,		2.07 (s, 3H), 1.53 (d, J = 7.2 Hz, 3H),
		1452,		1.49-1.34 (m, 3H), 1.11 (d, J = 6.3 Hz, 3H),
		1310,		0.95 (t, J = 7.3 Hz, 3H), 0.91-0.82 (m,
		1200,		2H), 0.78 (t, J = 7.2 Hz, 3H).
		1041,
		1002, 967,
		829, 735,
		704 cm−1.
175		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.36 (d,
		film) 3382,	calcd for C27H35N2O7,	J = 7.8 Hz, 1H), 8.28 (d, J = 5.2 Hz,
		2948,	499.2444; found, 499.2447	1H), 7.32-7.02 (m, 5H), 6.97 (dd, J = 5.4,
		2869,		2.6 Hz, 1H), 5.75 (s, 2H),
		1733,		5.45-5.17 (m, 1H), 4.85-4.40 (m, 1H),
		1501,		3.91 (s, 3H), 2.79 (dd, J = 10.0, 5.9 Hz, 1H),
		1437,		2.07 (s, 3H), 2.02-1.77 (m, 2H),
		1310,		1.67-1.19 (m, 7H), 1.13-0.86 (m, 6H).
		1200,
		1040,
		1002, 967,
		829, 734,
		703 cm−1.
176		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3, major) δ
		film) 2950,	calcd for C26H33N2O5S,	9.94 (d, J = 6.5 Hz, 1H), 8.33 (d, J = 5.5 Hz,
		1769,	485.2105; found, 485.2171	1H), 7.26-7.20 (m, 3H),
		1732,		7.14-7.10 (m, 2H), 7.00 (d, J = 5.5 Hz, 1H),
		1192,		5.38-5.31 (m, 1H), 5.17-5.08 (m,
		1175, 730 cm−1		1H), 3.91 (s, 3H), 2.79 (dd, J = 9.9, 6.0 Hz,
				1H), 2.36 (s, 3H), 2.28-2.12 (m,
				1H), 1.98-1.82 (m, 2H), 1.57 (d, J = 7.2 Hz,
				3H), 1.53-1.36 (m, 4H),
				1.34-1.20 (m, 2H), 1.13 (d, J = 6.5 Hz, 3H).
177		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 9.98 (d,
		film) 2950,	calcd for C26H32N2O5S,	J = 7.3 Hz, 1H), 8.35 (d, J = 5.4 Hz,
		2868,	507.1924; found, 507.1920	1H), 7.25-7.13 (m, 5H), 7.01 (d, J = 5.5 Hz,
		1770,		1H), 5.39 (qd, J = 6.3, 4.1 Hz,
		1731,		1H), 5.16 (p, J = 7.2 Hz, 1H), 3.91 (s,
		1585,		3H), 2.42 (dd, J = 10.3, 4.0 Hz, 1H),
		1496,		2.35 (s, 3H), 2.28-2.19 (m, 1H),
		1438,		1.93-1.83 (m, 1H), 1.68-1.59 (m, 1H),
		1365,		1.52 (d, J = 7.2 Hz, 3H), 1.50-1.31 (m, 4H),
		1311,		1.20 (dq, J = 12.5, 9.1 Hz, 1H), 1.08 (d,
		1278,		J = 6.4 Hz, 3H), 0.97-0.90 (m, 1H).
		1193,
		1175,
		1131,
		1102,
		1040,
		1010, 909,
		847, 824,
		759, 703 cm−1
178		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.52 (s,
		film) 3384,	calcd for C25H31FN2NaO6,	1H), 8.35 (d, J = 5.4 Hz, 1H),
		2968,	497.2058; found, 497.2056	7.31-7.22 (m, 1H), 7.02 (d, J = 5.5 Hz, 1H),
		1772,		6.84 (dd, J = 9.9, 2.9 Hz, 1H), 6.76 (td,
		1733,		J = 8.5, 2.8 Hz, 1H), 5.48-5.36 (m,
		1677,		1H), 4.76-4.62 (m, 1H), 3.91 (s, 3H),
		1499,		2.67 (dd, J = 9.4, 4.8 Hz, 1H), 2.39 (s,
		1176, 825,		3H), 2.27 (s, 3H), 2.01 (dp, J = 9.2, 6.6 Hz,
		734 cm−1		1H), 1.39 (d, J = 7.2 Hz, 3H),
				1.05 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.6 Hz,
				3H), 0.68 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.72.
179		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3384,	calcd for C27H35FN2NaO6,	J = 7.6 Hz, 1H), 8.35 (d, J = 5.5 Hz,
		2963,	525.2371; found, 525.2364	1H), 7.30 (dd, J = 8.8, 6.2 Hz, 1H),
		1771,		7.02 (dd, J = 5.5, 2.6 Hz, 1H), 6.83 (dd, J = 9.9,
		1732,		2.9 Hz, 1H), 6.75 (td, J = 8.6, 2.9 Hz,
		1676,		1H), 5.38 (qd, J = 6.3, 4.0 Hz, 1H),
		1498,		4.79-4.65 (m, 1H), 3.91 (s, 3H),
		1174, 825,		2.90 (dd, J = 10.1, 4.2 Hz, 1H), 2.39 (s, 3H),
		731 cm−1		2.27 (d, J = 3.5 Hz, 3H),
				1.82-1.67 (m, 1H), 1.58-1.28 (m, 4H), 1.26 (s,
				1H), 1.19-1.05 (m, 1H), 0.99 (dd, J = 10.0,
				6.3 Hz, 3H), 0.94-0.81 (m, 4H),
				0.72-0.63 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.69.
180		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3384,	calcd for C27H33FN2NaO6,	J = 8.0 Hz, 1H), 8.35 (d, J = 5.4 Hz,
		2950,	523.2215; found, 523.2210	1H), 7.31-7.22 (m, 1H), 7.02 (d, J = 5.4 Hz,
		1771,		1H), 6.83 (dd, J = 9.9, 2.8 Hz,
		1731,		1H), 6.73 (td, J = 8.5, 2.8 Hz, 1H),
		1675,		5.32 (qd, J = 6.4, 3.9 Hz, 1H), 4.72 (p, J = 7.3 Hz,
		1498,		1H), 3.91 (s, 3H), 2.78 (dd, J = 10.4,
		1175, 907,		4.2 Hz, 1H), 2.39 (s, 3H), 2.29 (s,
		730 cm−1		3H), 2.25-2.10 (m, 1H), 1.89 (ddt, J = 14.4,
				10.9, 5.2 Hz, 1H), 1.74-1.30 (m,
				7H), 1.30-1.13 (m, 2H), 1.06 (d, J = 6.3 Hz,
				3H), 1.00-0.78 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.09,
				168.86, 162.37, 160.90 (d, J = 243.9 Hz),
				159.56, 146.64, 141.54, 138.75 (d,
				J = 7.2 Hz), 137.63, 135.25 (d, J = 3.2 Hz),
				129.77 (d, J = 8.1 Hz), 116.34 (d, J = 20.2 Hz),
				112.67 (d, J = 20.5 Hz),
				109.82, 73.60, 56.31, 49.43, 48.20,
				42.91, 31.62, 31.42, 25.12, 24.42,
				20.73, 20.61, 18.63, 18.13.
				19F NMR (376 MHz, CDCl3) δ −117.78.
181		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3383,	calcd for C28H36FN2O6,	J = 7.5 Hz, 1H), 8.35 (d, J = 5.4 Hz,
		2928,	515.2552; found, 515.2557	1H), 7.31-7.27 (m, 1H), 7.02 (d, J = 5.4 Hz,
		1771,		1H), 6.87-6.73 (m, 2H),
		1675,		5.42 (qd, J = 6.3, 4.3 Hz, 1H),
		1498,		4.77-4.66 (m, 1H), 3.91 (s, 3H), 2.74 (dd, J = 9.5,
		1174,		4.7 Hz, 1H), 2.40 (s, 3H),
		1038, 825,		2.31-2.21 (m, 3H), 1.86 (d, J = 12.9 Hz, 1H),
		732 cm−1		1.78-1.49 (m, 3H), 1.41 (d, J = 7.2 Hz,
				3H), 1.36-1.15 (m, 3H),
				1.15-0.84 (m, 6H), 0.84-0.70 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.20,
				168.87, 162.36, 160.91 (d, J = 243.8 Hz),
				159.55, 146.65, 141.55, 139.40 (d,
				J = 7.1 Hz), 137.60, 134.70 (d, J = 3.4 Hz),
				129.50 (d, J = 7.7 Hz), 116.32 (d, J = 20.6 Hz),
				112.74 (d, J = 20.2 Hz),
				109.82, 71.63, 56.31, 49.64, 48.13,
				40.27, 31.28, 30.87, 29.30, 26.47,
				26.37, 26.27, 20.74, 18.66, 18.19.
				19F NMR (376 MHz, CDCl3) δ −117.74.
182		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3384,	calcd for C26H33FN2NaO6,	8.59-8.45 (m, 1H), 8.35 (dd, J = 5.4, 1.3 Hz,
		2965,	511.2215; found, 511.2207	1H), 7.31-7.23 (m, 1H),
		1771,		7.04-6.95 (m, 1H), 6.83 (dd, J = 9.9, 2.7 Hz, 1H),
		1732,		6.76 (dtd, J = 8.5, 5.3, 2.6 Hz, 1H),
		1674,		5.42 (ddt, J = 8.6, 6.1, 3.5 Hz, 1H),
		1498,		4.76-4.64 (m, 1H), 3.91 (s, 3H), 2.77 (ddd, J = 42.7,
		1175, 908,		9.3, 4.8 Hz, 1H), 2.39 (d, J = 2.0 Hz,
		731 cm−1		3H), 2.33-2.23 (m, 3H),
				1.97-1.50 (m, 2H), 1.48-1.31 (m, 3H),
				1.26 (s, 1H), 1.23-0.93 (m, 4H),
				0.94-0.58 (m, 5H).
				19F NMR (376 MHz, CDCl3) δ −117.69,
				−117.74.
183		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3380,	calcd for C26H31FN2NaO6,	8.49-8.39 (m, 1H), 8.33 (d, J = 5.4 Hz, 1H),
		2938,	509.2058; found, 509.2056	7.09 (dd, J = 8.6, 6.0 Hz, 1H), 7.00 (d, J = 5.5 Hz,
		1771,		1H), 6.81 (dd, J = 9.9, 2.9 Hz,
		1732,		1H), 6.74 (td, J = 8.4, 2.8 Hz, 1H),
		1674,		5.14 (p, J = 6.4 Hz, 1H), 4.59 (p, J = 7.4 Hz,
		1498,		1H), 3.90 (s, 3H), 3.02 (dd, J = 10.4,
		1175, 908,		6.4 Hz, 1H), 2.70-2.59 (m, 1H),
		730 cm−1		2.39 (s, 3H), 2.34 (s, 3H), 2.17 (d, J = 6.0 Hz,
				1H), 1.88-1.59 (m, 4H),
				1.42-1.33 (m, 1H), 1.20 (d, J = 7.2 Hz, 3H),
				1.17 (d, J = 6.3 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.62.
184		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.47 (d,
		film) 3379,	calcd for C27H33FN2NaO6,	J = 8.1 Hz, 1H), 8.31 (d, J = 5.4 Hz,
		2949,	523.2215; found, 523.2202	1H), 7.09 (dd, J = 8.7, 5.9 Hz, 1H),
		1770,		7.01 (d, J = 5.5 Hz, 1H), 6.84 (td, J = 8.3,
		1731,		3.1 Hz, 1H), 6.76 (dd, J = 9.9, 2.8 Hz,
		1675,		1H), 5.29 (p, J = 6.7 Hz, 1H),
		1499,		4.74-4.63 (m, 1H), 3.91 (s, 3H), 3.10 (dd, J = 9.2,
		1175, 907,		7.1 Hz, 1H), 2.40 (d, J = 2.6 Hz,
		730 cm−1		3H), 2.21-2.07 (m, 1H), 1.86 (dtd, J = 14.8,
				7.9, 7.1, 4.5 Hz, 1H),
				1.67-1.30 (m, 9H), 1.30-1.16 (m, 2H),
				1.16-1.08 (m, 4H), 0.98-0.81 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −117.62.
185		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.52 (d,
		film) 3379,	calcd for C28H36FN2O6,	J = 8.0 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2928,	515.2552; found, 515.2568	1H), 7.05 (dd, J = 8.6, 5.9 Hz, 1H),
		1771,		7.01 (d, J = 5.5 Hz, 1H), 6.88-6.78 (m,
		1733,		2H), 5.41-5.36 (m, 1H),
		1676,		4.77-4.67 (m, 1H), 3.91 (s, 3H), 3.11 (dd, J = 9.0,
		1499,		6.1 Hz, 1H), 2.40 (s, 3H), 2.28 (s, 3H),
		1193,		1.83-1.39 (m, 10H), 1.31-0.95 (m,
		1175, 825,		5H), 0.95-0.81 (m, 2H).
		732 cm−1		19F NMR (376 MHz, CDCl3) δ −117.48.
186		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
		film) 3381,	calcd for C25H31FN2NaO6,	J = 8.0 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2961,	497.2058; found, 497.2048	1H), 7.05 (dd, J = 8.5, 6.0 Hz, 1H),
		1771,		7.01 (d, J = 5.5 Hz, 1H), 6.84 (qd, J = 10.0,
		1732,		9.2, 2.8 Hz, 2H), 5.36 (dq, J = 9.3, 6.2 Hz,
		1675,		1H), 4.75-4.65 (m, 1H), 3.91 (d, J = 1.9 Hz,
		1499,		3H), 3.08 (dd, J = 8.9, 6.5 Hz,
		1174,		1H), 2.40 (d, J = 2.1 Hz, 3H), 2.29 (s,
		1045, 908,		3H), 2.12 (h, J = 6.8 Hz, 1H), 1.50 (dd,
		731 cm−1		J = 7.2, 2.0 Hz, 3H), 1.06 (d, J = 6.2 Hz,
				3H), 0.86 (dd, J = 6.9, 1.9 Hz, 3H),
				0.77 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.23,
				168.88, 162.36, 160.94 (d, J = 244.3 Hz),
				159.51, 146.65, 141.57, 139.90 (d,
				J = 6.5 Hz), 137.56, 133.65 (d, J = 2.9 Hz),
				129.31-129.08 (m), 116.96 (d, J = 20.5 Hz),
				112.33 (d, J = 20.7 Hz),
				109.77, 73.76, 56.30, 48.22, 29.69,
				29.30, 20.93, 20.91, 20.75, 18.92,
				18.59, 17.91.
				19F NMR (376 MHz, CDCl3) δ −117.42.
187		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.47 (d,
		film) 3379,	calcd for C27H36FN2O6,	J = 8.3 Hz, 1H), 8.31 (d, J = 5.5 Hz,
		2963,	503.2552; found, 503.2557	1H), 7.09 (dd, J = 8.7, 5.9 Hz, 1H),
		1771,		7.01 (dd, J = 5.4, 2.2 Hz, 1H), 6.83 (td, J = 8.5,
		1732,		3.3 Hz, 1H), 6.76 (dd, J = 9.9, 2.9 Hz,
		1675,		1H), 5.41 (dq, J = 7.8, 6.2 Hz, 1H),
		1499,		4.70 (dt, J = 8.0, 6.0 Hz, 1H), 3.91 (d, J = 1.7 Hz,
		1175, 907,		3H), 3.25 (q, J = 8.0 Hz, 1H),
		730 cm−1		2.40 (s, 3H), 2.27 (s, 2H), 1.62 (d, J = 10.7 Hz,
				2H), 1.54-1.24 (m, 6H),
				1.09 (d, J = 6.2 Hz, 3H), 1.07-0.81 (m,
				4H), 0.81-0.64 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.52.
188		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3379,	calcd for C26H33FN2NaO6,	8.56-8.45 (m, 1H), 8.32 (dd, J = 5.4, 3.2 Hz,
		2964,	511.2215; found, 511.2209	1H), 7.06 (ddd, J = 9.1, 5.8, 3.2 Hz,
		1771,		1H), 7.01 (d, J = 5.5 Hz, 1H), 6.83 (qd,
		1733,		J = 10.4, 9.3, 5.1 Hz, 2H), 5.38 (ddt, J = 18.2,
		1676,		9.3, 6.3 Hz, 1H), 4.76-4.63 (m,
		1500,		1H), 3.91 (s, 3H), 3.22-3.07 (m, 1H),
		1176,		2.40 (d, J = 1.3 Hz, 3H),
		1059, 732 cm−1		2.35-2.25 (m, 3H), 1.95-1.75 (m, 1H),
				1.54-1.33 (m, 4H), 1.06 (dd, J = 8.1, 6.2 Hz,
				3H), 1.00-0.81 (m, 4H), 0.78 (dt, J = 7.1,
				3.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.43,
				−117.48.
189		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.49 (d,
		film) 3379,	calcd for C26H31FN2NaO6,	J = 8.1 Hz, 1H), 8.33 (d, J = 5.5 Hz,
		2939,	509.2059; found, 509.2039	1H), 7.05-6.97 (m, 2H),
		1770,		6.87-6.77 (m, 2H), 5.17-5.04 (m, 1H),
		1732,		4.74-4.62 (m, 1H), 3.91 (s, 3H), 3.13 (t, J = 8.7 Hz,
		1674,		1H), 2.72 (dt, J = 19.2, 9.6 Hz,
		1499,		1H), 2.40 (s, 3H), 2.33 (s, 3H),
		1175, 908,		2.19-2.06 (m, 1H), 1.92-1.71 (m, 2H),
		730 cm−1		1.71-1.56 (m, 2H), 1.48 (d, J = 7.1 Hz,
				3H), 1.44-1.20 (m, 1H), 1.07 (d, J = 6.3 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.38.
190		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3383,	calcd for C27H33FN2NaO6,	8.61-8.49 (m, 1H), 8.35 (d, J = 5.4 Hz, 1H),
		2951,	523.2215; found, 523.2201	7.33 (dd, J = 8.7, 6.1 Hz, 1H), 7.02 (d, J = 5.5 Hz,
		1771,		1H), 6.86-6.72 (m, 2H),
		1732,		5.32 (qd, J = 6.4, 3.5 Hz, 1H), 4.74 (p, J = 7.2 Hz,
		1675,		1H), 3.92 (s, 3H), 2.77 (dd, J = 10.6,
		1498,		3.5 Hz, 1H), 2.40 (s, 3H),
		1175, 908,		2.29 (s, 3H), 2.27-2.15 (m, 1H),
		730 cm−1		1.99-1.86 (m, 1H), 1.74-1.29 (m, 7H),
				1.29-1.15 (m, 2H), 1.03 (d, J = 6.4 Hz,
				3H), 0.93-0.78 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.03,
				168.89, 162.41, 160.91 (d, J = 243.8 Hz),
				159.55, 146.65, 141.52, 138.75 (d,
				J = 7.2 Hz), 137.62, 135.15 (d, J = 3.2 Hz),
				129.97 (d, J = 8.1 Hz), 116.32 (d, J = 20.6 Hz),
				112.63 (d, J = 20.5 Hz),
				109.81, 73.36, 56.31, 49.51, 48.10,
				42.71, 31.73, 31.70, 25.18, 24.52,
				20.74, 20.62, 18.55, 17.78.
				19F NMR (376 MHz, CDCl3) δ −117.80.
191		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.53 (s,
		film) 3380,	calcd for C28H35FN2NaO6,	1H), 8.35 (d, J = 5.4 Hz, 1H), 7.33 (dd,
		2928,	537.2371; found, 537.2380	J = 8.7, 6.1 Hz, 1H), 7.03 (d, J = 5.4 Hz,
		1771,		1H), 6.88-6.69 (m, 2H), 5.42 (pd,
		1732,		J = 8.5, 7.4, 3.3 Hz, 1H),
		1675,		4.78-4.67 (m, 1H), 3.92 (s, 3H), 2.71 (dd, J = 9.9,
		1498,		3.9 Hz, 1H), 2.40 (s, 3H), 2.26 (s, 3H),
		1173, 909,		1.92 (d, J = 12.8 Hz, 1H),
		730 cm−1		1.79-1.49 (m, 4H), 1.44 (d, J = 7.2 Hz, 3H),
				1.38-1.16 (m, 3H), 1.16-0.84 (m, 5H),
				0.82-0.66 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.01,
				168.88, 162.37, 160.90 (d, J = 243.9 Hz),
				159.57, 146.64, 141.51, 139.38 (d,
				J = 7.3 Hz), 137.64, 134.61 (d, J = 3.1 Hz),
				129.69 (d, J = 7.8 Hz), 116.28 (d, J = 20.6 Hz),
				112.68 (d, J = 20.6 Hz),
				109.82, 71.31, 56.32, 49.62, 48.11,
				39.95, 31.32, 31.20, 29.29, 26.51,
				26.37, 26.24, 20.74, 18.52, 17.93.
				19F NMR (376 MHz, CDCl3) δ −117.81.
192		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ
		film) 3380,	calcd for C25H31FN2NaO6,	8.57-8.43 (m, 1H), 8.35 (d, J = 5.4 Hz, 1H),
		2963,	497.2058; found, 497.2059	7.32 (dd, J = 8.7, 6.1 Hz, 1H), 7.02 (d, J = 5.4 Hz,
		1771,		1H), 6.83 (dd, J = 9.9, 2.9 Hz,
		1732,		1H), 6.79-6.71 (m, 1H), 5.43 (qd, J = 6.4,
		1676,		3.9 Hz, 1H), 4.76-4.68 (m, 1H),
		1499,		3.92 (s, 3H), 2.67-2.60 (m, 1H),
		1176, 733 cm−1		2.40 (s, 3H), 2.27 (s, 3H), 2.12-1.94 (m,
				1H), 1.44 (d, J = 7.2 Hz, 3H), 1.01 (dd,
				J = 6.4, 3.0 Hz, 6H), 0.67 (d, J = 6.7 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.77.
193		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3378,	calcd for C28H35FN2NaO7,	J = 7.9 Hz, 1H), 8.30 (d, J = 5.4 Hz,
		2951,	553.2321; found, 553.2310	1H), 7.31-7.27 (m, 1H), 6.97 (d, J = 5.4 Hz,
		1732,		1H), 6.83 (dd, J = 9.9, 2.8 Hz,
		1674,		1H), 6.75 (td, J = 8.5, 2.9 Hz, 1H),
		1497,		5.75 (d, J = 2.4 Hz, 2H), 5.33 (qd, J = 6.3,
		1201,		4.0 Hz, 1H), 4.74 (p, J = 7.3 Hz, 1H),
		1003, 968,		3.92 (s, 3H), 2.80 (dd, J = 10.3, 4.2 Hz,
		730 cm−1		1H), 2.29 (s, 3H), 2.25-2.11 (m, 1H),
				2.07 (s, 3H), 1.89 (dtd, J = 10.9, 7.1, 3.4 Hz,
				1H), 1.77-1.29 (m, 7H),
				1.29-1.13 (m, 2H), 1.08 (d, J = 6.3 Hz, 3H),
				0.96-0.79 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.21,
				170.25, 162.95, 160.90 (d, J = 243.9 Hz),
				160.39, 145.69, 144.14, 142.51,
				138.78 (d, J = 7.2 Hz), 135.27 (d, J = 3.2 Hz),
				129.70 (d, J = 8.1 Hz),
				116.37 (d, J = 20.5 Hz), 112.69 (d, J = 20.6 Hz),
				109.63, 89.63, 73.62, 56.21, 49.42,
				48.41, 42.95, 31.62, 31.38, 25.11,
				24.41, 20.86, 20.62, 18.50, 18.17.
				19F NMR (376 MHz, CDCl3) δ −117.76.
194		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3379,	calcd for C29H38FN2O7,	J = 7.8 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2929,	545.2658; found, 545.2652	1H), 7.30 (dd, J = 8.7, 6.1 Hz, 1H),
		1733,		6.96 (d, J = 5.4 Hz, 1H), 6.87-6.76 (m,
		1675,		2H), 5.75 (d, J = 1.6 Hz, 2H),
		1498,		5.48-5.38 (m, 1H), 4.73 (p, J = 7.3 Hz, 1H),
		1202,		3.91 (s, 3H), 2.76 (dd, J = 9.3, 4.8 Hz,
		1004, 969,		1H), 2.27 (s, 3H), 2.07 (s, 3H), 1.86 (d,
		829, 731 cm−1		J = 12.8 Hz, 1H), 1.81-1.51 (m, 3H),
				1.42 (d, J = 7.1 Hz, 3H), 1.33 (d, J = 12.7 Hz,
				1H), 1.28-0.89 (m, 8H),
				0.85-0.72 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.32,
				170.25, 162.94, 160.91 (d, J = 244.0 Hz),
				160.37, 145.69, 144.10, 142.54,
				139.42 (d, J = 7.3 Hz), 134.70 (d, J = 3.3 Hz),
				129.47 (d, J = 8.1 Hz),
				116.34 (d, J = 20.3 Hz), 112.75 (d, J = 20.5 Hz),
				109.62, 89.62, 71.67, 56.21, 49.66,
				48.34, 40.30, 31.30, 30.79, 26.45,
				26.40, 26.32, 20.86, 20.74, 18.54,
				18.23.
				19F NMR (376 MHz, CDCl3) δ −117.73.
195		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.31 (d,
		film) 3379,	calcd for C28H35FN2NaO7,	J = 8.1 Hz, 1H), 8.26 (d, J = 5.4 Hz,
		2950,	553.2321; found, 553.2326	1H), 7.09 (dd, J = 8.6, 5.9 Hz, 1H),
		1756,		6.96 (d, J = 5.4 Hz, 1H), 6.89-6.72 (m,
		1676,		2H), 5.74 (s, 2H), 5.36-5.22 (m, 1H),
		1498,		4.71 (p, J = 7.2 Hz, 1H), 3.92 (s, 3H),
		1201,		3.11 (dd, J = 9.2, 7.2 Hz, 1H), 2.27 (s,
		1003, 969,		2H), 2.20-2.10 (m, 2H), 2.07 (s, 4H),
		829, 731 cm−1		1.87 (dtd, J = 14.8, 7.1, 3.4 Hz, 1H),
				1.75-1.30 (m, 7H), 1.30-1.16 (m,
				1H), 1.11 (d, J = 6.4 Hz, 3H),
				0.99-0.81 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −117.60.
196		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.34 (t, J = 8.5 Hz,
		film) 3379,	calcd for C27H35FN2NaO7,	1H), 8.28 (dd, J = 5.4, 2.6 Hz,
		2964,	541.2321; found, 541.2306	1H), 7.07 (ddd, J = 9.0, 6.0, 3.1 Hz,
		1734,		1H), 6.96 (d, J = 5.4 Hz, 1H),
		1675,		6.90-6.75 (m, 2H), 5.75 (d, J = 2.7 Hz, 2H),
		1498,		5.39 (ddq, J = 18.7, 9.3, 6.2 Hz, 1H),
		1202,		4.72 (td, J = 7.4, 6.2 Hz, 1H), 3.92 (s,
		1003, 968,		3H), 3.16 (ddd, J = 24.9, 9.0, 6.3 Hz,
		829, 731 cm−1		1H), 2.35-2.20 (m, 3H), 2.07 (d, J = 0.9 Hz,
				3H), 1.97-1.72 (m, 1H),
				1.58-1.34 (m, 4H), 1.07 (dd, J = 7.7, 6.2 Hz,
				3H), 1.02-0.82 (m, 4H), 0.78 (dd, J = 7.3,
				5.2 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.41,
				−117.46.
197		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.33 (d,
		film) 3379,	calcd for C27H34FN2O7,	J = 7.9 Hz, 1H), 8.28 (d, J = 5.4 Hz,
		2977,	517.2345; found, 517.2340	1H), 7.06-6.98 (m, 1H), 6.95 (d, J = 5.4 Hz,
		1733,		1H), 6.83 (dd, J = 9.5, 2.3 Hz,
		1674,		2H), 5.75 (s, 2H), 5.17-5.01 (m, 1H),
		1498,		4.71 (p, J = 7.2 Hz, 1H), 3.91 (s, 3H),
		1201,		3.14 (t, J = 8.7 Hz, 1H), 2.73 (p, J = 8.8 Hz,
		1041,		1H), 2.34 (s, 3H), 2.23-2.09 (m,
		1003, 968,		1H), 2.07 (s, 3H), 1.95-1.72 (m, 2H),
		829, 730 cm−1		1.72-1.55 (m, 2H), 1.50 (d, J = 7.1 Hz,
				3H), 1.37 (p, J = 10.0 Hz, 1H),
				1.08 (d, J = 6.3 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.38.
198		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3384,	calcd for C28H35FN2NaO7,	J = 7.7 Hz, 1H), 8.30 (d, J = 5.3 Hz,
		2951,	553.2321; found, 553.2313	1H), 7.34 (dd, J = 8.7, 6.1 Hz, 1H),
		1734,		6.97 (d, J = 5.4 Hz, 1H), 6.83 (dd, J = 9.9,
		1677,		2.8 Hz, 1H), 6.74 (td, J = 8.5, 3.0 Hz,
		1499,		1H), 5.77 (d, J = 6.4 Hz, 1H), 5.71 (d, J = 6.4 Hz,
		1202,		1H), 5.32 (qd, J = 6.4, 3.2 Hz,
		1005, 970,		1H), 4.76 (p, J = 7.3 Hz, 1H), 3.92 (s,
		830 cm−1		3H), 2.77 (dd, J = 10.7, 3.5 Hz, 1H),
				2.34-2.20 (m, 4H), 2.08 (s, 3H),
				1.99-1.86 (m, 1H), 1.74-1.30 (m, 8H),
				1.30-1.16 (m, 1H), 1.10-0.99 (m,
				3H), 0.84 (ddt, J = 12.2, 10.3, 5.9 Hz,
				1H).
				13C NMR (101 MHz, CDCl3) δ 172.14,
				170.25, 162.99, 160.92 (d, J = 243.9 Hz),
				160.41, 145.70, 144.13, 142.50,
				138.76 (d, J = 7.3 Hz), 135.17 (d, J = 3.4 Hz),
				129.97 (d, J = 8.1 Hz),
				116.32 (d, J = 20.7 Hz), 112.61 (d, J = 20.6 Hz),
				109.63, 89.62, 73.34, 56.22, 49.52,
				48.31, 42.72, 31.73, 31.70, 25.20,
				24.53, 20.86, 20.61, 18.46, 17.80.
				19F NMR (376 MHz, CDCl3) δ −117.78.
199		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 8.36 (d,
		film) 3379,	calcd for C29H37FN2NaO7,	J = 7.6 Hz, 1H), 8.30 (d, J = 5.4 Hz,
		2928,	567.2477; found, 567.2486	1H), 7.33 (dd, J = 8.7, 6.1 Hz, 1H),
		1733,		6.98 (d, J = 5.5 Hz, 1H), 6.82 (dd, J = 9.9,
		1675,		2.8 Hz, 1H), 6.71 (td, J = 8.5, 2.9 Hz,
		1497,		1H), 5.77 (d, J = 6.4 Hz, 1H), 5.70 (d, J = 6.4 Hz,
		1201,		1H), 5.43 (qd, J = 6.2, 3.8 Hz,
		1003, 969,		1H), 4.74 (p, J = 7.2 Hz, 1H), 3.92 (s,
		911, 829,		3H), 2.72 (dd, J = 9.9, 4.0 Hz, 1H),
		730 cm−1		2.26 (s, 3H), 2.07 (s, 3H), 1.99-1.87 (m,
				1H), 1.82-1.51 (m, 3H),
				1.51-1.39 (m, 3H), 1.37-1.01 (m, 6H), 0.99 (d, J = 6.3 Hz,
				3H), 0.84-0.67 (m, 1H).
				13C NMR (101 MHz, CDCl3) δ 172.12,
				170.24, 162.93, 160.90 (d, J = 243.7 Hz),
				160.44, 145.68, 144.17, 142.45,
				139.38 (d, J = 7.2 Hz), 134.63 (d, J = 2.9 Hz),
				129.67 (d, J = 8.0 Hz),
				116.28 (d, J = 20.5 Hz), 112.64 (d, J = 20.5 Hz),
				109.64, 89.64, 71.28, 56.22, 49.62,
				48.34, 39.99, 31.31, 31.21, 26.51,
				26.37, 26.27, 20.86, 20.73, 18.45,
				17.94.
				19F NMR (376 MHz, CDCl3) δ −117.79.
200		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.56 (s,
		film) 3383,	calcd for C26H35N2O6,	1H), 8.35 (d, J = 5.4 Hz, 1H), 7.19 (d, J = 7.9 Hz,
		2969,	471.2490; found, 471.2485	1H), 7.00 (d, J = 5.4 Hz, 1H),
		1772,		6.94 (d, J = 1.9 Hz, 1H), 6.90 (dd, J = 7.9,
		1733,		1.9 Hz, 1H), 5.41 (qd, J = 6.3, 4.7 Hz,
		1679,		1H), 4.77-4.61 (m, 1H), 3.91 (s,
		1200, 1176 cm−1		3H), 2.68 (dd, J = 9.3, 4.8 Hz, 1H),
				2.39 (s, 3H), 2.27 (s, 3H), 2.25 (s, 3H),
				2.03 (dp, J = 9.2, 6.6 Hz, 1H), 1.38 (d, J = 7.2 Hz,
				3H), 1.05 (d, J = 6.3 Hz, 3H),
				0.99 (d, J = 6.6 Hz, 3H), 0.69 (d, J = 6.8 Hz,
				3H).
201		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.58 (s,
		film) 3383,	calcd for C28H37N2O6,	1H), 8.35 (d, J = 5.5 Hz, 1H), 7.20 (d, J = 7.9 Hz,
		2950,	497.2646; found, 497.2640	1H), 7.01 (d, J = 5.4 Hz, 1H),
		1773,		6.97-6.86 (m, 2H), 5.31 (qd, J = 6.3,
		1734,		3.9 Hz, 1H), 4.78-4.64 (m, 1H),
		1679,		3.91 (s, 3H), 2.79 (dd, J = 10.4, 4.1 Hz, 1H),
		1507,		2.40 (s, 3H), 2.27 (s, 3H), 2.26 (s, 3H),
		1201, 1177 cm−1		2.26-2.16 (m, 1H), 1.93-1.82 (m,
				1H), 1.71-1.59 (m, 1H),
				1.59-1.23 (m, 7H), 1.29-1.15 (m, 1H), 1.07 (d, J = 6.4 Hz,
				3H), 0.92-0.83 (m, 1H).
202		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 8.58 (s,
		film) 3382,	calcd for C29H38N2O6Na,	1H), 8.35 (d, J = 5.4 Hz, 1H), 7.21 (d, J = 7.8 Hz,
		2929,	533.2622; found, 533.2615	1H), 7.01 (d, J = 5.5 Hz, 1H),/
		1173,		6.96-6.88 (m, 2H), 5.42 (qd, J = 6.3,
		1735,		4.5 Hz, 1H), 4.76-4.67 (m, 1H),
		1679,		3.91 (s, 3H), 2.75 (dd, J = 9.4, 4.6 Hz, 1H),
		1508,		2.40 (s, 3H), 2.28 (s, 3H), 2.24 (s, 3H),
		1201,		1.90-1.50 (m, 5H), 1.41 (d, J = 7.2 Hz,
		1176, 735 cm−1		3H), 1.39-1.31 (m, 1H),
				1.29-1.14 (m, 1H), 1.14-1.04 (m, 2H), 1.03 (d, J = 6.3 Hz,
				3H), 1.01-0.86 (m, 1H),
				0.84-0.73 (m, 1H).
203		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.56 (s,
		film) 2968,	calcd for C27H37N2O6,	1H), 8.35 (dd, J = 5.4, 2.6 Hz, 1H),
		29333,	485.2646; found, 485.2643	7.20 (t, J = 7.2 Hz, 1H), 7.06-6.87 (m, 3H),
		1773,		5.42 (dtd, J = 10.6, 6.3, 4.5 Hz, 1H),
		1734,		4.77-4.62 (m, 1H), 3.91 (s, 3H),
		1679,		2.88-2.68 (m, 1H), 2.39 (s, 3H),
		1507,		2.29-2.24 (m, 6H), 1.94-1.53 (m, 1H),
		1200, 1177 cm−1		1.46-0.62 (m, 14H).
204		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.38 (d,
		film) 3380,	calcd for C27H37N2O7,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2969,	501.2595; found, 501.2589	1H), 7.20 (d, J = 7.9 Hz, 1H),
		1732,		7.00-6.87 (m, 3H), 5.80-5.69 (m, 2H),
		1675,		5.42 (qd, J = 6.2, 4.7 Hz, 1H), 4.71 (p, J = 7.2 Hz,
		1502,		1H), 3.91 (s, 3H), 2.69 (dd, J = 9.2,
		1200,		4.9 Hz, 1H), 2.27 (s, 3H), 2.25 (s,
		1003, 967,		3H), 2.10-1.97 (m, 1H), 2.06 (s, 3H),
		829 cm−1		1.39 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 6.3 Hz,
				3H), 0.99 (d, J = 6.6 Hz, 3H),
				0.70 (d, J = 6.7 Hz, 3H).
205		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.39 (d,
		film) 3380,	calcd for C29H39N2O7,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2950,	527.2752; found, 527.2744	1H), 7.21 (d, J = 7.9 Hz, 1H),
		1756,		6.98-6.86 (m, 3H), 5.82-5.69 (m, 2H),
		1735,		5.32 (qd, J = 6.3, 4.1 Hz, 1H), 4.73 (p, J = 7.3 Hz,
		1678,		1H), 3.91 (s, 3H), 2.81 (dd, J = 10.3,
		1504,		4.2 Hz, 1H), 2.27 (s, 3H), 2.27 (s,
		1202, 1005 cm−1		3H), 2.25-2.19 (m, 1H), 2.07 (s, 3H),
				1.95-1.82 (m, 1H), 1.69-1.60 (m,
				1H), 1.57-1.34 (m, 7H),
				1.29-1.15 (m, 1H), 1.08 (d, J = 6.3 Hz, 3H),
				0.89 (tdd, J = 11.7, 9.4, 7.6 Hz, 1H).
206		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 8.39 (d,
		film) 3380,	calcd for C30H40N2O7Na,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.3 Hz,
		2963,	563.2728; found, 563.2725	1H), 7.23 (d, J = 7.7 Hz, 1H),
		1756,		6.97-6.90 (m, 3H), 5.81-5.68 (m, 2H),
		1735,		5.42 (qd, J = 6.2, 4.6 Hz, 1H),
		1678,		4.77-4.69 (m, 1H), 3.91 (s, 3H), 2.76 (dd, J = 9.4,
		1504,		4.7 Hz, 1H), 2.28 (s, 3H), 2.24 (s, 3H),
		1202,		2.06 (s, 3H), 1.91-1.51z (m, 5H),
		1005, 970 cm−1		1.42 (d, J = 7.2 Hz, 3H), 1.40-1.33 (m, 1H),
				1.25-0.91 (m, 7H), 0.85-0.73 (m,
				1H).
207		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.38 (d,
		film) 3381,	calcd for C28H39N2O7,	J = 16.9, 7.8 Hz, 1H), 8.32-8.26 (m,
		2968,	515.2752; found, 515.2746	1H), 7.21 (t, J = 8.3 Hz, 1H),
		2933,		7.00-6.86 (m, 3H), 5.81-5.66 (m, 2H),
		1757,		5.48-5.37 (m, 1H), 4.77-4.63 (m, 1H),
		1735,		3.91 (s, 3H), 2.88-2.70 (m, 1H),
		1678,		2.32-2.23 (m, 6H), 2.06 (s, 3H),
		1504,		1.90-1.52 (m, 1H), 1.46-0.66 (m, 14H).
		1202, 1005 cm−1
208		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.62 (d,
		film) 2958,	calcd for C25H31N2O6,	J = 5.3 Hz, 1H), 7.15 (d, J = 5.4 Hz,
		1770,	455.2177; found, 455.2171	1H), 6.90 (d, J = 7.9 Hz, 1H),
		1715,		6.87-6.83 (m, 1H), 6.32-6.24 (m, 1H),
		1371,		5.65 (q, J = 7.1 Hz, 1H), 5.43 (qd, J = 6.4,
		1244, 734 cm−1		3.2 Hz, 1H), 4.05 (s, 3H), 2.53 (dd, J = 10.4,
				3.2 Hz, 1H), 2.18 (s, 3H), 2.10 (s,
				3H), 2.06-1.96 (m, 1H), 1.71 (d, J = 7.0 Hz,
				3H), 1.04 (d, J = 6.5 Hz, 3H),
				0.95 (d, J = 6.3 Hz, 3H), 0.60 (d, J = 6.6 Hz,
				3H).
209		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.62 (d,
		film) 2949,	calcd for C27H33N2O6,	J = 5.3 Hz, 1H), 7.15 (d, J = 5.4 Hz,
		1770,	481.2333; found, 481.2325	1H), 6.93 (d, J = 7.9 Hz, 1H),
		1715,		6.87-6.82 (m, 1H), 6.33-6.28 (m, 1H),
		1502,		5.67 (q, J = 7.0 Hz, 1H), 5.29 (qd, J = 6.5,
		1371, 1243 cm−1		2.9 Hz, 1H), 4.05 (s, 3H), 2.68 (dd, J = 10.9,
				2.8 Hz, 1H), 2.30-2.18 (m, 4H),
				2.09 (s, 3H), 1.93 (dtd, J = 11.2, 7.2, 3.4 Hz,
				1H), 1.71 (d, J = 7.1 Hz, 3H),
				1.68-1.05 (m, 6H), 0.98 (d, J = 6.4 Hz,
				3H), 0.83-0.72 (m, 1H).
210		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.63 (d,
		film) 2928,	calcd for C28H35N2O6,	J = 5.3 Hz, 1H), 7.15 (d, J = 5.3 Hz,
		1771,	495.2490; found, 495.2485	1H), 6.90 (d, J = 7.9 Hz, 1H),
		1715,		6.86-6.83 (m, 1H), 6.29-6.24 (m, 1H),
		1502,		5.67 (q, J = 7.0 Hz, 1H), 5.43 (qd, J = 6.3,
		1371, 1243 cm−1		3.1 Hz, 1H), 4.06 (s, 3H),
				2.66-2.60 (m, 1H), 2.17 (s, 3H), 2.10 (s, 3H),
				2.01-1.94 (m, 1H), 1.78-1.54 (m, 6H),
				1.53-1.43 (m, 1H), 1.34-1.19 (m,
				2H), 1.14-0.88 (m, 6H),
				0.76-0.58 (m, 1H).
211		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 14.37 (s,
		film) 2964,	calcd for C24H33N2O6,	1H), 12.78 (d, J = 7.0 Hz, 1H), 7.88 (d,
		1734,	445.2333; found, 445.2370	J = 7.1 Hz, 1H), 7.15 (d, J = 7.7 Hz,
		1644,		1H), 6.90 (d, J = 8.0 Hz, 2H), 6.77 (d, J = 7.2 Hz,
		1571,		1H), 5.42 (qd, J = 6.3, 5.0 Hz,
		1480,		1H), 4.69-4.61 (m, 1H), 3.96 (s, 3H),
		1302, 1216 cm−1		2.69 (dd, J = 9.1, 5.0 Hz, 1H), 2.25 (s,
				3H), 2.23 (s, 3H), 2.00 (dp, J = 8.8, 6.6 Hz,
				1H), 1.44 (d, J = 7.2 Hz, 3H),
				1.08 (d, J = 6.3 Hz, 3H), 0.98 (d, J = 6.6 Hz,
				3H), 0.69 (d, J = 6.8 Hz, 3H).
212		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 14.38 (s,
		film) 2948,	calcd for C26H35N2O6,	1H), 12.79 (d, J = 7.2 Hz, 1H), 7.90 (d,
		2868,	471.2490; found, 471.2515	J = 7.1 Hz, 1H), 7.17 (d, J = 7.9 Hz,
		1734,		1H), 6.96-6.85 (m, 2H), 6.77 (d, J = 7.1 Hz,
		1570,		1H), 5.31 (qd, J = 6.3, 4.0 Hz,
		1480,		1H), 4.72-4.60 (m, 1H), 3.96 (s, 3H),
		1301, 1218 cm−1		2.80 (dd, J = 10.3, 4.2 Hz, 1H),
				2.28-2.24 (m, 6H), 2.21-2.10 (m, 1H),
				1.95-1.85 (m, 1H), 1.69-1.30 (m, 8H),
				1.20 (dq, J = 12.3, 9.2 Hz, 1H), 1.08 (d,
				J = 6.3 Hz, 3H), 0.94-0.81 (m, 1H).
213		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 14.37 (d,
		film) 2963,	calcd for C25H35N2O6,	J = 6.2 Hz, 1H), 12.75 (dd, J = 15.8, 7.1 Hz,
		2931,	459.2490; found, 459.2527	1H), 7.98-7.81 (m, 1H),
		1733,		7.21-6.71 (m, 4H), 5.50-5.33 (m, 1H),
		1569,		4.72-4.58 (m, 1H), 3.96 (s, 3H),
		1479,		2.92-2.70 (m, 1H), 2.31-2.19 (m, 6H),
		1453,		1.88-1.69 (m, 1H), 1.44 (dd, J = 48.4, 7.2 Hz,
		1301,		3H), 1.25-0.58 (m, 11H).
		1213, 729 cm−1
214		IR (thin	ESIMS m/z 461.1	1H NMR (500 MHz, CDCl3) δ 8.50 (d,
		film) 3382,	([M + H]+)	J = 8.0 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2962,		1H), 7.17-6.99 (m, 3H),
		1770,		6.99-6.86 (m, 2H), 5.38 (dq, J = 8.2, 6.2 Hz, 1H),
		1731,		4.75-4.60 (m, 1H), 3.92 (s, 3H),
		1674,		2.69 (dd, J = 8.3, 6.9 Hz, 1H), 2.40 (s, 3H),
		1590,		2.14-2.00 (m, 1H), 1.49 (d, J = 7.2 Hz,
		1571,		3H), 1.08 (d, J = 6.3 Hz, 3H),
		1507,		0.87 (d, J = 6.7 Hz, 3H), 0.74 (d, J = 6.7 Hz,
		1452,		3H).
		1435,		13C NMR (126 MHz, CDCl3) δ 172.15,
		1309,		168.93, 162.38, 161.69 (d, J = 244.5 Hz),
		1198,		159.48, 146.65, 141.52, 137.54,
		1174,		134.34 (d, J = 3.3 Hz), 131.04 (d, J = 7.7 Hz),
		1159,		114.75 (d, J = 20.9 Hz), 109.77,
		1045, 906,		72.50, 56.31, 55.80, 48.17, 28.29,
		833, 803,		21.24, 20.77, 18.75, 18.65, 17.41.
		729 cm−1
215		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.34 (d,
		film) 3381,	calcd for C26H34FN2O7,	J = 7.8 Hz, 1H), 8.28 (d, J = 5.3 Hz,
		2962,	505.2345; found, 505.2345	1H), 7.05 (dd, J = 8.5, 5.9 Hz, 1H),
		1756,		6.96 (d, J = 5.4 Hz, 1H), 6.91-6.77 (m,
		1677,		2H), 5.75 (s, 2H), 5.36 (dq, J = 9.0, 6.2 Hz,
		1499,		1H), 4.72 (p, J = 7.2 Hz, 1H),
		1203,		3.92 (s, 3H), 3.09 (dd, J = 9.0, 6.4 Hz, 1H),
		1044,		2.30 (s, 3H), 2.13 (q, J = 6.8 Hz, 1H),
		1004, 971,		2.08 (s, 3H), 1.52 (d, J = 7.2 Hz, 3H),
		830 cm−1		1.07 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.7 Hz,
				3H), 0.78 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.35,
				170.26, 162.95, 160.94 (d, J = 244.4 Hz),
				160.33, 145.69, 144.07, 142.53,
				139.88 (d, J = 7.3 Hz), 133.64 (d, J = 3.0 Hz),
				129.16 (d, J = 6.0 Hz),
				116.96 (d, J = 20.5 Hz), 112.34 (d, J = 20.7 Hz),
				109.59, 89.61, 73.75, 56.20, 48.43,
				29.70, 29.30, 20.92, 20.87, 18.88,
				18.44, 17.99.
				19F NMR (376 MHz, CDCl3) δ −117.40.
216		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.45 (d,
		film) 3382,	calcd for C27H36FN2O6,	J = 7.7 Hz, 1H), 8.32 (d, J = 5.4 Hz,
		2971,	503.2552; found, 503.2553	1H), 7.05 (dd, J = 8.6, 5.9 Hz, 1H),
		1733,		6.99 (d, J = 5.4 Hz, 1H), 6.90-6.73 (m,
		1678,		2H), 5.35 (dq, J = 8.9, 6.2 Hz, 1H),
		1499,		4.78-4.64 (m, 1H), 3.90 (s, 3H), 3.08 (dd, J = 8.9,
		1210,		6.5 Hz, 1H), 2.95 (p, J = 7.0 Hz,
		1153,		1H), 2.29 (s, 3H), 2.11 (h, J = 6.7 Hz,
		1123,		1H), 1.49 (d, J = 7.2 Hz, 3H), 1.37 (s,
		1045, 731 cm−1		3H), 1.35 (s, 3H), 1.06 (d, J = 6.2 Hz,
				3H), 0.86 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 174.67,
				172.31, 162.33, 160.93 (d, J = 244.3 Hz),
				159.48, 146.54, 141.94, 139.89 (d,
				J = 7.3 Hz), 137.73, 133.69 (d, J = 2.9 Hz),
				129.15 (d, J = 7.1 Hz), 116.95 (d, J = 20.5 Hz),
				112.31 (d, J = 20.7 Hz),
				109.62, 73.70, 56.30, 48.19, 33.97,
				29.70, 20.93, 20.90, 20.89, 18.95,
				18.82, 18.62, 17.90.
				19F NMR (376 MHz, CDCl3) δ −117.44.
217		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.60 (d,
		film) 2960,	calcd for C24H28FN2O6,	J = 5.3 Hz, 1H), 7.14 (d, J = 5.3 Hz,
		1714,	459.1926; found, 459.1926	1H), 6.97 (dd, J = 8.7, 6.0 Hz, 1H),
		1500,		6.62 (td, J = 8.5, 2.9 Hz, 1H), 6.23 (dd, J = 10.0,
		1371,		2.8 Hz, 1H), 5.49 (q, J = 7.0 Hz,
		1243,		1H), 5.34 (p, J = 6.3 Hz, 1H), 4.07 (s,
		1083, 731 cm−1		3H), 2.87 (dd, J = 9.9, 6.1 Hz, 1H),
				2.12 (s, 3H), 1.95 (dp, J = 9.8, 6.6 Hz, 1H),
				1.63 (d, J = 7.0 Hz, 3H), 1.15 (d, J = 6.3 Hz,
				3H), 1.00 (d, J = 6.5 Hz, 3H),
				0.63 (d, J = 6.6 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.44,
				−117.49.
218		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 14.33 (s,
		film) 2962,	calcd for C23H30FN2O6,	1H), 12.78 (d, J = 7.0 Hz, 1H), 7.88 (d,
		1736,	449.2082; found, 449.2085	J = 7.2 Hz, 1H), 7.05 (dd, J = 8.3, 5.9 Hz,
		1533,		1H), 6.88-6.75 (m, 3H), 5.37 (dq,
		1481,		J = 8.9, 6.3 Hz, 1H), 4.66 (p, J = 7.1 Hz,
		1302,		1H), 3.98 (s, 3H), 3.08 (dd, J = 9.0,
		1241,		6.5 Hz, 1H), 2.30 (s, 3H), 2.09 (hept, J = 6.9 Hz,
		1155,		1H), 1.57 (d, J = 7.2 Hz, 3H),
		1030, 953,		1.07 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.8 Hz,
		815, 758 cm−1		3H), 0.77 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.09,
				165.57, 160.90 (d, J = 244.3 Hz),
				152.59, 149.34, 139.86 (d, J = 7.3 Hz),
				133.66 (d, J = 3.1 Hz), 130.96,
				129.20 (d, J = 7.4 Hz), 123.74, 116.84 (d, J = 20.5 Hz),
				112.33 (d, J = 20.8 Hz),
				107.74, 73.95, 56.55, 48.90, 29.73,
				29.30, 20.93, 20.92, 18.96, 17.83,
				17.59.
				19F NMR (376 MHz, CDCl3) δ −117.36.
219		IR (thin	ESIMS m/z 491.2	1H NMR (400 MHz, CDCl3) δ 9.94 (d,
		film) 3281,	([M + H]+)	J = 7.5 Hz, 1H), 8.32 (d, J = 5.4 Hz,
		2962,		1H), 7.05 (dd, J = 8.4, 5.9 Hz, 1H),
		1770,		7.00 (d, J = 5.5 Hz, 1H), 6.90-6.80 (m,
		1733,		2H), 5.39 (dq, J = 9.1, 6.3 Hz, 1H),
		1498,		5.18 (p, J = 7.1 Hz, 1H), 3.91 (s, 3H),
		1192,		3.10 (dd, J = 9.1, 6.3 Hz, 1H), 2.36 (s, 3H),
		1175,		2.30 (s, 3H), 2.19-2.09 (m, 1H),
		1104, 821,		1.60 (d, J = 7.1 Hz, 3H), 1.08 (d, J = 6.2 Hz,
		730 cm−1		3H), 0.86 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 189.28,
				171.51, 168.58, 160.96 (d, J = 244.5 Hz),
				159.87, 146.29, 145.03, 139.87 (d,
				J = 7.4 Hz), 136.90, 133.53 (d, J = 2.9 Hz),
				129.16 (d, J = 6.9 Hz), 117.00 (d, J = 20.5 Hz),
				112.38 (d, J = 20.7 Hz),
				109.27, 74.11, 56.43, 53.08, 29.66,
				29.29, 21.26, 20.94, 20.91, 18.78,
				18.10, 16.84.
				19F NMR (376 MHz, CDCl3) δ −117.27.
220		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.49 (d,
		film) 3382,	calcd for C27H36FN2O7,	J = 7.9 Hz, 1H), 8.32 (d, J = 5.4 Hz,
		2961,	519.2501; found, 519.2497	1H), 7.05 (dd, J = 8.6, 5.9 Hz, 1H),
		1732,		7.01 (d, J = 5.5 Hz, 1H), 6.89-6.77 (m,
		1676,		2H), 5.36 (dp, J = 8.9, 6.2 Hz, 1H),
		1499,		4.74-4.64 (m, 1H), 3.91 (s, 3H), 3.81 (t, J = 6.6 Hz,
		1151,		2H), 3.41 (s, 3H), 3.08 (dd, J = 8.9,
		1110,		6.5 Hz, 1H), 2.99 (t, J = 6.6 Hz,
		1049, 730 cm−1		2H), 2.29 (s, 3H), 2.11 (h, J = 6.7 Hz,
				1H), 1.49 (d, J = 7.1 Hz, 3H), 1.06 (d, J = 6.3 Hz,
				3H), 0.86 (d, J = 6.8 Hz, 3H),
				0.77 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.23,
				169.40, 162.30, 160.93 (d, J = 244.3 Hz),
				159.51, 146.69, 141.58, 139.89 (d,
				J = 7.4 Hz), 137.41, 133.65 (d, J = 3.2 Hz),
				129.15 (d, J = 9.6 Hz), 116.96 (d, J = 20.5 Hz),
				112.32 (d, J = 20.8 Hz),
				109.77, 73.74, 67.62, 58.76, 56.33,
				48.22, 34.67, 29.70, 20.93, 20.90,
				18.95, 18.58, 17.90.
				19F NMR (376 MHz, CDCl3) δ −117.42.
221		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (s,
		film) 3375,	calcd for C25H32FN2O7,	1H), 8.35 (d, J = 5.4 Hz, 1H), 7.21 (dd,
		2964,	491.2188; found, 491.2184	J = 8.5, 6.9 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1771,		1H), 6.62-6.48 (m, 2H),
		1676,		5.46-5.37 (m, 1H), 4.74-4.64 (m, 1H),
		1502,		3.91 (s, 3H), 3.77 (s, 3H), 3.04 (dd, J = 9.5,
		1193,		4.8 Hz, 1H), 2.39 (s, 3H), 1.61 (s, 1H),
		1035, 953,		1.39 (d, J = 7.2 Hz, 3H), 1.03 (d, J = 6.3 Hz,
		832 cm−1		3H), 0.97 (d, J = 6.6 Hz, 3H),
				0.67 (d, J = 6.7 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.24.
222		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (s,
		film) 3379,	calcd for C27H36FN2O7,	1H), 8.35 (d, J = 5.5 Hz, 1H), 7.23 (dd,
		2963,	519.2501; found, 519.2499	J = 8.5, 6.9 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		1772,		1H), 6.60-6.49 (m, 2H),
		1733,		5.43-5.33 (m, 1H), 4.75-4.65 (m, 1H),
		1677,		3.91 (s, 3H), 3.77 (s, 3H), 3.30 (dd, J = 10.0,
		1502,		4.4 Hz, 1H), 2.39 (s, 3H),
		1194,		1.77-1.59 (m, 2H), 1.51-1.39 (m, 3H), 1.33 (dq,
		1177,		J = 14.4, 7.2 Hz, 1H), 1.19 (dtd, J = 14.9,
		1036, 954,		7.5, 3.3 Hz, 1H), 1.01 (d, J = 6.2 Hz,
		834 cm−1		3H), 0.99-0.91 (m, 1H), 0.88 (t, J = 7.4 Hz,
				3H), 0.67 (t, J = 7.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.23.
223		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3381,	calcd for C28H36FN2O7,	J = 7.8 Hz, 1H), 8.35 (d, J = 5.4 Hz,
		2929,	531.2501; found, 531.2496	1H), 7.22 (t, J = 7.7 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1771,		1H), 6.56 (ddd, J = 9.5, 7.3,
		1731,		4.1 Hz, 2H), 5.42 (t, J = 5.8 Hz, 1H),
		1675,		4.70 (p, J = 7.3 Hz, 1H), 3.91 (s, 3H),
		1501,		3.76 (s, 3H), 3.11 (s, 1H), 2.40 (s, 3H),
		1193,		1.78 (dd, J = 46.1, 13.0 Hz, 2H),
		1175, 953,		1.59 (dd, J = 20.5, 8.6 Hz, 3H), 1.42 (dd, J = 11.2,
		731 cm−1		7.1 Hz, 3H), 1.37-0.85 (m, 8H),
				0.83-0.67 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.25.
224		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (s,
		film) 3382,	calcd for C27H34FN2O7,	1H), 8.35 (d, J = 5.4 Hz, 1H), 7.23 (t, J = 7.7 Hz,
		2946,	517.2345; found, 517.2341	1H), 7.02 (d, J = 5.4 Hz, 1H),
		1771,		6.57 (dd, J = 11.1, 2.6 Hz, 1H),
		1731,		6.50 (td, J = 8.4, 2.5 Hz, 1H), 5.32 (dt, J = 10.1,
		1675,		5.0 Hz, 1H), 4.72 (p, J = 7.2 Hz,
		1501,		1H), 3.92 (s, 3H), 3.77 (s, 3H), 3.11 (d,
		1192,		J = 10.7 Hz, 1H), 2.40 (s, 3H),
		1176,		2.22-2.06 (m, 1H), 1.86 (dtd, J = 11.2, 6.9,
		1149, 951,		3.4 Hz, 1H), 1.71-1.59 (m, 2H),
		731 cm−1		1.59-1.29 (m, 5H), 1.29-1.16 (m, 2H),
				1.02 (d, J = 6.3 Hz, 3H), 0.88 (dq, J = 11.9,
				8.4, 8.0 Hz, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.34.
225		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.52 (s,
		film) 3378,	calcd for C26H34FN2O7,	1H), 8.34 (dd, J = 5.5, 3.2 Hz, 1H),
		2964,	505.2345; found, 505.2341	7.21 (ddd, J = 11.8, 8.4, 6.9 Hz, 1H),
		1771,		7.01 (dd, J = 5.5, 3.5 Hz, 1H), 6.55 (dddt, J = 13.6,
		1731,		8.1, 5.3, 2.7 Hz, 2H),
		1675,		5.48-5.36 (m, 1H), 4.75-4.58 (m, 1H),
		1501,		3.94-3.87 (m, 3H), 3.77 (d, J = 1.1 Hz,
		1193,		3H), 3.16 (ddd, J = 47.2, 9.4, 4.9 Hz,
		1175,		1H), 2.39 (d, J = 2.9 Hz, 3H),
		1035, 952,		1.86-1.71 (m, 1H), 1.61-1.36 (m, 2H),
		833, 732 cm−1		1.34-1.21 (m, 3H), 1.11-0.93 (m, 4H),
				0.89 (td, J = 7.3, 3.6 Hz, 2H),
				0.75-0.61 (m, 3H).
				19F NMR (376 MHz, CDCl3) δ −114.21,
				−114.28.
226		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.47 (s,
		film) 3379,	calcd for C26H32FN2O7,	1H), 8.33 (d, J = 5.4 Hz, 1H), 7.06 (dd,
		2938,	503.2188; found, 503.2181	J = 8.5, 6.8 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1771,		1H), 6.55 (dd, J = 11.0, 2.6 Hz,
		1731,		1H), 6.48 (td, J = 8.3, 2.5 Hz, 1H),
		1675,		5.21 (q, J = 6.1 Hz, 1H), 4.62 (p, J = 7.3 Hz,
		1502,		1H), 3.91 (s, 3H), 3.78 (s, 3H), 3.25 (s,
		1193,		1H), 2.65 (d, J = 14.9 Hz, 1H), 2.40 (s,
		1176,		3H), 2.15-2.06 (m, 1H),
		1035, 953,		1.87-1.58 (m, 4H), 1.43 (dt, J = 17.2, 8.4 Hz, 1H),
		733 cm−1		1.30 (d, J = 7.1 Hz, 3H), 1.11 (d, J = 6.3 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −114.16.
227		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3381,	calcd for C28H36FN2O7,	J = 7.8 Hz, 1H), 8.31 (d, J = 5.4 Hz,
		2927,	531.2501; found, 531.2493	1H), 7.00 (q, J = 4.9 Hz, 2H), 6.60 (td,
		1770,		J = 8.3, 2.5 Hz, 1H), 6.53 (dd, J = 11.0,
		1732,		2.5 Hz, 1H), 5.54-5.31 (m, 1H),
		1675,		4.78-4.63 (m, 1H), 3.91 (s, 3H), 3.73 (s, 3H),
		1502,		3.47 (d, J = 69.3 Hz, 1H), 2.40 (s, 3H),
		1192,		1.81-1.51 (m, 5H), 1.49 (d, J = 7.1 Hz,
		1175,		3H), 1.37-1.08 (m, 2H),
		1034, 953,		1.08-1.04 (m, 4H), 1.04-0.70 (m, 3H).
		908, 730 cm−1		19F NMR (376 MHz, CDCl3) δ −114.00.
228		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.50 (s,
		film) 3379,	calcd for C27H34FN2O7,	1H), 8.28 (d, J = 5.4 Hz, 1H), 7.05 (t, J = 7.7 Hz,
		2944,	517.2345; found, 517.2333	1H), 7.00 (d, J = 5.5 Hz, 1H),
		1770,		6.58 (td, J = 8.2, 2.5 Hz, 1H), 6.49 (dd,
		1732,		J = 11.1, 2.5 Hz, 1H), 5.32 (s, 1H),
		1675,		4.71-4.59 (m, 1H), 3.91 (s, 3H), 3.71 (s,
		1502,		3H), 3.48 (d, J = 40.6 Hz, 1H), 2.40 (s,
		1192,		3H), 2.18 (s, 1H), 1.92-1.78 (m, 1H),
		1176,		1.63 (s, 1H), 1.56-1.34 (m, 6H),
		1149,		1.34-1.20 (m, 2H), 1.11 (d, J = 6.4 Hz,
		1033, 952,		3H), 0.89 (td, J = 9.3, 8.3, 3.7 Hz, 1H).
		732 cm−1		19F NMR (376 MHz, CDCl3) δ −114.18.
229		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (s,
		film) 2963,	calcd for C27H36FN2O7,	1H), 8.30 (d, J = 5.4 Hz, 1H),
		1772,	519.2501; found, 519.2499	7.09-6.97 (m, 2H), 6.58 (td, J = 8.2, 2.5 Hz,
		1733,		1H), 6.51 (dd, J = 11.0, 2.6 Hz, 1H),
		1677,		5.49-5.37 (m, 1H), 4.74-4.63 (m,
		1503,		1H), 3.91 (s, 3H), 3.73 (s, 3H), 3.58 (s,
		1194,		1H), 2.40 (s, 3H), 1.61 (d, J = 18.5 Hz,
		1177,		1H), 1.48 (d, J = 7.1 Hz, 3H),
		1035, 954 cm−1		1.45-1.28 (m, 2H), 1.27-1.12 (m, 1H),
				1.09 (d, J = 6.2 Hz, 3H), 1.00-0.83 (m,
				4H), 0.74 (t, J = 7.3 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.98.
230		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (s,
		film) 2964,	calcd for C26H34FN2O7,	1H), 8.31 (dd, J = 8.1, 5.4 Hz, 1H),
		1770,	505.2345; found, 505.2333	7.08-6.97 (m, 2H), 6.65-6.55 (m, 1H),
		1732,		6.55-6.48 (m, 1H), 5.45 (d, J = 11.2 Hz,
		1675,		1H), 4.69 (ddd, J = 14.1, 8.0, 7.1 Hz,
		1502,		1H), 3.91 (s, 3H), 3.74 (d, J = 9.6 Hz,
		1193,		3H), 3.51 (d, J = 44.9 Hz, 1H),
		1175,		2.40 (d, J = 1.8 Hz, 3H), 1.90-1.58 (m,
		1034, 953,		1H), 1.55-1.44 (m, 3H),
		834, 731 cm−1		1.41-1.26 (m, 1H), 1.07 (dd, J = 11.1, 6.2 Hz,
				3H), 0.99-0.80 (m, 4H), 0.75 (t, J = 7.4 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −113.91,
				−114.00.
231		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
		film) 3381,	calcd for C26H32FN2O7,	J = 7.6 Hz, 1H), 8.31 (d, J = 5.4 Hz,
		2939,	503.2188; found, 503.2173	1H), 7.02-6.94 (m, 2H),
		1770,		6.65-6.49 (m, 2H), 5.16 (s, 1H), 4.73-4.59 (m,
		1731,		1H), 3.91 (s, 3H), 3.77 (s, 3H), 3.33 (s,
		1674,		1H), 2.78 (hept, J = 8.6, 7.8 Hz, 1H),
		1502,		2.40 (s, 3H), 2.17-2.04 (m, 1H),
		1193,		1.97-1.56 (m, 4H), 1.45 (d, J = 7.1 Hz,
		1175,		3H), 1.43-1.36 (m, 1H), 1.08 (d, J = 6.4 Hz,
		1148,		3H).
		1035, 953,		19F NMR (376 MHz, CDCl3) δ −113.98.
		731 cm−1
232		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (d,
		film) 3379,	calcd for C25H32FN2O7,	J = 7.3 Hz, 1H), 8.31 (d, J = 5.4 Hz,
		2962,	491.2188; found, 491.2179	1H), 7.05-6.97 (m, 2H), 6.60 (td, J = 8.3,
		1770,		2.6 Hz, 1H), 6.54 (dd, J = 11.1, 2.5 Hz,
		1732,		1H), 5.48-5.31 (m, 1H),
		1674,		4.77-4.64 (m, 1H), 3.91 (s, 3H), 3.74 (s, 3H),
		1502,		3.33 (s, 1H), 2.40 (s, 3H),
		1192,		2.14-2.01 (m, 1H), 1.66 (s, 1H), 1.49 (d, J = 7.1 Hz,
		1175,		2H), 1.07 (d, J = 6.2 Hz, 3H),
		1150,		0.85 (d, J = 6.7 Hz, 3H), 0.72 (d, J = 6.8 Hz,
		1034, 953,		3H).
		731 cm−1		19F NMR (376 MHz, CDCl3) δ −113.95.
233		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.36 (d,
		film) 3381,	calcd for C29H38FN2O8,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2928,	561.2607; found, 561.2602	1H), 7.26-7.22 (m, 1H), 6.96 (d, J = 5.4 Hz,
		1733,		1H), 6.61-6.52 (m, 2H),
		1675,		5.78-5.72 (m, 2H), 5.42 (q, J = 5.9 Hz, 1H),
		1501,		4.72 (p, J = 7.1 Hz, 1H), 3.91 (s, 3H),
		1201,		3.77 (s, 3H), 3.13 (s, 1H), 2.07 (s, 3H),
		1004, 953,		1.89-1.51 (m, 7H), 1.42 (d, J = 7.1 Hz,
		831, 730 cm−1		3H), 1.37-1.05 (m, 3H), 1.03 (d, J = 6.2 Hz,
				2H), 1.01-0.68 (m, 2H).
				19F NMR (376 MHz, CDCl3) δ −114.24.
234		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3381,	calcd for C28H36FN2O8,	J = 7.9 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2948,	547.2450; found, 547.2445	1H), 7.28-7.21 (m, 1H), 6.96 (d, J = 5.4 Hz,
		1732,		1H), 6.57 (dd, J = 11.1, 2.5 Hz,
		1674,		1H), 6.52 (td, J = 8.4, 2.5 Hz, 1H),
		1501,		5.81-5.71 (m, 2H), 5.33 (qd, J = 6.4, 3.8 Hz,
		1200,		1H), 4.73 (p, J = 7.2 Hz, 1H),
		1004, 951,		3.92 (s, 3H), 3.77 (s, 3H), 3.12 (d, J = 10.4 Hz,
		831 cm−1		1H), 2.18 (s, 1H), 2.07 (s, 3H),
				1.98-1.80 (m, 1H), 1.64 (d, J = 6.5 Hz,
				2H), 1.58-1.29 (m, 5H),
				1.29-1.15 (m, 2H), 1.02 (dd, J = 14.6, 6.3 Hz,
				3H), 0.94-0.83 (m, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.31.
235		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.32 (d,
		film) 3379,	calcd for C28H36FN2O8,	J = 7.8 Hz, 1H), 8.25 (d, J = 5.4 Hz,
		2945,	547.2450; found, 547.2444	1H), 7.05 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 5.4 Hz,
		1733,		1H), 6.59 (td, J = 8.2, 2.5 Hz,
		1674,		1H), 6.50 (dd, J = 11.1, 2.5 Hz, 1H),
		1501,		5.74 (s, 2H), 5.32 (s, 1H), 4.68 (p, J = 7.2 Hz,
		1200,		1H), 3.91 (s, 3H), 3.73 (s, 3H),
		1035,		3.49 (d, J = 46.2 Hz, 1H), 2.07 (s, 3H),
		1003, 953,		1.90-1.78 (m, 1H), 1.63 (d, J = 24.2 Hz,
		831, 731 cm−1		1H), 1.55-1.31 (m, 8H),
				1.31-1.19 (m, 1H), 1.12 (d, J = 6.4 Hz, 3H),
				0.90 (td, J = 9.4, 8.3, 3.6 Hz, 1H).
				19F NMR (376 MHz, CDCl3) δ −114.15.
236		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.33 (d,
		film) 3381,	calcd for C27H34FN2O8,	J = 7.9 Hz, 1H), 8.27 (d, J = 5.4 Hz,
		2939,	533.2294; found, 533.2286	1H), 7.02-6.92 (m, 2H),
		1733,		6.60-6.47 (m, 2H), 5.80-5.70 (m, 2H), 5.16 (s,
		1674,		1H), 4.78-4.63 (m, 1H), 3.91 (s, 3H),
		1501,		3.78 (s, 3H), 3.34 (s, 1H), 2.79 (h, J = 8.6 Hz,
		1200,		1H), 2.20-2.09 (m, 1H),
		1147,		2.07 (s, 3H), 1.99-1.57 (m, 4H), 1.48 (dd, J = 7.1,
		1037,		3.0 Hz, 3H), 1.45-1.37 (m, 1H),
		1003, 953,		1.09 (d, J = 6.4 Hz, 3H).
		831, 731 cm−1		19F NMR (376 MHz, CDCl3) δ −113.97.
237		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.36 (d,
		film) 3379,	calcd for C26H34FN2O8,	J = 7.8 Hz, 1H), 8.27 (d, J = 5.3 Hz,
		2962,	521.2294; found, 521.2284	1H), 7.01 (dd, J = 8.5, 6.8 Hz, 1H),
		1733,		6.95 (d, J = 5.4 Hz, 1H), 6.60 (td, J = 8.3,
		1674,		2.5 Hz, 1H), 6.55 (dd, J = 11.1, 2.5 Hz,
		1501,		1H), 5.75 (s, 2H), 5.56-5.31 (m, 1H),
		1200,		4.71 (p, J = 7.3 Hz, 1H), 3.92 (s, 3H),
		1036,		3.75 (s, 3H), 3.34 (s, 1H), 2.07 (s, 3H),
		1003, 953,		1.67 (s, 1H), 1.51 (d, J = 7.1 Hz, 3H),
		831, 731 cm−1		1.08 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.8 Hz,
				3H), 0.73 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.93.
238		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.49 (s,
		film) 3380,	calcd for C28H36FN2O8,	1H), 8.31 (d, J = 5.4 Hz, 1H), 6.98 (dd,
		2937,	547.2450; found, 547.2439	J = 15.2, 6.2 Hz, 2H), 6.61-6.46 (m,
		1768,		2H), 5.16 (s, 1H), 4.70-4.59 (m, 1H),
		1732,		3.90 (s, 3H), 3.82 (t, J = 6.6 Hz, 2H),
		1675,		3.77 (s, 3H), 3.41 (s, 3H),
		1502,		3.37-3.23 (m, 1H), 2.99 (t, J = 6.7 Hz, 2H),
		1146,		2.77 (h, J = 8.8, 8.4 Hz, 1H), 2.16-2.05 (m,
		1110,		1H), 1.97-1.55 (m, 5H), 1.44 (d, J = 7.2 Hz,
		1035, 953,		3H), 1.08 (d, J = 6.4 Hz, 3H).
		833, 731 cm−1		19F NMR (376 MHz, CDCl3) δ −113.97.
239		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.52 (s,
		film) 3377,	calcd for C27H36FN2O8,	1H), 8.31 (d, J = 5.4 Hz, 1H),
		2961,	535.2450; found, 535.2441	7.07-6.97 (m, 2H), 6.60 (td, J = 8.3, 2.6 Hz,
		1768,		1H), 6.54 (dd, J = 11.0, 2.5 Hz, 1H),
		1675,		5.49-5.35 (m, 1H), 4.72-4.60 (m,
		1502,		1H), 3.90 (s, 3H), 3.81 (t, J = 6.6 Hz,
		1310,		2H), 3.74 (s, 3H), 3.41 (s, 3H), 3.28 (d,
		1148,		J = 41.3 Hz, 1H), 2.99 (t, J = 6.6 Hz,
		1112,		2H), 2.08 (dp, J = 13.6, 7.0 Hz, 1H),
		1034, 953,		1.48 (d, J = 7.1 Hz, 3H), 1.07 (d, J = 6.2 Hz,
		833, 732 cm−1		3H), 0.85 (d, J = 6.7 Hz, 3H),
				0.72 (d, J = 6.9 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −113.94.
240		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ
		film) 1733,	calcd for C28H37N2O7,	8.35-8.23 (m, 2H), 7.02 (d, J = 7.9 Hz, 1H),
		1674,	513.2595; found, 513.2591	6.95-6.84 (m, 3H), 5.79-5.68 (m,
		1503,		2H), 5.20-5.08 (m, 1H),
		1201,		4.66-4.55 (m, 1H), 3.90 (s, 3H), 3.04 (dd, J = 10.5,
		1003, 968,		6.3 Hz, 1H), 2.70 (dh, J = 16.8,
		911, 729 cm−1		8.8, 8.2 Hz, 1H), 2.32 (s, 3H), 2.24 (s,
				3H), 2.19-2.10 (m, 1H), 2.06 (s, 3H),
				1.89-1.63 (m, 4H), 1.46-1.36 (m,
				1H), 1.21 (d, J = 7.2 Hz, 3H), 1.18 (d, J = 6.3 Hz,
				3H).
241		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.48 (s,
		film) 2938,	calcd for C27H35N2O6,	1H), 8.33 (d, J = 5.5 Hz, 1H),
		1771,	483.2490; found, 483.2484	7.04-6.85 (m, 4H), 5.20-5.10 (m, 1H),
		1675,		4.65-4.52 (m, 1H), 3.90 (s, 3H), 3.03 (dd, J = 10.5,
		1505,		6.3 Hz, 1H), 2.69 (h, J = 9.1 Hz,
		1199,		1H), 2.39 (s, 3H), 2.32 (s, 3H), 2.25 (s,
		1175, 908,		3H), 2.20-2.10 (m, 1H),
		730 cm−1		1.88-1.63 (m, 4H), 1.46-1.35 (m, 1H), 1.20 (d, J = 7.1 Hz,
				3H), 1.16 (d, J = 6.4 Hz, 3H).
242		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.49 (d,
		film) 3380,	calcd for	J = 8.1 Hz, 1H), 8.34 (d, J = 5.5 Hz,
		2961,	C24H30ClN2O6, 479.1769;	1H), 7.21 (d, J = 8.4 Hz, 2H),
		1771,	found, 479.1772	7.07-6.97 (m, 3H), 5.46-5.33 (m, 1H),
		1734,		4.75-4.61 (m, 1H), 3.92 (s, 3H), 2.68 (t, J = 7.6 Hz,
		1676,		1H), 2.40 (s, 3H),
		1508,		2.12-2.02 (m, 1H), 1.49 (d, J = 7.1 Hz, 3H),
		1310,		1.08 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.6 Hz,
		1200,		3H), 0.73 (d, J = 6.8 Hz, 3H).
		1175,
		1061, 827 cm−1
243		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.54 (s,
		film) 3380,	calcd for C25H32FN2O6,	1H), 8.34 (d, J = 5.4 Hz, 1H),
		2962,	476.2271; found, 476.2275	7.11-6.97 (m, 2H), 6.83-6.64 (m, 2H),
		1772,		5.44-5.29 (m, 1H), 4.77-4.60 (m, 1H),
		1735,		3.92 (s, 3H), 2.71-2.60 (m, 1H),
		1677,		2.40 (s, 3H), 2.24 (d, J = 1.8 Hz, 3H),
		1508,		2.13-2.00 (m, 1H), 1.49 (d, J = 7.1 Hz, 3H),
		1202,		1.09 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.8 Hz,
		1176, 1061 cm−1		3H), 0.75 (d, J = 6.7 Hz, 3H).
244		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.48 (d,
		film) 3382,	calcd for C24H29F2N2O6,	J = 8.1 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2963,	480.202; found, 480.202	1H), 7.08-6.97 (m, 2H), 6.92 (ddd, J = 11.7,
		1771,		7.6, 2.2 Hz, 1H), 6.85-6.72 (m,
		1734,		1H), 5.41-5.26 (m, 1H),
		1676,		4.75-4.63 (m, 1H), 3.92 (s, 3H), 2.73-2.57 (m,
		1513,		1H), 2.40 (s, 3H), 2.12-1.99 (m, 1H),
		1203,		1.48 (d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.3 Hz,
		1175, 1061 cm−1		3H), 0.89 (d, J = 6.5 Hz, 3H),
				0.74 (d, J = 6.7 Hz, 3H).
245		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (d,
		film) 3380,	calcd for C27H37N2O7,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.5 Hz,
		2960,	501.2595; found, 501.2589	1H), 7.06 (t, J = 7.0 Hz, 2H),
		1769,		7.02-6.95 (m, 3H), 5.39 (dq, J = 8.7, 6.2 Hz,
		1732,		1H), 4.74-4.63 (m, 1H), 3.90 (s, 3H),
		1676,		3.81 (t, J = 6.6 Hz, 2H), 3.40 (s, 3H),
		1508,		2.99 (t, J = 6.6 Hz, 2H), 2.67 (dd, J = 8.7,
		1210,		6.3 Hz, 1H), 2.32 (s, 3H), 2.09 (h, J = 6.7 Hz,
		1111,		1H), 1.50 (d, J = 7.1 Hz, 3H),
		1061, 823 cm−1		1.08 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.8 Hz,
				3H), 0.75 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.29,
				169.42, 162.35, 159.50, 146.71, 141.69,
				137.40, 136.06, 135.51, 129.68, 128.62,
				109.74, 72.83, 67.62, 58.76, 56.32,
				56.24, 48.23, 34.66, 28.22, 21.36,
				21.01, 18.68, 18.57, 17.84.
246		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
		film) 3380,	calcd for C27H36FN2O7,	J = 7.7 Hz, 1H), 8.33 (d, J = 5.5 Hz,
		2961,	519.2501; found, 519.2498	1H), 7.01 (d, J = 5.5 Hz, 1H),
		1733,		6.93-6.80 (m, 3H), 5.36 (dq, J = 8.6, 6.3 Hz,
		1676,		1H), 4.73-4.62 (m, 1H), 3.91 (s, 3H),
		1503,		3.81 (t, J = 6.6 Hz, 2H), 3.40 (s, 3H),
		1208,		2.99 (t, J = 6.6 Hz, 2H), 2.65 (dd, J = 8.6,
		1115,		6.6 Hz, 1H), 2.24 (d, J = 1.9 Hz,
		1051, 731 cm−1		3H), 2.08 (hept, J = 6.7 Hz, 1H),
				1.49 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.3 Hz,
				3H), 0.85 (d, J = 6.7 Hz, 3H), 0.74 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.24,
				169.42, 162.36, 160.27 (d, J = 243.5 Hz),
				159.52, 146.72, 141.64, 137.42,
				134.08 (d, J = 3.9 Hz), 132.56 (d, J = 5.0 Hz),
				128.37 (d, J = 7.7 Hz),
				124.07 (d, J = 17.1 Hz), 114.38 (d, J = 22.0 Hz),
				109.78, 72.67, 67.62, 58.76, 56.33,
				55.84, 48.22, 34.67, 28.28, 21.30,
				18.67, 18.63, 17.67, 14.63 (d, J = 3.6 Hz).
				19F NMR (376 MHz, CDCl3) δ −120.90.
247		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (d,
		film) 3377,	calcd for C27H36FN2O8,	J = 7.7 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2962,	535.2450; found, 535.2446	1H), 7.06-6.97 (m, 2H),
		1734,		6.69-6.62 (m, 1H), 6.58 (dd, J = 12.0, 2.6 Hz,
		1676,		1H), 5.40 (ddt, J = 8.6, 6.8, 3.4 Hz, 1H),
		1507,		4.75-4.60 (m, 1H), 3.90 (s, 3H),
		1209,		3.81 (t, J = 6.6 Hz, 2H), 3.78 (s, 3H), 3.40 (s,
		1113,		3H), 3.09 (t, J = 7.6 Hz, 1H), 2.99 (t, J = 6.6 Hz,
		1061, 833,		2H), 2.10 (h, J = 6.8 Hz, 1H),
		731 cm−1		1.49 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.3 Hz,
				3H), 0.93-0.87 (m, 3H), 0.75 (d, J = 6.7 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.25,
				169.41, 162.33, 162.10 (d, J = 244.3 Hz),
				159.48, 159.32 (d, J = 11.2 Hz),
				146.71, 141.67, 137.38, 130.69 (d, J = 6.6 Hz),
				117.57 (d, J = 15.3 Hz),
				109.73, 109.58 (d, J = 2.9 Hz),
				101.39 (d, J = 28.0 Hz), 72.48, 67.62, 58.76,
				56.31, 55.44, 48.21, 34.66, 29.29,
				28.36, 21.10, 18.97, 18.50, 17.43.
				19F NMR (376 MHz, CDCl3) δ −112.98.
248		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.51 (d,
		film) 3380,	calcd for C27H36FN2O8,	J = 7.9 Hz, 1H), 8.34 (d, J = 5.4 Hz,
		2962,	535.2450; found, 535.2444	1H), 7.01 (d, J = 5.5 Hz, 1H),
		1732,		6.92-6.75 (m, 3H), 5.34 (dq, J = 8.3, 6.2 Hz,
		1676,		1H), 4.66 (dt, J = 8.1, 7.1 Hz, 1H),
		1511,		3.90 (s, 3H), 3.86 (s, 3H), 3.81 (t, J = 6.6 Hz,
		1273,		2H), 3.40 (s, 3H), 2.99 (t, J = 6.6 Hz,
		1210,		2H), 2.64 (dd, J = 8.6, 6.5 Hz, 1H),
		1113, 731 cm−1		2.05 (h, J = 6.8 Hz, 1H), 1.49 (d, J = 7.2 Hz,
				3H), 1.09 (d, J = 6.3 Hz, 3H), 0.87 (d, J = 6.7 Hz,
				3H), 0.75 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.19,
				169.42, 162.36, 159.51, 151.94 (d, J = 245.0 Hz),
				146.73, 146.25 (d, J = 10.8 Hz),
				141.62, 137.42, 131.84 (d, J = 5.6 Hz),
				125.47 (d, J = 3.6 Hz), 117.15 (d, J = 18.2 Hz),
				113.05-112.84 (m),
				109.77, 72.51, 67.62, 58.76, 56.33,
				56.24, 55.74, 48.21, 34.67, 28.35,
				21.25, 18.77, 18.63, 17.47.
				19F NMR (376 MHz, CDCl3) δ −135.76.
249		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (s,
		film) 3379,	calcd for C28H39N2O8,	1H), 8.32 (d, J = 5.4 Hz, 1H), 6.99 (d, J = 5.5 Hz,
		2960,	531.2701; found, 531.2703	1H), 6.94 (d, J = 7.7 Hz, 1H),
		1769,		6.75-6.69 (m, 1H), 6.65 (d, J = 1.6 Hz,
		1732,		1H), 5.41 (d, J = 7.8 Hz, 1H),
		1678,		4.73-4.62 (m, 1H), 3.90 (s, 3H), 3.82 (t, J = 6.6 Hz,
		1506,		2H), 3.75 (s, 3H), 3.40 (s, 3H),
		1311,		2.99 (t, J = 6.7 Hz, 2H), 2.31 (s, 3H),
		1210,		2.09 (h, J = 6.7 Hz, 1H), 1.69 (s, 1H),
		1111,		1.49 (d, J = 7.1 Hz, 3H), 1.07 (d, J = 6.2 Hz,
		1041, 808 cm−1		3H), 0.84 (d, J = 6.7 Hz, 3H),
				0.74 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.30,
				169.43, 162.30, 159.47, 158.10, 146.70,
				141.75, 137.36, 137.15, 124.61, 120.69,
				111.71, 109.69, 73.50, 67.63, 58.76,
				56.31, 55.31, 48.32, 34.67, 29.30,
				28.80, 21.43, 21.12, 18.87, 18.61,
				18.11.
250		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (d,
		film) 3381,	calcd for C25H32FN2O6,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.4 Hz,
		2962,	475.2239; found, 475.2236	1H), 7.01 (d, J = 5.5 Hz, 1H),
		1771,		6.92-6.84 (m, 3H), 5.36 (dq, J = 8.6, 6.3 Hz,
		1733,		1H), 4.69 (dq, J = 8.1, 7.1 Hz, 1H),
		1677,		3.91 (s, 3H), 2.70-2.62 (m, 1H), 2.40 (s,
		1503,		3H), 2.24 (d, J = 1.9 Hz, 3H), 2.07 (h, J = 6.7 Hz,
		1311,		1H), 1.50 (d, J = 7.1 Hz, 3H),
		1203,		1.08 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.7 Hz,
		1176,		3H), 0.74 (d, J = 6.8 Hz, 3H).
		1049, 733 cm−1		13C NMR (101 MHz, CDCl3) δ 172.23,
				168.89, 162.41, 160.27 (d, J = 243.4 Hz),
				159.51, 146.66, 141.63, 137.57,
				134.08 (d, J = 3.8 Hz), 132.56 (d, J = 4.9 Hz),
				128.37 (d, J = 7.7 Hz),
				124.08 (d, J = 17.2 Hz), 114.38 (d, J = 22.0 Hz),
				109.78, 72.69, 56.30, 55.84, 48.22,
				28.28, 21.30, 20.75, 18.67, 18.64,
				17.67, 14.63 (d, J = 3.6 Hz).
				19F NMR (376 MHz, CDCl3) δ −120.91.
251		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (d,
		film) 3376,	calcd for C25H32FN2O7,	J = 7.7 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2963,	491.2188; found, 491.2183	1H), 7.06-6.97 (m, 2H), 6.65 (ddd, J = 8.6,
		1771,		2.6, 0.8 Hz, 1H), 6.58 (dd, J = 12.0,
		1733,		2.6 Hz, 1H), 5.41 (dqd, J = 7.6, 6.2, 1.2 Hz,
		1675,		1H), 4.68 (dq, J = 8.1, 7.2 Hz, 1H),
		1507,		3.91 (s, 3H), 3.78 (s, 3H),
		1195,		3.15-3.03 (m, 1H), 2.40 (s, 3H), 2.14-2.05 (m,
		1175,		1H), 1.50 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1150,		3H), 0.90 (dd, J = 6.7, 0.8 Hz,
		1033, 833,		3H), 0.75 (d, J = 6.7 Hz, 3H).
		731 cm−1		13C NMR (101 MHz, CDCl3) δ 172.24,
				168.89, 162.39, 162.11 (d, J = 244.3 Hz),
				159.49, 159.34 (d, J = 11.2 Hz),
				146.66, 141.67, 137.54, 130.71 (d, J = 6.5 Hz),
				117.58 (d, J = 15.5 Hz),
				109.73, 109.59 (d, J = 3.0 Hz),
				101.40 (d, J = 27.9 Hz), 72.50, 56.29, 55.45,
				48.22, 29.30, 28.37, 21.10, 20.75,
				18.98, 18.51, 17.42.
				19F NMR (376 MHz, CDCl3) δ −112.96.
252		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (d,
		film) 3379,	calcd for C25H32FN2O7,	J = 8.0 Hz, 1H), 8.34 (d, J = 5.4 Hz,
		2962,	491.2188; found, 491.2182	1H), 7.01 (d, J = 5.5 Hz, 1H),
		1770,		6.90-6.76 (m, 3H), 5.34 (dq, J = 8.4, 6.3 Hz,
		1732,		1H), 4.73-4.63 (m, 1H), 3.91 (s, 3H),
		1675,		3.86 (s, 3H), 2.68-2.61 (m, 1H),
		1512,		2.40 (s, 3H), 2.05 (dq, J = 13.5, 6.8 Hz, 1H),
		1202,		1.49 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
		1176,		3H), 0.87 (d, J = 6.7 Hz, 3H),
		1030, 731 cm−1		0.75 (d, J = 6.7 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.17,
				168.90, 162.41, 159.50, 151.94 (d, J = 245.0 Hz),
				146.68, 146.25 (d, J = 10.6 Hz),
				141.59, 137.56, 131.84 (d, J = 5.7 Hz),
				125.48 (d, J = 3.6 Hz), 117.13 (d, J = 18.2 Hz),
				112.94 (d, J = 1.6 Hz),
				109.77, 72.53, 56.27 (d, J = 6.4 Hz),
				55.73, 48.21, 29.29, 28.35, 21.25,
				20.75, 18.76, 18.64, 17.47.
				19F NMR (376 MHz, CDCl3) δ −135.76.
253		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.57 (d,
		film) 3381,	calcd for C26H35N2O7,	J = 7.9 Hz, 1H), 8.32 (d, J = 5.4 Hz,
		2961,	487.2439; found, 487.2430	1H), 7.00 (d, J = 5.5 Hz, 1H), 6.94 (d, J = 7.7 Hz,
		1772,		1H), 6.75-6.68 (m, 1H),
		1732,		6.65 (d, J = 1.6 Hz, 1H),
		1678,		5.51-5.39 (m, 1H), 4.76-4.60 (m, 1H), 3.90 (s,
		1507,		3H), 3.75 (s, 3H), 3.33 (s, 1H), 2.40 (s,
		1201,		3H), 2.31 (s, 3H), 2.09 (h, J = 6.7 Hz,
		1176,		1H), 1.50 (d, J = 7.1 Hz, 3H), 1.07 (d, J = 6.2 Hz,
		1041, 733 cm−1		3H), 0.84 (d, J = 6.8 Hz, 3H),
				0.74 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.29,
				168.90, 162.35, 159.46, 158.10, 146.65,
				141.73, 137.51, 137.15, 124.61, 120.69,
				111.71, 109.69, 73.52, 56.28, 55.31,
				48.33, 29.30, 28.80, 21.43, 21.13,
				20.75, 18.85, 18.62, 18.11.
254		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.55 (d,
		film) 3379,	calcd for C26H35N2O7,	J = 8.0 Hz, 1H), 8.33 (d, J = 5.4 Hz,
		2959,	487.2439; found, 487.2436	1H), 7.06-6.92 (m, 2H), 6.70 (d, J = 8.1 Hz,
		1771,		2H), 5.35 (dq, J = 9.2, 6.2 Hz,
		1731,		1H), 4.70 (dq, J = 8.1, 7.1 Hz, 1H),
		1677,		3.91 (s, 3H), 3.78 (s, 3H), 3.06 (dd, J = 9.3,
		1503,		6.0 Hz, 1H), 2.40 (s, 3H), 2.29 (s, 3H),
		1201,		2.12 (dq, J = 13.4, 6.7 Hz, 1H), 1.51 (d,
		1175,		J = 7.1 Hz, 3H), 1.05 (d, J = 6.2 Hz,
		1046, 733 cm−1		3H), 0.84 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.9 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.34,
				168.88, 162.37, 159.49, 157.56, 146.65,
				141.65, 138.91, 137.54, 130.04, 128.84,
				115.90, 110.86, 109.74, 74.13, 56.29,
				55.05, 48.27, 29.64, 29.30, 21.09,
				20.99, 20.75, 18.74, 18.61, 18.26.
255		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3379,	calcd for C26H35N2O7,	J = 7.8 Hz, 1H), 8.29 (d, J = 5.3 Hz,
		2961,	487.2439; found, 487.2433	1H), 7.11-7.03 (m, 2H),
		1756,		7.03-6.93 (m, 3H), 5.75 (d, J = 0.6 Hz, 2H),
		1675,		5.40 (dq, J = 8.8, 6.3 Hz, 1H),
		1503,		4.79-4.66 (m, 1H), 3.91 (s, 3H), 2.68 (dd, J = 8.8,
		1201,		6.3 Hz, 1H), 2.32 (s, 3H),
		1042,		2.16-2.03 (m, 4H), 1.53 (d, J = 7.1 Hz, 3H),
		1003, 969,		1.09 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.8 Hz,
		827, 731 cm−1		3H), 0.76 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.40,
				170.26, 162.98, 160.32, 145.70, 144.04,
				142.66, 136.08, 135.50, 129.69, 128.62,
				109.55, 89.63, 72.83, 56.26, 56.19,
				48.44, 28.23, 21.36, 21.01, 20.87,
				18.57, 18.54, 17.89.
256		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.36 (d,
		film) 3380,	calcd for C26H34FN2O7,	J = 7.7 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2962,	505.2345; found, 505.2339	1H), 6.96 (d, J = 5.4 Hz, 1H),
		1735,		6.93-6.85 (m, 3H), 5.75 (s, 2H), 5.37 (dq, J = 8.6,
		1674,		6.2 Hz, 1H), 4.78-4.65 (m, 1H),
		1503,		3.92 (s, 3H), 2.67 (dd, J = 8.6, 6.5 Hz,
		1203,		1H), 2.24 (d, J = 2.0 Hz, 3H), 2.07 (s,
		1043,		4H), 1.52 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
		1004, 969,		3H), 0.85 (d, J = 6.7 Hz, 3H),
		829, 731 cm−1		0.75 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.35,
				170.27, 163.00, 160.33, 160.28 (d, J = 243.4 Hz),
				145.71, 144.07, 142.60,
				134.07 (d, J = 3.8 Hz), 132.59 (d, J = 4.9 Hz),
				128.35 (d, J = 7.7 Hz),
				124.09 (d, J = 17.2 Hz), 114.38 (d, J = 22.1 Hz),
				109.59, 89.62, 72.67, 56.20, 55.85,
				48.43, 28.28, 21.31, 20.87, 18.62,
				18.51, 17.74, 14.63 (d, J = 3.5 Hz).
				19F NMR (376 MHz, CDCl3) δ −120.87.
257		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3380,	calcd for C26H34FN2O8,	J = 7.8 Hz, 1H), 8.28 (d, J = 5.4 Hz,
		2963,	521.2294; found, 521.2286	1H), 7.03 (t, J = 8.5 Hz, 1H), 6.95 (d = 5.4 Hz,
		1736,		1H), 6.66 (ddd, J = 8.6, 2.6,
		1676,		0.7 Hz, 1H), 6.58 (dd, J = 12.0, 2.6 Hz,
		1507,		1H), 5.78-5.68 (m, 2H),
		1200,		5.47-5.36 (m, 1H), 4.75-4.65 (m, 1H), 3.91 (s,
		1040,		3H), 3.79 (s, 3H), 3.10 (t, J = 7.7 Hz,
		1004, 969,		1H), 2.07 (s, 4H), 1.52 (d, J = 7.2 Hz,
		831 cm−1		3H), 1.11 (d, J = 6.3 Hz, 3H), 0.90 (dd,
				J = 6.7, 0.8 Hz, 3H), 0.76 (d, J = 6.7 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.36,
				170.27, 162.99, 162.11 (d, J = 244.3 Hz),
				160.32, 159.34 (d, J = 11.2 Hz),
				145.70, 144.04, 142.64, 130.70 (d, J = 5.5 Hz),
				117.58 (d, J = 15.5 Hz),
				109.58 (d, J = 3.3 Hz), 109.55, 101.40 (d, J = 27.9 Hz),
				89.63, 72.58-72.37 (m),
				56.19, 55.45, 48.42, 29.30, 28.39,
				21.10, 20.87, 18.98, 18.37, 17.44.
				19F NMR (376 MHz, CDCl3) δ −112.98.
258		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.36 (d,
		film) 3378,	calcd for C26H34FN2O8,	J = 7.8 Hz, 1H), 8.29 (d, J = 5.4 Hz,
		2962,	521.2294; found, 521.2288	1H), 6.96 (d, J = 5.4 Hz, 1H),
		1736,		6.90-6.76 (m, 3H), 5.75 (s, 2H), 5.35 (dq, J = 8.5,
		1674,		6.3 Hz, 1H), 4.70 (p, J = 7.2 Hz,
		1513,		1H), 3.92 (s, 3H), 3.87 (s, 3H),
		1203,		2.69-2.60 (m, 1H), 2.13-2.01 (m, 4H),
		1043,		1.52 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1004, 969,		3H), 0.87 (d, J = 6.7 Hz, 3H), 0.76 (d, J = 6.7 Hz,
		732 cm−1		3H).
				13C NMR (101 MHz, CDCl3) δ 172.31,
				170.27, 163.01, 160.33, 151.95 (d, J = 245.4 Hz),
				146.27 (d, J = 10.8 Hz),
				145.72, 144.07, 142.57, 131.82 (d, J = 5.8 Hz),
				125.46 (d, J = 3.5 Hz),
				117.16 (d, J = 18.0 Hz), 113.05-112.84 (m),
				109.59, 89.62, 72.51, 56.22 (d, J = 5.0 Hz),
				55.76, 48.41, 29.30, 28.35, 21.26,
				20.87, 18.70, 18.51, 17.55.
				19F NMR (376 MHz, CDCl3) δ −135.75.
259		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.39 (d,
		film) 3376,	calcd for C27H37N2O8,	J = 7.7 Hz, 1H), 8.28 (d, J = 5.4 Hz,
		2960,	517.2544; found, 517.2539	1H), 6.97-6.92 (m, 2H),
		1737,		6.76-6.68 (m, 1H), 6.66 (d, J = 1.6 Hz, 1H),
		1678,		5.80-5.72 (m, 2H), 5.42 (d, J = 8.1 Hz,
		1505,		1H), 4.76-4.65 (m, 1H), 3.91 (s, 3H),
		1203,		3.76 (s, 3H), 3.34 (s, 1H), 2.32 (s, 3H),
		1042,		2.15-2.02 (m, 4H), 1.52 (d, J = 7.1 Hz,
		1004, 971,		3H), 1.07 (d, J = 6.2 Hz, 3H),
		736 cm−1		0.84 (d, J = 6.8 Hz, 3H), 0.74 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.43,
				170.26, 162.95, 160.30, 158.11, 145.71,
				143.99, 142.75, 137.16, 124.61, 120.70,
				111.72, 109.51, 89.64, 73.51, 56.18,
				55.32, 48.52, 29.30, 28.82, 21.43,
				21.14, 20.87, 18.83, 18.49, 18.17.
260		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.37 (d,
		film) 3379,	calcd for C27H37N2O8,	J = 7.8 Hz, 1H), 8.28 (d, J = 5.4 Hz,
		2960,	517.2544; found, 517.2536	1H), 7.04-6.97 (m, 1H), 6.95 (d, J = 5.4 Hz,
		1732,		1H), 6.70 (d, J = 7.5 Hz, 2H),
		1674,		5.75 (d, J = 0.7 Hz, 2H), 5.36 (dq, J = 9.3,
		1502,		6.2 Hz, 1H), 4.77-4.65 (m, 1H),
		1201,		3.91 (s, 3H), 3.78 (s, 3H), 3.07 (dd, J = 9.3,
		1043,		6.0 Hz, 1H), 2.30 (s, 3H),
		1003, 969,		2.18-2.09 (m, 1H), 2.07 (s, 3H), 1.53 (d, J = 7.1 Hz,
		830, 730 cm−1		3H), 1.06 (d, J = 6.2 Hz, 3H),
				0.84 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.47,
				170.26, 162.97, 160.31, 157.57, 145.70,
				144.04, 142.62, 138.90, 130.02, 128.86,
				115.89, 110.88, 109.56, 89.62, 74.11,
				56.19, 55.05, 48.48, 29.65, 29.30,
				21.09, 20.99, 20.87, 18.71, 18.47,
				18.31.
261		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.58 (d,
		film) 3379,	calcd for C25H33N2O7,	J = 7.7 Hz, 1H), 8.32 (d, J = 5.4 Hz,
		2961,	473.2282; found, 473.2264	1H), 7.22-7.13 (m, 1H), 7.07 (dd, J = 7.6,
		1770,		1.8 Hz, 1H), 7.00 (d, J = 5.6 Hz,
		1732,		1H), 6.97-6.80 (m, 2H),
		1675,		5.64-5.28 (m, 1H), 4.77-4.57 (m, 1H), 3.91 (s,
		1508,		3H), 3.77 (s, 3H), 3.55-3.28 (m, 1H),
		1175, 731 cm−1		2.40 (s, 3H), 2.12 (dq, J = 13.4, 6.7 Hz,
				1H), 1.50 (d, J = 7.1 Hz, 3H), 1.08 (d, J = 6.3 Hz,
				3H), 0.85 (d, J = 6.8 Hz, 3H),
				0.74 (d, J = 6.7 Hz, 3H).
262		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.58 (s,
		film) 3379,	calcd for C26H35N2O8,	1H), 8.32 (d, J = 5.4 Hz, 1H), 7.00 (d, J = 5.5 Hz,
		2960,	503.2388; found, 503.2374	1H), 6.96 (d, J = 8.2 Hz, 1H),
		1770,		6.47-6.39 (m, 2H), 5.42 (d, J = 9.2 Hz,
		1732,		1H), 4.79-4.61 (m, 1H), 3.91 (s,
		1676,		3H), 3.78 (s, 3H), 3.74 (s, 3H),
		1505,		3.45-3.16 (m, 1H), 2.40 (s, 3H),
		1205, 730 cm−1		2.13-2.01 (m, 1H), 1.50 (d, J = 7.1 Hz, 3H),
				1.07 (d, J = 6.3 Hz, 3H), 0.83 (d, J = 6.7 Hz,
				3H), 0.73 (d, J = 6.8 Hz, 3H).
263		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.38 (d,
		film) 3379,	calcd for C26H35N2O8,	J = 7.8 Hz, 1H), 8.27 (d, J = 5.4 Hz,
		2961,	503.2388; found, 503.2359	1H), 7.22-7.13 (m, 1H), 7.07 (dd, J = 7.6,
		1735,		1.8 Hz, 1H), 6.94 (d, J = 5.4 Hz,
		1674,		1H), 6.92-6.75 (m, 2H),
		1493,		5.82-5.69 (m, 2H), 5.45 (s, 1H), 4.81-4.59 (m,
		1203, 969,		1H), 3.91 (s, 3H), 3.77 (s, 3H),
		733 cm−1		3.53-3.23 (m, 1H), 2.16-2.05 (m, 4H),
				1.52 (d, J = 7.1 Hz, 3H), 1.08 (d, J = 6.2 Hz,
				3H), 0.85 (d, J = 6.7 Hz, 3H), 0.74 (d, J = 6.8 Hz,
				3H).
264		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.38 (d,
		film) 3379,	calcd for C27H37N2O9,	J = 7.8 Hz, 1H), 8.27 (d, J = 5.4 Hz,
		2960,	533.2494; found, 533.2488	1H), 7.03-6.84 (m, 2H), 6.43 (d, J = 7.8 Hz,
		1734,		2H), 5.74 (d, J = 1.2 Hz, 2H),
		1675,		5.46-5.34 (m, 1H), 4.78-4.62 (m,
		1505,		1H), 3.90 (s, 3H), 3.78 (s, 3H), 3.74 (s,
		1204,		3H), 3.42-2.96 (m, 1H),
		1041, 830,		2.15-2.04 (m, 4H), 1.51 (d, J = 7.2 Hz, 3H),
		731 cm−1		1.07 (d, J = 6.2 Hz, 3H), 0.82 (d, J = 6.7 Hz,
				3H), 0.73 (d, J = 6.8 Hz, 3H).
265			ESIMS m/z 268.3
			([M + H]+)
266			ESIMS m/z 310.3
			([M + H]+)
267			ESIMS m/z 324.3
			([M + H]+)
268			ESIMS m/z 324.3
			([M + H]+)
269		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2969,	calcd for C17H28NO2,
		1743,	278.2115; found, 278.2108
		1502,
		1449,
		1365,
		1230,
		1216,
		1203,
		1120,
		1053, 805 cm−1
270		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2961,	calcd for C16H25FNO2,
		2826,	282.1864; found, 282.1877
		1739,
		1578,
		1508,
		1466,
		1368,
		1253,
		1235,
		1197,
		1166,
		1094,
		1044, 786,
		754 cm−1
271		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2959,	calcd for C15H23FNO2,
		2851,	268.1707; found, 268.1718
		1739,
		1583,
		1491,
		1454,
		1248,
		1231,
		1197,
		1120,
		1051, 761 cm−1
272		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2959,	calcd for C16H25FNO2,
		2873,	282.1864; found, 282.1869
		1737,
		1587,
		1530,
		1498,
		1457,
		1284,
		1238,
		1190,
		1114,
		1047, 873,
		813 cm−1
273		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2870,	calcd for C17H28NO2,
		1742,	278.2115; found, 278.2119
		1594,
		1502,
		1454,
		1377,
		1251,
		1226,
		1199,
		1118,
		1048, 887,
		818 cm−1
274		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2871,	calcd for C17H28NO2,
		1740,	278.2115; found, 278.2110
		1588,
		1407,
		1455,
		1384,
		1252,
		1239,
		1200,
		1117,
		1044, 783 cm−1
275		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2871,	calcd for C16H26NO2,
		1738,	264.1958; found, 264.1953
		1586,
		1505,
		1455,
		1244,
		1196,
		1162,
		1119,
		1053, 754 cm−1
276		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2961,	calcd for C15H22F2NO2,
		2872,	286.1613; found, 286.1628
		1754,
		1740,
		1602,
		1501,
		1244,
		1116,
		1082, 967,
		846 cm−1
277		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2960,	calcd for C16H25FNO2,
		1757,	282.1864; found, 282.1871
		1508,
		1458,
		1269,
		1236,
		1212,
		1124,
		1050, 853,
		819 cm−1
278		IR (thin
		film) 2967,
		2873,
		1737,
		1589,
		1476,
		1382,
		1251,
		1229,
		1121,
		1107,
		1043, 871,
		845, 824 cm−1
279		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2963,	calcd for C15H22F2NO2,
		1740,	286.1613; found, 286.1637
		1602,
		1501,
		1458,
		1234,
		1207,
		1172,
		1113, 964,
		846 cm−1
280		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2961,	calcd for C16H25FNO2,
		1740,	282.1864; found, 282.1878
		1506,
		1456,
		1235,
		1207,
		1115, 939 cm−1
281		IR (thin	HRMS-ESI (m/z) [M + H]+
		film) 2962,	calcd for C15H22Cl2NO2,
		1739,	318.1022; found, 318.1022
		1470,
		1381,
		1233,
		1192,
		1109,
		1044,
		1007, 806 cm−1
282		IR (thin
		film) 3391,
		2959,
		2875,
		1736,
		1488,
		1231,
		1196,
		1114, 1035 cm−1
283			HRMS-ESI (m/z) [M + H]+
			calcd for C16H23F3NO3,
			334.1625; found, 334.1616
284		IR (thin
		film) 2973,
		1738,
		1509,
		1237,
		1117, 831 cm−1
285			HRMS-ESI (m/z) [M + H]+
			calcd for C18H30NO3,
			308.2226; found, 308.2074
286			HRMS-ESI (m/z) [M + Na]+
			calcd for C16H25NO3Na,
			302.1727; found, 302.1723
287
288		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.04 (dd,
		film) 3367,	calcd for C20H30FNNaO4,	J = 8.5, 5.9 Hz, 1H), 6.87 (ddt, J = 11.6,
		2964,	390.2051; found, 390.2053	8.3, 4.1 Hz, 2H), 5.40 (dq, J = 8.3, 6.3 Hz,
		1713,		1H), 5.02 (s, 1H), 3.93-3.85 (m,
		1498,		2H), 3.02 (t, J = 7.7 Hz, 1H), 2.31 (s,
		1366,		3H), 2.07 (h, J = 6.8 Hz, 1H), 1.46 (s,
		1164,		9H), 1.04 (d, J = 6.3 Hz, 3H), 0.91 (d, J = 6.7 Hz,
		1052, 954,		3H), 0.77 (d, J = 6.8 Hz, 3H).
		862 cm−1		13C NMR (101 MHz, CDCl3) δ 169.85,
				160.98 (d, J = 244.6 Hz), 155.63,
				139.89 (d, J = 8.0 Hz), 133.68 (d, J = 2.8 Hz),
				129.24 (d, J = 7.3 Hz),
				117.01 (d, J = 20.5 Hz), 112.37 (d, J = 20.8 Hz),
				79.96, 73.61, 49.56, 42.78, 29.85,
				28.33, 20.96, 20.78, 19.55, 17.64.
				19F NMR (376 MHz, CDCl3) δ −117.37.
289		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.04 (dd,
		film) 2964,	calcd for C23H36FNNaO4,	J = 8.6, 6.0 Hz, 1H), 6.87 (qd, J = 9.3,
		1712,	432.2521; found, 432.2521	8.4, 2.8 Hz, 2H), 5.33 (dq, J = 9.5, 6.2 Hz,
		1498,		1H), 4.97 (d, J = 9.4 Hz, 1H),
		1366,		4.24 (dd, J = 9.3, 4.4 Hz, 1H), 3.09 (dd, J = 9.5,
		1158,		5.7 Hz, 1H), 2.33 (s, 3H),
		1049, 863 cm−1		2.26-2.07 (m, 2H), 1.46 (s, 9H), 1.02 (d, J = 6.2 Hz,
				3H), 1.00 (d, J = 6.9 Hz, 3H),
				0.88 (d, J = 6.9 Hz, 3H), 0.83 (d, J = 6.8 Hz,
				3H), 0.80 (d, J = 6.9 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.82,
				160.99 (d, J = 244.4 Hz), 155.66,
				139.90 (d, J = 7.6 Hz), 133.39 (d, J = 2.7 Hz),
				129.26 (d, J = 7.4 Hz),
				117.04 (d, J = 20.5 Hz), 112.37 (d, J = 20.6 Hz),
				79.70, 73.46, 58.88, 49.31, 31.26,
				29.27, 28.34, 20.91, 19.38, 18.39, 17.03.
				19F NMR (376 MHz, CDCl3) δ −117.33.
290		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.04 (dd,
		film) 2964,	calcd for C24H38FNNaO4,	J = 8.6, 5.9 Hz, 1H), 6.93-6.81 (m,
		1712,	446.2677; found, 446.2681	2H), 5.33 (dq, J = 9.5, 6.2 Hz, 1H),
		1498,		4.96 (d, J = 9.3 Hz, 1H), 4.28 (dd, J = 9.3,
		1366,		4.5 Hz, 1H), 3.10 (dd, J = 9.6, 5.5 Hz,
		1158,		1H), 2.33 (s, 3H), 2.14 (dt, J = 13.5, 6.7 Hz,
		1049, 863 cm−1		1H), 1.99-1.83 (m, 1H),
				1.54-1.32 (m, 10H), 1.21-1.08 (m, 1H),
				1.02 (d, J = 6.2 Hz, 3H), 0.97 (d, J = 6.8 Hz,
				3H), 0.91 (t, J = 7.4 Hz, 3H),
				0.82 (d, J = 6.9 Hz, 3H), 0.80 (d, J = 6.9 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 171.79,
				161.00 (d, J = 244.4 Hz), 155.59,
				139.90 (d, J = 7.3 Hz), 133.33 (d, J = 2.9 Hz),
				129.28 (d, J = 7.6 Hz),
				117.05 (d, J = 20.5 Hz), 112.37 (d, J = 20.7 Hz),
				79.69, 73.41, 58.61, 49.35, 37.97,
				29.19, 28.35, 24.40, 20.92, 18.45, 18.21,
				15.71, 11.56.
				19F NMR (376 MHz, CDCl3) δ −117.32.
291		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (400 MHz, CDCl3) δ 7.05 (dd,
		film) 3365,	calcd for C24H38FNNaO4,	J = 8.5, 5.9 Hz, 1H), 6.93-6.82 (m,
		2960,	446.2677; found, 446.2675	2H), 5.31 (dq, J = 9.2, 6.2 Hz, 1H),
		1714,		4.85 (d, J = 8.8 Hz, 1H), 4.29 (td, J = 9.1, 4.8 Hz,
		1499,		1H), 3.08 (dd, J = 9.2, 6.1 Hz, 1H),
		1367,		2.33 (s, 3H), 2.12 (h, J = 6.7 Hz, 1H),
		1165,		1.70 (dq, J = 13.1, 6.8 Hz, 1H),
		1049, 863 cm−1		1.58 (ddd, J = 13.5, 8.4, 5.1 Hz, 1H),
				1.52-1.36 (m, 10H), 1.03 (d, J = 6.2 Hz, 3H),
				0.95 (dd, J = 6.6, 3.0 Hz, 6H), 0.85 (d, J = 6.8 Hz,
				3H), 0.78 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 172.88,
				160.98 (d, J = 244.5 Hz), 155.31,
				139.86 (d, J = 7.3 Hz), 133.62 (d, J = 2.9 Hz),
				129.25 (d, J = 8.4 Hz),
				116.99 (d, J = 20.5 Hz), 112.37 (d, J = 20.6 Hz),
				79.73, 73.45, 52.55, 49.36, 41.84,
				29.51, 28.33, 24.82, 23.05, 21.82, 20.95,
				18.75, 18.09.
				19F NMR (376 MHz, CDCl3) δ −117.42.
292		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.04 (d, J = 7.6 Hz,
		film) 3357,	calcd for C22H35NO4Na,	1H), 6.92 (dd, J = 7.7, 1.7 Hz,
		2963,	400.2458; found, 400.2450	1H), 6.89 (s, 1H), 5.35 (dq, J = 9.4, 6.2 Hz,
		2874,		1H), 5.08 (d, J = 7.9 Hz, 1H),
		1712,		4.30 (t, J = 7.6 Hz, 1H), 3.09 (dd, J = 9.4, 6.0 Hz,
		1501,		1H), 2.29 (s, 3H), 2.28 (s, 3H),
		1451,		2.14 (dq, J = 13.5, 6.7 Hz, 1H), 1.45 (s, 9H),
		1365,		1.40 (d, J = 7.1 Hz, 3H), 1.04 (d, J = 6.2 Hz,
		1160, 1049 cm−1		3H), 0.84 (d, J = 6.8 Hz, 3H),
				0.81 (d, J = 6.9 Hz, 3H).
293		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.11 (td,
		film) 3356,	calcd for C21H32FNO4Na,	J = 7.9, 5.9 Hz, 1H), 6.99-6.82 (m,
		2965,	404.2208; found, 404.2208	2H), 5.36 (dq, J = 9.1, 6.2 Hz, 1H),
		1712,		5.05 (d, J = 7.8 Hz, 1H), 4.29 (t, J = 7.5 Hz,
		1500,		1H), 3.14 (dd, J = 9.0, 6.4 Hz, 1H),
		1455,		2.24 (d, J = 2.3 Hz, 3H), 2.14 (dq, J = 13.4,
		1365,		6.7 Hz, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
		1245,		3H), 1.04 (d, J = 6.2 Hz, 3H),
		1161,		0.86 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.8 Hz,
		1045, 820 cm−1		3H).
294		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3363,	calcd for C20H30FNO4Na,	7.25-7.19 (m, 1H), 7.12 (dtd, J = 22.9, 7.6,
		2965,	390.2051; found, 390.2053	1.6 Hz, 2H), 7.03 (ddd, J = 9.7, 8.1, 1.3 Hz,
		2933,		1H), 5.43 (dqd, J = 7.5, 6.3, 1.3 Hz,
		1712,		1H), 5.06 (d, J = 7.9 Hz, 1H),
		1491,		4.39-4.15 (m, 1H), 3.18 (t, J = 7.7 Hz, 1H),
		1453,		2.22-2.03 (m, 1H), 1.45 (s, 9H),
		1365,		1.38 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1162,		3H), 1.04-0.86 (m, 3H), 0.77 (d, J = 6.7 Hz,
		1052, 757 cm−1		3H).
295		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.12 (dd,
		film) 3356,	calcd for C21H32FNO4Na,	J = 8.5, 6.0 Hz, 1H), 6.88-6.75 (m,
		2969,	404.2208; found, 404.2204	2H), 5.31 (dq, J = 9.0, 6.3 Hz, 1H),
		1712,		5.05 (d, J = 7.9 Hz, 1H), 4.43-4.15 (m, 1H),
		1497,		3.10 (t, J = 7.4 Hz, 1H), 2.29 (s, 3H),
		1365,		2.12 (h, J = 6.8 Hz, 1H), 1.45 (s, 9H),
		1243,		1.38 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 6.3 Hz,
		1161,		3H), 0.87 (d, J = 6.7 Hz, 3H),
		1051, 731 cm−1		0.81 (d, J = 6.8 Hz, 3H).
296		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3356,	calcd for C22H35NO4Na,	7.04-6.91 (m, 3H), 5.35 (dq, J = 9.3, 6.3 Hz,
		2962,	400.2458; found, 400.2462	1H), 5.07 (s, 1H), 4.29 (t, J = 7.6 Hz,
		1713,		1H), 3.08 (dd, J = 9.4, 6.0 Hz, 1H),
		1501,		2.29 (s, 3H), 2.29 (s, 3H), 2.12 (dq, J = 13.4,
		1451,		6.8 Hz, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
		1365,		3H), 1.03 (d, J = 6.2 Hz, 3H),
		1160,		0.84 (d, J = 6.7 Hz, 3H), 0.80 (d, J = 6.9 Hz,
		1049, 732 cm−1		3H).
297		IR (thin	HRMS-ESI (m/z)	1H NMR (500 MHz, CDCl3) δ
		film) 3352,	[M + NH4]+ calcd for	7.07-7.01 (m, 2H), 6.95 (dd, J = 7.0, 2.3 Hz,
		2964,	C22H35NO4NH4, 395.2904;	1H), 5.37 (dq, J = 9.2, 6.3 Hz, 1H),
		1712,	found, 395.2889	5.08 (s, 1H), 4.30 (t, J = 7.8 Hz, 1H),
		1499,		3.23 (dd, J = 9.3, 6.0 Hz, 1H), 2.30 (s, 3H),
		1452,		2.24 (s, 3H), 2.13 (dq, J = 13.4, 6.7 Hz,
		1365,		1H), 1.45 (s, 9H), 1.40 (d, J = 7.1 Hz,
		1160,		3H), 1.03 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.8 Hz,
		1050, 731 cm−1		3H), 0.79 (d, J = 6.9 Hz, 3H).
298		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3359,	calcd for C21H33NO4Na,	7.20-7.06 (m, 4H), 5.37 (dq, J = 9.3, 6.2 Hz,
		2965,	386.2302; found, 386.2301	1H), 5.07 (d, J = 7.8 Hz, 1H), 4.29 (t, J = 7.2 Hz,
		2875,		1H), 3.13 (dd, J = 9.2, 6.1 Hz,
		1714,		1H), 2.34 (s, 3H), 2.15 (dq, J = 13.4, 6.8 Hz,
		1161, 1054 cm−1		1H), 1.45 (s, 9H), 1.39 (d, J = 7.2 Hz,
				3H), 1.04 (d, J = 6.2 Hz, 3H),
				0.86 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.8 Hz,
				3H).
299		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.10 (td,
		film) 3365,	calcd for C20H29F2NO4Na,	J = 8.4, 6.4 Hz, 1H), 6.93-6.74 (m,
		2966,	408.1957; found, 408.1955	2H), 5.39 (tt, J = 7.0, 5.5 Hz, 1H),
		1712,		5.04 (d, J = 7.9 Hz, 1H), 4.26 (t, J = 7.6 Hz,
		1503,		1H), 3.13 (t, J = 7.7 Hz, 1H), 2.10 (h, J = 6.8 Hz,
		1454,		1H), 1.45 (s, 9H), 1.37 (d, J = 7.2 Hz,
		1366,		3H), 1.09 (d, J = 6.3 Hz, 3H),
		1165,		0.91 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.7 Hz,
		1053, 966,		3H).
		849 cm−1
300		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.00 (t, J = 7.7 Hz,
		film) 2969,	calcd for C21H32FNO4Na,	1H), 6.90 (dd, J = 7.9, 1.7 Hz,
		1716,	404.2208; found, 404.2202	1H), 6.87-6.74 (m, 1H), 5.40 (tt, J = 6.9,
		1506,		5.5 Hz, 1H), 5.07 (d, J = 8.1 Hz,
		1456,		1H), 4.33-4.16 (m, 1H), 3.11 (t, J = 7.7 Hz,
		1365,		1H), 2.33 (s, 3H), 2.10 (h, J = 6.8 Hz,
		1164, 1053 cm−1		1H), 1.45 (s, 9H), 1.38 (d, J = 7.2 Hz,
				3H), 1.09 (d, J = 6.3 Hz, 3H),
				0.90 (d, J = 6.7 Hz, 3H), 0.76 (d, J = 6.7 Hz,
				3H).
301		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 2.3 Hz,
		film) 3358,	calcd for	1H), 7.23 (dd, J = 8.5, 2.2 Hz,
		2966,	C20H29Cl2NO4Na,	1H), 7.13 (d, J = 8.5 Hz, 1H),
		1712,	440.1366; found, 440.1366	5.47-5.25 (m, 1H), 5.03 (d, J = 7.6 Hz, 1H),
		1500,		4.28 (d, J = 7.7 Hz, 1H), 3.51 (s, 1H),
		1474,		2.24-1.99 (m, 1H), 1.45 (s, 9H),
		1453,		1.39 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.4 Hz,
		1365,		3H), 0.92 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
		1162, 1045 cm−1		3H).
302		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3346,	calcd for C20H29F2NO4Na,	7.27 (m, 1H), 6.90-6.82 (m, 1H),
		2975,	408.1957; found, 408.1956	6.82-6.75 (m, 1H), 5.54-5.30 (m, 1H),
		1710,		5.01 (d, J = 8.6 Hz, 1H), 4.35-4.18 (m,
		1502,		1H), 2.84 (dd, J = 9.1, 5.2 Hz, 1H),
		1366,		2.09-1.87 (m, 1H), 1.44 (s, 9H), 1.24 (d, J = 7.3 Hz,
		1249,		3H), 1.10 (d, J = 6.3 Hz, 3H),
		1163,		0.97 (d, J = 6.5 Hz, 3H), 0.72 (d, J = 6.8 Hz,
		1064, 965		3H).
		847 cm−1
303		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.17 (t, J = 7.8 Hz,
		film) 3364,	calcd for C21H32FNO4Na,	1H), 6.90 (d, J = 7.6 Hz, 1H),
		2974,	404.2208; found, 404.2206	6.84 (dd, J = 11.0, 1.8 Hz, 1H),
		2932,		5.44-5.38 (m, 1H), 5.04 (d, J = 7.4 Hz, 1H),
		1714		4.46-4.15 (m, 1H) 2.83 (dd, J = 9.0,
		1506,		5.1 Hz, 1H), 2.33 (d, J = 3.0 Hz, 3H),
		1454,		2.11-1.97 (m, 1H), 1.44 (s, 9H),
		1336,		1.22 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1167, 1065 cm−1		3H), 0.97 (d, J = 6.6 Hz, 3H), 0.73 (d, J = 6.9 Hz,
				3H).
304		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 2.2 Hz,
		film) 3353,	calcd for	1H), 7.36 (d, J = 8.5 Hz, 1H),
		2975,	C20H29Cl2NO4Na,	7.24-7.06 (m, 1H), 5.62-5.20 (m,
		1710,	440.1366; found, 440.1360	1H), 5.02 (d, J = 8.1 Hz, 1H),
		1475,		4.46-4.13 (m, 1H), 3.13 (dd, J = 9.6, 4.6 Hz,
		1366,		1H), 2.20-1.92 (m, 1H), 1.44 (s, 9H),
		1163,		1.37-1.26 (m, 3H), 1.06 (d, J = 6.3 Hz,
		1111,		3H), 1.01 (d, J = 6.6 Hz, 3H), 0.70 (d, J = 6.8 Hz,
		1020, 863,		3H).
		809 cm−1
305		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 6.74 (d, J = 7.9 Hz,
		film) 3375,	calcd for C21H31NO6Na,	1H), 6.60 (d, J = 1.8 Hz, 1H),
		2969,	416.2044; found, 416.2040	6.54 (dd, J = 8.0, 1.7 Hz, 1H), 5.94 (s,
		1711,		2H), 5.31 (dq, J = 8.8, 6.3 Hz, 1H),
		1504,		5.07 (d J = 7.8 Hz, 1H), 4.33-4.20 (m, 1H),
		1488,		2.61 (dd, J = 8.8, 6.4 Hz, 1H),
		1160,		2.12-1.98 (m, J = 6.8 Hz, 1H), 1.45 (s, 9H),
		1038, 731 cm−1		1.38 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.2 Hz,
				3H), 0.85 (d, J = 6.7 Hz, 3H),
				0.76 (d, J = 6.7 Hz, 3H).
306		IR (thin		1H NMR (500 MHz, CDCl3) δ 7.13 (q, J = 8.8 Hz,
		film) 3361,		4H), 5.37 (dq, J = 8.7, 6.3 Hz,
		2970,		1H), 5.04 (d, J = 8.0 Hz, 1H),
		1715,		4.37-4.22 (m, 1H), 2.72 (dd, J = 8.6, 6.6 Hz,
		1366,		1H), 2.10 (h, J = 6.7 Hz, 1H), 1.45 (s,
		1262,		9H), 1.37 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 6.3 Hz,
		1218, 1165 cm−1		3H), 0.87 (d, J = 6.8 Hz, 3H),
				0.75 (d, J = 6.7 Hz, 3H).
				19F NMR (471 MHz, CDCl3) δ −57.9.
307		IR (thin		1H NMR (500 MHz, CDCl3) δ
		film) 3363,		7.06-6.91 (m, 2H), 6.90-6.75 (m, 2H),
		2976,		5.35 (dq, J = 8.9, 6.3 Hz, 1H), 5.08 (d, J = 8.0 Hz,
		2933,		1H), 4.52 (hept, J = 6.1 Hz, 1H),
		2875,		4.36-4.22 (m, 1H), 2.63 (dd, J = 9.0,
		1712,		6.1 Hz, 1H), 2.14-2.00 (m, 1H),
		1508,		1.45 (s, 9H), 1.38 (d, J = 7.2 Hz, 3H),
		1238,		1.33 (d, J = 6.1 Hz, 6H), 1.06 (d, J = 6.2 Hz,
		1165, 1050 cm−1		3H), 0.84 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.7 Hz,
				3H).
				13C NMR (126 MHz, CDCl3) δ 172.8,
				156.6, 155.0, 130.6, 130.3, 115.2, 79.7,
				72.7, 69.7, 60.4, 55.8, 49.5, 28.3, 28.2,
				22.1, 21.4, 18.9, 18.3, 18.0.
308		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3357,	calcd for C23H37NO5Na,	7.23-7.11 (m, 1H), 7.06 (dd, J = 7.8, 1.8 Hz,
		2976,	430.2569; found, 430.2431	1H), 6.92-6.78 (m, 2H), 5.42 (s, 1H),
		2933,		5.13 (d, J = 7.7 Hz, 1H), 4.56 (hept, J = 6.1 Hz,
		2874,		1H), 4.30 (t, J = 7.5 Hz, 1H),
		1712,		3.44 (s, 1H), 2.12 (h, J = 6.7 Hz, 1H),
		1489,		1.45 (s, 9H), 1.40 (d, J = 7.2 Hz, 3H),
		1238,		1.39-1.26 (m, 6H), 1.04 (d, J = 6.2 Hz,
		1160,		3H), 0.83 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
		1050, 732 cm−1		3H).
309		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ
		film) 3361,	calcd for C21H33NO5Na,	7.09-6.90 (m, 2H), 6.90-6.77 (m, 2H),
		2962,	402.2251; found, 402.2221	5.35 (dq, J = 8.9, 6.3 Hz, 1H), 5.07 (s, 1H),
		1713,		4.28 (t, J = 7.6 Hz, 1H), 3.80 (s, 3H),
		1512,		2.64 (dd, J = 8.9, 6.2 Hz, 1H), 2.07 (h, J = 6.7 Hz,
		1246,		1H), 1.45 (s, 9H), 1.38 (d, J = 7.2 Hz,
		1165, 1050 cm−1		3H), 1.06 (d, J = 6.2 Hz, 3H),
				0.84 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.8 Hz,
				3H).
310			ESIMS m/z 400	1H NMR (400 MHz, CDCl3) δ
			([M + Na]+)	7.23-7.04 (m, 4H), 5.38 (dq, J = 9.6, 6.1 Hz,
				1H), 5.09 (s, 1H), 4.41-4.22 (m, 1H),
				3.32-3.07 (m, 1H), 2.34 (d, J = 2.6 Hz,
				3H), 1.89 (dtd, J = 12.5, 6.2, 5.6, 3.2 Hz,
				1H), 1.54-1.33 (m, 12H),
				1.32-1.20 (m, 1H), 1.14-0.69 (m, 10H).
311			ESIMS m/z 392 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				7.20-7.03 (m, 4H), 5.41 (dq, J = 8.3, 6.2 Hz,
				1H), 5.06 (s, 1H), 4.27 (s, 1H), 3.30 (t, J = 7.6 Hz,
				1H), 2.33 (s, 3H),
				1.72-1.58 (m, 1H), 1.44 (s, 10H), 1.36 (dd, J = 10.9,
				7.2 Hz, 5H), 1.08 (d, J = 6.3 Hz,
				4H), 0.93 (t, J = 7.4 Hz, 3H), 0.78 (t, J = 7.3 Hz,
				3H).
312				1H NMR (400 MHz, CDCl3) δ 6.67 (d, J = 9.3 Hz,
				2H), 5.54 (ddt, J = 8.1, 6.3,
				2.0 Hz, 1H), 5.04 (s, 1H), 4.27 (d, J = 8.5 Hz,
				1H), 3.17 (t, J = 7.7 Hz, 1H),
				2.30-2.15 (m, 1H), 1.45 (s, 9H),
				1.37 (d, J = 7.3 Hz, 3H), 1.12 (dt, J = 6.3, 1.2 Hz,
				3H), 0.95 (d, J = 6.6 Hz, 3H),
				0.77 (dt, J = 6.8, 1.4 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −103.51,
				−108.05, −110.09.
313				1H NMR (400 MHz, CDCl3) δ 7.09 (dtt,
				J = 8.3, 5.6, 2.7 Hz, 3H),
				5.47-5.32 (m, 1H), 5.03 (s, 1H), 4.26 (s, 1H),
				3.13 (t, J = 7.7 Hz, 1H), 2.10 (q, J = 6.8 Hz,
				1H), 1.45 (s, 9H), 1.37 (d, J = 7.2 Hz,
				3H), 1.09 (d, J = 6.3 Hz, 3H),
				0.99-0.85 (m, 3H), 0.75 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −112.35.
314				1H NMR (400 MHz, CDCl3) δ 7.23 (dd,
				J = 8.4, 1.2 Hz, 1H), 7.16 (td, J = 8.0,
				5.6 Hz, 1H), 6.96 (ddd, J = 10.9, 8.1,
				1.5 Hz, 1H), 5.58 (ddq, J = 12.5, 9.1,
				3.1 Hz, 1H), 5.07 (s, 1H), 4.30 (d, J = 8.5 Hz,
				1H), 3.60-3.48 (m, 1H),
				2.24 (dqd, J = 13.7, 6.8, 2.1 Hz, 1H), 1.45 (s,
				9H), 1.40 (d, J = 7.2 Hz, 3H), 1.08 (dd,
				J = 6.3, 1.8 Hz, 3H), 0.99 (d, J = 6.8 Hz,
				3H), 0.78 (dd, J = 6.8, 2.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −105.00
315				1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 7.8 Hz,
				1H), 7.05 (d, J = 7.6 Hz, 1H),
				6.89 (s, 2H), 5.45-5.32 (m, 1H),
				5.08 (s, 1H), 4.28 (s, 1H), 2.65 (dd, J = 8.9,
				6.2 Hz, 1H), 2.33 (s, 3H),
				2.14-2.04 (m, 1H), 1.45 (s, 9H), 1.39 (d, J = 7.3 Hz,
				3H), 1.07 (d, J = 6.2 Hz, 3H),
				0.85 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
				3H).
316			ESIMS m/z 386 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 7.00 (td,
				J = 9.1, 4.7 Hz, 1H), 6.88 (dddd, J = 24.6,
				8.9, 6.3, 3.3 Hz, 2H),
				5.49-5.28 (m, 1H), 5.04 (s, 1H), 4.26 (d, J = 9.3 Hz,
				1H), 3.15 (t, J = 7.7 Hz, 1H),
				2.09 (h, J = 6.9 Hz, 1H), 1.45 (s, 9H),
				1.37 (d, J = 7.3 Hz, 3H), 1.12 (d, J = 6.3 Hz,
				3H), 0.94 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ
				−118.45-−122.20 (m).
317		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ
		film) 3374,	calcd for C22H28FN2O5,	12.06-12.02 (m, 1H), 8.47 (t, J = 5.8 Hz, 1H),
		2961,	419.1977; found, 419.1976	7.99 (d, J = 5.3 Hz, 1H), 7.05 (dd, J = 8.3,
		1740,		5.9 Hz, 1H), 6.90-6.81 (m, 3H),
		1650,		5.45 (dq, J = 8.2, 6.3 Hz, 1H), 4.19 (d, J = 5.7 Hz,
		1533,		2H), 3.95 (s, 3H), 3.04 (t, J = 7.7 Hz,
		1497,		1H), 2.30 (s, 3H), 2.08 (h, J = 6.8 Hz,
		1437,		1H), 1.09 (d, J = 6.3 Hz, 3H),
		1262,		0.93 (d, J = 6.7 Hz, 3H), 0.77 (d, J = 6.8 Hz,
		1240,		3H).
		1215,		13C NMR (101 MHz, CDCl3) δ 169.35,
		1188, 801,		168.66, 160.95 (d, J = 244.4 Hz),
		729 cm−1		155.42, 148.73, 140.59, 139.90 (d, J = 7.5 Hz),
				133.63 (d, J = 3.3 Hz), 130.43,
				129.20 (d, J = 6.9 Hz), 116.98 (d, J = 20.5 Hz),
				112.35 (d, J = 20.7 Hz),
				109.57, 74.06, 56.09, 49.55, 41.17,
				29.95, 20.95, 20.80, 19.71, 17.46.
				19F NMR (376 MHz, CDCl3) δ −117.31.
318		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.16 (s,
		film) 3371,	calcd for C25H34FN2O5,	1H), 8.43 (d, J = 9.5 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2963,	461.2466; found, 461.2453	1H), 7.03 (dd, J = 8.7, 5.9 Hz,
		1731,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.83 (td, J = 8.4,
		1651,		2.9 Hz, 1H), 6.77 (dd, J = 9.9, 2.8 Hz,
		1527,		1H), 5.37 (dq, J = 9.1, 6.1 Hz, 1H),
		1262,		4.66 (dd, J = 9.5, 4.9 Hz, 1H), 3.96 (s,
		1240, 730 cm−1		3H), 3.09 (dd, J = 9.2, 6.1 Hz, 1H),
				2.42-2.29 (m, 1H), 2.27 (s, 3H),
				2.20-2.06 (m, 1H), 1.07 (d, J = 6.2 Hz, 3H),
				1.06 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.9 Hz,
				3H), 0.82 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.9 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 170.53,
				169.10, 160.93 (d, J = 244.6 Hz),
				155.43, 148.78, 140.48, 139.88 (d, J = 7.3 Hz),
				133.35 (d, J = 3.3 Hz), 130.52,
				129.15 (d, J = 7.9 Hz), 116.98 (d, J = 20.5 Hz),
				112.31 (d, J = 20.6 Hz),
				109.50, 73.81, 57.39, 56.10, 49.30,
				31.34, 29.46, 20.88, 19.48, 18.63, 18.11,
				17.43.
				19F NMR (376 MHz, CDCl3) δ −117.29.
319		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.17 (s,
		film) 3374,	calcd for C26H36FN2O5,	1H), 8.42 (d, J = 9.5 Hz, 1H), 7.98 (d, J = 5.2 Hz,
		2963,	475.2603; found, 475.2599	1H), 7.03 (dd, J = 8.7, 5.9 Hz,
		1731,		1H), 6.89 (d, J = 5.3 Hz, 1H), 6.83 (td, J = 8.4,
		1651,		2.9 Hz, 1H), 6.77 (dd, J = 9.9, 2.8 Hz,
		1526,		1H), 5.37 (dq, J = 9.2, 6.2 Hz, 1H),
		1261,		4.71 (dd, J = 9.5, 4.9 Hz, 1H), 3.96 (s,
		1240,		3H), 3.09 (dd, J = 9.3, 6.0 Hz, 1H),
		1046, 800,		2.27 (s, 3H), 2.19-2.03 (m, 2H), 1.54 (dddd,
		730 cm−1		J = 14.9, 11.4, 6.8, 4.0 Hz, 1H),
				1.28 (tdd, J = 14.3, 9.8, 7.3 Hz, 1H), 1.07 (d,
				J = 6.2 Hz, 3H), 1.04 (d, J = 6.8 Hz,
				3H), 1.01-0.87 (m, 3H), 0.81 (d, J = 6.8 Hz,
				3H), 0.76 (d, J = 6.9 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 170.48,
				168.99, 160.93 (d, J = 244.4 Hz),
				155.43, 148.77, 140.47, 139.89 (d, J = 7.3 Hz),
				133.30 (d, J = 3.3 Hz), 130.53,
				129.16 (d, J = 7.8 Hz), 116.98 (d, J = 20.5 Hz),
				112.30 (d, J = 20.6 Hz),
				109.49, 73.77, 56.98, 56.10, 49.29,
				37.88, 29.40, 24.69, 20.88, 18.48, 18.15,
				15.83, 11.48.
				19F NMR (376 MHz, CDCl3) δ −117.28.
320		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
		film) 3367,	calcd for C26H36FN2O5,	1H), 8.28 (d, J = 9.0 Hz, 1H), 7.98 (d, J = 5.2 Hz,
		2959,	475.2603; found, 475.2600	1H), 7.04 (dd, J = 8.7, 5.9 Hz,
		1733,		1H), 6.89 (d, J = 5.2 Hz, 1H), 6.83 (td, J = 8.4,
		1650,		2.9 Hz, 1H), 6.77 (dd, J = 9.9, 2.8 Hz,
		1529,		1H), 5.35 (dq, J = 8.8, 6.2 Hz, 1H),
		1263,		4.79-4.68 (m, 1H), 3.95 (s, 3H),
		1244,		3.07 (dd, J = 8.8, 6.6 Hz, 1H), 2.27 (s, 3H),
		1049, 800,		2.08 (h, J = 6.8 Hz, 1H), 1.80-1.66 (m,
		731 cm−1		2H), 1.08 (d, J = 6.2 Hz, 3H),
				1.05-0.86 (m, 7H), 0.84 (d, J = 6.7 Hz, 3H),
				0.75 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.49,
				168.88, 160.90 (d, J = 244.3 Hz),
				155.43, 148.80, 140.41, 139.83 (d, J = 7.3 Hz),
				133.54 (d, J = 3.3 Hz), 130.45,
				129.10 (d, J = 7.1 Hz), 116.91 (d, J = 20.4 Hz),
				112.28 (d, J = 20.7 Hz),
				109.48, 73.83, 56.08, 50.94, 49.28,
				41.40, 29.68, 24.91, 23.00, 21.70, 20.89,
				18.98, 17.74.
				19F NMR (376 MHz, CDCl3) δ −117.37.
321		IR (thin	ESIMS m/z 429.2	1H NMR (500 MHz, CDCl3) δ 12.15 (s,
		film) 3370,	([M + H]+)	1H), 8.50 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2959,		1H), 7.02 (d, J = 7.6 Hz, 1H),
		2873,		6.95-6.86 (m, 3H), 5.39 (dq, J = 9.3,
		1731,		6.2 Hz, 1H), 4.81-4.60 (m, 1H),
		1648,		3.95 (s, 3H), 3.20-2.96 (m, 1H), 2.30 (s,
		1576,		3H), 2.27 (s, 3H), 2.14 (dq, J = 13.4, 6.7 Hz,
		1526,		1H), 1.57 (d, J = 7.2 Hz, 3H),
		1480,		1.07 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.8 Hz,
		1450,		3H), 0.81 (d, J = 6.8 Hz, 3H).
		1325,
		1280,
		1262,
		1241,
		1149,
		1046, 953,
		800, 730 cm−1
322		IR (thin	ESIMS m/z 433.2	1H NMR (500 MHz, CDCl3) δ 12.12 (s,
		film) 3370,	([M + H]+)	1H), 8.48 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2962,		1H), 7.12 (td, J = 8.0, 5.9 Hz,
		2875,		1H), 6.94-6.85 (m, 3H), 5.40 (dq, J = 9.0,
		1734,		6.2 Hz, 1H), 4.70 (p, J = 7.3 Hz,
		1649,		1H), 3.95 (s, 3H), 3.15 (t, J = 7.7 Hz,
		1576,		1H), 2.22 (d, J = 2.4 Hz, 3H), 2.14 (h, J = 6.8 Hz,
		1527,		1H), 1.56 (d, J = 7.2 Hz, 3H),
		1480,		1.08 (d, J = 6.2 Hz, 3H), 0.86 (d, J = 6.8 Hz,
		1453,		3H), 0.79 (d, J = 6.9 Hz, 3H).
		1324,
		1280,
		1263,
		1241,
		1163,
		1043, 786,
		732 cm−1
323		IR (thin	ESIMS m/z 419.2	1H NMR (500 MHz, CDCl3) δ 12.15 (s,
		film) 3370,	([M + H]+)	1H), 8.49 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2962,		1H), 7.24-7.18 (m, 1H),
		1733,		7.15 (td, J = 7.4, 1.9 Hz, 1H), 7.09 (td, J = 7.5,
		1648,		1.3 Hz, 1H), 7.00 (ddd, J = 10.3,
		1576,		8.2, 1.2 Hz, 1H), 6.88 (d, J = 5.2 Hz,
		1527,		1H), 5.47 (dqd, J = 7.6, 6.4, 1.2 Hz,
		1480,		1H), 4.73-4.62 (m, 1H), 3.95 (s, 3H),
		1452,		3.20 (t, J = 7.7 Hz, 1H), 2.18-2.08 (m,
		1280,		1H), 1.55 (d, J = 7.3 Hz, 3H), 1.13 (d, J = 6.3 Hz,
		1262,		3H), 0.92 (d, J = 6.8 Hz, 3H),
		1241,		0.77 (d, J = 6.7 Hz, 3H).
		1216,
		1148,
		1049, 849,
		800, 757,
		730 cm−1
324		IR (thin	ESIMS m/z 433.2	1H NMR (500 MHz, CDCl3) δ 12.12 (s,
		film) 3370,	([M + H]+)	1H), 8.46 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2959,		1H), 7.07 (dd, J = 8.3, 6.2 Hz,
		1731,		1H), 6.88 (d, J = 5.2 Hz, 1H),
		1648,		6.84-6.76 (m, 2H), 5.36 (dq, J = 8.7, 6.2 Hz,
		1576,		1H), 4.75-4.61 (m, 1H), 3.95 (s, 3H),
		1526,		3.11 (t, J = 7.9 Hz, 1H), 2.27 (s, 3H),
		1480,		2.11 (h, J = 6.7 Hz, 1H), 1.55 (d, J = 7.2 Hz,
		1450,		3H), 1.10 (d, J = 6.3 Hz, 3H),
		1438,		0.88 (d, J = 6.8 Hz, 3H), 0.80 (d, J = 6.8 Hz,
		1280,		3H).
		1262,
		1241,
		1149,
		1046, 953,
		819, 799,
		730 cm−1
325		IR (thin	ESIMS m/z 429.2	1H NMR (500 MHz, CDCl3) δ 12.15 (s,
		film) 3370,	([M + H]+)	1H), 8.50 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2961,		1H), 7.02-6.94 (m, 3H),
		1733,		6.88 (d, J = 5.2 Hz, 1H), 5.39 (dq, J = 9.2,
		1648,		6.2 Hz, 1H), 4.71 (p, J = 7.3 Hz, 1H),
		1576,		3.95 (s, 3H), 3.10 (dd, J = 9.3, 6.1 Hz,
		1527,		1H), 2.28 (s, 6H), 2.12 (dq, J = 13.4, 6.8 Hz,
		1497,		1H), 1.56 (d, J = 7.2 Hz, 3H),
		1451,		1.07 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.8 Hz,
		1280,		3H), 0.80 (d, J = 6.8 Hz, 3H).
		1261,
		1240,
		1148,
		1048, 952,
		800, 730 cm−1
326		IR (thin	ESIMS m/z 429.2	1H NMR (500 MHz, CDCl3) δ 12.15 (s,
		film) 3369,	([M + H]+)	1H), 8.51 (d, J = 7.7 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2961,		1H), 7.09-7.00 (m, 2H),
		2873,		6.95 (dd, J = 7.4, 1.8 Hz, 1H), 6.88 (d, J = 5.3 Hz,
		1732,		1H), 5.41 (dq, J = 9.0, 6.2 Hz,
		1648,		1H), 4.76-4.63 (m, 1H), 3.95 (s, 3H),
		1576,		3.25 (dd, J = 9.2, 6.1 Hz, 1H), 2.28 (s,
		1526,		3H), 2.23 (s, 3H), 2.18-2.08 (m, 1H),
		1480,		1.57 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 6.3 Hz,
		1451,		3H), 0.84 (d, J = 6.7 Hz, 3H),
		1384,		0.79 (d, J = 6.8 Hz, 3H).
		1359,
		1262,
		1241,
		1213,
		1150,
		1045, 849,
		800, 779,
		729 cm−1
327		IR (thin	ESIMS m/z 415 ([M + H]+)	1H NMR (500 MHz, CDCl3) δ 12.15 (d,
		film) 3369,		J = 0.6 Hz, 1H), 8.50 (d, J = 7.9 Hz,
		2960,		1H), 8.00 (d, J = 5.2 Hz, 1H),
		2932,		7.19-7.06 (m, 4H), 6.88 (d, J = 5.2 Hz, 1H),
		2874,		5.41 (dq, J = 9.2, 6.2 Hz, 1H),
		1732,		4.76-4.66 (m, 1H), 3.95 (s, 3H), 3.15 (dd, J = 9.2,
		1649,		6.2 Hz, 1H), 2.32 (s, 3H), 2.15 (dq,
		1527,		J = 13.4, 6.7 Hz, 1H), 1.56 (d, J = 7.2 Hz,
		1451,		3H), 1.08 (d, J = 6.2 Hz, 3H),
		1150,		0.86 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.8 Hz,
		1053, 731 cm−1		3H).
328		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.14 (d,
		film) 2964,	calcd for C22H27F2N2O5,	J = 0.6 Hz, 1H), 8.45 (d, J = 7.9 Hz,
		1733,	437.1883; found, 437.1879	1H), 7.99 (d, J = 5.2 Hz, 1H), 7.10 (td, J = 8.4,
		1714,		6.4 Hz, 1H), 6.88 (d, J = 5.2 Hz,
		1652,		1H), 6.86-6.81 (m, 1H), 6.74 (ddd, J = 10.2,
		1528,		8.9, 2.6 Hz, 1H), 5.52-5.31 (m,
		1503,		1H), 4.79-4.55 (m, 1H), 3.95 (s, 3H),
		1280,		3.14 (t, J = 7.7 Hz, 1H), 2.09 (h, J = 6.8 Hz,
		1263, 966,		1H), 1.58-1.53 (m, 3H), 1.12 (d, J = 6.3 Hz,
		848 cm−1		3H), 0.93 (d, J = 6.7 Hz, 3H),
				0.75 (d, J = 6.7 Hz, 3H).
329		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.16 (d,
		film) 2962,	calcd for C23H30FN2O5,	J = 0.7 Hz, 1H), 8.49 (d, J = 8.0 Hz,
		1733,	433.2133; found, 433.2129	1H), 8.00 (d, J = 5.2 Hz, 1H), 7.01 (t, J = 7.7 Hz,
		1650,		1H), 6.93-6.84 (m, 2H),
		1576,		6.83-6.78 (m, 1H), 5.45 (dqd, J = 7.6, 6.3,
		1528,		1.2 Hz, 1H), 4.73-4.60 (m, 1H),
		1481,		3.95 (s, 3H), 3.14 (t, J = 7.7 Hz, 1H), 2.32 (s,
		1450,		3H), 2.10 (h, J = 6.8 Hz, 1H), 1.55 (d, J = 7.2 Hz,
		1362,		3H), 1.12 (d, J = 6.3 Hz, 3H),
		1327,		1.01-0.88 (m, 3H), 0.76 (d, J = 6.7 Hz,
		1263,		3H).
		1242,
		1149,
		1050, 800 cm−1
330		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.13 (d,
		film) 2963,	calcd for C22H27Cl2N2O5,	J = 0.6 Hz, 1H), 8.44 (d, J = 8.0 Hz,
		1734,	469.1292; found, 469.1293	1H), 7.99 (d, J = 5.2 Hz, 1H), 7.34 (d, J = 2.2 Hz,
		1648,		1H), 7.22 (dd, J = 8.4, 2.2 Hz,
		1576,		1H), 7.13 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 5.2 Hz,
		1527,		1H), 5.45-5.32 (m, 1H),
		1478,		4.78-4.61 (m, 1H), 3.95 (s, 3H), 3.52 (s,
		1451,		1H), 2.09 (dt, J = 13.7, 6.9 Hz, 1H),
		1438,		1.55 (d, J = 7.2 Hz, 3H), 1.12 (d, J = 6.3 Hz,
		1262,		3H), 0.93 (d, J = 6.7 Hz, 3H),
		1150,		0.76 (d, J = 6.8 Hz, 3H).
		1044, 799,
		730 cm−1
331		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ
		film) 2965,	calcd for C22H27F2N2O5,	12.24-11.76 (m, 1H), 8.42 (d, J = 8.0 Hz, 1H),
		1734,	437.1883; found, 437.1887	8.01 (d, J = 5.2 Hz, 1H), 7.25-7.10 (m,
		1648,		1H), 6.89 (d, J = 5.1 Hz, 1H),
		1576,		6.74 (dddd, J = 14.1, 11.6, 7.5, 1.9 Hz, 2H),
		1528,		5.50-5.41 (m, 1H), 4.78-4.62 (m,
		1502,		1H), 3.95 (s, 3H), 2.84 (dd, J = 9.1, 5.1 Hz,
		1480,		1H), 2.00 (dq, J = 9.0, 6.9 Hz, 1H),
		1438,		1.42 (d, J = 7.2 Hz, 3H), 1.12 (d, J = 6.3 Hz,
		1322,		3H), 0.99 (d, J = 6.6 Hz, 3H),
		1263,		0.70 (d, J = 6.7 Hz, 3H).
		1241,
		1150,
		1060, 964,
		848, 800,
		731 cm−1
332		IR (thin		1H NMR (500 MHz, CDCl3) δ 12.14 (d,
		film) 2964,		J = 0.7 Hz, 1H), 8.46 (d, J = 8.0 Hz,
		1733,		1H), 8.01 (d, J = 5.2 Hz, 1H), 7.13 (t, J = 7.9 Hz,
		1648,		1H), 6.88 (d, J = 5.3 Hz, 1H),
		1576,		6.86-6.71 (m, 2H), 5.55-5.40 (m,
		1527,		1H), 4.80-4.59 (m, 1H), 3.95 (s, 3H),
		1438,		2.85 (dd, J = 8.9, 5.3 Hz, 1H), 2.30 (s,
		1323,		3H), 2.02 (dp, J = 13.6, 6.8 Hz, 1H),
		1262,		1.40 (d, J = 7.2 Hz, 3H), 1.13 (d, J = 6.2 Hz,
		1132, 800,		3H), 1.01-0.89 (m, 3H), 0.72 (d, J = 6.6 Hz,
		730 cm−1		3H).
				13C NMR (126 MHz, CDCl3) δ 171.60,
				168.63, 161.50 (d, J = 243.0 Hz),
				155.39, 148.77, 140.46, 138.17, 130.49,
				124.61, 123.34 (d, J = 14.9 Hz),
				115.43 (d, J = 23.9 Hz), 109.44, 72.12, 56.09,
				48.06, 34.67, 31.59, 29.04, 20.91, 18.19.
333		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.11 (d,
		film) 2964,	calcd for C22H27Cl2N2O5,	J = 0.6 Hz, 1H), 8.43 (d, J = 7.9 Hz,
		2872,	469.1292; found, 469.1282	1H), 8.02 (d, J = 5.3 Hz, 1H), 7.37 (d, J = 2.2 Hz,
		1734,		1H), 7.28 (d, J = 8.5 Hz, 1H),
		1649,		7.05 (dd, J = 8.5, 2.3 Hz, 1H), 6.90 (d, J = 5.1 Hz,
		1576,		1H), 5.46 (qd, J = 6.3, 4.7 Hz,
		1528,		1H), 4.77-4.65 (m, 1H), 3.96 (s, 3H),
		1472,		3.12 (dd, J = 9.6, 4.5 Hz, 1H),
		1438,		2.02-1.92 (m, 1H), 1.48 (d, J = 7.2 Hz, 3H),
		1323,		1.08 (d, J = 6.3 Hz, 3H), 1.02 (d, J = 6.6 Hz,
		1263,		3H), 0.68 (d, J = 6.7 Hz, 3H).
		1241,		13C NMR (126 MHz, CDCl3) δ 171.40,
		1129, 800 cm−1		168.71, 155.48, 148.85, 140.54, 136.78,
				136.31, 132.55, 130.48, 130.37, 128.95,
				127.06, 109.56, 72.00, 56.13, 51.39,
				48.06, 34.53, 30.14, 20.75, 20.47, 18.22.
334		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.14 (s,
		film) 3368,	calcd for C23H29N2O7,	1H), 8.48 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2961,	445.1969; found, 445.1961	1H), 6.87 (d, J = 5.2 Hz, 1H),
		1731,		6.69 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 1.7 Hz,
		1648,		1H), 6.53 (dd, J = 8.0, 1.7 Hz, 1H),
		1528,		5.92 (q, J = 1.6 Hz, 2H), 5.34 (dq, J = 8.5,
		1482,		6.3 Hz, 1H), 4.75-4.60 (m, 1H),
		1438,		3.94 (s, 3H), 2.63 (dd, J = 8.5, 6.6 Hz,
		1240,		1H), 2.03 (dq, J = 13.5, 6.8 Hz, 1H),
		1037, 729 cm−1		1.54 (d, J = 7.2 Hz, 3H), 1.11 (d, J = 6.3 Hz,
				3H), 0.85 (d, J = 6.7 Hz, 3H),
				0.76 (d, J = 6.7 Hz, 3H).
335		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.13 (d,
		film) 3370,	calcd for C23H28F3N2O6,	J = 0.6 Hz, 1H), 8.44 (d, J = 7.9 Hz,
		2964,	485.1894; found, 485.1896	1H), 7.99 (d, J = 5.2 Hz, 1H),
		1735,		7.15-7.05 (m, 4H), 6.88 (d, J = 5.2 Hz, 1H),
		1649,		5.41 (dq, J = 8.2, 6.3 Hz, 1H),
		1528,		4.76-4.59 (m, 1H), 3.95 (s, 3H), 2.73 (dd, J = 8.2,
		1258,		7.0 Hz, 1H), 2.09 (h, J = 6.8 Hz,
		1217, 1153 cm−1		1H), 1.54 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.4 Hz,
				3H), 0.88 (d, J = 6.7 Hz, 3H),
				0.74 (d, J = 6.7 Hz, 3H).
				19F NMR (471 MHz, CDCl3) δ −57.8.
336		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.16 (s,
		film) 3369,	calcd for C25H35N2O6,	1H), 8.50 (d, J = 7.8 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2974,	459.2490; found, 459.2468	1H), 7.08-6.94 (m, 2H),
		1732,		6.87 (d, J = 5.2 Hz, 1H), 6.84-6.75 (m, 2H),
		1649,		5.38 (dq, J = 8.7, 6.3 Hz, 1H),
		1527,		4.79-4.58 (m, 1H), 4.50 (hept, J = 6.1 Hz,
		1509,		1H), 3.95 (s, 3H), 2.65 (dd, J = 8.7, 6.3 Hz,
		1239, 953,		1H), 2.15-1.97 (m, 1H), 1.55 (d, J = 7.2 Hz,
		730 cm−1		3H), 1.33 (d, J = 6.0 Hz, 6H),
				1.10 (d, J = 6.3 Hz, 3H), 0.84 (d, J = 6.7 Hz,
				3H), 0.75 (d, J = 6.7 Hz, 3H).
337		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 12.19 (s,
		film) 3369,	calcd for C25H35N2O6,	1H), 8.54 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2972,	459.2490; found, 459.2476	1H), 7.14 (ddd, J = 8.5, 7.5,
		1733,		1.7 Hz, 1H), 7.06 (dd, J = 7.6, 1.8 Hz,
		1649,		1H), 6.93-6.74 (m, 3H), 5.47 (s, 1H),
		1527,		4.84-4.62 (m, 1H), 4.54 (hept, J = 6.0 Hz,
		1450,		1H), 3.94 (s, 3H), 3.45 (s, 1H),
		1238, 953,		2.12 (hept, J = 6.8 Hz, 1H), 1.57 (d, J = 7.2 Hz,
		752, 732 cm−1		3H), 1.33 (d, J = 6.0 Hz, 3H),
				1.31 (d, J = 6.0 Hz, 3H), 1.08 (d, J = 6.2 Hz,
				3H), 0.83 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
				3H).
338		IR (thin	HRMS-ESI (m/z) [M + Na]+	1H NMR (500 MHz, CDCl3) δ 12.16 (s,
		film) 3368,	calcd for C23H30N2O6Na,	1H), 8.49 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		2960,	453.1996; found, 453.1983	1H), 7.00 (d, J = 8.6 Hz, 2H),
		1732,		6.88 (d, J = 5.2 Hz, 1H), 6.84-6.75 (m,
		1649,		2H), 5.39 (dq, J = 8.6, 6.3 Hz, 1H),
		1512,		4.76-4.63 (m, 1H), 3.95 (s, 3H), 3.79 (s,
		1453,		3H), 2.66 (dd, J = 8.7, 6.4 Hz, 1H),
		1241, 800,		2.07 (h, J = 6.8 Hz, 1H), 1.55 (d, J = 7.2 Hz,
		730 cm−1		3H), 1.10 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.8 Hz,
				3H), 0.75 (d, J = 6.7 Hz, 3H).
339		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
		film) 2963,	calcd for C24H33N2O5,	1H), 8.50 (d, J = 7.8 Hz, 1H), 8.00 (d, J = 5.2 Hz,
		1734,	429.2310; found, 429.2381	1H), 7.21-7.02 (m, 4H),
		1650,		6.88 (d, J = 5.2 Hz, 1H), 5.43 (ddq, J = 12.3,
		1528,		9.6, 6.2 Hz, 1H), 4.77-4.59 (m, 1H),
		1452, 1264 cm−1		3.95 (s, 3H), 3.31-3.11 (m, 1H),
				2.33 (d, J = 4.9 Hz, 3H), 2.00-1.79 (m, 1H),
				1.55 (d, J = 6.6 Hz, 2H), 1.41 (ddd, J = 12.2,
				7.3, 4.5 Hz, 1H), 1.34-1.19 (m,
				1H), 1.12-0.67 (m, 10H).
340		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 12.15 (s,
		film) 3370,	calcd for C25H35N2O5,	1H), 8.47 (d, J = 8.1 Hz, 1H), 7.99 (d, J = 5.2 Hz,
		2961,	443.2465; found, 443.2536	1H), 7.19-7.04 (m, 4H),
		1528,		6.88 (d, J = 5.2 Hz, 1H), 5.46 (dq, J = 8.5,
		1263, 1057 cm−1		6.2 Hz, 1H), 4.70 (p, J = 7.5 Hz, 1H),
				3.95 (s, 3H), 3.32 (t, J = 7.6 Hz, 1H),
				2.31 (s, 3H), 1.75-1.59 (m, 1H),
				1.54 (d, J = 7.2 Hz, 3H), 1.49-1.17 (m, 3H),
				1.14-0.97 (m, 4H), 0.90 (t, J = 7.4 Hz,
				3H), 0.77 (t, J = 7.3 Hz, 3H).
341			ESIMS m/z 455 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 12.14 (s,
				1H), 8.47 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 5.2 Hz,
				1H), 6.88 (d, J = 5.2 Hz, 1H),
				6.62 (s, 2H), 5.58 (ddt, J = 8.0, 6.4, 1.9 Hz,
				1H), 4.68 (dq, J = 9.3, 7.3 Hz, 1H),
				3.95 (s, 3H), 3.19 (t, J = 7.7 Hz, 1H),
				2.35-2.19 (m, 1H), 1.54 (d, J = 7.2 Hz,
				3H), 1.15 (dt, J = 6.4, 1.3 Hz, 3H),
				0.96 (d, J = 6.7 Hz, 3H), 0.78 (dt, J = 6.8, 1.3 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ
				−105.84 (d, J = 1667.9 Hz), −110.02.
342				1H NMR (400 MHz, CDCl3) δ 12.13 (s,
				1H), 8.44 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 5.2 Hz,
				1H), 7.08 (dd, J = 3.8, 2.0 Hz,
				2H), 7.04-6.96 (m, 1H), 6.86 (dd, J = 19.5,
				5.2 Hz, 1H), 5.44 (ddd, J = 7.7,
				6.4, 1.3 Hz, 1H), 4.80-4.49 (m, 1H),
				3.95 (s, 3H), 3.14 (t, J = 7.8 Hz, 1H),
				2.09 (q, J = 6.9 Hz, 1H), 1.54 (d, J = 7.2 Hz,
				3H), 1.12 (d, J = 6.3 Hz, 3H),
				0.93 (d, J = 6.6 Hz, 3H), 0.75 (d, J = 6.7 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −112.37.
343				1H NMR (400 MHz, CDCl3) δ 12.15 (s,
				1H), 8.50 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 5.2 Hz,
				1H), 7.24-7.07 (m, 3H),
				6.96 (dddd, J = 9.5, 8.1, 2.8, 1.5 Hz, 1H),
				6.87 (d, J = 5.2 Hz, 1H), 5.82-5.37 (m,
				1H), 4.71 (dd, J = 7.9, 7.1 Hz, 1H),
				3.62-3.24 (m, 1H), 2.31-2.21 (m, 1H),
				1.57 (d, J = 7.2 Hz, 3H), 1.36 (s, 1H),
				1.18-0.96 (m, 7H), 0.78 (ddd, J = 6.8,
				2.7, 0.9 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.59,
				168.70, 155.38, 148.78, 140.43,
				137.03 (d, J = 9.3 Hz), 129.07-127.37 (m),
				125.68 (d, J = 3.5 Hz), 114.81 (dd, J = 24.5,
				2.1 Hz), 109.43, 73.22 (d, J = 5.4 Hz),
				72.04 (d, J = 5.2 Hz), 56.06,
				52.18-50.01 (m), 48.25, 29.65 (d, J = 3.2 Hz),
				21.72 (d, J = 3.8 Hz), 20.38,
				18.59 (d, J = 2.4 Hz), 18.16.
				19F NMR (376 MHz, CDCl3) δ
				−105.04 (d, J = 14.1 Hz).
344			ESIMS m/z 415 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 12.16 (s,
				1H), 8.51 (d, J = 7.9 Hz, 1H), 8.01 (dd,
				J = 5.2, 3.5 Hz, 1H), 7.17 (q, J = 8.2 Hz,
				1H), 7.04 (t, J = 6.0 Hz, 1H), 6.89 (td, J = 5.2,
				4.7, 2.6 Hz, 3H), 5.41 (ddt, J = 17.9,
				8.7, 6.2 Hz, 1H), 4.69 (p, J = 7.3 Hz,
				1H), 3.94 (d, J = 5.1 Hz, 2H),
				2.66 (ddd, J = 12.1, 8.8, 6.4 Hz, 1H), 2.33 (d,
				J = 4.2 Hz, 3H), 1.70-1.48 (m, 6H),
				1.09 (dd, J = 16.5, 6.2 Hz, 2H),
				0.86 (dd, J = 8.0, 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 171.75,
				168.73, 155.40, 148.81, 140.46, 137.37,
				130.65, 130.57, 127.73, 127.39, 126.82,
				109.45, 108.39, 73.18, 72.02, 56.07,
				48.22, 28.31, 21.49, 21.33, 18.66, 18.33,
				17.89.
345			ESIMS m/z 431 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 12.13 (s,
				1H), 8.46 (d, J = 8.0 Hz, 1H), 8.00 (dd,
				J = 8.4, 5.2 Hz, 1H), 7.09-6.65 (m,
				4H), 5.59-5.25 (m, 1H),
				4.85-4.56 (m, 1H), 3.94 (d, J = 5.0 Hz, 4H),
				3.27-3.08 (m, 1H), 1.54 (d, J = 7.2 Hz, 3H),
				1.15 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.7 Hz,
				3H), 0.78 (d, J = 6.7 Hz, 3H).
346		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.48 (t, J = 5.4 Hz,
		film) 3391,	calcd for C24H30FN2O6,	1H), 8.34 (d, J = 5.4 Hz, 1H),
		2962,	461.2082; found, 461.2077	7.08-6.97 (m, 2H), 6.86 (ddd, J = 9.5,
		1770,		6.3, 2.4 Hz, 2H), 5.43 (dq, J = 8.5, 6.4 Hz,
		1743,		1H), 4.16 (d, J = 5.4 Hz, 2H),
		1677,		3.92 (s, 3H), 3.03 (t, J = 7.7 Hz, 1H), 2.40 (s,
		1513,		3H), 2.30 (s, 3H), 2.13-2.02 (m, 1H),
		1499,		1.07 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.7 Hz,
		1311,		3H), 0.76 (d, J = 6.7 Hz, 3H).
		1192,		19F NMR (376 MHz, CDCl3) δ −117.43.
		1175,
		1009, 732 cm−1
347		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 9.5 Hz,
		film) 3382,	calcd for C27H36FN2O6,	1H), 8.32 (d, J = 5.5 Hz, 1H),
		2963,	503.2552; found, 503.2554	7.03 (dd, J = 9.1, 5.7 Hz, 2H), 6.83 (td,
		1771,		J = 8.4, 2.9 Hz, 1H), 6.77 (dd, J = 10.0,
		1730,		2.8 Hz, 1H), 5.35 (dq, J = 9.1, 6.2 Hz,
		1681,		1H), 4.66 (dd, J = 9.6, 4.8 Hz, 1H),
		1499,		3.92 (s, 3H), 3.07 (dd, J = 9.1, 6.1 Hz, 1H),
		1311,		2.40 (s, 3H), 2.36-2.22 (m, 4H),
		1191,		2.14 (td, J = 13.4, 12.6, 5.9 Hz, 1H), 1.05 (d,
		1173, 907,		J = 6.2 Hz, 3H), 1.02 (d, J = 6.8 Hz,
		731 cm−1		3H), 0.97 (d, J = 6.9 Hz, 3H), 0.82 (d, J = 6.8 Hz,
				3H), 0.76 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 171.03,
				168.84, 162.69, 160.91 (d, J = 244.3 Hz),
				159.51, 146.61, 141.66, 139.97 (d,
				J = 7.3 Hz), 137.57, 133.48 (d, J = 3.2 Hz),
				129.19 (d, J = 7.8 Hz), 116.95 (d, J = 20.4 Hz),
				112.24 (d, J = 20.7 Hz),
				109.74, 73.47, 57.33, 56.31, 49.32,
				31.55, 29.38, 20.91, 20.89-20.83 (m),
				20.77, 19.38, 18.63, 18.10, 17.51.
				19F NMR (376 MHz, CDCl3) δ −117.47.
348		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 9.5 Hz,
		film) 3383,	calcd for C28H37FN2O6,	1H), 8.31 (d, J = 5.4 Hz, 1H),
		2963,	517.2708; found, 517.2715	7.03 (dd, J = 9.5, 5.6 Hz, 2H), 6.83 (td,
		1771,		J = 8.4, 2.9 Hz, 1H), 6.77 (dd, J = 9.9,
		1730,		2.8 Hz, 1H), 5.35 (dq, J = 9.2, 6.2 Hz,
		1680,		1H), 4.71 (dd, J = 9.5, 4.9 Hz, 1H),
		1499,		3.92 (s, 3H), 3.08 (dd, J = 9.2, 6.0 Hz, 1H),
		1191,		2.40 (s, 3H), 2.26 (s, 3H), 2.14 (td, J = 13.3,
		1173, 731 cm−1		12.8, 6.1 Hz, 1H), 2.09-1.98 (m,
				1H), 1.51 (dtd, J = 16.7, 7.4, 3.6 Hz,
				1H), 1.30-1.18 (m, 1H), 1.04 (d, J = 6.2 Hz,
				3H), 1.00 (d, J = 6.8 Hz, 3H),
				0.93 (t, J = 7.4 Hz, 3H), 0.82 (d, J = 6.8 Hz,
				3H), 0.76 (d, J = 6.9 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 170.99,
				168.84, 162.59, 160.91 (d, J = 244.3 Hz),
				159.51, 146.60, 141.67, 139.98 (d,
				J = 7.5 Hz), 137.58, 133.44 (d, J = 3.3 Hz),
				129.21 (d, J = 7.6 Hz), 116.95 (d, J = 20.5 Hz),
				112.23 (d, J = 20.8 Hz),
				109.72, 73.43, 56.98, 56.31, 49.32,
				38.12, 29.31, 24.73, 20.92,
				20.90-20.83 (m), 20.78, 18.48, 18.16, 15.72,
				11.56.
				19F NMR (376 MHz, CDCl3) δ −117.47.
349		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.31 (t, J = 5.8 Hz,
		film) 3378,	calcd for C28H38FN2O6,	2H), 7.08-6.96 (m, 2H),
		2959,	517.2708; found, 517.2707	6.84 (td, J = 8.4, 2.9 Hz, 1H), 6.78 (dd, J = 9.9,
		1772,		2.8 Hz, 1H), 5.33 (dq, J = 8.9, 6.3 Hz,
		1733,		1H), 4.72 (dt, J = 9.0, 7.0 Hz, 1H),
		1679,		3.91 (s, 3H), 3.06 (dd, J = 8.9, 6.5 Hz,
		1499,		1H), 2.39 (s, 3H), 2.26 (s, 3H),
		1191,		2.15-2.04 (m, 1H), 1.78-1.59 (m, 3H),
		1173,		1.05 (d, J = 6.2 Hz, 3H), 0.99-0.93 (m, 6H),
		1049, 825 cm−1		0.84 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.05,
				168.83, 162.46, 160.90 (d, J = 244.3 Hz),
				159.52, 146.57, 141.63, 139.94 (d,
				J = 7.5 Hz), 137.58, 133.69 (d, J = 3.3 Hz),
				129.18 (d, J = 6.9 Hz), 116.90 (d, J = 20.5 Hz),
				112.25 (d, J = 20.6 Hz),
				109.74, 73.52, 56.30, 51.04, 49.33,
				41.69, 29.59, 24.93, 23.03, 21.98, 20.94,
				20.92-20.86 (m), 20.76, 18.94, 17.82.
				19F NMR (376 MHz, CDCl3) δ −117.54.
350		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.46 (t, J = 5.4 Hz,
		film) 3387,	calcd for C26H34FN2O7,	1H), 8.33 (d, J = 5.4 Hz, 1H),
		2961,	505.2345; found, 505.2339	7.08-6.99 (m, 2H), 6.90-6.80 (m,
		1767,		2H), 5.43 (dq, J = 8.2, 6.3 Hz, 1H),
		1742,		4.15 (d, J = 5.4 Hz, 2H), 3.91 (s, 3H), 3.82 (t,
		1678,		J = 6.6 Hz, 2H), 3.41 (s, 3H),
		1498,		3.09-2.95 (m, 3H), 2.30 (s, 3H), 2.07 (h, J = 6.8 Hz,
		1208,		1H), 1.07 (d, J = 6.3 Hz, 3H),
		1112,		0.92 (d, J = 6.7 Hz, 3H), 0.76 (d, J = 6.8 Hz,
		1047,		3H).
		1009, 730 cm−1		19F NMR (376 MHz, CDCl3) δ −117.43.
351		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.44 (d, J = 9.5 Hz,
		film) 3383,	calcd for C29H40FN2O7,	1H), 8.32 (d, J = 5.4 Hz, 1H),
		2963,	547.2814; found, 547.2813	7.09-6.98 (m, 2H), 6.83 (td, J = 8.4,
		1769,		2.9 Hz, 1H), 6.77 (dd, J = 10.0, 2.8 Hz,
		1730,		1H), 5.35 (dq, J = 9.1, 6.2 Hz, 1H),
		1681,		4.65 (dd, J = 9.5, 4.8 Hz, 1H), 3.91 (s, 3H),
		1499,		3.81 (t, J = 6.6 Hz, 2H), 3.40 (s, 3H),
		1311,		3.07 (dd, J = 9.1, 6.1 Hz, 1H), 2.99 (t, J = 6.7 Hz,
		1110, 826 cm−1		2H), 2.34-2.21 (m, 4H),
				2.14 (dq, J = 13.4, 6.5 Hz, 1H), 1.05 (d, J = 6.2 Hz,
				3H), 1.01 (d, J = 6.8 Hz, 3H),
				0.97 (d, J = 6.9 Hz, 3H), 0.82 (d, J = 6.8 Hz,
				3H), 0.76 (d, J = 6.9 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.47.
352		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 9.4 Hz,
		film) 3382,	calcd for C30H42FN2O7,	1H), 8.31 (d, J = 5.4 Hz, 1H),
		2963,	561.2971; found, 561.2969	7.06-6.96 (m, 2H), 6.83 (td, J = 8.4,
		1769,		2.9 Hz, 1H), 6.77 (dd, J = 10.0, 2.8 Hz,
		1730,		1H), 5.35 (dq, J = 9.1, 6.2 Hz, 1H),
		1681,		4.69 (dd, J = 9.5, 4.9 Hz, 1H), 3.91 (s, 3H),
		1499,		3.81 (t, J = 6.6 Hz, 2H), 3.41 (s, 3H),
		1111,		3.07 (dd, J = 9.2, 6.0 Hz, 1H), 2.99 (t, J = 6.7 Hz,
		1046, 825,		2H), 2.26 (s, 3H),
		731 cm−1		2.18-2.08 (m, 1H), 2.08-1.97 (m, 1H),
				1.50 (dddd, J = 13.3, 11.3, 6.8, 3.8 Hz, 1H),
				1.29-1.17 (m, 1H), 1.04 (d, J = 6.2 Hz,
				3H), 0.99 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.4 Hz,
				3H), 0.82 (d, J = 6.8 Hz, 3H),
				0.76 (d, J = 6.8 Hz, 3H).
				13C NMR (101 MHz, CDCl3) δ 170.99,
				169.35, 162.55, 160.91 (d, J = 243.9 Hz),
				159.52, 146.64, 141.69, 139.97 (d,
				J = 7.5 Hz), 137.44, 133.44 (d, J = 3.1 Hz),
				129.20 (d, J = 8.2 Hz), 116.95 (d, J = 20.3 Hz),
				112.24 (d, J = 20.7 Hz),
				109.72, 73.43, 67.65, 58.75, 56.97,
				56.34, 49.30, 38.13, 34.69, 29.32, 24.73,
				20.92, 20.90-20.86 (m), 18.49, 18.15,
				15.72, 11.55.
				19F NMR (376 MHz, CDCl3) δ −117.46.
353		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.31 (t, J = 3.9 Hz,
		film) 3377,	calcd for C30H42FN2O7,	2H), 7.08-6.98 (m, 2H),
		2958,	561.2971; found, 561.2974	6.84 (td, J = 8.4, 2.9 Hz, 1H), 6.78 (dd, J = 10.0,
		1769,		2.8 Hz, 1H), 5.37-5.27 (m, 1H),
		1733,		4.79-4.63 (m, 1H), 3.91 (s, 3H),
		1679,		3.81 (t, J = 6.7 Hz, 2H), 3.40 (s, 3H),
		1499,		3.06 (dd, J = 8.9, 6.5 Hz, 1H), 2.98 (t, J = 6.7 Hz,
		1309,		2H), 2.26 (s, 3H), 2.09 (h, J = 6.8 Hz,
		1110,		1H), 1.75-1.62 (m, 3H), 1.05 (d, J = 6.2 Hz,
		1049, 826 cm−1		3H), 0.99-0.93 (m, 6H),
				0.84 (d, J = 6.8 Hz, 3H), 0.74 (d, J = 6.8 Hz,
				3H).
				13C NMR (101 MHz, CDCl3) δ 172.06,
				169.33, 162.42, 160.91 (d, J = 244.3 Hz),
				159.53, 146.61, 141.64, 139.93 (d,
				J = 7.6 Hz), 137.45, 133.69 (d, J = 3.1 Hz),
				129.19 (d, J = 8.0 Hz), 116.91 (d, J = 20.5 Hz),
				112.25 (d, J = 20.6 Hz),
				109.74, 73.51, 67.65, 58.74, 56.33,
				51.03, 49.32, 41.74, 34.69, 29.60, 24.91,
				23.05, 21.97, 21.01-20.80 (m), 20.94,
				18.95, 17.82.
				19F NMR (376 MHz, CDCl3) δ −117.54.
354		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 8.1 Hz,
		film) 3383,	calcd for C29H38FN2O6,	1H), 8.31 (d, J = 5.4 Hz, 1H),
		2960,	529.2708; found, 529.2705	7.05 (dd, J = 8.6, 5.9 Hz, 1H), 6.99 (d, J = 5.5 Hz,
		1736,		1H), 6.90-6.77 (m, 2H),
		1499,		5.35 (dq, J = 8.9, 6.2 Hz, 1H),
		1208,		4.77-4.64 (m, 1H), 3.89 (s, 3H), 3.15 (q, J = 8.0 Hz,
		1122, 730 cm−1		1H), 3.11-3.03 (m, 1H), 2.29 (s,
				3H), 2.21-1.97 (m, 6H),
				1.83-1.70 (m, 2H), 1.70-1.57 (m, 1H), 1.49 (d, J = 7.2 Hz,
				3H), 1.06 (d, J = 6.2 Hz, 3H),
				0.86 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.44.
355		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.42 (d, J = 10.8 Hz,
		film) 3382,	calcd for C28H38FN2O6,	1H), 8.32 (d, J = 5.4 Hz,
		2968,	517.2708; found, 517.2702	1H), 7.05 (dd, J = 8.6, 5.9 Hz, 1H),
		1734,		6.99 (d, J = 5.5 Hz, 1H), 6.91-6.77 (m, 2H),
		1679,		5.35 (dq, J = 8.7, 6.2 Hz, 1H),
		1499,		4.77-4.66 (m, 1H), 3.89 (s, 3H), 3.07 (dd, J = 8.8,
		1155,		6.5 Hz, 1H), 2.77 (q, J = 6.9 Hz,
		1109,		1H), 2.29 (s, 3H), 2.11 (h, J = 6.7 Hz,
		1059, 731 cm−1		1H), 1.92 (dp, J = 14.2, 7.0 Hz, 1H),
				1.65 (dt, J = 13.9, 7.2 Hz, 1H), 1.49 (d,
				J = 7.2 Hz, 3H), 1.37-1.30 (m, 3H),
				1.05 (dd, J = 7.8, 7.0 Hz, 6H), 0.86 (d, J = 6.8 Hz,
				3H), 0.77 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.44.
356		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 8.1 Hz,
		film) 3380,	calcd for C28H38FN2O6,	1H), 8.32 (d, J = 5.4 Hz, 1H),
		2960,	517.2708; found, 517.2706	7.05 (dd, J = 8.6, 5.9 Hz, 1H), 7.00 (d, J = 5.4 Hz,
		1678,		1H), 6.88-6.77 (m, 2H),
		1499,		5.36 (dq, J = 8.9, 6.3 Hz, 1H), 4.70 (dq, J = 8.2,
		1311,		7.2 Hz, 1H), 3.90 (s, 3H), 3.08 (dd,
		1149,		J = 8.9, 6.5 Hz, 1H), 2.58 (d, J = 7.1 Hz,
		1049, 731 cm−1		2H), 2.35-2.20 (m, 4H),
				2.17-2.05 (m, 1H), 1.49 (d, J = 7.2 Hz, 3H),
				1.09-1.03 (m, 9H), 0.86 (d, J = 6.7 Hz, 3H),
				0.77 (d, J = 6.8 Hz, 3H).
				19F NMR (376 MHz, CDCl3) δ −117.43.
357		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 8.0 Hz,
		film) 3379,	calcd for C26H34FN2O6,	1H), 8.32 (d, J = 5.5 Hz, 1H),
		2961,	489.2395; found, 489.2389	7.05 (dd, J = 8.6, 5.9 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1734,		1H), 6.89-6.78 (m, 2H),
		1676,		5.36 (dq, J = 8.9, 6.2 Hz, 1H),
		1499,		4.76-4.64 (m, 1H), 3.91 (s, 3H), 3.08 (dd, J = 8.9,
		1310,		6.5 Hz, 1H), 2.73 (q, J = 7.5 Hz, 2H),
		1211,		2.29 (s, 3H), 2.11 (h, J = 6.8 Hz, 1H),
		1125,		1.50 (d, J = 7.2 Hz, 3H), 1.28 (t, J = 7.5 Hz,
		1049, 731 cm−1		3H), 1.06 (d, J = 6.3 Hz, 3H),
				0.86 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −117.43.
358		IR (thin	ESIMS m/z 471.2	1H NMR (500 MHz, CDCl3) δ 8.56 (s,
		film) 3378,	([M + H]+)	1H), 8.34 (d, J = 5.5 Hz, 1H),
		2959,		7.04-6.98 (m, 2H), 6.95-6.84 (m, 2H),
		1770,		5.37 (dq, J = 9.4, 6.2 Hz, 1H),
		1731,		4.76-4.65 (m, 1H), 3.91 (s, 3H), 3.10 (dd, J = 9.1,
		1675,		5.9 Hz, 1H), 2.40 (s, 3H), 2.29 (s, 3H),
		1504,		2.27 (s, 3H), 2.14 (dp, J = 14.1, 7.4, 6.9 Hz,
		1451,		1H), 1.52 (d, J = 7.1 Hz, 3H),
		1435,		1.05 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.8 Hz,
		1365,		3H), 0.80 (d, J = 6.8 Hz, 3H).
		1309,
		1199,
		1174,
		1044, 907,
		804, 729 cm−1
359		IR (thin	ESIMS m/z 475.2	1H NMR (500 MHz, CDCl3) δ 8.53 (s,
		film) 3381,	([M + H]+)	1H), 8.34 (d, J = 5.5 Hz, 1H), 7.11 (td, J = 8.0,
		2961,		5.9 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		1770,		1H), 6.90 (dt, J = 8.8, 4.9 Hz, 2H),
		1732,		5.38 (dq, J = 8.9, 6.2 Hz, 1H),
		1675,		4.75-4.63 (m, 1H), 3.91 (s, 3H), 3.14 (t, J = 7.7 Hz,
		1506,		1H), 2.40 (s, 3H), 2.22 (d, J = 2.4 Hz,
		1457,		3H), 2.14 (dq, J = 13.5, 6.9 Hz, 1H),
		1436,		1.51 (d, J = 7.1 Hz, 3H), 1.06 (d, J = 6.3 Hz,
		1366,		3H), 0.86 (d, J = 6.8 Hz, 3H),
		1310,		0.78 (d, J = 6.9 Hz, 3H).
		1199,
		1164,
		1041, 907,
		785, 731 cm−1
360		IR (thin	ESIMS m/z 461.2	1H NMR (500 MHz, CDCl3) δ 8.55 (s,
		film) 3381,	([M + H]+)	1H), 8.34 (d, J = 5.4 Hz, 1H),
		2963,		7.22-7.17 (m, 1H), 7.14 (td, J = 7.5, 1.9 Hz,
		1771,		1H), 7.08 (td, J = 7.5, 1.2 Hz, 1H),
		1734,		7.00 (d, J = 5.4 Hz, 2H), 5.52-5.37 (m, 1H),
		1676,		4.75-4.60 (m, 1H), 3.91 (s, 3H),
		1508,		3.19 (t, J = 7.7 Hz, 1H), 2.40 (s, 3H),
		1490,		2.18-2.09 (m, 1H), 1.50 (d, J = 7.2 Hz, 3H),
		1453,		1.11 (d, J = 6.3 Hz, 3H), 0.91 (d, J = 6.7 Hz,
		1436,		3H), 0.77 (d, J = 6.7 Hz, 3H).
		1366,
		1310,
		1202,
		1175,
		1050, 907,
		759, 732 cm−1
361		IR (thin	ESIMS m/z 475.2	1H NMR (500 MHz, CDCl3) δ 8.53 (s,
		film) 3377,	([M + H]+)	1H), 8.33 (d, J = 5.4 Hz, 1H), 7.07 (dd,
		2961,		J = 8.2, 6.2 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1770,		1H), 6.88-6.73 (m, 2H),
		1734,		5.41-5.24 (m, 1H), 4.76-4.64 (m, 1H), 3.91 (s,
		1676,		3H), 3.10 (t, J = 7.8 Hz, 1H), 2.40 (s,
		1500,		3H), 2.27 (s, 3H), 2.16-2.08 (m, 1H),
		1453,		1.50 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.3 Hz,
		1436,		3H), 0.88 (d, J = 6.8 Hz, 3H),
		1365,		0.80 (d, J = 6.8 Hz, 3H).
		1310,
		1201,
		1175,
		1048, 907,
		805, 731 cm−1
362		IR (thin	ESIMS m/z 471.2	1H NMR (400 MHz, CDCl3) δ 8.56 (s,
		film) 3376,	([M + H]+)	1H), 8.34 (d, J = 5.5 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		2959,		1H), 6.96 (d, J = 2.9 Hz, 3H),
		1771,		5.46-5.29 (m, 1H), 4.77-4.65 (m,
		1731,		1H), 3.91 (s, 3H), 3.09 (dd, J = 9.2, 5.9 Hz,
		1676,		1H), 2.36 (s, 3H), 2.28 (s, 6H),
		1505,		2.19-2.07 (m, 1H), 1.51 (d, J = 7.1 Hz, 3H),
		1452,		1.04 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.8 Hz,
		1437,		3H), 0.79 (d, J = 6.8 Hz, 3H).
		1200,
		1175,
		1045, 823 cm−1
363		IR (thin	ESIMS m/z 471.2	1H NMR (400 MHz, CDCl3) δ 8.57 (s,
		film) 3377,	([M + H]+)	1H), 8.34 (d, J = 5.4 Hz, 1H),
		2961,		7.06-6.99 (m, 3H), 6.97-6.92 (m, 1H),
		1771,		5.39 (dq, J = 12.5, 6.5 Hz, 1H), 4.69 (dt, J = 8.1,
		1733,		7.1 Hz, 1H), 3.91 (s, 3H), 3.25 (dd,
		1677,		J = 9.2, 6.0 Hz, 1H), 2.36 (s, 3H),
		1507,		2.28 (s, 3H), 2.23 (s, 3H), 2.13 (dt, J = 14.1,
		1452,		7.1 Hz, 1H), 1.52 (d, J = 7.2 Hz, 3H),
		1437,		1.04 (d, J = 6.2 Hz, 3H), 0.84 (d, J = 6.7 Hz,
		1365,		3H), 0.79 (d, J = 6.9 Hz, 3H).
		1310,
		1202,
		1175, 1043 cm−1
364		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.55 (s,
		film) 3382,	calcd for C25H33N2O6,	1H), 8.34 (d, J = 5.5 Hz, 1H),
		2960,	457.2333; found, 457.2332	7.18-7.06 (m, 4H), 7.01 (d, J = 5.4 Hz, 1H),
		1771,		5.39 (dq, J = 9.3, 6.2 Hz, 1H),
		1732,		4.75-4.66 (m, 1H), 3.91 (s, 3H), 3.14 (dd, J = 9.3,
		1676,		6.2 Hz, 1H), 2.40 (s, 3H), 2.32 (s,
		1507,		3H), 2.21-2.10 (m, 1H), 1.51 (d, J = 7.1 Hz,
		1200,		3H), 1.05 (d, J = 6.2 Hz, 3H),
		1175, 731 cm−1		0.86 (d, J = 6.9 Hz, 3H), 0.80 (d, J = 6.9 Hz,
				3H).
365		IR (thin	ESIMS m/z 479.2	1H NMR (500 MHz, CDCl3) δ 8.52 (s,
		film) 2964,	([M + H]+)	1H), 8.33 (d, J = 5.4 Hz, 1H), 7.10 (td, J = 8.4,
		1770,		6.4 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		1734,		1H), 6.85-6.79 (m, 1H), 6.75 (ddd, J = 10.2,
		1675,		8.9, 2.6 Hz, 1H), 5.41 (tt, J = 7.1,
		1502,		5.8 Hz, 1H), 4.83-4.58 (m, 1H),
		1453,		3.91 (s, 3H), 3.13 (t, J = 7.7 Hz, 1H), 2.40 (s,
		1309,		3H), 2.09 (td, J = 13.3, 6.5 Hz, 1H),
		1192,		1.49 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1174,		3H), 0.92 (d, J = 6.8 Hz, 3H),
		1049, 965,		0.75 (d, J = 6.7 Hz, 3H).
		907, 846,
		730 cm−1
366		IR (thin	ESIMS m/z 475.2	1H NMR (500 MHz, CDCl3) δ 8.55 (s,
		film) 2962,	([M + H]+)	1H), 8.34 (d, J = 5.5 Hz, 1H),
		1770,		7.05-6.95 (m, 2H), 6.89 (dd, J = 7.6, 1.5 Hz,
		1733,		1H), 6.85-6.77 (m, 1H),
		1676,		5.50-5.38 (m, 1H), 4.83-4.55 (m, 1H), 3.91 (s,
		1506,		3H), 3.13 (t, J = 7.7 Hz, 1H), 2.40 (s,
		1452,		3H), 2.32 (s, 3H), 2.10 (dt, J = 13.5, 6.8 Hz,
		1310,		1H), 1.50 (d, J = 7.1 Hz, 3H),
		1197,		1.10 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.7 Hz,
		1174,		3H), 0.76 (d, J = 6.7 Hz, 3H).
		1049, 907,		13C NMR (126 MHz, CDCl3) δ 172.25,
		823, 731 cm−1		168.92, 162.36, 160.50, 159.45, 146.65,
				141.61, 138.33 (d, J = 8.2 Hz), 137.50,
				130.10, 124.31 (d, J = 3.0 Hz),
				122.50 (d, J = 15.0 Hz), 115.94 (d, J = 23.8 Hz),
				109.70, 72.47, 56.28, 48.17, 28.32,
				21.07, 20.90, 20.77, 18.96, 18.52, 17.42.
367		IR (thin	ESIMS m/z 511.1 ([M]+)	1H NMR (500 MHz, CDCl3) δ 8.51 (s,
		film) 2963,		1H), 8.33 (d, J = 5.4 Hz, 1H), 7.36 (d, J = 2.2 Hz,
		1771,		1H), 7.22 (dd, J = 8.5, 2.2 Hz,
		1735,		1H), 7.13 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 5.4 Hz,
		1677,		1H), 5.37 (t, J = 7.3 Hz, 1H),
		1508,		4.83-4.56 (m, 1H), 3.91 (s, 3H),
		1365,		3.51 (s, 1H), 2.40 (s, 3H), 2.16-1.99 (m,
		1310,		1H), 1.50 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1200,		3H), 0.92 (d, J = 6.7 Hz, 3H),
		1175,		0.76 (d, J = 6.8 Hz, 3H).
		1044, 825,
		732 cm−1
368		IR (thin	ESIMS m/z 479.2	1H NMR (500 MHz, CDCl3) δ 8.49 (s,
		film) 3379,	([M + H]+)	1H), 8.34 (d, J = 5.4 Hz, 1H), 7.26 (s,
		2967,		1H), 7.02 (dd, J = 5.5, 2.3 Hz, 1H),
		1770,		6.82-6.71 (m, 2H), 5.45 (td, J = 6.2, 4.7 Hz,
		1733,		1H), 4.75-4.59 (m, 1H), 3.92 (d, J = 2.5 Hz,
		1675,		3H), 2.82 (dd, J = 9.3, 4.8 Hz,
		1502,		1H), 2.39 (s, 3H), 2.01 (ddt, J = 15.8,
		1192,		13.3, 6.8 Hz, 1H), 1.39 (d, J = 7.1 Hz,
		1173, 965,		3H), 1.08 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.6 Hz,
		846, 731 cm−1		3H), 0.70 (d, J = 6.6 Hz, 3H).
369		IR (thin	ESIMS m/z 475.2	1H NMR (500 MHz, CDCl3) δ 8.62 (dt,
		film) 2965,	([M + H]+)	J = 4.3, 1.8 Hz, 1H), 8.35 (d, J = 5.5 Hz,
		1771,		1H), 7.70 (tt, J = 7.7, 1.8 Hz, 1H),
		1732,		7.31 (dd, J = 7.7, 5.8 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		1676,		1H), 6.82 (dd, J = 9.4, 7.0 Hz,
		1506,		2H), 5.53-5.33 (m, 1H),
		1437,		4.76-4.54 (m, 1H), 3.91 (s, 3H), 2.83 (dd, J = 9.2,
		1310,		5.0 Hz, 1H), 2.39 (s, 3H), 2.31 (s, 3H),
		1190,		1.36 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.3 Hz,
		1175,		3H), 0.98 (d, J = 6.6 Hz, 3H),
		1061,		0.72 (d, J = 6.8 Hz, 3H).
		1008, 821,
		803 cm−1
370		IR (thin	ESIMS m/z 511.1	1H NMR (500 MHz, CDCl3) δ 8.50 (s,
		film) 2964,	([M + H]+)	1H), 8.35 (d, J = 5.4 Hz, 1H),
		1771,		7.41-7.30 (m, 2H), 7.07 (dd, J = 8.5, 2.2 Hz,
		1733,		1H), 7.03 (d, J = 5.4 Hz, 1H), 5.44 (qd,
		1714,		J = 6.2, 4.3 Hz, 1H), 4.80-4.61 (m,
		1676,		1H), 3.92 (d, J = 1.9 Hz, 3H), 3.10 (dd,
		1506,		J = 9.8, 4.3 Hz, 1H), 2.40 (s, 3H),
		1472,		2.04-1.88 (m, 1H), 1.44 (d, J = 7.2 Hz, 3H),
		1365,		1.05 (d, J = 6.3 Hz, 3H), 1.02 (d, J = 6.6 Hz,
		1310,		3H), 0.68 (d, J = 6.7 Hz, 3H).
		1192,		13C NMR (126 MHz, CDCl3) δ 171.98,
		1175, 826,		168.88, 162.37, 159.57, 149.73, 146.66,
		804, 734 cm−1		141.41, 137.63, 136.93, 136.28, 132.49,
				130.70, 128.86, 127.08, 123.76, 109.88,
				71.68, 56.33, 48.10, 30.13, 20.73, 20.64,
				18.62, 18.30.
371		IR (thin	ESIMS m/z 577.3	1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 5.5 Hz,
		film) 2961,	([M + H]+)	1H), 7.04 (dd, J = 8.6, 5.9 Hz,
		1773,		1H), 6.95 (d, J = 5.6 Hz, 1H),
		1742,		6.91-6.79 (m, 2H), 5.44-5.31 (m, 1H),
		1685,		5.25 (q, J = 7.0 Hz, 1H), 4.31 (q, J = 7.1 Hz,
		1594,		2H), 3.98-3.85 (m, 5H), 3.01 (t, J = 7.6 Hz,
		1490,		1H), 2.31 (s, 3H),
		1441,		2.15-2.04 (m, 1H), 1.63 (d, J = 7.0 Hz, 3H),
		1375,		1.36 (t, J = 7.2 Hz, 3H), 1.01 (d, J = 6.3 Hz,
		1342,		3H), 0.90 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.2 Hz,
		1306,		3H), 0.77 (d, J = 6.7 Hz, 3H).
		1246,
		1217,
		1201, 1090 cm−1
372		IR (thin	ESIMS m/z 505.3	1H NMR (500 MHz, CDCl3) δ 8.47 (d, J = 8.1 Hz,
		film) 3379,	([M + H]+)	1H), 8.34 (d, J = 5.5 Hz, 1H),
		2962,		7.08-6.99 (m, 2H), 6.88-6.79 (m,
		1767,		2H), 5.36 (dq, J = 8.9, 6.3 Hz, 1H),
		1734,		4.81-4.69 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H),
		1678,		3.94 (s, 3H), 3.08 (dd, J = 8.9, 6.5 Hz,
		1499,		1H), 2.29 (m, 3H), 2.15-2.05 (m, 1H),
		1312,		1.50 (d, J = 7.1 Hz, 3H), 1.41 (t, J = 7.1 Hz,
		1251,		3H), 1.06 (d, J = 6.3 Hz, 3H),
		1215,		0.86 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
		1051, 731 cm−1		3H).
373		IR (thin	ESIMS m/z 519.3	1H NMR (400 MHz, CDCl3) δ 8.44 (d, J = 8.1 Hz,
		film) 3384,	([M + H]+)	1H), 8.33 (d, J = 5.4 Hz, 1H),
		2981,		7.08-6.97 (m, 2H), 6.91-6.75 (m,
		1764,		2H), 5.44-5.31 (m, 1H), 4.98 (dq, J = 12.9,
		1736,		6.4 Hz, 1H), 4.81-4.61 (m, 1H),
		1681,		3.93 (s, 3H), 3.08 (dd, J = 8.9, 6.5 Hz,
		1500,		1H), 2.29 (s, 3H), 2.11 (dt, J = 13.5, 6.8 Hz,
		1313,		1H), 1.50 (d, J = 7.1 Hz, 3H),
		1259,		1.41 (d, J = 6.3 Hz, 6H), 1.06 (d, J = 6.3 Hz,
		1217,		3H), 0.86 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz,
		1180,		3H).
		1100, 915 cm−1
374		IR (thin	ESIMS m/z 517.3	1H NMR (400 MHz, CDCl3) δ 8.40 (s,
		film) 3382,	([M + H]+)	1H), 8.31 (d, J = 5.4 Hz, 1H), 7.05 (dd,
		2968,		J = 8.5, 5.9 Hz, 1H), 6.98 (d, J = 5.5 Hz,
		2874,		1H), 6.91-6.72 (m, 2H), 5.35 (dq, J = 8.9,
		1756,		6.3 Hz, 1H), 4.77-4.62 (m, 1H),
		1735,		3.89 (s, 3H), 3.07 (dd, J = 8.8, 6.6 Hz,
		1681,		1H), 2.29 (s, 3H), 2.11 (h, J = 6.7 Hz,
		1611,		1H), 1.49 (d, J = 7.1 Hz, 3H), 1.41 (s,
		1500,		9H), 1.05 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.8 Hz,
		1311,		3H), 0.77 (d, J = 6.8 Hz, 3H).
		1274,		13C NMR (126 MHz, CDCl3) δ 176.05,
		1208,		172.39, 162.25, 160.89 (d, J = 244.3 Hz),
		1154,		159.38, 146.49, 142.15, 139.92,
		1108,		137.85, 133.67, 116.93 (d, J = 20.4 Hz),
		1060, 819,		112.29 (d, J = 20.6 Hz), 109.49, 73.65,
		730 cm−1		56.29, 53.43, 49.29, 48.13, 39.15, 29.67,
				27.17, 20.92, 18.92, 18.66, 17.87.
375		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.49 (s,
		film) 3382,	calcd for C27H37N2O6,	1H), 8.33 (d, J = 5.4 Hz, 1H),
		2970,	485.2646; found, 485.2642	7.18-7.06 (m, 4H), 6.99 (d, J = 5.5 Hz, 1H),
		2875,		5.39 (dq, J = 9.2, 6.2 Hz, 1H),
		1762,		4.76-4.66 (m, 1H), 3.89 (s, 3H), 3.13 (dd, J = 9.2,
		1733,		6.2 Hz, 1H), 2.95 (p, J = 7.0 Hz,
		1678,		1H), 2.32 (s, 3H), 2.21-2.10 (m, 1H),
		1504,		1.50 (d, J = 7.1 Hz, 3H), 1.36 (dd, J = 7.0,
		1208, 730 cm−1		0.9 Hz, 6H), 1.05 (d, J = 6.2 Hz,
				3H), 0.86 (d, J = 6.8 Hz, 3H), 0.80 (d, J = 6.8 Hz,
				3H).
376		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.59 (s,
		film)	calcd for C27H37N2O7,	1H), 8.33 (d, J = 5.5 Hz, 1H), 7.14 (td, J = 7.8,
		3383, 2974,	501.2601; found, 501.2515	1.7 Hz, 1H), 7.06 (dd, J = 7.5, 1.7 Hz,
		1771,		1H), 7.00 (d, J = 5.5 Hz, 1H),
		1732,		6.94-6.73 (m, 2H), 5.45 (s, 1H),
		1676,		4.86-4.64 (m, 1H), 4.54 (hept, J = 6.0 Hz, 1H),
		1506,		3.90 (s, 3H), 3.44 (s, 1H), 2.40 (s, 3H),
		1193,		2.14 (dq, J = 13.3, 6.4 Hz, 1H), 1.52 (d,
		1174, 751 cm−1		J = 7.1 Hz, 3H), 1.33 (d, J = 6.0 Hz,
				3H), 1.31 (d, J = 6.0 Hz, 3H), 1.05 (d, J = 6.1 Hz,
				3H), 0.83 (d, J = 6.8 Hz, 3H),
				0.76 (d, J = 6.8 Hz, 3H).
377		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.56 (s,
		film) 3381,	calcd for C27H37N2O7,	1H), 8.34 (d, J = 5.4 Hz, 1H), 7.00 (d, J = 5.5 Hz,
		2975,	501.2601; found, 501.2493	1H), 6.99-6.96 (m, 2H),
		1771,		6.81-6.76 (m, 2H), 5.36 (dq, J = 8.6, 6.2 Hz,
		1732,		1H), 4.75-4.62 (m, 1H),
		1676,		4.51 (hept, J = 6.0 Hz, 1H), 3.91 (s, 3H),
		1507,		2.64 (dd, J = 8.8, 6.3 Hz, 1H), 2.40 (s,
		1175, 730 cm−1		3H), 2.12-2.02 (m, 1H), 1.50 (d, J = 7.1 Hz,
				3H), 1.33 (d, J = 6.0 Hz, 6H),
				1.08 (d, J = 6.3 Hz, 3H), 0.84 (d, J = 6.8 Hz,
				3H), 0.75 (d, J = 6.7 Hz, 3H).
378		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 7.8 Hz,
		film) 3381,	calcd for C26H32F3N2O8,	1H), 8.28 (d, J = 5.3 Hz, 1H),
		2964,	557.2107; found, 557.2107	7.15-7.04 (m, 4H), 6.96 (d, J = 5.4 Hz,
		1737,		1H), 5.75 (s, 2H), 5.40 (dq, J = 8.3, 6.3 Hz,
		1677,		1H), 4.70 (p, J = 7.3 Hz, 1H),
		1506,		3.92 (s, 3H), 2.73 (dd, J = 8.3, 6.9 Hz, 1H),
		1256,		2.15-2.04 (m, 4H), 1.51 (d, J = 7.2 Hz,
		1201,		3H), 1.09 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.7 Hz,
		1160, 1004 cm−1		3H), 0.74 (d, J = 6.8 Hz, 3H).
379		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 7.8 Hz,
		film) 3382,	calcd for C28H39N2O8,	1H), 8.29 (d, J = 5.3 Hz, 1H),
		2976,	531.2701; found, 531.2688	6.98 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 5.4 Hz,
		1755,		1H), 6.79 (d, J = 8.6 Hz, 2H),
		1733,		5.80-5.71 (m, 2H), 5.37 (dq, J = 8.8, 6.3 Hz,
		1675,		1H), 4.80-4.64 (m, 1H), 4.51 (hept, J = 6.1 Hz,
		1506,		1H), 3.91 (s, 3H), 2.65 (dd, J = 8.8,
		1236,		6.3 Hz, 1H), 2.15-2.00 (m, 4H),
		1201, 955,		1.52 (d, J = 7.2 Hz, 3H), 1.33 (d, J = 6.1 Hz,
		829 cm−1		6H), 1.08 (d, J = 6.3 Hz, 3H),
				0.84 (d, J = 6.7 Hz, 3H), 0.75 (d, J = 6.8 Hz,
				3H).
380		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.54 (s,
		film) 3380,	calcd for C25H31N2O8,	1H), 8.34 (d, J = 5.5 Hz, 1H), 7.01 (d, J = 5.5 Hz,
		2961,	487.2080; found, 487.2065	1H), 6.70 (d, J = 7.9 Hz, 1H),
		1770,		6.60 (d, J = 1.6 Hz, 1H), 6.54 (dd, J = 8.0,
		1731,		1.7 Hz, 1H), 5.93 (q, J = 1.5 Hz,
		1675,		2H), 5.33 (dq, J = 8.6, 6.3 Hz, 1H),
		1504,		4.75-4.63 (m, 1H), 3.91 (s, 3H), 2.63 (dd, J = 8.5,
		1488,		6.6 Hz, 1H), 2.40 (s, 3H),
		1192,		2.09-2.00 (m, 1H), 1.49 (d, J = 7.2 Hz, 3H),
		1175,		1.09 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.7 Hz,
		1037, 730 cm−1		3H), 0.76 (d, J = 6.8 Hz, 3H).
381		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 7.5 Hz,
		film) 3385,	calcd for C25H30F3N2O7,	1H), 8.33 (d, J = 5.5 Hz, 1H),
		2964,	527.2000; found, 527.2000	7.16-7.05 (m, 4H), 7.01 (d, J = 5.5 Hz,
		1772,		1H), 5.39 (dq, J = 8.2, 6.3 Hz, 1H),
		1734,		4.74-4.60 (m, 1H), 3.91 (s, 3H), 2.72 (dd, J = 8.1,
		1677,		7.0 Hz, 1H), 2.40 (s, 3H),
		1507,		2.15-2.02 (m, 1H), 1.48 (d, J = 7.2 Hz, 3H),
		1258,		1.08 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.7 Hz,
		1199, 1162 cm−1		3H), 0.74 (d, J = 6.8 Hz, 3H).
382		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (300 MHz, CDCl3) δ 8.38 (d, J = 7.7 Hz,
		film) 3378,	calcd for C26H35N2O8,	1H), 8.29 (d, J = 5.4 Hz, 1H),
		2960,	503.2388; found, 503.2356	7.05-6.98 (m, 2H), 6.96 (d, J = 5.4 Hz,
		1733,		1H), 6.87-6.75 (m, 2H), 5.75 (s, 2H),
		1675,		5.45-5.30 (m, 1H), 4.80-4.60 (m,
		1511,		1H), 3.92 (s, 3H), 3.79 (s, 3H), 2.67 (dd,
		1201,		J = 8.8, 6.3 Hz, 1H), 2.19-1.98 (m,
		1038, 968,		4H), 1.53 (d, J = 7.2 Hz, 3H), 1.09 (d, J = 6.3 Hz,
		829 cm−1		3H), 0.85 (d, J = 6.8 Hz, 3H),
				0.75 (d, J = 6.8 Hz, 3H).
383		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (500 MHz, CDCl3) δ 8.55 (s,
		film) 3378,	calcd for C25H33N2O7,	1H), 8.34 (d, J = 5.4 Hz, 1H),
		2960,	473.2282; found, 473.2259	7.07-6.95 (m, 3H), 6.88-6.74 (m, 2H),
		1770,		5.37 (dq, J = 8.7, 6.3 Hz, 1H),
		1732,		4.75-4.61 (m, 1H), 3.91 (s, 3H), 3.79 (s, 3H),
		1675,		2.66 (dd, J = 8.7, 6.4 Hz, 1H), 2.40 (s, 3H),
		1511,		2.08 (dq, J = 13.4, 6.7 Hz, 1H), 1.50 (d,
		1176,		J = 7.2 Hz, 3H), 1.07 (d, J = 6.2 Hz,
		1035, 730 cm−1		3H), 0.84 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.8 Hz,
				3H).
384		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.56 (s,
		film) 2963,	calcd for C26H35N2O6,	1H), 8.34 (dd, J = 5.4, 2.0 Hz, 1H),
		1772,	471.2416; found, 471.2487	7.19-7.06 (m, 4H), 7.01 (d, J = 5.5 Hz, 1H),
		1678,		5.40 (dq, J = 12.1, 6.6 Hz, 1H), 4.72 (p,
		1507,		J = 7.3 Hz, 1H), 3.91 (s, 3H),
		1200, 733 cm−1		3.39-3.05 (m, 1H), 2.40 (d, J = 1.7 Hz, 3H),
				2.33 (d, J = 5.7 Hz, 3H), 1.90 (s, 1H),
				1.55-1.18 (m, 5H), 1.04 (d, J = 6.3 Hz,
				3H), 1.01-0.71 (m, 6H).
385		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.53 (s,
		film) 2961,	calcd for C27H37N2O6,	1H), 8.33 (d, J = 5.4 Hz, 1H),
		1771,	485.2572; found, 485.2643	7.22-7.05 (m, 4H), 7.01 (d, J = 5.5 Hz, 1H),
		1732,		5.43 (dq, J = 8.3, 6.2 Hz, 1H), 4.69 (p, J = 7.3 Hz,
		1677,		1H), 3.91 (s, 3H), 3.31 (t, J = 7.6 Hz,
		1506,		1H), 2.39 (s, 3H), 2.31 (s, 3H),
		1198,		1.63 (d, J = 6.2 Hz, 1H), 1.54-1.17 (m,
		1175, 731 cm−1		6H), 1.17-0.85 (m, 7H), 0.77 (t, J = 7.3 Hz,
				3H).
386		IR (thin	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.49 (s,
		film) 2970,	calcd for C28H39N2O6,	1H), 8.33 (dd, J = 5.4, 2.1 Hz, 1H),
		1736,	499.2729; found, 499.2729	7.22-7.05 (m, 4H), 6.99 (d, J = 5.5 Hz, 1H),
		1506,		5.39 (dq, J = 9.6, 6.7, 6.2 Hz, 1H),
		1210, 733 cm−1		4.72 (p, J = 7.3 Hz, 1H), 3.89 (s, 3H),
				3.30-3.12 (m, 1H), 2.95 (tt, J = 7.0, 6.0 Hz,
				1H), 2.33 (s, 3H), 1.88 (d, J = 13.8 Hz,
				1H), 1.43 (dd, J = 59.5, 7.0 Hz, 11H),
				1.04 (d, J = 6.3 Hz, 3H), 0.83 (qd, J = 15.1,
				13.7, 7.1 Hz, 6H).
387		IR (thin
		film) 2964,	HRMS-ESI (m/z) [M + H]+	1H NMR (400 MHz, CDCl3) δ 8.46 (s,
		1681,	calcd for C29H41N2O6,	1H), 8.32 (d, J = 5.5 Hz, 1H),
		1505,	513.2883; found, 513.2953	7.17-7.03 (m, 5H), 6.99 (d, J = 5.5 Hz, 1H),
		1211, 1111 cm−1		5.50-5.36 (m, 1H), 4.69 (p, J = 7.3 Hz,
				1H), 3.89 (s, 3H), 3.31 (t, J = 7.6 Hz,
				1H), 2.94 (p, J = 7.0 Hz, 1H), 2.31 (s,
				3H), 1.61 (s, 1H), 1.51-0.94 (m, 15H),
				0.90 (t, J = 7.4 Hz, 3H), 0.77 (t, J = 7.3 Hz,
				3H).
388			ESIMS m/z 497 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 8.0 Hz,
				1H), 8.43-8.20 (m, 1H),
				7.01 (d, J = 5.5 Hz, 1H), 6.62 (t, J = 9.0 Hz,
				2H), 5.65-5.47 (m, 1H), 4.68 (dq, J = 8.3,
				7.2 Hz, 1H), 3.91 (s, 3H), 3.19 (t, J = 7.7 Hz,
				1H), 2.40 (s, 3H),
				2.31-2.13 (m, 1H), 1.49 (d, J = 7.2 Hz, 3H),
				1.13 (dt, J = 6.4, 1.2 Hz, 3H), 0.96 (dd, J = 6.7,
				3.5 Hz, 3H), 0.77 (dt, J = 6.7, 1.3 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ
				−105.79 (d, J = 1613.0 Hz), −110.18 (t, J = 6.4 Hz).
389			ESIMS m/z 495 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 6.7 Hz,
				1H), 8.33 (d, J = 5.4 Hz, 1H),
				7.13-6.92 (m, 4H), 5.42 (dqd, J = 7.6,
				6.4, 1.2 Hz, 1H), 4.75-4.51 (m, 1H),
				3.91 (s, 3H), 3.13 (t, J = 7.7 Hz, 1H),
				2.40 (s, 3H), 2.20-2.01 (m, 1H),
				1.49 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.3 Hz,
				3H), 0.93 (d, J = 6.5 Hz, 3H), 0.75 (d, J = 6.7 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −112.27.
390			ESIMS m/z 495 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ
				8.40-8.29 (m, 1H), 7.25-7.08 (m, 3H),
				7.06-6.90 (m, 2H), 5.75-5.47 (m, 1H),
				4.89-4.39 (m, 1H), 3.91 (s, 3H),
				3.62-3.47 (m, 1H), 2.40 (s, 3H),
				2.33-2.17 (m, 1H), 1.47 (dd, J = 38.1, 7.2 Hz, 3H),
				1.14-1.06 (m, 3H), 0.99 (dd, J = 6.8,
				5.6 Hz, 3H), 0.78 (dt, J = 6.9, 2.4 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ
				−105.07 (d, J = 18.2 Hz).
391			ESIMS m/z 457 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 8.1 Hz,
				1H), 8.34 (d, J = 5.4 Hz, 1H),
				7.22-7.10 (m, 1H), 7.09-6.98 (m,
				2H), 6.89 (d, J = 6.0 Hz, 2H),
				5.47-5.24 (m, 1H), 4.62 (dp, J = 51.8, 7.2 Hz,
				1H), 3.91 (s, 3H), 2.67 (dt, J = 8.7, 6.9 Hz,
				1H), 2.40 (s, 3H), 2.33 (d, J = 5.2 Hz,
				3H), 2.10 (dt, J = 13.6, 6.8 Hz, 1H),
				1.46 (dd, J = 37.4, 7.2 Hz, 3H), 1.09 (d,
				J = 6.3 Hz, 3H), 0.86 (t, J = 7.0 Hz,
				3H), 0.76 (d, J = 6.7 Hz, 3H).
392			ESIMS m/z 479 ([M + H]+)	1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 7.8 Hz,
				1H), 8.33 (d, J = 5.5 Hz, 1H),
				7.07-6.78 (m, 4H), 5.45-5.34 (m,
				1H), 4.76-4.62 (m, 1H), 3.91 (s, 3H),
				3.22-3.08 (m, 1H), 2.40 (s, 3H),
				2.09 (dt, J = 13.5, 6.8 Hz, 1H), 1.49 (d, J = 7.1 Hz,
				3H), 1.13 (d, J = 6.3 Hz, 3H),
				0.95 (t, J = 5.2 Hz, 3H), 0.77 (d, J = 6.7 Hz,
				3H).
				19F NMR (376 MHz, CDCl3) δ −119.17,
				−120.97.
*Cmpd. No.—Compound Number

TABLE 3
Biological Testing Rating Scale
Rating Table for Fungal Pathogens
% Control  Rating
>80        A
≤80        B
Not Tested C
≤0         D

TABLE 4
Biological Activity - PUCCRT and SEPTTR Disease
Control in High and Low Volume Applications
	HV activity at 100 ppm	LV activity at 121.5 g/H
Cmpd.	PUCCRT*	SEPTTR*	PUCCRT*	SEPTTR*
No.	1DP*	3DC*	1DP*	3DC*	1DP*	3DC*	1DP*	3DC*
105	A	D	B	B	C	C	C	C
106	B	D	D	D	C	C	C	C
112	A	A	A	A	C	C	C	C
113	A	A	A	A	C	C	C	C
114	A	B	A	B	C	C	C	C
115	D	D	B	D	C	C	C	C
116	A	D	D	B	C	C	C	C
117	A	D	A	A	C	C	C	C
118	A	B	B	B	C	C	C	C
119	A	B	A	A	C	C	C	C
120	A	D	D	B	C	C	C	C
121	A	B	B	A	C	C	C	C
122	A	A	A	B	C	C	C	C
123	A	A	A	A	C	C	C	C
124	A	A	A	A	C	C	C	C
125	A	B	A	A	C	C	C	C
126	A	B	A	A	C	C	C	C
127	A	A	A	B	C	C	C	C
128	B	D	D	B	C	C	C	C
129	A	D	A	B	C	C	C	C
130	A	B	B	B	C	C	C	C
131	A	A	B	B	C	C	C	C
132	A	A	A	B	C	C	C	C
133	A	B	A	B	C	C	C	C
134	B	B	B	B	C	C	C	C
135	B	A	B	A	C	C	C	C
136	A	A	A	A	C	C	C	C
138	A	A	D	D	C	C	C	C
139	A	B	A	D	C	C	C	C
140	A	A	D	B	C	C	C	C
141	B	A	D	A	C	C	C	C
142	A	A	D	B	C	C	C	C
143	A	A	A	B	C	C	C	C
144	A	A	B	A	C	C	C	C
145	A	A	B	A	C	C	C	C
146	A	A	B	A	C	C	C	C
147	A	A	D	B	C	C	C	C
148	B	A	D	B	C	C	C	C
149	B	B	B	A	C	C	C	C
160	C	C	C	C	A	B	B	A
161	C	C	C	C	A	B	B	A
162	C	C	C	C	A	A	B	A
163	C	C	C	C	A	B	B	A
164	C	C	C	C	A	A	A	A
165	C	C	C	C	A	A	A	A
166	C	C	C	C	A	A	B	A
167	C	C	C	C	A	A	A	A
168	C	C	C	C	A	A	B	B
169	C	C	C	C	A	A	B	A
170	C	C	C	C	A	A	A	A
171	C	C	C	C	A	A	A	A
172	C	C	C	C	A	A	A	A
173	C	C	C	C	A	B	A	A
174	C	C	C	C	A	A	A	A
175	C	C	C	C	A	A	A	A
176	C	C	C	C	A	B	A	A
177	C	C	C	C	B	D	B	D
178	C	C	C	C	A	B	D	B
179	C	C	C	C	A	D	A	A
180	C	C	C	C	A	B	B	B
181	C	C	C	C	B	B	B	A
182	C	C	C	C	A	B	B	A
183	C	C	C	C	B	B	B	A
184	C	C	C	C	A	A	A	A
185	C	C	C	C	A	B	A	A
186	C	C	C	C	A	A	A	A
187	C	C	C	C	A	B	A	A
188	C	C	C	C	A	B	A	A
189	C	C	C	C	A	B	A	A
190	C	C	C	C	D	D	D	B
191	C	C	C	C	D	B	B	B
192	C	C	C	C	A	B	D	A
193	C	C	C	C	B	B	D	B
194	C	C	C	C	B	D	B	A
195	C	C	C	C	A	A	A	A
196	C	C	C	C	A	A	A	A
197	C	C	C	C	A	A	A	A
198	C	C	C	C	B	D	B	B
199	C	C	C	C	B	D	A	B
200	C	C	C	C	B	B	D	B
201	C	C	C	C	A	B	B	B
202	C	C	C	C	A	D	B	B
203	C	C	C	C	B	B	B	B
204	C	C	C	C	A	B	D	B
205	C	C	C	C	A	D	B	B
206	C	C	C	C	B	D	B	B
207	C	C	C	C	A	B	B	A
208	C	C	C	C	B	B	D	B
209	C	C	C	C	D	D	B	B
210	C	C	C	C	B	D	A	B
211	B	D	B	B	D	D	B	D
212	A	B	B	A	B	D	D	D
213	C	C	C	C	B	D	B	B
214	C	C	C	C	A	A	A	A
215	C	C	C	C	A	A	A	A
216	C	C	C	C	A	A	A	A
217	C	C	C	C	A	A	A	A
218	C	C	C	C	A	B	A	B
219	C	C	C	C	A	A	B	A
220	C	C	C	C	A	A	A	A
221	C	C	C	C	B	B	B	A
222	C	C	C	C	A	B	A	A
223	C	C	C	C	B	B	A	A
224	C	C	C	C	B	B	B	D
225	C	C	C	C	A	B	A	A
226	C	C	C	C	B	B	B	B
227	C	C	C	C	A	A	A	A
228	C	C	C	C	A	B	A	B
229	C	C	C	C	A	B	A	A
230	C	C	C	C	A	A	A	B
231	C	C	C	C	B	B	B	B
232	C	C	C	C	A	A	A	B
233	C	C	C	C	B	B	A	A
234	C	C	C	C	A	B	B	B
235	C	C	C	C	A	B	B	B
236	C	C	C	C	B	B	B	B
237	C	C	C	C	A	A	B	B
238	C	C	C	C	B	B	B	B
239	C	C	C	C	A	A	A	B
240	C	C	C	C	A	A	B	A
241	C	C	C	C	B	B	D	A
242	C	C	C	C	A	A	A	A
243	C	C	C	C	A	B	D	B
244	C	C	C	C	A	A	A	B
245	C	C	C	C	A	A	B	C
246	C	C	C	C	A	A	A	C
247	C	C	C	C	A	A	B	C
248	C	C	C	C	B	B	B	C
249	C	C	C	C	A	A	B	C
250	C	C	C	C	A	A	A	C
251	C	C	C	C	A	A	B	C
252	C	C	C	C	A	B	B	C
253	C	C	C	C	A	A	B	C
254	C	C	C	C	A	A	A	C
255	C	C	C	C	A	A	B	C
256	C	C	C	C	A	A	A	C
257	C	C	C	C	A	A	A	C
258	C	C	C	C	A	B	B	C
259	C	C	C	C	A	A	B	C
260	C	C	C	C	A	A	A	C
261	C	C	C	C	A	B	B	B
262	C	C	C	C	A	B	B	B
263	C	C	C	C	A	A	B	A
264	C	C	C	C	A	A	B	B
317	A	A	B	B	C	C	C	C
318	A	A	B	B	C	C	C	C
319	B	B	B	B	C	C	C	C
320	B	B	B	B	C	C	C	C
321	A	A	B	B	C	C	C	C
322	A	A	B	B	C	C	C	C
323	A	A	B	A	C	C	C	C
324	A	A	B	B	C	C	C	C
325	A	A	A	B	C	C	C	C
326	A	A	B	A	C	C	C	C
327	A	A	B	A	C	C	C	C
328	A	A	A	A	C	C	C	C
329	A	A	B	B	C	C	C	C
330	A	A	B	B	C	C	C	C
331	B	B	B	B	C	C	C	C
332	B	B	B	B	C	C	C	C
333	A	B	B	B	C	C	C	C
334	A	A	B	D	C	C	C	C
335	A	A	A	B	C	C	C	C
336	A	B	B	B	C	C	C	C
337	A	A	B	D	C	C	C	C
338	A	A	B	B	C	C	C	C
339					C	C	C	C
340	C	C	C	C	C	C	C	C
341	A	A	A	A	C	C	C	C
342	C	C	C	C	C	C	C	C
343	A	A	A	A	C	C	C	C
344	C	C	C	C	C	C	C	C
345	C	C	C	C	C	C	C	C
346	C	C	C	C	A	A	B	B
347	C	C	C	C	A	B	A	A
348	C	C	C	C	A	B	B	B
349	C	C	C	C	A	B	B	B
350	C	C	C	C	A	A	B	B
351	C	C	C	C	A	B	A	B
352	C	C	C	C	A	B	B	B
353	C	C	C	C	B	B	B	B
354	C	C	C	C	A	B	A	A
355	C	C	C	C	A	B	A	A
356	C	C	C	C	A	B	A	A
357	C	C	C	C	A	A	A	A
358	C	C	C	C	A	B	B	B
359	C	C	C	C	A	A	B	A
360	C	C	C	C	A	A	B	A
361	C	C	C	C	A	B	B	B
362	C	C	C	C	A	A	A	A
363	C	C	C	C	A	A	B	B
364	C	C	C	C	A	B	B	B
365	C	C	C	C	A	A	A	A
366	C	C	C	C	A	A	B	B
367	C	C	C	C	A	A	A	B
368	C	C	C	C	B	D	B	B
369	C	C	C	C	A	B	B	B
370	C	C	C	C	B	D	B	B
371	C	C	C	C	C	C	C	C
372	C	C	C	C	C	C	C	C
373	C	C	C	C	A	B	A	A
374	C	C	C	C	A	B	A	A
375	C	C	C	C	A	A	B	A
376	C	C	C	C	A	B	B	B
377	C	C	C	C	A	B	B	B
378	C	C	C	C	A	A	A	A
379	C	C	C	C	A	B	B	B
380	C	C	C	C	A	A	B	B
381	C	C	C	C	A	B	A	A
382	C	C	C	C	A	A	B	A
383	C	C	C	C	A	B	B	B
384	C	C	C	C	A	A	A	A
385	C	C	C	C	A	A	A	A
386	C	C	C	C	A	A	B	A
387	C	C	C	C	A	B	B	A
388	C	C	C	C	A	A	A	A
389	C	C	C	C	A	A	A	A
390	C	C	C	C	A	A	A	A
391	C	C	C	C	A	B	B	B
392	C	C	C	C	A	A	B	A
*Cmpd. No.—Compound Number
*PUCCRT—Wheat Brown Rust (Puccinia triticina)
*SEPTTR—Wheat Leaf Blotch (Zymoseptoria tritici)
*1DP—1 Day Protectant
*3DC—3 Day Curative
*ppm—Parts Per Million

TABLE 5
Biological Activity - High Volume Disease Control at 25 ppm
	PHAKPA*
Cmpd. No.*	1DP*	3DC*
162	A	B
164	A	B
177	A	D
178	D	B
179	B	B
180	B	B
181	D	B
182	B	B
183	B	B
184	A	B
185	A	B
186	A	A
187	A	B
188	A	A
189	A	B
190	B	B
191	B	D
192	A	B
193	B	B
194	B	B
195	A	B
196	A	B
197	A	A
198	B	B
199	B	B
200	B	D
201	B	D
202	B	D
203	A	D
204	B	D
205	B	D
206	B	D
207	A	D
208	B	D
209	B	D
210	B	B
211	B	D
212	B	B
213	D	D
214	A	B
215	A	A
216	A	A
217	A	A
218	B	B
219	A	A
220	A	A
221	B	B
222	A	B
223	B	D
224	B	D
225	A	B
226	B	D
227	A	B
228	A	B
229	A	B
230	A	B
231	A	B
232	A	A
233	B	B
234	A	D
235	A	B
236	A	B
237	A	A
238	B	B
239	A	A
240	A	B
241	B	B
242	A	B
243	A	B
244	A	B
346	A	B
347	A	A
348	A	B
349	A	B
350	A	A
351	A	B
352	A	B
353	A	B
354	A	A
355	A	A
356	A	A
357	A	A
358	A	B
359	A	A
360	A	A
361	A	A
362	A	A
363	A	A
364	A	A
365	A	A
366	A	B
367	A	A
368	B	B
369	B	B
370	B	B
371	A	A
372	A	A
373	A	A
374	A	B
375	A	A
376	A	B
377	B	B
378	B	B
379	B	B
380	B	B
381	B	B
382	A	B
383	A	B
*Cmpd. No.—Compound Number
*PHAKPA—Asian Soybean Rust (Phakopsora pachyrhizi)
*1DP—1 Day Protectant
*3DC—3 Day Curative

TABLE 6
Biological Activity - Disease Control in 1DP* test at 100 ppm
Cmpd. No.*	ALTESO*	CERCBE*	COLLLA*	LEPTNO*
186	A	A	D	A
187	B	A	A	B
216	B	A	B	A
217	B	A	D	A
218	D	A	B	A
219	B	A	B	A
220	B	A	B	A
354	B	A	A	A
355	A	A	A	A
356	A	A	B	A
357	B	A	A	A
359	B	A	A	A
363	D	A	B	B
364	B	A	A	B
371	B	A	A	A
372	A	A	A	A
373	B	A	A	A
374	B	A	B	A
375	B	A	A	A
*Cmpd. No.—Compound Number
*ALTESO—Tomato Early Blight (Alternaria solani)
*CERCBE—Leaf Spot of Sugar Beets (Cercospora beticola)
*COLLLA—Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotricum lagenarium)
*LEPTNO—Wheat Glume Blotch (Parastagonospora nodorum)

TABLE 7
Biological Activity - Disease Control in 1DP* Test at 100 ppm
Cmpd. No.*	PSPECU*	PYRIOR*	RHYNSE*	UNCINE*
186	B	A	B	A
187	D	A	A	A
216	B	A	B	A
217	D	A	B	A
218	D	A	B	A
219	B	A	B	A
220	D	A	B	A
354	A	B	B	A
355	B	B	B	A
356	B	B	B	A
357	B	B	B	A
359	B	A	A	A
363	D	A	B	A
364	B	A	B	A
371	B	B	B	A
372	A	B	B	A
373	B	B	B	A
374	B	B	B	A
375	B	A	B	A
*Cmpd. No.—Compound Number
*PSPECU—Cucumber Downy Midlew (Pseudoperonospora cubensis)
*PYRIOR—Rice Blast (Magnaporthe grisea; Anamorph: Pyricularia oryzae)
*RHYNSE—Barley Scald (Rhyncosporium secalis)
*UNCINE—Grape Powdery Mildew (Uncinula necator)
*1DP—1 Day Protectant

Claims

1. A compound of Formula I

wherein:

X is hydrogen or C(O)R5;

Y is hydrogen, C(O)R5, or Q;

Q is

wherein Z is N or N+→O− and W is O or S;

R1 is hydrogen or alkyl, substituted with 0, 1 or multiple R8;

R2 is methyl;

R3 and R3′ are independently chosen from C2-C6 alkyl, C3-C6 cycloalkyl, aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R8; Alternatively, R3 and R3′ may be taken together to form a 3-6 membered saturated or partially saturated carbocycle or heterocycle, optionally substituted with 0, 1 or multiple R8;

R4 is chosen from aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R8;

R5 is chosen from alkoxy or benzyloxy, each optionally substituted with 0, 1, or multiple R8;

R6 is chosen from hydrogen, alkoxy, or halo, each optionally substituted with 0, 1, or multiple R8;

R7 is chosen from hydrogen, —C(O)R9, or —CH2OC(O)R9;

R8 is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkynyl, alkoxy, cyano, or heterocyclyl, each optionally substituted with 0, 1, or multiple R10,

R9 is chosen from alkyl, alkoxy, or aryl, each optionally substituted with 0, 1, or multiple R8;

R10 is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkoxy, or heterocyclyl; and

R11 is chosen from hydrogen or alkyl, each substituted with 0, 1 or multiple R8.

2. The compound according to claim 1, wherein X and Y are hydrogen.

3. The compound according to claim 2, wherein R1 and R11 are independently chosen from hydrogen or alkyl.

4. The compound according to claim 2, wherein R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8.

5. The compound according to claim 2, wherein R4 is aryl, optionally substituted with 0, 1 or multiple R8.

6. The compound according to claim 2, wherein R1 and R11 are independently chosen from hydrogen or alkyl, R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8, and R4 is aryl, optionally substituted with 0, 1 or multiple R8.

7. The compound according to claim 1, wherein X is C(O)R5 and Y is hydrogen.

8. The compound according to claim 7, wherein R1 and R11 are independently chosen from hydrogen or alkyl.

9. The compound according to claim 7, wherein R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8.

10. The compound according to claim 7, wherein R4 is aryl, optionally substituted with 0, 1 or multiple R8.

11. The compound according to claim 7, wherein R1 and R11 are independently chosen from hydrogen or alkyl, R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8, and R4 is aryl, optionally substituted with 0, 1 or multiple R8.

12. The compound according to claim 1, wherein X is hydrogen and Y is Q.

13. The compound according to claim 12 wherein Z is N.

14. The compound according to claim 13 wherein W is O.

15. The compound according to claim 14, wherein R6 is alkoxy.

16. The compound according to claim 15, wherein R7 is hydrogen.

17. The compound according to claim 16, wherein R1 and R11 are independently chosen from hydrogen or alkyl.

18. The compound according to claim 16, wherein R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8.

19. The compound according to claim 16, wherein R4 is aryl, optionally substituted with 0, 1 or multiple R8.

20. The compound according to claim 16, wherein R1 and R11 are independently chosen from hydrogen or alkyl, R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8, and R4 is aryl, optionally substituted with 0, 1 or multiple R8.

21. The compound according to claim 15, wherein R7 is chosen from —C(O)R9, or —CH2OC(O)R9.

22. The compound according to claim 21, wherein R1 and R11 are independently chosen from hydrogen or alkyl.

23. The compound according to claim 21, wherein R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8.

24. The compound according to claim 21, wherein R4 is aryl, optionally substituted with 0, 1 or multiple R8.

25. The compound according to claim 21, wherein R1 and R11 are independently chosen from hydrogen or alkyl, R3 and R3′ are independently chosen from C2-C6 alkyl or taken together to form a 3-6 membered saturated carbocycle, each optionally substituted with 0, 1 or multiple R8, and R4 is aryl, optionally substituted with 0, 1 or multiple R8.

26. A composition for the control of a fungal pathogen including mixtures of at least one of the compounds of claim 1 and another pesticide including fungicides, insecticides, nematocides, miticides, arthropodicides, bactericides and combinations thereof.

27. A composition for the control of a fungal pathogen including mixtures of at least one of the compounds of claim 16 and another pesticide including fungicides, insecticides, nematocides, miticides, arthropodicides, bactericides and combinations thereof.

28. A composition for the control of a fungal pathogen including mixtures of at least one of the compounds of claim 21 and another pesticide including fungicides, insecticides, nematocides, miticides, arthropodicides, bactericides and combinations thereof.

29. A method for the control and prevention of fungal attack on a plant, the method including the step of:

applying a fungicidally effective amount of at least one of the compounds of claim 1 to at least one of the plant, an area adjacent to the plant, soil adapted to support growth of the plant, a root of the plant, and foliage of the plant.

30. A method for the control and prevention of fungal attack on a plant, the method including the step of:

applying a fungicidally effective amount of at least one of the compounds of any of claim 26 to at least one of the plant, an area adjacent to the plant, soil adapted to support growth of the plant, a root of the plant, and foliage of the plant.